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Executive Summary 224 
The Working Party make more than 100 tabulated recommendations in antimicrobial 225 
prescribing for the treatment of infections caused by MDR GNB and suggest additional 226 
further research, and algorithms for hospital and community antimicrobial usage in 227 
urinary infection. The international definition of multi-drug resistance is complex, 228 
unsatisfactory and hinders the setting and monitoring of improvement programmes. 229 
We give a new definition of multi-resistance. The background information on the 230 
mechanisms, global spread, and the UK prevalence of antibiotic prescribing and 231 
resistance has been systematically reviewed. The treatment options available in 232 
hospitals using intravenous antibiotics and in primary care using oral agents have been 233 
reviewed, ending with a consideration of antibiotic stewardship and recommendations 234 
given. 235 
The guidance has been derived from current peer-reviewed publications and expert 236 
opinion with open consultation. Methods for systematic review were NICE compliant 237 
and in accordance with the SIGN 50 Handbook; critical appraisal was applied using 238 
AGREE II. Published guidelines were used as part of the evidence base and to support 239 
expert consensus.  240 
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The guidance includes recommendations for stakeholders, including prescribers, and 241 
antibiotic-specific recommendations. The clinical efficacy of different agents is critically 242 
reviewed. We found there are very few good quality comparative randomized clinical 243 
trials to support treatment regimens, particularly for licensed older agents.  244 
Susceptibility testing of MDR GNB causing infection to guide treatment needs critical 245 
enhancements. Meropenem- or imipenem resistant Enterobacteriaceae should have 246 
their carbapenem MICs tested urgently, and any carbapenemase class determined: 247 
mandatory reporting of these isolates from all anatomical sites and specimens would 248 
improve risk assessments. Broth microdilution methods should be adopted for colistin 249 
susceptibility testing.  250 
Antimicrobial stewardship programmes should be instituted in all care settings, based 251 
on resistance rates and audit of compliance with guidelines, but should be augmented 252 
by improved surveillance of outcome in Gram-negative bacteraemia, and feedback to 253 
prescribers. Local and national surveillance of antibiotic use, resistance and outcome 254 
should be supported and antibiotic prescribing guidelines should be informed by these 255 
data. 256 
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The diagnosis and treatment of both presumptive and confirmed cases of infection by 257 
GNB should be improved. This guidance, with infection control to arrest increases in 258 
MDR, should be used to improve outcome of infections with such strains. Anticipated 259 
users include medical, scientific, nursing, antimicrobial pharmacy and paramedical staff 260 
where they can be adapted for local use. 261 
Lay Summary 262 
Multi-drug resistant (MDR) Gram-negative bacteria (GNB) are bacteria (or germs) that 263 
remain susceptible to only one or two antibiotics. Gram-negative bacteria usually live in 264 
the gut (or in the environment), where they do no harm, but can appear and cause 265 
infection at other body sites that normally lack any bacteria, for example in the bladder 266 
or blood. This especially occurs in patients who are made vulnerable by underlying 267 
disease, injury or hospitalization. MDR GNB may be acquired from other patients who 268 
have received antibiotics. Infections caused by MDR GNB are difficult to treat and so 269 
may cause more prolonged symptoms in the site of infection and can cause additional 270 
complications such as pneumonia or infection in the blood. This can prolong the length 271 
of stay in hospital, and in some cases, can cause death. Some types of MDR GNB e.g. 272 
Acinetobacter spp. can be carried on the skin rather than the gut, again with no obvious 273 
signs or symptoms. ‘Colonization’ describes carriage of bacteria on body surfaces or in 274 
the gut without infection. When patients develop infection and require antibiotic 275 
treatment, selecting the correct antibiotic can be difficult. This report provides advice 276 
on the best choice of antibiotics currently available.  277 
1  Introduction 278 
This guidance has been prepared by a joint Working Party of the British Society for 279 
Antimicrobial Chemotherapy (BSAC), the Healthcare Infection Society (HIS) and the 280 
British Infection Association (BIA) to advise on the treatment of infections caused by 281 
MDR GNB. It also describes best practice in antimicrobial prescribing. There is an 282 
accompanying guideline describing appropriate infection prevention and control 283 
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precautions, including hand hygiene, equipment and environmental cleaning and 284 
guidance on screening for MDR GNB 3. The infection control and prevention guideline 285 
should be used in conjunction with the present document. There is a glossary for 286 
technical terms (See Appendix 1). 287 
The Working Party comprised a group of medical microbiologists and scientists, 288 
infectious disease physicians, infection control practitioners, epidemiologists, and 289 
patient representatives nominated by the Societies. The patient representatives were 290 
lay members and had direct experience of the treatment of healthcare-associated 291 
infections through personal experience, membership of SURF (Healthcare-acquired 292 
Infection Service Users Research Forum), patient charities or through involvement in 293 
the development of NICE guidelines. The representatives were:  294 
Susan Bennett, Member of Health Care Acquired Infections, Service Users Research 295 
Forum, Leicester, UK 296 
Jennifer Bostock, Member of Health Care Acquired Infections, Service Users Research 297 
Forum, Leicester, UK 298 
Maria Cann, Trustee, MRSA Action, Kirkham, UK 299 
They were involved in the preparation of the remit of the Working Party remit 300 
(Appendix 3), were invited to all meetings, invited to comment on the final draft 301 
prepared by the authors and endorsed the final version. 302 
2 Guideline Development Team 303 
2.1 Guideline Advisory Group 304 
Phil Wiffen, Cochrane Pain, Palliative and Supportive Care Group Pain Research, 305 
Churchill Hospital Oxford, Nuffield Dept. of Clinical Neurosciences, Oxford. 306 
Karla Soares-Wieser, Enhance Reviews, Ltd, Wantage. 307 
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2.2 Responsibility for Guidelines 308 
The views expressed in this publication are those of the authors and have been 309 
endorsed by the three sponsoring societies following consultation. Patient 310 
representatives confirmed the guidelines addressed the questions raised in setting the 311 
Working Party’s remit. 312 
3 The Working Party report 313 
Date of publication: TBC 2017 (Published online TBC) 314 
3.1 What is The Working Party Report? 315 
This Report is a set of recommendations covering the treatment of infections caused by 316 
MDR GNB (i.e. herein defined as susceptible to only to one or two different antibiotics). 317 
Strains internationally defined as MDR GNB by possession of resistance to three or 318 
more classes of antibiotics can nevertheless be treated with a wide range of antibiotics 319 
so we argue the case for a re-definition below (See Section 6.2.).  320 
The Working Party recommendations have been developed systematically through a 321 
multi-professional group based on published evidence. They should be used to develop 322 
local protocols for acute and long-term healthcare settings. 323 
3.2 ..... Why do we need a Working Party Report for these infections? 324 
MDR GNB have become more prevalent internationally, including in the UK and Europe. 325 
The increased use of broad-spectrum agents encourages their proliferation4 . The 326 
spread of these bacteria causes infections that can increase the length of hospital stay 327 
and adversely affect the quality of life of patients. Public awareness has been increasing, 328 
and the relative lack of new antimicrobial agents to treat infections due to Gram-329 
negative bacteria has resulted in the formulation of the five-year Antimicrobial 330 
Resistance Strategy by the UK Department of Health 5. Outbreaks are associated with 331 
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considerable, physical, psychological and financial costs. Evidence-based treatment 332 
regimens are effective in improving the outcome of infections due to these bacteria.  333 
3.3 What is the purpose of the Report’s recommendations? 334 
The Report describes appropriate antimicrobial chemotherapy for infections due to 335 
MDR Gram–negative bacteria. 336 
3.4 What is the scope of these guidelines? 337 
We examine the background information on the mechanisms, global spread, and the UK 338 
prevalence of resistance, prescribing, and then discuss treatment i) in hospitals using 339 
antibiotics intravenously and ii) in primary care using agents given orally, ending with a 340 
consideration of antibiotic stewardship. Data (and doses, where given) usually refer to 341 
adults as there are few data for children and neonates. Extrapolation from adult data for 342 
β-lactams seems reasonably secure but this is not necessarily the case for other agents. 343 
Another set of guidelines considers appropriate infection control principles, best 344 
practice hand hygiene, screening and environmental cleaning3 . For the detailed scope 345 
for this guideline see Appendix 2.5 and for the review questions see Appendix 3.7. 346 
3.5 What is the evidence for these guidelines? 347 
In the preparation of these recommendations, systematic reviews were performed of 348 
peer-reviewed research using the searches show in Appendix 4. Expert opinion was also 349 
derived from published guidelines subjected to validated appraisal2. Evidence was 350 
assessed for methodological quality and clinical applicability according to protocols of 351 
the Scottish Intercollegiate Guidelines Network (SIGN) initially using SIGN 20111 352 
guidelines and then updating this as the working party continued to comply with the 353 
SIGN 2014 guidance6. 354 
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3.6 Who developed these guidelines? 355 
A group of medical microbiologists, scientists, infectious disease physicians, infection 356 
control practitioners, epidemiologists, and patient representatives. 357 
3.7 Who are these guidelines for? 358 
Any hospital or general practitioner can use these guidelines and adapt them for local 359 
use. Expected users include clinical medical, nursing, antimicrobial pharmacy and 360 
paramedical staff. Paediatric licenses and formulation may limit the suitability of some 361 
of the discussed agents for children and neonates. . Where there are specific issues 362 
relating to dosage, outcome or toxicity that are outside current license information, 363 
these are discussed. The guidelines should be used to improve the treatment of both 364 
presumptive and confirmed cases of infection by MDR GNB. 365 
3.8 How are the guidelines structured? 366 
Most areas (defined by questions) comprise an introduction, a summary of the evidence 367 
base with levels and a recommendation graded according to the available evidence. The 368 
guidelines are not organised by clinical indication. 369 
3.9 How frequently are the guidelines reviewed and updated? 370 
The guidelines will be reviewed and updated every four years if warranted by sufficient 371 
changes in the evidence or by the availability of new agents or formulations. 372 
3.10 Aim 373 
The primary aim of the review was to assess the current evidence for antimicrobial 374 
prescribing in the treatment of MDR Gram-negative infections. The secondary aims 375 
were: (a) to evaluate the efficacy of antibiotics to treat community, and hospital 376 
infections caused by MDR GNB (b) to evaluate the impact of educating and providing 377 
support to professionals and patients to reduce unnecessary use of antibiotics leading 378 
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to a reduction in the selective pressure for resistance, thereby assisting antibiotic 379 
stewardship. 380 
4 Summary of Guidelines 381 
The guidance has been derived from current best peer-reviewed publications and 382 
expert opinion. Each recommendation is graded according to standard grades 1 and is 383 
associated with a class of supporting evidence, or it is presented as a Good Practice 384 
Point. General recommendations for stakeholders, including prescribers are made in 385 
Table 1. Specific antibiotic recommendations are made in Table 2.  386 
4.1 How can the guidelines be used to improve clinical effectiveness? 387 
The Guidelines can be used to direct and formulate antibiotic policies and to aid the 388 
prescribing practice of infection specialists and other clinicians. They provide a 389 
framework for clinical audit tools for quality improvement. 390 
4.2 How much will implementation of the guidelines cost?  391 
The majority of antimicrobial agents that are described in these guidelines are generic 392 
and are currently widely used. Newer -lactam/-lactamase inhibitors (BL/BLI) are 393 
more expensive than older BL/BLIs and most alternatives to carbapenems against MDR 394 
GNB are also more expensive. Extra financial support will be required for the 395 
surveillance of outcomes of bacteraemia. Implementation of these guidelines should 396 
enable better-focused therapy, with no increase in drug utilization and possibly a 397 
modest decrease. 398 
4.3 Summary of suggested audit measures 399 
Patients with infections with MDR GNB, should receive empirical (best guess) or 400 
definitive (i.e. after results of laboratory tests) appropriate antibiotic treatment (alone 401 
or in combination) and the former should be active in at least 80% of cases. It is 402 
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important to note that the basis on which resistance was defined was changed by 403 
EUCAST from predicting failed clinical response to deviation from the normal 404 
susceptibility of the species. In an era of multiple resistance, continuing to select for 405 
such resistant strains even when the patient has clinically responded to antibiotics to 406 
which the organism is resistant is undesirable. Control groups with infections at the 407 
same site and caused by the same species, but not MDR, or infections without known 408 
aetiology should not receive definitive treatment reserved for patients with MDR GNB. 409 
This audit should be conducted first for bacteraemias.  410 
To reduce total antibiotic consumption, measured as defined daily doses. 411 
Quarterly use of carbapenems and piperacillin/tazobactam should be reduced if either 412 
is in the top quintile/1000 patient days as assessed in each quarter. Specialist and 413 
tertiary care units may have special needs and should be excluded from the quintile 414 
assessment. Reductions of use in such units should be undertaken but should be 415 
tailored by consideration of their speciality case mix. . 416 
Trimethoprim use should be reduced and nitrofurantoin use increased in primary care.  417 
Risk assessment tools for colonization and infection with MDR GNB in patients should 418 
be developed for the UK and put in place in all settings. Only infected patients known to 419 
be, or at risk of being (by these assessments), colonized with these bacteria should 420 
receive empirical treatment with drugs reserved for MDR GNB.  421 
No antibiotic prescriptions for treating the elderly with asymptomatic bacteriuria 422 
(ASB), or urinary tract infection (UTI) in the presence of a urinary catheter unless 423 
bacteraemia or renal infection suspected. 424 
No antibiotic prophylaxis for urinary catheter insertion or change unless previous 425 
history of symptomatic urinary infection (UTI) associated with a change of catheter, or 426 
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if there is trauma during catheter insertion, or if a urinary continence device has been 427 
inserted.  428 
Gram-negative bacteraemia incidence should be decreased and outcome should be 429 
improved both in cases which developed in primary care, wider healthcare settings, and 430 
secondary and tertiary units.  431 
Enhancements to surveillance should be planned and supported by information 432 
technology (IT) that allows record linkage and simplification of surveillance from the 433 
laboratory to national level.  434 
4.4 E-learning tools 435 
 Continuing Professional Development questions and model answers are listed for self-436
assessment in Appendix 5.  437 
5 Methodology 438 
5.1 Evidence appraisal 439 
Methods were in accordance with SIGN 50 and Cochrane Collaboration criteria 1, 7 and 440 
critical appraisal was applied using AGREEII.2  Accepted guidelines were used as part of 441 
the evidence base and to support expert consensus. Questions for review (See Appendix 442 
3.7.) were derived from the Working Party Group which included patient 443 
representatives in accordance with Patient Intervention Comparison Outcome (PICO)6. 444 
K Soares-Wiesner of Enhance Reviews Ltd. and Dr P Wiffen of Pain Research and 445 
Nuffield Department of Clinical Neurosciences, Oxford University used a systematic 446 
review process. Guidelines and research studies were identified for each search 447 
question. Systematic reviews, randomized controlled trials (RCT) and observational 448 
studies were included. The latter comprised cohort non-RCT, controlled before- and 449 
after-studies, and interrupted time series. All languages were searched. Search 450 
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strategies for each area are given in the sections below and in Appendix 4. MeSH 451 
headings and free text terms were used in the Cochrane Library (Issue 11 2012), 452 
Medline (1946-2012), Embase (1980-2012) and Cumulated Index of Nursing and Allied 453 
Health Literature (CINAHL) (1984-2012). On 23rd May 2014, an update search was 454 
conducted on Medline alone using the same strategy for references after 1st January 455 
2013. Reference lists of included studies were searched. Additional references were 456 
added in October 2016 and June 2017 to cover specific issues. Two review authors 457 
independently screened all citations and abstracts identified, and screened full reports 458 
of potentially eligible studies (those that addressed the review questions in primary or 459 
systematic secondary research, or a clinical, in vitro, or in use study). Disagreements 460 
were resolved by discussion, and rationales for exclusion of studies were documented. 461 
Pre-tested data extraction forms were used, and study characteristics and results 462 
collected. Data were extracted from observational studies for multiple effect estimates: 463 
these included the number of cases analyzed, adjusted and unadjusted effect estimates, 464 
with standard error or 95% confidence interval (CI), confounding variables and 465 
methods used to adjust the analysis. If available, data were extracted from contingency 466 
tables. Risk of bias was assessed using SIGN critical appraisal checklists. Interrupted 467 
time series were assessed using the Cochrane Effective Practice and Organisation of 468 
Care (EPOC) Group6, 8. Quality was judged by report of details of protection against 469 
secular changes (intervention independent of other changes) and detection bias 470 
(blinded assessment of primary outcomes and completeness of data). For outbreak 471 
patterns associated with particular pathogens, the Working Party made additional 472 
searches of descriptive studies to extract effective treatments for infections caused by 473 
bacteria with specific resistance.  474 
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5.2 Data analysis and interpretation 475 
Clinical outcomes were mortality, effectiveness of treatment, and length of hospital stay. 476 
Microbial outcome measures were decreases in the prevalence of MDR GNB, or 477 
decreases in colonization or infection by specific GNB. Risk ratios (RR) were used for 478 
dichotomous variables, and mean differences with 95% CI were used for continuous 479 
variables9. Analyses were performed in Revman 5.22 10. SIGN summary tables were 480 
used. Evidence tables and judgment reports were presented and discussed by the 481 
Working Party and the guidelines were prepared according to the nature and 482 
applicability of the evidence, patient preference and acceptability and likely costs. The 483 
level of evidence was as defined by SIGN (Table 3), and the strength of recommendation 484 
was based upon GRADE (Grading of Recommendations Assessment, Development and 485 
Evaluation) (Table 4) 11. The grading relates to the strength of the supporting evidence 486 
and predictive power of the study designs, rather than the importance of the 487 
recommendation. Any disagreements between members were resolved by discussion. 488 
For some areas and recommendations, only expert opinion is available; in such cases, a 489 
good practice recommendation has been made. A flow chart of the systematic review 490 
process is given in Figure 1. 491 
5.3 Consultation process 492 
These guidelines were opened to consultation with circulation to the stakeholders listed 493 
(See Appendix 6). The draft report was placed on the BSAC website for one month in 494 
June 2016 for open consultation. Views were invited on format, content, local 495 
applicability, patient acceptability and recommendations. The Working Party 496 
considered and collated comments, and agreed revisions. 497 
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6 Rationale for recommendations 498 
6.1 Usage 499 
It is beyond the scope of this guideline to define optimal quantitative usage of 500 
antibiotics by hospital beds or community populations and the UK is not an 501 
exceptionally high antibiotic user in international terms. Equally, measures to reduce 502 
antibiotic usage will depend on what apparent over usage is occurring in any 503 
community or hospital department. For this reason, the assessment of reduction 504 
measures whilst based on comparative epidemiology must also consider both clinical 505 
outcome measures and usage at the local level. Suggestions for reducing overall usage 506 
must therefore be largely implemented at the local level where risk to patients and 507 
benefit can be adequately assessed and lie beyond the practical scope of this guideline. 508 
6.2 What is the definition of multi-drug-resistant Gram-negative bacteria? 509 
Multi-drug resistant (MDR) is a vexed term. From 1980 it was used to mean, ‘resistant 510 
to multiple agents’ without the number or types of agents being specified. More recently 511 
the European Centre for Disease Prevention and Control (ECDC) has attempted to 512 
formalise the term as ‘resistant to three or more antibiotic classes’, whilst extremely 513 
drug resistant (XDR) is ‘susceptible only to one or two drug classes. These definitions, 514 
based on those for tuberculosis, are epidemiologically attractive, but can prove to be 515 
impractical. An international consensus is difficult to achieve, as not all products are 516 
available and tested by laboratories in all countries, and there is no universal testing 517 
policy for laboratories which make pragmatic decisions on what to test. Some antibiotic 518 
resistances are now very common and stable, e.g. to ampicillin and sulphonamides, so 519 
they are seldom tested, but if they are present the organism needs only one further 520 
resistance to count as MDR GNB by the “three classes of resistance” rule. There also is 521 
scope for disagreement on which antibiotics should be considered as separate classes, 522 
for example, monobactams behave similarly to oxyimino-cephalosporins in respect of 523 
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most resistance mechanisms but very differently in the case of metallo-lactamases 524 
(MBL). 525 
Difficulties arise also if in vitro “susceptibility” is poorly defined e.g. with the absence of 526 
EUCAST breakpoints as, for example, for i) Acinetobacter spp. and sulbactam, and ii) for 527 
temocillin. Furthermore differences between European (EUCAST) and US (CLSI or FDA) 528 
breakpoints can affect fundamentally whether isolates are regarded as MDR or XDR and 529 
recruitment to, and results in, clinical trials. Separate breakpoints for urinary isolates 530 
although needed to take account of high urinary concentrations with some antibiotics 531 
also complicate assessments. Lack of laboratory uniformity in breakpoints can make 532 
comparisons and data aggregation meaningless. For example, EUCAST and CLSI 533 
breakpoints differ for piperacillin/tazobactam and amoxicillin/clavulanate. EUCAST 534 
defines Enterobacteriaceae isolates as piperacillin/tazobactam susceptible if they have 535 
an MIC<=8mg/L (R>16mg/L) compared with <=16+4mg/L (R>=128+4 mg/L) in CLSI 536 
guidance. For amoxicillin/clavulanate susceptibility is defined by EUCAST as 537 
<=8+2mg/L (R>8mg/L (or 32+2mg/L for uncomplicated UTI) and by CLSI as 538 
<=8+4mg/L (R>=32+16mg/L). The FDA regard Pseudomonas aeruginosa isolates as 539 
susceptible to piperacillin/tazobactam if the MIC is <=64mg/L (the historical CLSI 540 
breakpoint for piperacillin) whereas EUCAST and CLSI now consider the breakpoint 541 
should be S<=16+4mg/L. The EUCAST and CLSI definitions have changed with time and 542 
from previous national guidelines e.g. the pre-EUCAST BSAC breakpoint for 543 
amoxicillin/clavulanate in systemic infections was 8+4mg/L. Cefepime is a further 544 
example of an antibiotic with breakpoint changes: the old CLSI breakpoint for 545 
Enterobacteriaceae was =<8mg/L but is now =<2mg/L based on 1g.twice daily doses. 546 
Organisms with MICs of 4or 8mg/L are viewed as being “susceptible but dose-547 
dependent” by CLSI. EUCAST categorises an MIC <=1mg/L as susceptible and >4mg/L as 548 
resistant. A failure rate of 83% in a prospective trial of cephalosporins for “susceptible” 549 
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serious infections due to ESBL-producing Klebsiella spp. and E. coli partly reflected the 550 
use of high breakpoints 12. Breakpoint differences and changes over time in the 551 
categorization of isolates with the same MIC as “susceptible” or “resistant” profoundly 552 
challenge conclusions in the clinical literature, including reports of regulatory trials on 553 
the response to be expected of infections due to “susceptible” or “resistant” strain or 554 
indeed which patients have been included in trials where susceptibility of the organism 555 
is a selection criterion. 556 
For all these reasons, the international definitions have not lead to better surveillance of 557 
MDR strains and their usefulness must still be questioned. In our literature search 558 
routines, we have employed the international definitions but have had to augment these 559 
with literature on specific resistances. A useful pragmatic approach to the definition of 560 
MDR is to consider oral and parenteral drugs separately as, in the UK, these will be 561 
largely used in primary, and secondary with tertiary, care respectively, with multi-562 
resistance constituting different challenges in each setting. Furthermore, one should 563 
base definitions on susceptibility rather than resistance as the former is more likely to 564 
be sought clinically by further testing with MDR strains. This gives a basis for 565 
alternative definitions for MDR which we would advocate. For oral drugs, multi-566 
resistance can usefully be defined as an organism susceptible to only one or no readily 567 
available oral agent active against infections systemically or in the upper urinary tract. 568 
This definition is vulnerable to the introduction of new, or newly re-licensed, oral 569 
agents, but this is appropriate and may emphasise the importance of new agents to the 570 
licensing authorities. By this definition the following would be classed as multi-resistant 571 
isolates for the community: 572 
i) Escherichia coli resistant to co-amoxiclav (amoxicillin with clavulanic acid), oral 573 
cephalosporins, quinolones, trimethoprim but susceptible to nitrofurantoin, mecillinam 574 
and fosfomycin. Although providing options in cystitis these oral agents lack evidence of 575 
Accepted manuscript 23 
achieving systemically active concentrations and efficacy in upper and complicated 576 
UTIs, which is particularly relevant if these are caused by ESBL- and AmpC-producing 577 
strains ii) P. aeruginosa resistant to quinolones. This approach could be modified to 578 
exclude agents where the mutation frequency is sufficiently high so that resistance 579 
commonly emerges during treatment. 580 
For parenteral antibiotics a similar approach can be considered. Susceptibility to oral 581 
agents that have no licensed, or available, parenteral form e.g. pivmecillinam and 582 
nitrofurantoin should not be taken into account. Specific agents to which impaired 583 
susceptibility might be significant include carbapenems, relevant cephalosporins 584 
(cefotaxime for Enterobacteriaceae, ceftazidime for P. aeruginosa), aztreonam, 585 
ceftolozane/tazobactam, ceftazidime/avibactam , temocillin, piperacillin/tazobactam, 586 
colistin, quinolones, fosfomycin, tigecycline and aminoglycosides (including amikacin). 587 
Given this greater number of agents and the paucity of new pipeline antibiotics active 588 
against Gram-negative bacteria, it is pragmatic to consider ‘multi-resistant’ as isolates 589 
where only two, or fewer, unrelated antibiotics are active against the bacterium. By such 590 
a definition the following would be considered multi-resistant isolates in hospitals:  591 
i) Acinetobacter baumannii susceptible to two or fewer of meropenem or 592 
imipenem, (third generation cephalosporins), piperacillin/tazobactam, 593 
(tigecycline), aminoglycosides, quinolones, (trimethoprim), colistin, where 594 
agents in brackets lack EUCAST breakpoints. 595 
ii) Klebsiella spp., Enterobacter spp., Serratia spp. and Citrobacter spp. that are 596 
susceptible to two or fewer of carbapenems, third-generation cephalosporins, 597 
including with β-lactamase inhibitors, piperacillin/tazobactam, temocillin, 598 
tigecycline, aminoglycosides, quinolones, trimethoprim or colistin. 599 
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iii) Proteus spp., Morganella spp. and Providencia spp. that are resistant to third-600 
generation cephalosporin, piperacillin/tazobactam, and aminoglycosides and 601 
susceptible only to carbapenems, and the new beta-lactam/beta-lactam 602 
inhibitors (BL/BLI) combinations (ceftolozane/tazobactam or 603 
ceftazidime/avibactam). Unlike the species considered in ii) above, these 604 
Proteeae are inherently resistant to tigecycline and colistin. 605 
The following would not be regarded as multi-resistant:  606 
i) E. coli that is susceptible to carbapenems, ceftolozane/tazobactam, 607 
ceftazidime/avibactam, colistin and fosfomycin but resistant to unprotected 608 
third-generation cephalosporins, co-amoxiclav, piperacillin/tazobactam, 609 
quinolones, and trimethoprim. 610 
The effect of new parenteral antibiotic introductions on the definition of MDR GNB in 611 
hospitals is illustrated by the licensing of ceftazidime/avibactam and the availability of 612 
parenteral fosfomycin. Both drugs join temocillin, tigecycline or colistin, as potentially 613 
effective agents against some Enterobacteriaceae with KPC carbapenemases. Such 614 
strains would no longer be classified as MDR GNB by our definition. Clearly acquired 615 
resistance of KPC-producing strains to colistin, ceftazidime/avibactam, fosfomycin and 616 
tigecycline may all arise so some will be MDR GNB and some will not. From a 617 
therapeutic view this is probably appropriate although all should remain major targets 618 
for infection control, given the cost of new agents and the need to conserve their 619 
usefulness, along with plasmid-mediated transmission of blaKPC gene, and transmission 620 
of their host strains. The use of alternative β-lactams or new BL/BLIs rather than 621 
carbapenems may be expensive but might reduce the selective pressure for 622 
carbapenem-resistant MDR GNB. These antimicrobials, with activities against different 623 
β-lactamases, may have differential effects on the prevalence of particular β-lactamases 624 
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and other carbapenem-resistant bacteria. They may select more for MBLs which are 625 
particularly resistant to β-lactams which will limit their ultimate usefulness in a locality. 626 
The activity of different β-lactamase inhibitors against, and stability of β-lactams to, 627 
different β-lactamases is shown in Table 5. 628 
The difficulty in international surveillance of MDR GNB need not preclude the 629 
establishment of surveillance for specific organism-antibiotic resistance combinations. 630 
This has been adopted by Public Health England for the English Surveillance 631 
Programme for Antibiotic Use and Resistance (ESPAUR) and is weighted towards 632 
resistance to third-generation cephalosporins, quinolones and carbapenems of E. coli, 633 
Klebsiella spp., and P. aeruginosa. 634 
6.3 What is the global epidemiology of MDR GNB? 635 
6.3.1 Origins and impact of multi-resistance 636 
Resistance to multiple agents can develop via successive mutations, through the 637 
dissemination of multi resistance plasmids/genes (e.g. transposons), or through a 638 
combination of both processes. Resistance narrows antibiotic choices for definitive 639 
therapy. More critically, it increases the likelihood that empirical therapy will prove 640 
ineffective, increasing mortality in septic patients. Plasmids are the main source of 641 
multi-drug resistance in Enterobacteriaceae and Acinetobacter spp., except for 642 
mutations in DNA gyrase genes gyrA/B conferring fluoroquinolone resistance, 643 
mutational up-regulation of arcA/B-mediated efflux compromising tigecycline, and for 644 
mutational derepression of AmpC β-lactamases giving resistance to third-generation 645 
cephalosporins in Enterobacter spp. , Citrobacter spp., Serratia spp., Morganella morgani 646 
13 14. By contrast, sequential accumulation of mutations is paramount in Pseudomonas 647 
spp.. 648 
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A recent review has discussed the emergence of specific resistance lineages and the role 649 
of different plasmid groups in emerging resistance problems in E. coli 15. Some clones 650 
have spread widely for reasons that are not clear. Resistance may increase their 651 
competitiveness, but some strains are adept at acquiring multi-drug resistance.  Several 652 
strands of evidence support this view. First, some ‘high-risk clones’, e.g. E. coli ST131, 653 
frequently acquire diverse resistance determinants, including different extended-654 
spectrum β-lactamases (ESBLs), AmpC and even carbapenemases16. Secondly, there is 655 
co-selection of hypermutability with resistance in P. aeruginosa in patients with cystic 656 
fibrosis, facilitating development of further resistance. Thirdly, it is commonplace for 657 
plasmids and resistance islands to carry multiple genes encoding resistance to an 658 
antibiotic via two or more different mechanisms not all of which can remain under 659 
effective selection pressure. Fourthly the presence of toxin-antitoxin systems in 660 
plasmids may prevent loss of plasmids even when selective pressure is removed17. 661 
Fifthly, integrons, which provide efficient gene-capture and expression systems, and 662 
which are now frequent in plasmids but were not present prior to the widespread use of 663 
antibiotics, provide a mechanism whereby resistance acquisition has accelerated. 664 
Finally, the presence of MDR GNB in the environment including foodstuffs and water 665 
sources provides important pathways for amplification and the spread of some 666 
resistance genes to man 18 19 20-23.  667 
Until recently, environmental sources of carbapenemase genes did not appear to exist 668 
but the description of high levels of NDM-producing E. coli in chicken in China24 669 
suggests this position will not be maintained with current international practices and 670 
biosecurity of food as a source. Surprisingly, the ST131 clone of E. coli did not seem to 671 
have significant environmental sources in its initial spread although it has now been 672 
described occasionally in chickens25, 26. 673 
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6.3.2 Epidemiological trends among multi-drug resistant 674 
Enterobacteriaceae: cephalosporin and quinolone resistance 675 
Countries historically varied in the prevalence of different CTX-M ESBLs conferring 676 
cephalosporin resistance and in the plasmids encoding these enzymes 27. The 677 
prevalence of different CTX-M enzymes has changed with time and latterly in Europe 678 
and North America CTX-M-15 has become the dominant enzyme, often associated with 679 
E. coli ST13128.  Whole genome sequencing suggests that the acquisition of CTX-M 680 
enzymes occurred a number of times in clade C of E. coli ST13129. Frequent co-carriage 681 
of OXA-1 penicillinases impairs susceptibility to combinations of clavulanate and 682 
tazobactam with penicillins. Ceftolozane appears stable to this OXA-1 enzyme. Other 683 
factors associated with the rise of multi-drug resistant Enterobacteriaceae include the 684 
spread of plasmids encoding AmpC β-lactamase. These seem around 10-fold less 685 
frequent than plasmids encoding ESBLs in the UK30 although more recently, in Canada a 686 
plasmid-mediated AmpC enzyme (CMY-2 which shares a promoter gene, ISEcp1, with 687 
CTX-M-15) was almost half as common as ESBL production and one third of such strains 688 
belonged to E. coli ST13131. Distinguishing AmpC and ESBL cephalosporin-resistant 689 
strains is important epidemiologically and in routine testing, although both EUCAST and 690 
CLSI do not recommend it for guiding treatment32. However early information on 691 
AmpC/ESBL status in Enterobacteriaceae may predict respectively 692 
ceftolozane/tazobactam resistance/susceptibility.  Mutations can augment multi-drug 693 
resistance: for example, porin loss can engender resistance to ertapenem (and, 694 
sometimes, other carbapenems) in ESBL- and AmpC- producing Enterobacteriaceae. 695 
6.3.3 Carbapenem resistance 696 
Carbapenem resistance was initially slow to emerge in Enterobacteriaceae but is now 697 
steadily increasing, and mediated more and more by acquired carbapenemases 698 
(predominantly by KPC, VIM, IMP, NDM and OXA-48-like types) 33-36. Internationally 699 
Accepted manuscript 28 
there has been a considerable spread of K. pneumoniae clonal complex (CC) 258 isolates 700 
with KPC carbapenemases. The rise of NDM and OXA-48 carbapenemases is more often 701 
associated with the spread of their encoding plasmids or transposons among bacterial 702 
strains. Carbapenem resistance due to ESBL or AmpC enzymes combined with  Omp 703 
K35 porin loss, may lead to treatment failure but is often unstable and may impose a 704 
fitness cost on bacteria, meaning that spread of such strains among patients is rare, 705 
though not unknown 33. Loss of the Omp K36 porin conferred resistance to new 706 
carbapenem-β-lactamase inhibitor combinations, relebactam with 707 
imipenem/cilastatin37 and meropenem with vaborbactam38. Resistance conferred by 708 
acquired carbapenemases is of much greater concern, and is generally associated with 709 
considerable resistance to other agents.  710 
Data from EARS-Net suggest that the prevalence of carbapenem-resistant 711 
Enterobacteriaceae causing bacteraemia markedly increased in most parts of Europe 712 
between 2013and 2015 39 . European prevalence of carbapenem-resistant 713 
K.pneumoniae was higher than 5% in 2015 (and much higher in some of the 714 
countries)40 in Greece, Italy, Cyprus and Romania. In Greece, the proportion of 715 
bloodstream K. pneumoniae isolates resistant to carbapenems increased from 27.8% in 716 
2005 to 62.3% in 2014. VIM enzymes dominated early in this period but were replaced 717 
by KPC types, often carried by CC258. The rise of carbapenem-resistant K. pneumoniae 718 
in Italy has been dramatic and recent: from 1% of bacteraemias in 2009, to 15% in 2010 719 
to 32.3% in 2014. This increase again is mainly due to CC258 K. pneumoniae with KPC 720 
enzymes 41. This clone also spread widely earlier in the USA42 and then in Israel43, 721 
where an aggressive, nationwide infection control intervention was successful in 722 
bringing it under control44, 45. In Romania the major problem is K. pneumoniae 723 
producing OXA-48 carbapenemase 46. 724 
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Outbreaks of carbapenemase-producing Enterobacteriaceae (CPE) have been reported 725 
in many other parts of the world, including all US states47 (where KPC enzymes 726 
dominate), South Asia (predominantly NDM enzymes), the Middle East (OXA-48), Brazil 727 
and Colombia (KPC) 36, 48. The MBL IMP-4 has spread widely in China, often together 728 
with KPC-2. IMP-4, without KPC, is the dominant carbapenemase in Australia. Further 729 
global spread is to be expected 49 as IMP-4 has now been observed in South London 730 
(unpublished observations, Prof. D. Livermore). In the absence of comprehensive 731 
international prevalence data for infection and carriage, risk factors for CPE are difficult 732 
to derive, but seem to include travel to high prevalence areas, notably including the 733 
Indian subcontinent for NDM-producers, and exposure to healthcare and 734 
antimicrobials33. Travel locations are becoming convergent with those where ESBLs are 735 
prevalent. Case-number trigger points for carbapenem-resistant isolates and regional 736 
coordination in control action has recently been modeled in the USA to show the high 737 
importance of early intervention with effective control measures50 for K. pneumoniae 738 
strains and other Enterobacteriaceae. Carbapenem resistance in Enterobacteriaceae has 739 
been associated with increased attributable mortality probably owing to the greater 740 
likelihood that initial empirical therapy proves inadequate 33, 51, 52. 741 
6.3.4 Global resistance issues with oral drugs with low resistance rates 742 
in the UK  743 
A 2008 study of clinical isolates from women aged 18–65 years with symptoms of 744 
uncomplicated lower UTI in ten countries, found susceptibility rates above 90% only for 745 
fosfomycin (98%), mecillinam (96%), and nitrofurantoin (95%)53. Nitrofurantoin 746 
resistance in E. coli as assessed on European and Canadian isolates made in 1999-2000 747 
and 2007-8 was associated with a very diverse range of sequence types although many 748 
strains showed multiple resistances: mecillinam resistance was similarly diverse but 749 
not associated with multiple-resistance54. A further study from Munster and Seattle 750 
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suggests nitrofurantoin resistance is particularly common in ST58 55. Nitrofurantoin 751 
resistance is now described in 11% of the dominant H30 sub-clone of ST13156 752 
suggesting the drug may be selective in the upper intestine although this drug does not 753 
usually eliminate Enterobacteriaceae from the faecal flora of patients receiving it. In 754 
Canada, nitrofurantoin resistance rates in ESBL-producing E. coli were 16% but in 755 
ESBL-producing Klebsiella spp. were 71% (nosocomial) and 93% (non-nosocomial) 57. 756 
Well-described mutations in nitrofuran reductases confer resistance and plasmid-757 
mediated resistance due to an efflux pump (oqxAB) has recently been described from 758 
Hong Kong 58. This efflux pump and its encoding plasmid (with the oqxAB gene flanked 759 
by IS26 insertion sequences) was found in 26/103nitrofurantoin resistant or 760 
intermediate human isolates (by CLSI criteria) and was commoner in ESBL-producing 761 
isolates. The combination of oqxAB with the nitroreductase genes caused high-level 762 
nitrofurantoin resistance. This two level resistance process is analogous to the 763 
hypothetical role of AAC-6’-1b-cr in aiding the emergence of quinolone resistance by 764 
chromosomal mutation. Notably oqxAB also mediates resistance to mequindox, which is 765 
used in China as a growth promoter in animal feed. In China 322/1123 veterinary 766 
isolates of E. coli carried this gene but these mainly belonged to phylogroups A and B1 767 
that are less associated with extra intestinal pathogenicity in man.59 768 
Fosfomycin use has been complicated by the emergence of resistance in some 769 
populations60. In Spain when use increased some fifty percent between 2005 and 2008, 770 
resistance rates in CTX-M-15 ESBL producing E. coli rose to 16% and among all ESBL-771 
producing isolates increased from 4.4% in 2005 to 11.4% in 2009. The increase was 772 
particularly associated with nursing homes61. Fosfomycin resistance developed in E. coli 773 
ST131 (previously present there but not typed)62 and was not associated with described 774 
mutational mechanisms of fosfomycin resistance63.  Such mutations involve inactivation 775 
of genes encoding the hexose and triose sugar phosphate transport impairing drug 776 
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uptake. A different mechanism is present in the acquired fosA gene, which encodes a 777 
drug-inactivating metalloglutathione transferase60. Fosfomycin resistance was present 778 
in 2009-2010 in 7.8% human E. coli in mainland China and approximately half of this 779 
was due to fosA364. A recent survey of food animals in Hong Kong found plasmid-780 
mediated fosA to be increasing in frequency and associated with CTX-M ESBL-encoding 781 
plasmids 65. A recent Chinese survey of isolates collected from 2010 to 2013 detected 782 
fosfomycin resistance in 12% of ESBL-producing Klebsiella and 169/278 (61%) of KPC-783 
producing Klebsiella pneumoniae: 94 KPC-producing strains carried fosA 3 flanked by 784 
two IS26 insertions and were clonally related66. Similar genetic findings were made in 785 
non-clonally related E. coli and Klebsiella sp. in Korea67.  786 
Mecillinam resistance is said to remain uncommon in the clinic – at 5-7% of ESBL-787 
producing E coli in Sweden68. In a wider European study, overall susceptibility was 788 
similar with 4.8% resistance in E coli from uncomplicated UTI, although gradually rising 789 
69, notably in Spain where the resistant proportion of strains rose from1% in 2000 to 790 
6.5% in 2014. 791 
6.4 How do multi-drug resistant Enterobacteriaceae differ from non-fermenters 792 
in terms of their prevalence and associated resistance genes? 793 
Carbapenem resistance is more common in non-fermenting Gram-negative bacteria 794 
than in Enterobacteriaceae. In A. baumannii, it was common by the year 2000, to see 795 
isolates resistant to all treatment options except carbapenems, colistin and tigecycline. 796 
Subsequently, carbapenem resistance has proliferated, reaching c. 30% of bloodstream 797 
isolates. It is largely associated with acquired OXA-23, -40 or 58-like carbapenemases or 798 
with insertion-sequence mediated upregulation of the chromosomal OXA-51-like 799 
carbapenemase. The strain structure of A. baumannii is extremely clonal, making it 800 
difficult, without a history of patient transfers, to distinguish place-to-place spread from 801 
repeated independent selection of lineage variants that were previously circulating at 802 
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low frequency. UK A. baumannii isolates producing OXA-23 carbapenemases often co-803 
produce ArmA encoded 16S ribosomal methyltransferases conferring pan-804 
aminoglycoside resistance. Multi-drug resistant Acinetobacter spp. largely cause 805 
outbreaks in ICU settings 70-72, whereas carbapenem-resistant Enterobacteriaceae, 806 
principally E. coli and Klebsiella spp., cause infection in a wider group of patients, and 807 
have far greater potential to spread rapidly when introduced into wider patient 808 
populations 36, 44, 45, 48, 73, 74.  809 
Most UK P. aeruginosa remain susceptible to β-lactams, including ceftazidime, 810 
piperacillin/tazobactam and carbapenems, aminoglycosides and fluoroquinolones, with 811 
resistance rates of 5-10% for these agents; and fewer than 1% for 812 
ceftolozane/tazobactam 75 . Nevertheless, single multi-drug resistant lineages, some 813 
with carbapenemases, have persisted in a few UK hospitals for up to 9 years, causing 814 
multiple infections widely scattered over time and possibly reflecting colonisation of the 815 
hospital water systems. The most frequently encountered carbapenemase is VIM, which 816 
may be plasmid-mediated, with multiple gene copies conferring high level meropenem 817 
resistance 76 but is usually integron associated. IMP-9, another MBL is as common as 818 
VIM in China 77, and has been shown to be derived (as probably are many 819 
carbapenemase genes) from environmental bacteria by horizontal gene transfer 78. 820 
Multi-drug resistance is also a major problem in P. aeruginosa from cystic fibrosis (CF), 821 
with resistance increasing over time in the individual patient’s lung microflora. Multi-822 
drug resistance profiles are extremely variable even within widely successful CF 823 
lineages, e.g. the Liverpool Epidemic Strain, which has circulated in multiple CF patients 824 
and units. Rates of carbapenem-resistance in P. aeruginosa vary greatly across Europe, 825 
with high rates in Eastern Europe – Lithuania, Poland, Slovakia, Hungary, Croatia, 826 
Romania, Bulgaria and Greece all having rates of resistance >25% and sometimes 827 
>50%)40.  More generally, these rates of resistance show a gradient, rising from NW to 828 
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SE Europe, with extensive spread of carbapenemase-producing clones in Belarus, 829 
Kazakhstan and Russia, which are outside the EU surveillance area. 79 In contrast to 830 
Enterobacteriaceae rates of resistance to carbapenem are generally higher than those to 831 
ceftazidime, piperacillin/tazobactam or aminoglycosides. 832 
6.5 Prevalence of antibiotic resistance in Gram-negative bacilli in the UK and 833 
relevant antibiotic prescribing 834 
There are no epidemiological reports in the UK that specifically study defined MDR GNB. 835 
In this section, we discuss information on resistance to individual antibiotics and, where 836 
available, their associated resistances. Analysis is complex. Different reports from 837 
English, Welsh, Northern Irish and Scottish devolved administrations need drawing 838 
together to give a UK summary: bacteria and antibiotic resistances do not respect 839 
national boundaries.  840 
Reduced prescribing may be followed by reduced resistance (See 11.1) but this is not 841 
invariable at a national level. Such reduced resistance has not occurred as older 842 
antibiotics (e.g. sulphonamides and streptomycin) have been abandoned 80, perhaps 843 
because of resistance linkage and for reasons already discussed in (See 6.3.) Reduced 844 
prescribing may reduce the likelihood of new resistance becoming prevalent but this is 845 
only a hypothesis set within the modern issues of travel and migration, which may 846 
import and spread resistance. Overall antibiotic consumption in England has fallen by 847 
4.5% between 2012 and 2015 to 21.8 DDD/1000 population/day. It has yet to decline in 848 
general practice to the levels seen in 2010. After 5 years of increases in prescribing, 849 
hospital antibiotic use declined by 5% in 2014 from 5190 to 4933 DDD/1000 850 
admissions and is now at approximately 2010 and 2011 levels. This decrease is 851 
concentrated in teaching hospitals which may reflect their case-mix or different 852 
pressures in other hospitals 4 . 853 
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In Scotland antibiotic use in primary care fell for the third consecutive year in 2015 (by 854 
2.4%) and is now 9.5% lower than the peak rate of use in 2012. The level of prescribing 855 
was related to population deprivation scores and to residence in nursing homes where 856 
antibiotic use among those aged over 65 years was 83% than for similarly-aged patients 857 
not resident in nursing homes81. Since 2012, antibiotic use in Scottish nursing homes 858 
has fallen by 7.8% compared with 5.1% in all patients aged >65 years. Nevertheless, 859 
hospital use rose by 3.5% and is now 9.9% higher than it was in 2012. The rate of 5880 860 
DDDs/1000 admissions is now 19% higher than in England81. Of course, this may reflect 861 
use of less selective combination regimens such as penicillin, metronidazole and 862 
gentamicin rather than the number of days a patient receives antibiotics which is a 863 
weakness both of using Defined Daily Doses and the number of admission to estimate 864 
the number of people exposed to an individual antibiotic. Although England has the 865 
lowest antibiotic consumption in the UK, Scottish hospitals show significantly less 866 
consumption of carbapenems and piperacillin/tazobactam. 867 
Information on primary and secondary care prescribing for Wales for 2015 82, 83 is only 868 
available at the level of health board and hospital respectively, and has not been 869 
reported as aggregate totals .  870 
An overview of current antibiotic-resistance in Gram-negative serious infections in the 871 
UK can be secured in various ways. The BSAC Bacteraemia Surveillance Programme 872 
(http://www.bsacsurv.org) provides historical and current information with a marked 873 
time lag for centrally-tested isolates from a restricted sample of 24-40 hospitals and can 874 
be examined on a national or regional basis by species. It has an archive of organisms 875 
that can be studied in retrospect, which is an important strength. Other surveillance 876 
depends on collection of local data rather than isolates. In England reporting is 877 
mandatory for all cases of E. coli bacteraemia with an improvement in case 878 
ascertainment. However mandatory data are needed for Klebsiella, other 879 
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Enterobacteriaceae and Proteeae, Acinetobacter spp. and P. aeruginosa if early national 880 
interventions in emerging problems are to be reliably detected. Mandatory reporting of 881 
MRSA bacteraemia in England was established in 2001 and has improved with more 882 
comprehensive data capture from 2005 onwards. Health Protection Scotland now has 883 
mandatory reporting of E. coli bacteraemia but other species of Gram negative bacilli 884 
are only reported across the UK on a voluntary basis. Such voluntary laboratory 885 
reporting of all bacteraemias has been in place since the Devonport incident of 886 
contaminated intravenous infusions in 1972 and is believed now to capture data for 887 
82% of all bacteraemias. This data includes antibiotic susceptibility data which has not 888 
been present in mandatory data. The collection of voluntary and mandatory data 889 
suggests that voluntary reporting should be replaced by mandatory reporting as soon as 890 
possible to reduce the laboratory workload. Most laboratories in England and Wales 891 
examining human samples now download bacteria identified and their antibiotic 892 
susceptibilities irrespective of anatomical site to regional and national repositories 893 
where trends but not additional information e.g. demographic details of patients’ 894 
residence etc. can be analysed.  895 
Bacteraemia due to E. coli has increased over the last ten years in England and Wales, 896 
and analysis of the data-set showed that receipt of antibiotics in the 4 weeks preceding 897 
bacteraemia was the most important risk factor, followed by age over 65 years, and 898 
occurrence during summer months84 A study by the E. coli subgroup of the UKs DH 899 
Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcarel 900 
Associated Infection on the first 891 cases of E coli bacteraemia with enhanced 901 
surveillance data are available in Committee papers for 28 March  2014 on line 85. This 902 
showed that urinary catherisation was a factor in only 10% of cases but that in 72% of 903 
episodes  from a urogenital source involved  individuals aged >=65 years. A urogenital 904 
infection had been treated in 310/891 (34.8%) cases in the 4 weeks preceding 905 
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bacteraemia and this sub-population differed very significantly in its antibiotic 906 
resistances. Resistance in this subpopulation to ciprofloxacin was 80% vs. 17% overall, 907 
76.9% vs. 39% to trimethoprim, and 49.3% vs. 45% to co-amoxiclav. The 3rd generation 908 
cephalosporin resistance rate in the population overall was 10% but no figure was 909 
provided  for the resistance rate in this sub-population treated. Although the rates for 910 
ciprofloxacin seem surprising, the figures show a marked selection for multiply 911 
resistant, if not necessarily MDR, strains because of either failed treatment that did not 912 
cover the multi-resistant organisms or selection of resistant organisms in the gut flora 913 
that subsequently caused a urinary infection which then progressed to bacteraemia. 914 
Approximately half of the bacteraemias appeared to be associated only with a lower UTI 915 
but this probably represents symptomatically silent upper UTI giving rise to 916 
bacteraemia, either initially, or through spread to the upper tract despite treatment. The 917 
implication of this important study is that failure to give effective antibiotics may be the 918 
reason for 70% of E. coli bacteraemias whilst 30% of cases are associated with 919 
antibiotic resistance and, possibly, directly with treatment failure. The former requires 920 
detailed study which is beyond the scope of this guideline. The consistent use of an 921 
active antibiotic regimen for those either aged over 65 years or with signs and 922 
symptoms of an upper UTI, would make a sizeable contribution to the target of a 50% 923 
reduction in  the rate of in E. coli bacteraemias by 2020 that was announced as a target 924 
by the then UK Prime Minister at the Japan 2016 G7 meeting 86. This enhanced 925 
surveillance study has now been analysed and published87. Most patients (69.6%) were 926 
aged over 65 years. Most patients (68.3%) had a positive blood culture taken within 24 927 
hours of admission but 46.7% of these had a healthcare exposure within the previous 928 
month and 546 out of these 930 (58.7% of this subgroup, 31.5% overall) had received 929 
antibiotics in te orededing month, In 281 there was a clear urinary focus for the 930 
bacteraemia for which 145 had received antibiotics (most commonly trimethoprim or 931 
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co-amoxiclav). The largest independent risk factor for a bacteraemia’s focus being the 932 
urogenital tract was previous treatment for UTI within 4 weeks of the bacteraemia’s 933 
onset (adjusted Odds Ratio:10.7&(95% CI 3.6-8.1) but details of antibiotic resistance in 934 
this subpopulation for the whole study was not given. Twenty one per cent of patients 935 
had either a urinary catheter in situ or had one inserted, removed or manipulated in the 936 
previous 7 days.  Since the 2014 initial report, Public Health England has changed its 937 
recommendation for first line treatment of UTI in all but those under 50 years from 938 
trimethoprim to nitrofurantoin which is a urinary antiseptic that is only effective for 939 
treating lower UTI although it can be effective for preventing pyelonephritis associated 940 
with bacteriuria of pregnancy. It is too early to tell whether this will be effective in 941 
reducing bacteraemia or whether an oral combination regimen that attains systemically 942 
active concentrations will be necessary to achieve the desired outcome. APRHAI (The 943 
UK Advisory Committee on Antimicrobial Prescribing, Resistance, and Healthcare 944 
Associated Infection) on 28th March 2014 opined that in suspected pyelonephritis or 945 
upper UTI, the patient should be admitted if a) ciprofloxacin, piperacillin/tazobactam or 946 
co-amoxiclav had been used in the previous 2 months and b) the patient’s symptoms 947 
worsened or did not improve in the 12-48 hours after prescription.  In UK strains of E. 948 
coli ST131from various sources collected in 2011-2, when O16 and non- typeable 949 
strains are excluded, there is evidence that trimethoprim resistance occurs in at least 950 
69% of CTX-M positive strains which comprised 32% of recent UK strains studied but 951 
39%, at most, of CTX-M-negative strains 88. All CTX-M producers were ciprofloxacin 952 
resistant and 71% of non-CTX-M producers were quinolone resistant. Quinolones are 953 
not therefore useful if ST131 strains are prevalent even if these strains are not ESBLs. 954 
A study reported that sequence typed E. coli isolates from the BSAC Bacteraemia 955 
Surveillance Programme showed that the significant change in E. coli bacteraemia was 956 
almost exclusively due to an increase in clonal complexes 12, 69, 73, 95 and 13184. This 957 
Accepted manuscript 38 
reflects the sequence types in these clonal complexes. The clonal complexes, which each 958 
may contain more than one sequence type, belong to phylogroups B2 and D that have 959 
the virulence factors associated with extraintestinal spread. Phylogroup A and B1 960 
strains, which may be more antibiotic resistant are usually confined to the gut and lack 961 
these virulence factors. Clonal Complex 131 unlike the other clonal complexes includes 962 
multi-resistant isolates (of ST131) hosting CTX-M ESBLS with almost invariably now, 963 
resistance to quinolones 84. In a 2010-2012 Yorkshire study of bacteraemias 129/768, 964 
39/129 ESBL producers, were ST131 confirming the importance of ST131 strains even 965 
in the absence of production of ESBLs. 142/768 were ST73 (3/142ESBL producers), 81 966 
were ST69 (1 an ESBL producer), 73 were ST95 (1 an ESBL producer), 31 were ST12 967 
(no ESBL producer, quinolone-resistant), 27 ST127 (no ESBL producers or quinolone-968 
resistant strains) 89. Phylogroup D-ST69 strains (which include the previously 969 
designated clonal group A) were not fluoroquinolone-resistant in a recent Italian 970 
study90 although they were commonly detected in Italy in a previous cystitis study 91. 971 
ST69 is usually ampicillin, trimethoprim and suphamethoxazole resistant. Quinolone-972 
resistant D-ST69 strains were also uncommon in a Spanish survey with isolates from 973 
2009 accounting for 3% of quinolone-resistant strains respectively, compared with 26% 974 
for O25:H4-B2 ST131 strains 92. We did not consider it feasible to introduce control 975 
measures for ST131 when preparing our earlier guidance on infection control3 and 976 
indeed cephalosporin resistance has spread into many other STs 93. 977 
More recent data from 2012 to 2014 on antibiotic resistance in E. coli bacteraemia in 978 
England were collected on 82% (54,301/66,512) of cases recorded by mandatory 979 
surveillance by record-linking with the national records of all bacterial isolates.  74% 980 
were classified as community onset whereas 16% of cases occurred 7 or more days 981 
after hospital admission. Antibiotic resistances reported were 8439(18.4%) to 982 
ciprofloxacin, 4256 (10.4%) to third generation cephalosporin, 4694 (10.2%) to 983 
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piperacillin/tazobactam, 4770 (9.7%) to gentamicin and 91 (0.2%) to carbapenems94 . 984 
Non-susceptibility to quinolones and cephalosporins decreased by 10% and 11% 985 
respectively over the two years in hospital onset cases whereas third-generation 986 
cephalosporin resistance increased by 10% in community onset cases. Trends in 987 
hospital or community onset changes in antibiotic susceptibility in other species such as 988 
Klebsiella are precluded by lack of mandatory surveillance of bacteraemia.  989 
A 12 year single centre-study in England suggested that the increase in E. coli 990 
bacteraemias was essentially confined to ciprofloxacin, co-amoxiclav, cefotaxime and 991 
aminoglycoside resistance and accompanied a similar change in urinary isolates95. The 992 
major rise in cephalosporin and multi-drug resistant E. coli in the UK occurred between 993 
2000 and 2007 largely reflecting the spread of IncF (pEK499 or similar) plasmids, and 994 
was associated initially with the internationally-successful E. coli ST131 lineage with 995 
chromosomal fluoroquinolone resistance. These IncF plasmids encoding the CTX-M-15 996 
β-lactamase, along with resistances to trimethoprim, sulphonamides, tetracyclines and 997 
aminoglycosides (often associated with aac(6’)-Ib –cr also augmenting ciprofloxacin 998 
resistance) also spread in other E. coli Sequence types and other Enterobacteriaceae 999 
notably K. pneumoniae. Since approximately 2007 (the date varies with the species and 1000 
resistance) the rise of cephalosporin- and fluoroquinolone-resistant Enterobacteriaceae 1001 
has slowed and fluctuated (E. coli) or reversed (Klebsiella spp. and Enterobacter spp.) in 1002 
the UK, though not in continental Europe 96 . This shift in percentage resistance may 1003 
reflect the reduction in prescribing of cephalosporins and quinolones in the UK, 1004 
predicated not only by the Enterobacteriaceae problem but also by concern about 1005 
Clostridium difficile. It is important to know if this reflects an absolute decrease in 1006 
numbers. Some data suggests that increased quinolone use largely mirrored the 1007 
selection of such strains 97. An increase in quinolone resistance in bacteraemias 1008 
preceded the arrival of ESBL-producing strains. Cephalosporin use in England is now 1009 
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reported to be the lowest in Europe 4, 98. Cephalosporin usage fell by a further 9.2% 1010 
between 2012 and 2015 following larger previous declines from a peak in 2006-7 1011 
because of the national C. difficile problems. From 2012-5, oral cephalexin use fell by 1012 
25.7% but parenteral cefotaxime use by only 1.6%, whilst parenteral ceftriaxone use 1013 
increased by 37.4% probably reflecting use of this once daily antibiotic in outpatient 1014 
parenteral antibiotic therapy 4. The microbiological need for preferring this broad-1015 
spectrum agent to teicoplanin or daptomycin, which are only active against Gram-1016 
positive bacteria, should be critically reassessed.  1017 
General practice quinolone use in terms of DDDs/1000 inhabitants/day has fallen 1018 
consistently since 2012 reducing by 3.6% between 2014 and 2015. However the 1019 
national overall usage of ciprofloxacin has declined only slightly from approximately 1020 
0.48 DDDs/1000 inhabitants/day in 2012 to 0.43 in 2015: quinolone use in hospitals 1021 
has increased despite an 18.4% incidence of ciprofloxacin resistance in E. coli 1022 
bacteraemia94. A 53.6% rise in the respiratory quinolone levofloxacin which is the L 1023 
isomer of ofloxacin seems unjustifiable but reflects a recommendation for use in 1024 
penicillin-allergic patients with pneumonia. A similar increase (50.3%) was seen in 1025 
Scotland accompanied by a 17% increase in ofloxacin use. An English target of a 10% 1026 
reduction on 2013-4 levels of cephalosporin, quinolone ,and co-amoxiclav use in 1027 
primary care or a reduction in use to be below the 2013-4 median value(11.3%) of 1028 
Clinical Commissioning Groups (CCGs) for antibiotic prescribing of these agents, was 1029 
achieved in 189/209 CCGs 4. Prescribing of these antibiotics is substantially lower in 1030 
Scotland and is not the subject of targets. Scottish reductions in primary care use in 1031 
2015 were 4.9% for co-amoxiclav, 5.8% for fluoroquinolones, and 6.0% for 1032 
cephalosporins, with an 8% overall reduction in use81.  1033 
Despite these reductions, cephalosporin and quinolone resistances continues to be seen 1034 
frequently in UK bloodstream and urinary E. coli and K. pneumoniae isolates, with 1035 
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significant circulation in older patients who move between hospitals, nursing homes, 1036 
and the community and who have frequent exposure to cross-infection and antibiotics. 1037 
Resistance to both quinolones and third generation cephalosporins in E. coli 1038 
bacteraemias is concentrated in those aged over 65 years and over and in England is at 1039 
least twice as prevalent in those aged over 74 years compared with those aged 65 to 74 1040 
years 4. An Italian scoring system for carriage of ESBL-producing organisms has not 1041 
been tested in the UK or modeled to see if the group of patients at risk of carrying these 1042 
strains on admission to hospital is increasing 99.  1043 
The total number of E. coli bacteraemias in England and therefore the absolute burden 1044 
of resistance , continues to rise – by 4.6% from 35659 to 37310 between 2014 and 2015 1045 
in England 4. The same publication notes an increase in Klebsiella bacteraemias by 9% 1046 
over the same period. Over the period from 2000 to 2014 the incidence of E. coli 1047 
bacteraemia in England has risen inexorably from 20 to 50 cases/100,000 population 94.  1048 
In England, rates of resistance to piperacillin/tazobactam are said to have increased in 1049 
E. coli bacteraemias from 8.5% to 11.7% and in Klebsiella ssp. bacteraemias from 12.6% 1050 
to 18.5% over the period from 2011 to 2015 4. Equivalent rises in resistance to co-1051 
amoxiclav from 31% to 42% in E. coli bacteraemias and 18.7% to 28.2% in Klebsiella 1052 
spp. bacteraemias over the same period have occurred.  1053 
Record linkage for E. coli bacteraemias between 2012 and 2014 showed 1054 
piperacillin/tazobactam resistance increasing by 15.1% for hospital onset cases 1055 
compared with 8.7% for community-onset cases94. This study also revealed significant 1056 
variations in resistance rates by age and sex. Similar trends were seen in Scotland with 1057 
an 8.6% increase for piperacillin tazobactam resistance and 6.1% for co-amoxiclav 1058 
resistance in E. coli bloodstream isolates and 14.8% and 28.7% respectively in Klebsiella 1059 
sp. in 2015. Changes from CLSI to EUCAST criteria may have produced these large rises 1060 
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in resistance in Scotland (See 6.2.) but there were no changes in EUCAST criteria for 1061 
these antibiotics between 2013 and 2015 81 and in England few laboratories use CLSI 1062 
criteria In Wales 11/18 hospitals in 2015 recorded an increase in 1063 
piperacillin/tazobactam resistance in E. coli in 2015100. In England 1064 
piperacillin/tazobactam use rose linearly by 62% between 2010 and 2015 to 135 1065 
DDD/1000 admissions across all hospital types 4. In Scotland, use fell by 7.9% in 201581.  1066 
These changes are important. The main antibiotics used in a recent prospective study in 1067 
10 English hospitals of treatment of Gram negative bacteraemia were co-amoxiclav in 1068 
32% of patients and piperacillin/tazobactam in 34% 101. Despite empirical therapy 1069 
being inactive against responsible organisms based on in vitro tests in 34% of cases, all-1070 
cause mortality was said to be low, 8% assessed at 7 days and 15% at 30 days. Given the 1071 
increasing resistance rates and use, explorations of comparative outcome in relation to 1072 
resistance and use are needed at each national level and also by source of infection (See 1073 
11.2). Mortality in E. coli bacteraemia throughout England was measured between July 1074 
2011 and June 2012 as 18.2% at 30 days or 10.34/100,000 population in 1 year. These 1075 
data were derived by record linkage of E coli bacteraemia cases mandatorily reported to 1076 
Public Health England; voluntary reporting of antibiotic susceptibilities on all isolates to 1077 
Public Health England, and records at the Office for National Statistics Death 1078 
Registrations and at the NHS Spine. 102 Mortality is high as compared with Finland (8%), 1079 
and inpatient only mortality in Canada (11%), and New Zealand (9%). Analysis showed 1080 
important associated features: 30% of deaths occurred on, or on the day after, the blood 1081 
sample was taken and 76.3% within 14 days making the separate mortality analysis of 1082 
community-onset and hospital-onset bacteraemia important. Overall 19,174/26216 1083 
(73.1%) patients had their bacteraemia recorded within 1 day of admission. Mortality 1084 
was higher (34.0%) if a respiratory focus of infection was diagnosed or the focus of 1085 
infection was unknown (25.9%) than if a urogenital focus was diagnosed (13.2%). No 1086 
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information was available on the antibiotics prescribed precluding any test of whether 1087 
higher mortality was correlated with failure to provide adequate Gram-negative cover 1088 
in suspected respiratory or unknown foci of infection; moreover, there was no audit 1089 
data to show if the reported foci of infection was supported by evidence. A recent audit 1090 
of coding and diagnosis of pneumonia by the British Thoracic Society did not support 1091 
the diagnosis in 15.8% of cases and noted a 14.3% rate of mortality in this group 103. At 1092 
a population level the high burden of urogenital-related infection for E. coli was such as 1093 
to make this the largest cause of deaths, even though mortality in this group was lower. 1094 
The lower rate of mortality with urogenital infection correlates with information in an 1095 
earlier study which showed that the excess mortality for bacteraemia with ESBL-1096 
producting Enterobacteriaceae was confined to non-urinary infections 104. The study by 1097 
Abernethy and colleagues102 identified a urogenital source for 55.3% of community-1098 
onset cases of bacteraemia and 45.1% of healthcare-onset cases. In 17.3% of cases the 1099 
source was unknown. Mortality was lowest in those aged 1 to 44 years (5.4%) versus 1100 
those aged 45-84 (17.9%) and >85 years (25.2%). Mortality rates varied by the 1101 
susceptibility of the isolated causative bacterium; ciprofloxacin S 17.0% (95%CI 16.4% -1102 
17.5%), ciprofloxacin I or R 21.9% (95%CI 20.5%-23.2%); cephalosporin S 17.5% 1103 
(95%CI 16.9%-18.1%), cephalosporin I or R 21.3% (95%CI 19.4%-23.2%). The 1104 
inclusion of a factor in the adjusted model to allow for hospital and case mix related 1105 
mortality eliminated any significance to the difference in mortality by cephalosporin 1106 
susceptibility.  Cephalosporins are unlikely to have been used in infections due to ESBL-1107 
producing organisms in England, but piperacillin/tazobactam may have been used and 1108 
the absence of a difference in mortality may reflect some improved outcome in urinary 1109 
infection, despite the presence of bacteraemia. Different cephalosporins are not equally 1110 
associated with C. difficile 105. Oral first generation cephalosporins would be useful in 1111 
early treatment. It might be appropriate, whilst keeping C. difficile under review, to 1112 
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abandon downward pressure on the whole class of antibiotics and introduce a 1113 
cephalosporin-specific approach. There were no data on mortality in relation to 1114 
susceptibility to piperacillin/tazobactam-, co-amoxiclav-, or aminoglycosides: 1115 
carbapenem-resistance rates were too low for robust assessment.  1116 
Resistance to any one of quinolones, cephalosporins or carbapenems was associated 1117 
with a 30% increase in mortality. The association of increased mortality in quinolone-1118 
resistant strains needs explanation and it is not clear if this relates to hospital case-mix. 1119 
Furthermore, if reduced use of oral quinolones is attempted, care is needed in the 1120 
controversial area of prophylaxis in neutropenia where quinolones are widely used. 1121 
Studies of withdrawing quinolones for this indication show an increase in Gram 1122 
negative bacteraemia with susceptible strains without any diminution at least initially 1123 
in resistant strains 106-108 and recent Cochrane reviews support the efficacy of quinolone 1124 
prophylaxis109, 110.  1125 
Rates of carbapenemase-production by Enterobacteriaceae (<2%) remain low in the UK 1126 
but reference laboratory submissions of these organisms are growing annually (Figure 1127 
2), with many of the isolates coming from clinical rather than screening samples. It is 1128 
noteworthy that surveillance of carbapenem-resistant strains depends on voluntary 1129 
submission to reference laboratories and that regional molecular testing necessary for 1130 
rapid turnaround has not been converted into national surveillance 4. Given the 1131 
importance of reducing carbapenem resistance, consideration should be given to 1132 
introducing mandatory reporting of all isolates of carbapenem-resistant 1133 
Enterobacteriaceae so the evolving picture can be properly assessed  English data 1134 
suggests the proportion of carbapenem-resistant Klebsiella sp. rose from 0.2% to 1.1% 1135 
between 2011 and 2015 4. There are pockets of local endemicity, especially of K. 1136 
pneumoniae and other Enterobacteriaceae with KPC enzymes around Manchester or 1137 
with VIM and OXA-48 in north Cheshire. These have persisted for 5-6 years (D.M. 1138 
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Livermore, unpublished data). Many other sites, notably London teaching hospitals, are 1139 
currently being repeatedly challenged with a diversity of carbapenemase producers, 1140 
many imported from overseas. Clonal complex 258 K. pneumoniae with KPC 1141 
carbapenemase remains rare in the UK, despite repeated introduction, and the greater 1142 
issue, particularly in NW England is dissemination of plasmids encoding KPC 1143 
carbapenemases among different K. pneumoniae and Enterobacteriaceae. Carbapenem-1144 
resistant isolates submitted to reference laboratories in Scotland increased from 47 in 1145 
2014 to 63 in 201581.The dual loss of both quinolone and cephalosporin susceptibility 1146 
has driven increased usage of carbapenems particularly meropenem from some 75 1147 
DDD/1000 admissions in 2010 to 104 DDD/1000 admissions in 2015 in England, a 1148 
38.6% increase, but in 2015 the increase was only 1%4, 81. In Scotland the picture is 1149 
different, there was a 6.5% increase in use of carbapenems between 2014 and 2015 but 1150 
this is now only 9.3% higher than in 2012. 1151 
Phenotypic information on aminoglycoside susceptibility is available. Frequent 1152 
gentamicin-resistance was noted in ESBL-producing strains of E. coli from all sites in 1153 
one region, representative of the UK, with resistance rates of 48.7% for E. coli ST131 1154 
and 55.1% for E. coli non-ST131 93. The record linkage data previously discussed shows 1155 
that overall gentamicin-resistance rates (i.e. irrespective of ESBL production) varied by 1156 
region between 5.5% and 15.4% in the years 2012 to 2014 and that the overall rate in 1157 
community-onset cases was 8.6%94. The region with lowest rate of resistance had a 1158 
34% higher incidence of E. coli bacteraemias than that with the highest rates, which 1159 
suggests the possibility of dilution of the denominator by an increase in more 1160 
susceptible bacteraemias (e.g.ST73 in northern England). In Wales in 2015 only 5/18 1161 
hospitals reported gentamicin resistance rates less than 8.6% in E. coli bacteraemia and 1162 
two had rates over 20% 100. Rates of 8.6% to 15% would seem too high for empirical use 1163 
of gentamicin alone. However, the 8.6% rate of gentamicin resistance in community 1164 
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onset bacteraemia is very similar to the 8.7% resistance rate to piperacillin/tazobactam 1165 
which is widely used alone 94. National data on amikacin are hard to interpret because 1166 
fewer laboratories test it as well as gentamicin and the amount of testing that is second 1167 
line because of resistance on first line testing remains unresolved, potentially skewing 1168 
the data Nevertheless, as expected, amikacin resistance is rarer than gentamicin 1169 
resistance (2% in 2015) in England4.  1170 
Rates of co-resistance in bacteraemia isolates for 2015 for gentamicin and third 1171 
generation cephalosporins were 4.6% for E. coli and 5.9% for Klebsiella sp. compared 1172 
with resistance rates to third-generation cephalosporins alone of 7.5% and 5.2% 1173 
suggesting some useful activity for gentamicin against ESBL-producing E. coli but less 1174 
against ESBL-producing Klebsiella sp. Rates of co-resistance in bacteraemia isolates for 1175 
2015 to gentamicin with co-amoxiclav are 7.8% in both E. coli and Klebsiella sp. 1176 
compared with resistance rates to co-amoxiclav alone of 35.2% and 19.3% 4. This 1177 
confirms the potential utility of an aminoglycoside compared with co-amoxiclav alone 1178 
for both E. coli and Klebsiella spp. bacteraemias. The same data source indicates a 1179 
somewhat different situation with ciprofloxacin-gentamicin combinations. For E coli 1180 
and Klebsiella spp. rates of co-resistance were respectively 6.8% and 5.8% whereas 1181 
resistance to ciprofloxacin alone occurred in 11.8% and 5.0% suggesting that addition 1182 
of an aminoglycoside was seldom advantageous in Klebsiella infection. Overall this co-1183 
resistance data4 suggests only a modest improvement on gentamicin monotherapy and 1184 
the benefit compared with the harm of continuing selection of resistance by the non-1185 
aminoglycoside may not be great.  1186 
Consumption of aminoglycosides is now low in England in hospital inpatients 1187 
(approximately 0.08 DDD/1000 population/day) and fell in 2015. By contrast use rose 1188 
in Scotland by 5.9% becoming 16.9% more frequent than in 2012. Falls in use are likely 1189 
to reflect concern about resistance in ESBL-producers and about potential toxicity; they 1190 
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may also reflect a change in clinical contacts with microbiologists as antibiotic assays 1191 
are increasingly undertaken by clinical chemistry departments. A comparison with 1192 
Scotland to understand the differences would be informative.  1193 
Bacteraemia represents a group of community infections selected for virulence factors 1194 
sometimes but not always by antibiotics. Antibiotic resistance in Gram-negative 1195 
infections in the community was thought, even a decade ago, to be quite uncommon in 1196 
the UK. A historical European study of acute, community-acquired, uncomplicated, non-1197 
recurrent UTI in 2008 caused by E. coli involved 12 GP practices in the UK and enrolled 1198 
200 unselected women aged 18-65 years. Resistance was rare to mecillinam (1%), 1199 
nitrofurantoin (0%), fosfomycin (0.5%) amoxicillin/clavulanic acid (2.0%) and 1200 
ciprofloxacin (0.5%), but commoner to amoxicillin (32%), sulfamethoxazole (26%), 1201 
trimethoprim (15%) and trimethoprim/sulfamethoxazole (14%) 111. In this survey the 1202 
co-amoxiclav resistance rate seems low in relation to the amoxicillin resistance rate. 1203 
Reported resistance rates to co-amoxiclav in lower urinary infections have increased 1204 
since the time of this study partly because of the substitution of EUCAST’s (32+2mg/L) 1205 
breakpoint for the previous BSAC (16+8mg/L) value. A contemporaneous UK study with 1206 
a large community sample reported 12.0% resistance to co-amoxiclav versus 54% for 1207 
ampicillin 112. Welsh data in 2014 reports the following resistance rates in “coliforms” 1208 
from urine in different communities:: co-amoxiclav 12.9% (Range:5.1% to 25.4%) , 1209 
third-generation cephalosporin (ESBL) 6.8% (Range 3.3% to 17.9%), nitrofurantoin 1210 
10.0% (range 8.7% to 22.4%), trimethoprim 36.7% (Range:30.3 to 41.8%) and 1211 
fluoroquinolone 10% (range 7.6% to 16.4% 113. A 2010-3 large UK study 114 of all 1212 
community urinary isolates from a UK region with a population of 5.6 million found that 1213 
by 2013 resistance to third generation cephalosporins in E. coli had risen to 5.5% and 1214 
ciprofloxacin resistance to 15.5%; for Klebsiella spp. the cephalosporin resistance rate 1215 
was higher at 10.1%. Only 0.06% of the E. coli isolates were reported as resistant to one 1216 
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or more carbapenems as were 0.32% of the Klebsiella spp. isolates. In this regional 1217 
survey, VIM enzymes were found in Pseudomonas spp. whereas among E. coli and 1218 
Klebsiella spp., 16 had NDM genes, 5 KPC and 2 OXA-48. These findings support the view 1219 
that carbapenemases are rare in the community in the UK. A further study of isolates in 1220 
the same English region over the period 2007-2014 showed, after deduplication 69 with 1221 
blaNDM, 26 with blaKPC, 16 with blaOXA-48-like, and 7 with blaVIM115 . 1222 
A historical audit of urine samples taken at presentation from primary and secondary 1223 
care in South London before the widest dissemination of ESBL positive E. coli ST131 1224 
occurred, found that 22.6% of isolates were resistant to trimethoprim, 43.3% to 1225 
amoxicillin, and 10.3% nitrofurantoin 116. Since this audit resistance to trimethoprim 1226 
has slowly risen across the UK, and in Wales is significantly commoner in isolates from 1227 
patients over 65 years. Trimethoprim resistance rates vary widely by CCG in England. In 1228 
2011 it ranged in these from 16.3% to 66.7% but by 2015 86% showed >25% 1229 
resistance with an almost uniform median of 29% in CCGs 4, 82. The reason for these 1230 
variations in a minority of CCGs remains uncertain. In Wales resistance rates of 38.2% 1231 
overall are currently reported. A caveat is that high resistance rates may reflect 1232 
selective testing of previously treated patients in the community and different local 1233 
policies for submitting samples, and the true rate of resistance to trimethoprim in 1234 
patients presenting in the community with uncomplicated UTI may be lower than 1235 
current figures suggest 117. Trimethoprim use in England fell by 14.5% between 2014 1236 
and 2015 reversing the increase seen between 2012 and 2014. This fall should be many 1237 
times larger in 2016 if there is expeditious compliance with the Public Health England 1238 
recommendation in 2014 to substitute nitrofurantoin for trimethoprim as the first line 1239 
antimicrobial for cystitis in the older patient. A Swedish trimethoprim-sparing switch in 1240 
one region resulted in an 86% decline in trimethoprim use between 2004 and 2006 118. 1241 
In 2015 in England rates of trimethoprim prescribing were approximately 1242 
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1.1DDDs/1000 population/day compared with 0.8DDDs/1000 population for 1243 
nitrofurantoin4.  1244 
UK data on resistance to nitrofurantoin, fosfomycin and mecillinam is scanty. In a single 1245 
centre study nitrofurantoin resistance was commoner in Klebsiella spp. of community 1246 
origin (around 15%) than E. coli (3%) 119. English national data for the 2nd quarter  of 1247 
2016 suggests resistance in E. coli in community UTIs varied with CCG between 0.3% 1248 
and 12.8% with a median of 3.8% 4 whilst in Scotland, 5.9% of isolates tested in 2015 1249 
showed nitrofurantoin resistance81.  Nitrofurantoin resistance is also common in UK 1250 
CPE isolates120. Proteeae are inherently resistant to nitrofurantoin and data on their 1251 
prevalence in UTI and resistance linkage for nitrofurantoin resistance in England is 1252 
needed given the recommendation to use this antimicrobial first-line (See 9.1 for 1253 
previous experience of changes in prevalent phylogroups and STs of E. coli). There are 1254 
no recent data on fosfomycin resistance in the UK. A survey of fosfomycin resistance in 1255 
Leeds found fosA in 2 urinary tract isolates collected months after its UK introduction in 1256 
1994 despite a lack of use in the study hospital 121. In the same publication, a study of 1257 
foods in Leeds in 1995 identified 2 Enterobacteriaceae isolates carrying fosA in 1258 
vegetables imported from Spain. Fosfomycin resistance (MIC>=64mg/L was present in 1259 
32/81 strains of CPE in 2011; 27 of these were Klebsiella spp. 120. In Wales, only 6.2% of 1260 
cefpodoxime-resistant E coli (i.e. probably ESBL- and AmpC-producing strains) were 1261 
apparently resistant to mecillinam 122 but this is discussed further later in the article 1262 
(See 9.4.).  1263 
The impact of the successful clone ST131 clone of E. coli on multiple resistances has 1264 
been assessed. In one 2011 UK study, resistance rates in ESBL-producing E. coli ST131 1265 
(mostly with CTX-M-15 enzyme) compared with non ST131 (producing CTX-M-15 or 1266 
CTX-M-14) were respectively 99% versus 83% respectively for ciprofloxacin, and 92% 1267 
vs. 86% for trimethoprim 93. Fluoroquinolone resistance alleles gyrA/B and parC are 1268 
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characteristic on whole genome sequencing of the Clade C of E. coli ST131, which is 1269 
almost exclusively the clade carrying CTX-M ESBLs 29.  1270 
There is no reliable information on acquired colistin resistance. Usage sharply increased 1271 
by 30% between 2013 and 2015 in England , entirely in specialist and teaching 1272 
hospitals4. Given i)the growing use of colistin as a drug of last resort, ii) the prevalence 1273 
of colistin resistance in KPC-producing Klebsiella pneumoniae, especially in Italy, but 1274 
also in the USA. iii) the lack of mandatory surveillance of Klebsiella sp. and iv) the 1275 
recognition of plasmid-mediated colistin resistance due to mcr1 and mcr2, there is an 1276 
urgent need for enhanced surveillance of colistin resistance at a national level 4. Mcr-1 1277 
has been isolated from British pigs 123 but is widespread in the European food chain 1278 
including additionally turkeys and veal calves 124 and mcr-2 has been found in pork and 1279 
cattle products 125. 1280 
6.6 What impact have returning travelers made on UK epidemiology? 1281 
Whilst mutational resistances often emerge locally, strains with acquired resistance 1282 
genes are often clearly imported to the UK from other countries. Examples include 1283 
multi-drug resistant K. pneumoniae with OXA-48 carbapenemases with Libyan conflict 1284 
casualties and with patient transfers from elsewhere in the Middle East; K. pneumoniae 1285 
with KPC carbapenemases from Greece, and Israel and, also most significantly, 1286 
Enterobacteriaceae with the NDM MBL, from south Asia and China 126.  Colonisation of 1287 
travellers may be frequent, although precise rates are largely unknown. A systematic 1288 
review confirms travel to certain areas is a significant risk factor 127. Most data concerns 1289 
ESBL-producing strains and there is a notable dearth of information on other important 1290 
resistances including aminoglycosides, carbapenems, colistin, and fosfomycin. 1291 
Nevertheless an Australian study suggests that travel associated aminoglycoside- and 1292 
quinolone- resistance may be even commoner than travel associated cephalosporin 1293 
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resistance 128. Interestingly prolonged carriage was significantly associated with the 1294 
pathogenic phylogroups B2 and D rather than A and B1 but strains of ST131 were rare 1295 
even with Asian travel.  A Canadian study showed that bacteraemia due to CTX-M-14 1296 
ESBL-producing E. coli was associated with travel to Europe and Africa whilst CTX_M-1297 
15-producing strains were associated with travel to Asia 129, Analysis of risk factors in 1298 
Norway for new cases of ESBL-producing infection was undertaken in a case-control 1299 
study of adults who had been resident for 1 year or more, with no previous hospital or 1300 
nursing home residence >24 hours in the previous 31 days. It identified as risk factors 1301 
travel to Asia, the Middle East or Africa within the past 6 weeks (OR=21 95% CI 4.5-97) 1302 
or 6weeks to 24 months (OR=2.3 95% CI1.1-4.4), recent use of fluoroquinolones 1303 
(OR=16 95%CI3.2-80) or recent use of β-lactams other than pivmecillinam (OR=5.0 1304 
95%CI 2.1-12, diabetes (OR-3.2 95%CI 1.0-11), and freshwater swimming in the last 1305 
year (OR=2.1 95%CI 1.0-4.0) were associated with UTI due to ESBL-producing E. coli or 1306 
Klebsiella spp.. Factors associated with decreased risk were the number of fish 1307 
meals/week (OR=0.68/fish meal 95%CI 0.51-0.90) and increasing age (OR=0.89/5 year 1308 
increase 95% CI 0.82-0.97).  Almost 1 in 4 (23%) ESBL-positive patients had travelled 1309 
to the risk countries within the previous 6 weeks and 39% in the 6 week to 24 month 1310 
period compared with 1% and 19% respectively. Travel to Europe (11% and 67% in 1311 
ESBL producers and 7% and 57% non ESBL producers), America or Oceania (including 1312 
Japan) was not a risk factor 130. This emphasises that there is a longer-term effect of 1313 
travel or migration that is often not considered. A placebo-controlled trial of 1314 
ciprofloxacin to prevent traveller’s diarrhoea showed that the prophylaxis selected for 1315 
quinolone- and other-drug resistant GNB suggesting that such practices need review 131. 1316 
Previous travel to destinations where resistance is prevalent is a risk factor for acquired 1317 
multi-drug resistant bacteria and should be considered in respect of empirical therapy 1318 
However many patients with multi-drug resistant organisms lack any relevant travel 1319 
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and it is not known if their organisms represent spread from carriers, especially in the 1320 
same household, who have a history of high risk travel 132-134, or who have 1321 
asymptomatically acquired the organism in hospital.  1322 
The most significant impact that the movement of people can have on the problem of 1323 
resistance in Gram-negative bacteria is the maintenance of higher levels of resistance in 1324 
commensal bacteria after return from high incidence areas. Data on faecal carriage rates 1325 
may mislead when compared with correlates of clinical infection since it will include 1326 
phylogroup A and B1 strains of lower pathogenicity than the B2 and D strains seen 1327 
commonly in urinary and bacteraemia 135 Tangden in Sweden showed that 7/8 1328 
previously uncolonised travellers to South Asia and 10/32 to East Asia returned with 1329 
gut carriage of ESBL E. coli 136. One study in Birmingham showed that 22% of 1330 
individuals with names of Middle Eastern or south Asian origin had faecal carriage of 1331 
CTX-M ESBL-producing E. coli compared with 8.1% in those with names of European 1332 
origin 137. A very recent large scale survey studying 2,430 healthy individuals in four 1333 
areas in England found similar carriage rates of 25% and 5.6%, respectively. In a 1334 
multivariable logistic regression model the percentage contribution made to risk of 1335 
colonisation was apportioned .Being born in South Asia (India, Pakistan, Bangladesh) or 1336 
coming from those countries was 26.6%, travel to those countries 12.1%. In contrast 1337 
being born in UK of UK origin 9.9% and travel to all other parts of the world was 17.8% 1338 
(McNulty et al. (2017) submitted for publication).  Hence, the choice of antibiotics for 1339 
empirical treatment may need to take into account recent travel history and cultural 1340 
background.  1341 
The second ESPAUR report (2016)4 includes details from a research study of faecal 1342 
carriage rates of ESBL-producing Enterobacteriaceae in England. This showed 1343 
variations in carriage from 4.9% in Shropshire to 16% in Heart of Birmingham Primary 1344 
Care Trust with intermediate rates in Southampton and Newham (East London). Risk 1345 
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factors in this study, which is yet to be published in full, included birth in India, 1346 
Pakistan, Bangladesh, Sri Lanka, Afghanistan (which collectively accounted for 24% of 1347 
all carriage) or the Middle East (including Egypt, Iraq, Saudi Arabia and other countries 1348 
in the Persian Gulf) and travel in the last year to Africa, South Asia (Indian sub-continent 1349 
and Afghanistan), South East Asia (Thailand, Burma, Cambodia, Laos, Malaysia, 1350 
Singapore or Pacific Asia (including Vietnam, Koreas, China), South or Central 1351 
America,(WHO regions). Until control measures reduce prevalence and at present only, 1352 
(given the rate of change) travel to, and most particularly healthcare in, the following 1353 
countries are also risk factors for either ESBL carriage or carbapenemase acquisition or 1354 
both: the Eastern Mediterranean (the Balkans, Greece, Cyprus, Turkey, and Syria) and 1355 
Eastern Europe and Russia, Belarus and Kazakhstan, and Italy. 1356 
There is a need for further studies with controls (non-travellers from different 1357 
households of the same ethnic background) on the carriage of antibiotic-resistant E. coli, 1358 
with strain typing and phylogroup allocation to better predict the potential for 1359 
extraintestinal infection. This is further reviewed in elsewhere. Studies are needed also 1360 
of Klebsiella sp. and on the time elapsed since travel to specified locations of high 1361 
prevalence. Information on healthcare and antibiotic exposure is required as well as 1362 
details of many non-ESBLantibiotic resistance mechanisms. 1363 
Evidence: 1364 
There is a clear indication of association of infection with ESBL-producing E. coli and 1365 
travel. There is no information on other antibiotic resistances in association with travel 1366 
and minimal information on carriage duration after travel. 1367 
Evidence level: 3 1368 
Recommendation: 1369 
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Need to quantify risks of infection with/ carriage of, extraintestinal pathogenic E. coli 1370 
and of Klebsiella sp. resistant to all antibiotics and relate to time since travel to countries 1371 
with high prevalence of MDR GNB and incorporate in risk assessments for clinical 1372 
infection with MDR GNB in the community and on admission to hospital to guide 1373 
therapy 1374 
Grading: Strong recommendation for 1375 
6.7 What is the clinical importance of carbapenemase- versus CTX-M- and AmpC-1376 
producing strains  1377 
ESBL-producing Enterobacteriaceae, multi-drug-resistant P. aeruginosa and A. 1378 
baumannii are associated with increased mortality, length of stay and expense in most 1379 
but not all studies evaluating the impact of antibiotic resistance in Gram-negative 1380 
bacteria 138, 139. Nevertheless, variability in the setting (mainly ICU), study design, 1381 
organisms included (most notably, which Enterobacteriaceae species), resistance 1382 
profile, and site of infection make the studies difficult to compare138, 139. 1383 
Fluoroquinolone resistance in P. aeruginosa was associated with increased hospital 1384 
costs, and, if associated with imipenem resistance (MDR strains), increased mortality 1385 
140. Four of eight studies in one review of MDR strains of P. aeruginosa showed 1386 
increased mortality 138. With A. baumannii, carbapenem-resistance was generally 1387 
associated with increased length of stay and expense of care; mortality was generally 1388 
increased, most clearly if blood-stream infection was involved 138, 139. However, two 1389 
studies of MDR, but carbapenem-susceptible, A. baumannii did not identify a significant 1390 
increase in mortality, whereas studies of carbapenem-resistance in A. baumannii 1391 
consistently identify a significant increase in mortality only partly due to use of inactive 1392 
carbapenems 139, 141-143  1393 
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More recently, studies have emerged evaluating the impact of carbapenem resistance in 1394 
Enterobacteriaceae 144. Pooled analysis of nine studies comparing mortality in 1395 
Enterobacteriaceae infections including bacteraemia found that mortality was more 1396 
than two fold higher when infections were caused by CPE. Broad-spectrum antibiotics 1397 
other than carbapenems can select for colonization (detectable by active surveillance) 1398 
that precedes later infection with bacteria resistant to a range of other antibiotics 1399 
because of linkage of with multiple resistance factors 145-149. Carbapenem resistance in 1400 
Acinetobacter spp. is similarly linked with multiple resistances that can be selected for 1401 
by antibiotics that are not carbapenems, and can be detected as colonization prior to 1402 
development of infection 150 and this is likely to be the case with Enterobacteriaceae.  1403 
Carbapenem resistance is an increasing problem in Enterobacter spp. in the absence of 1404 
carbapenemases. In E. aerogenes ertapenem resistance is associated with loss of 1405 
Omp35, a porin, and meropenem resistance with loss of Omp36 together with 1406 
derepressed overproduction of AmpC 151. 1407 
Bacteria producing CTX-M are of international importance. In the community they are 1408 
usually MDR with few and hitherto little used antibiotics offering the sole effective 1409 
treatment. The spread of these strains requires widespread changes in primary care 1410 
prescribing practice which can be slow to take effect. Further, systemic infection with 1411 
these strains usually requires parenteral drugs involving additional hospital admissions 1412 
or outpatient parenteral antibiotics. Particular successful clones such as E. coli ST131 1413 
and ST69 are frequently involved. The fundamental reason for the success of these 1414 
clones remains obscure and strategies to counter their spread nationally and 1415 
internationally have so far been based on antibiotic restriction alone.  1416 
AmpC-producing strains of Enterobacteriaceae were a problem when third generation 1417 
cephalosporins and monobactams were widely used because stable derepression of this 1418 
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enzyme occurred by mutation at the regulatory gene ampD 13 in Enterobacter spp., 1419 
Serratia spp., Citrobacter freundi and Morganella morganii. Selection of such mutants 1420 
during cephalosporin treatment of bacteraemia with these species can cause treatment 1421 
failure 152, 153. Amoxicillin/clavulanate, both components of which are strong inducers of 1422 
AmpC in such species is not active against such species but piperacillin although 1423 
inactive against derepressed mutants seems less prone than third generation 1424 
cephalosporins to select such strains from the induced population. Genes encoding 1425 
AmpC enzymes have also escaped to plasmids that have spread into E. coli; such plasmid 1426 
carrying strains are widespread in food stuffs. The main enzyme is CMY-2. In the UK it 1427 
remains considerably rarer than ESBLs 30 . Cefepime is more stable than other third-1428 
generation cephalosporins to AmpC but in E. cloacae high-level cefepime resistance is 1429 
associated with mutation in AmpC 151. Carbapenems and temocillin are active against 1430 
AmpC-β-lactamase whether of chromosomal or plasmid origin but ertapenem is more 1431 
labile and, if OmpK35 porin loss occurs, resistance arises from this enzymes action.  1432 
7 Intravenous treatment options for MDR GNB: What is the efficacy of 1433 
carbapenems, temocillin, fosfomycin, colistin and other antibiotics against 1434 
specific MDR GNB and what are the recommended antibiotics for 1435 
secondary/tertiary care? 1436 
The evidence base (and grading) for all agents is generally weak, as most studies were 1437 
retrospective case series, only rarely including a comparator agent. Our suggestions for 1438 
intravenous treatment are summarized in the algorithm in Figure 3. Each intravenous 1439 
agent is individually further considered. 1440 
7.1 Carbapenems 1441 
Carbapenems should be regarded as the drugs of choice for serious infections with 1442 
ESBL-producing Enterobacteriaceae154 and they are the drugs of choice for the 1443 
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empirical therapy of patients with serious sepsis caused by Gram-negative bacteria, 1444 
depending on local resistance rates and clinical experience. 1445 
Meropenem was found to be narrowly superior to imipenem/cilastatin (cilastatin 1446 
prevents degradation of imipenem by urinary and ileal dehydropeptidase) in both 1447 
clinical and bacteriological outcomes in one meta-analysis of 27 RCTs 155. The clinical 1448 
response rates (complete remission or improvement in signs and symptoms of sepsis) 1449 
for meropenem and imipenem were 91.4% and 87.2%, whereas bacteriological 1450 
response rates were 85.1% and 82.8% respectively. There was no significant difference 1451 
in mortality in the nine trials reporting data (7.4% for meropenem, 9.7% for imipenem). 1452 
Meropenem and imipenem (sometimes referred to as ‘Group 2’ carbapenems, based 1453 
upon activity against Gram-negative non-fermentative bacteria) are typically preferred 1454 
to ertapenem for the empirical treatment of bacteraemiass (often arising from the 1455 
urinary tract) because of the broader spectrum (see below). A switch to ertapenem may 1456 
be rational with susceptible isolates if it leads to earlier discharge with OPAT but 1457 
without this, is not a mechanism for reducing selection for carbapenem resistance. In 1458 
Singapore, de-escalation of meropenem-regimens by ID physicians (including in a small 1459 
proportion to ertapenem) was associated with no increased in clinical failure rates or 1460 
hospital mortality, reduced duration of carbapenem treatment from 8 to 6 days, less 1461 
diarrhoea and C. difficile infection and less carbapenem-resistant Acinetobacter 1462 
baumannii acquisition 156. 1463 
Meropenem or imipenem select respectively for carbapenem-resistant Gram-negative 1464 
organisms including pre-existing carbapenem-resistant A. baumannii 157, and porin 1465 
oprD mutants, the commonest mechanism of imipenem resistance, arising during 1466 
imipenem treatment of P. aeruginosa 158. Overproduction of AmpC type enzymes , and 1467 
efflux pumps which are common, are implicated, in meropenem resistance in P. 1468 
aeruginosa: MBLs usually of a VIM type occur but are much less common 159 A multi-1469 
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centre Spanish study of isolates in 2008 from P. aeruginosa bacteraemia showed similar 1470 
resistance rates to piperacillin/tazobactam, ceftazidime and meropenem. Meropenem 1471 
resistance was more commonly associated with mexB or mexY and AmpC 1472 
overexpression whereas resistance to piperacillin/tazobactam and ceftazidime was 1473 
more commonly associated with AmpC overexpression alone, making non-carbapenems 1474 
preferable agents for avoidance of MDR strains. Nevertheless, AmpC overexpression 1475 
was associated with quinolone resistance, which with aminoglycoside resistance is 1476 
already known to be associated with efflux pumps 160. Whilst both imipenem and 1477 
meropenem have a similar spectrum of activity, use of imipenem has declined and 1478 
meropenem is now the most widely prescribed carbapenem in the UK154 .  1479 
 Widespread usage particularly internationally, has driven the emergence of resistance 1480 
and careful and considered empirical usage is essential. If the bacteria responsible for 1481 
the infection are subsequently shown to produce neither ESBLs nor AmpC β-lactamase, 1482 
carbapenem use reasonably should be stepped down to narrower spectrum agents. An 1483 
Italian cohort study across 5 hospitals showed that rectal carriage of KPC-producing 1484 
Klebsiella was predictive of bacteraemia with such strains in the subsequent 2 years; 1485 
sensitivity and specificity were 93% and 42% respectively; positive and negative 1486 
predictive values were 29% and 93% respectively. Bacteraemia was associated with 1487 
ICU admission, invasive abdominal procedures, cancer chemotherapy or radiation 1488 
therapy and the number of colonization sites 161. This suggest that screening may play a 1489 
role in anticipating a requirement for treatment other than carbapenems active against 1490 
such strains but this will not necessarily apply to other bacteria with carbapenemases.  1491 
The ominous changes and increase in meropenem resistance in Enterobacteriaceae in 1492 
the UK (Evidenced in 8.4), and the clinical importance of such resistance and the need to 1493 
know the resistance mechanism to use appropriate chemotherapy, mean that an 1494 
accurate overall view of the emerging picture is essential so appropriate action can be 1495 
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taken. We include recommendations on this epidemiological matter because of its 1496 
importance. We recommend the introduction of mandatory reporting of carbapenem-1497 
resistant Enterobacteriaceae from all anatomical sites and specimens. Such isolates 1498 
should be tested contemporaneously to determine the responsible carbapenemase and 1499 
meropenem MIC. Isolates should be submitted to reference laboratories to determine 1500 
susceptibility to a wider range of appropriate agents and for those agents, such as 1501 
colistin or ceftazidime-avibactam, for which susceptibility testing is technically 1502 
demanding. The determination of susceptibilities is a part of essential surveillance.  1503 
Appropriate patient treatment also depends on performing these susceptibilities in an 1504 
expeditious manner but the methodology required may be beyond the scope of most 1505 
routine diagnostic laboratories.   1506 
Ertapenem is licensed in Europe for the treatment of intra-abdominal and gynecological 1507 
infections and community-acquired pneumonia. In the rest of the world, including in the 1508 
USA, it is also licensed for skin and skin structure infections and for complicated urinary 1509 
tract infections (for which it is widely used ‘off-label’ in the UK). Ertapenem shares the 1510 
broad spectrum of imipenem and meropenem against Enterobacteriaceae, some Gram-1511 
positive species .and anaerobes, but is inactive against Acinetobacter spp. and P. 1512 
aeruginosa 162. It is sometimes called a Group 1 carbapenem on this basis. Its main 1513 
benefit is its once-daily mode of administration.  1514 
Use of ertapenem for the treatment of infections caused by Enterobacteriaceae is less 1515 
well established than for imipenem or meropenem but it has good in vitro activity. A 1516 
retrospective cohort study compared outcomes of bacteraemias due to ESBL-producing 1517 
E. coli and K. pneumoniae treated with ertapenem and group 2 carbapenems. Outcomes 1518 
were equivalent between patients (mortality rates of 6% and 18%, respectively; 1519 
P=0.18). However, more patients treated with group 2 carbapenems had severe sepsis / 1520 
septic shock / multi-organ failure - 5/49 (10.2%) for ertapenem versus 36/109 (33.3%) 1521 
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for other carbapenems (odds ratio of 0.23; 95% confidence intervals 0.08–0.62; 1522 
p<0.002), suggesting clinicians were more likely to treat “sicker” patients with a group 2 1523 
carbapenem than ertapenem 163. A retrospective study in Taiwan evaluated 251 1524 
patients with bacteraemia caused by ESBL-producing E. coli and K. pneumoniae isolates 1525 
treated with a carbapenem164 Two hundred and thirty patients received carbapenems 1526 
appropriately – 57 ertapenem, 136 imipenem and 37 meropenem: 21 received 1527 
carbapenems inappropriately, 18 received ertapenem and 3 imipenem when the MICs 1528 
were respectively >0.5mg /L and >1mg/L. Among the isolates, rates of susceptibility to 1529 
ertapenem (MIC ≤0.5 mg/L EUCAST) were 83.8% in E. coli, and 76.4% in Klebsiella spp., 1530 
respectively and those to meropenem were 100% and 99.3%. Sepsis-related mortality 1531 
varied if the lower breakpoint CLSI breakpoint, for susceptibility (≤0.25mg/L) was used. 1532 
By this criterion, mortality was 5.3% (3/57) in those patients infected with an 1533 
ertapenem-susceptible strain versus 33% (6/18) for an ertapenem non-susceptible 1534 
isolate if they were treated with ertapenem. If categorisation was based on the EUCAST 1535 
breakpoints MIC <=0.5mg/l or >0.5mg/l, there was no significant difference in 1536 
mortality. Propensity matching of patients showed that patients with isolates that were 1537 
ertapenem non-susceptible by CLSI criteria had a similar raised mortality if treated with 1538 
imipenem or meropenem but numbers were small. A recently published multinational 1539 
retrospective cohort study of 195 patients given empirical carbapenem and 509 given 1540 
targeted therapy for bacteraemia with ESBL producing Enterobacteriaceae found 1541 
ertapenem to be equivalent to other carbapenems 165. The authors recognized that as in 1542 
other similar studies ertapenem was more frequently used in lower risk patients and 1543 
that more studies are needed in the severely ill patient populations. 1544 
Resistance (MIC=>1mg/L) and high-level resistant (taken here as MIC>16mg/L) by 1545 
EUCAST breakpoints to ertapenem in Klebsiella spp. and Enterobacter spp. were well 1546 
recognised before CPE began to spread and were associated with combinations of a β-1547 
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lactamase (often a CTX-M ESBL in Klebsiella spp. or AmpC in Enterobacter spp.) plus 1548 
impermeability due to omp K35 porin loss. Despite the results of Lee et al. (2012)164 1549 
imipenem and meropenem appear to remain active against most isolates with low-level 1550 
ertapenem resistance caused by these mechanisms but with raised MICs compared with 1551 
normal levels for the species. An in vitro study showed the frequent emergence of this 1552 
type of resistance in ESBL-producing E. coli in a pharmacokinetic model 166 but most 1553 
resistant isolates are Klebsiella spp. or Enterobacter spp. not E. coli. In a survey of UK 1554 
isolates in 2007 only one of 95 ertapenem-resistant isolates of Klebsiella pneumoniae 1555 
produced a defined carbapenemase, namely IMP-1with the remainder inferred to have 1556 
impermeability (porin-loss) mediated resistance167. However, this situation has 1557 
changed radically as KPC, OXA-48 and NDM are enzymes now regularly encountered in 1558 
the UK 168, 169 . A retrospective case-control study from the Eastern USA found that risk 1559 
factors for infection caused by ertapenem-resistant Enterobacteriaceae with such 1560 
impermeability-mediated resistance included exposure to any antibiotic (not just β-1561 
lactams and carbapenems) during the 30 days before a positive culture result, 170. A 1562 
study from Singapore found that hospitalization and fluoroquinolone treatment were 1563 
predictors for the appearance of ertapenem resistant imipenem susceptible variants 171. 1564 
The use of ertapenem has no detrimental effect in terms of selecting for P. aeruginosa 1565 
172. Results from ten clinical studies showed that use of ertapenem did not result in 1566 
decreased susceptibility to carbapenems in Pseudomonas. This was confirmed in study 1567 
of hospitals in Queensland 173.A further study found that one hospital’s use of 1568 
ertapenem was balanced by less use of imipenem and ciprofloxacin, and this may have 1569 
contributed to a reduced prevalence of resistance of P. aeruginosa to imipenem 174. In 1570 
contrast to these findings a study in Singapore associated increasing consumption of 1571 
ertapenem with a rising incidence density of carbapenem-resistant P. aeruginosa 175. 1572 
Ertapenem use had no impact on the susceptibility of A. baumannii to imipenem 176. 1573 
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Prolonged infusion therapy with meropenem for MDR GNB including carbapenem 1574 
resistant organisms has been advocated on pharmacokinetic grounds in children for A. 1575 
baumannii, P. aeruginosa and Enterobacteriaceae with meropenem MICs up to 8mg/l. 1576 
177. There is a general trend towards considering continuous infusion of beta-lactams in 1577 
critically ill patients with severe Gram-negative sepis (See 7.18) 178. Continuous infusion 1578 
meropenem has been assessed in 375 obese patients for its ability to produce steady 1579 
state levels above the MIC at levels from 2mg/L to >16mg/L 179 . Dosing nomograms to 1580 
sustain this had previously been constructed in critical care patients 180.  1581 
Meropenem combined with vaborbactam (RPX7009); a boronic acid derived β-1582 
lactamase inhibitor is progressing through Phase 111 trials and may cover 1583 
Enterobacteriaceae strains with KPC producing carbapenemases but not those with 1584 
MBLs or OXA-48-like enzymes. Some isolates with ompK36 porin loss (See 6.3.3 & 6.7.) 1585 
are resistant 38. Relebactam in combination with imipenem/cilastatin is entering Phase 1586 
3 trials with trials against imipenem-resistant bacteria compared with a combination of 1587 
colistin and imipenem/cilastatin and a comparative study against 1588 
piperacillin/tazobactam in ventilator-associated pneumonia. Phase 2 studies are as yet 1589 
unpublished. In vitro studies show no enhanced activity against Acinetobacter spp. but 1590 
activity against KPC-producing K. pneumoniae (unless it has an OmpK 36 porin loss 1591 
which is responsible for meropenem resistance (See 6.3.3 & 6.7), and many but not all P. 1592 
aeruginosa with enhanced AmpC production and depressed oprD37. 1593 
Evidence 1594 
Carbapenems are drug of choice for treatment of serious infection with 1595 
Enterobacteriaceae including those producing ESBLs or AmpC. 1596 
Evidence level:     1+ 1597 
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Imipenem use is associated with emergence of resistance in P. aeruginosa 1598 
Evidence level: 3 1599 
Ertapenem treatment is associated with emergence of resistance via porin loss in ESBL- 1600 
and AmpC-producing Klebsiella spp. and Enterobacter spp.  1601 
Evidence level 3 1602 
Recommendations 1603 
 Use meropenem, imipenem or ertapenem to treat serious infections with ESBL 1604 
and AmpC-producing Enterobacteriaceae. 1605 
Grading: Strong recommendation for 1606 
 Apply antibiotic stewardship to use of all carbapenems to minimize the risk of 1607 
developing resistance either by acquisition of carbapenemase-producing strains 1608 
or, with ertapenem, by porin loss.    1609 
Grading: Strong recommendation for 1610 
 Do not use imipenem to treat susceptible Pseudomonas infections  1611 
Grading: Conditional recommendation for 1612 
 Introduce in the UK mandatory reporting of meropenem- or imipenem- resistant 1613 
Enterobacteriaceae from all anatomical sites and specimens. 1614 
Grading: Strong recommendation for 1615 
 Test immediately for the precise level of meropenem resistance and for an 1616 
indication of the responsible class of carbapenemase (e.g. MBL/KPC/OXA48-like) 1617 
all meropenem- or imipenem- resistant isolates of Enterobacteriaceae. Submit to 1618 
Accepted manuscript 64 
agreed reference laboratories to determine susceptibility to a wide range of 1619 
potentially active agents including, as appropriate colistin, 1620 
ceftazidime/avibactam, temocillin, aminoglycosides, fosfomycin and tigecycline. 1621 
Grading: Strong recommendation for 1622 
 Prefer ertapenem for outpatient antibiotic treatment (OPAT) of susceptible 1623 
infections in view of the once daily dosing regimen. 1624 
Grading: Conditional recommendation for 1625 
7.2 Ceftazidime 1626 
Observational studies of ceftazidime-susceptible ESBL-producing E. coli and Klebsiella 1627 
spp. infections treated with ceftazidime frequently show treatment failure, mainly 1628 
during bacteraemias 12, 181-184. One study of 7 patients treated with ceftazidime in China 1629 
suggested useful activity but this may reflect the type of ESBL; CTX-M-14. -27 and -9 1630 
enzymes predominate in parts of China (and Spain) and have weak activity against 1631 
ceftazidime as compared with CTX-M-15 enzymes with lower ceftazidime MICs.  The 1632 
higher CLSI susceptible breakpoint (<=4mg/L was found to classify 34% of CTX-M 1633 
positive E. coli as susceptible to ceftazidime with normal inocula. Most CTX-M-14 1634 
isolates became resistant at higher inocula 185. The EUCAST breakpoint for susceptibility 1635 
is <1mg/L reducing this problem, Early problems arose with apparent ceftazidime 1636 
susceptibility by disc testing of CTX-M-15-producing E. coli ST131 isolates in the UK 1637 
down regulated by an IS26 insertion between promoter and structural gene186. 1638 
Ceftazidime is active against some OXA-48-producing CPE principally those that do not 1639 
co-produce ESBLs or AmpC enzymes. Ceftazidime retains activity against many isolates 1640 
of P. aeruginosa including in the presence of mutation to imipenem or ciprofloxacin 1641 
resistance 187. However strains with derepressed class C (AmpC) β-lactamases or 1642 
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strongly upregulated efflux mechanisms are resistant, as are strains producing MBLs, 1643 
other carbapenemases or ESBLs.  1644 
Evidence 1645 
Ceftazidime is usually ineffective in treating multi-resistant infections with 1646 
Enterobacteriaceae except against some OXA-48 carbapenemase-producing strains. 1647 
Evidence level: 3 1648 
Ceftazidime remains useful for infections due to quinolone or imipenem resistant h P. 1649 
aeruginosa  1650 
Evidence level: 3 1651 
Recommendations 1652 
 Use ceftazidime for susceptible infections with P. aeruginosa including 1653 
quinolone- or some imipenem- resistant strains 1654 
Grading: Strong recommendation for 1655 
 Do not use ceftazidime to treat infections due to ESBL-or AmpC-producing 1656 
Enterobacteriaceae or CPE (other than OXA-48 producers), even if in vitro tests 1657 
suggest the isolate is susceptible.  1658 
Grading: Conditional recommendation against use 1659 
7.3 Ceftazidime/avibactam 1660 
Ceftazidime has recently been combined with the β-lactamase inhibitor avibactam. This 1661 
combination has broad Gram-negative activity including Enterobacteriaceae and P. 1662 
aeruginosa. Ceftazidime-susceptible bacteria remain susceptible to the combination, but 1663 
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avibactam protects additionally against class A (TEM, SHV, CTX-M, KPC) class C (AmpC) 1664 
and some class D (OXA) β-lactamases 188-192. Ceftazidime/Avibactam has no inhibitory 1665 
activity against the MBLs (NDM-1, IMP and VIM) but it is the first BL/BLI combination 1666 
to retain activity against KPC-2 carbapenemase-producing and most OXA-48 1667 
carbapenemase producing strains. Ceftazidime/avibactam has minimal activity against 1668 
Acinetobacter spp., anaerobic or Gram-positive organisms 190, 193, 194. A recent 1669 
susceptibility study that included 120 KPC-producing Enterobacteriaceae collected from 1670 
US hospitals found that ceftazidime/avibactam had MIC50/90 values of 0.5/2mg/L 195. 1671 
The first case series of use of ceftazidime/avibactam against carbapenem-resistant 1672 
Enterobacteriaceae has recently been published 196. Among 37 patients with severe 1673 
infections due to these organisms 31 had strains with KPC carbapenemases. Resistance 1674 
to ceftazidime/avibactam emerged independently in 3 cases infected by K. pneumoniae 1675 
ST258 with KPC-3 enzymes. In 2 of these isolates meropenem MICs were reduced >=4-1676 
fold to the susceptible range in parallel with the rise in ceftazidime-avibactam MICs. The 1677 
overall clinical success rate was 59% of patients whilst microbiological failure occurred 1678 
in 10 patients, including the 3 patients where resistant mutants were selected. An 1679 
earlier epidemiological study had shown that ceftazidime/avibactam median MICs of 1680 
ceftazidime/avibactam are higher for KPC3-producing isolates than those with KPC-2 1681 
enzymes although it was unclear if this represents enzyme specificity or quantity 197. 1682 
Isolates that produce KPC3 enzyme are internationally widespread including in South 1683 
America and Southern Europe. Ceftazidime/avibactam resistant isolates with similar or 1684 
identical mutations can be selected in vitro 198. The mechanism involves the enzyme 1685 
becoming a stronger ceftazidime-destroying enzyme, not in it becoming avibactam 1686 
resistant. The licensing of avibactam –a non- β-lactam – β-lactamase inhibitor with 1687 
ceftazidime offers a new choice where organisms that produce both AmpC and an ESBL, 1688 
or KPC2 carbapenemase cause systemic infection. 1689 
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In phase II double-blind randomized trials, the efficacy of ceftazidime/avibactam was 1690 
similar to imipenem/cilastatin in treatment of complicated urinary tract infection, 1691 
(19/27) and (21/35) respectively 199. A Phase 3 RCT of doripenem versus ceftazidime 1692 
avibactam in complicated UTI or pyelonephritis, with patients not selected for antibiotic 1693 
resistance, showed equivalence with microbiological eradication in 304/393 (77.4%) in 1694 
the ceftazidime/avibactam arm and 296/417 (71%) in the doripenem arm 200. Efficacy 1695 
combined with metronidazole was similar to meropenem in a RCT of 203 patients with 1696 
intra-abdominal infection 201. A Phase 3 RCT comparison of meropenem against 1697 
ceftazidime/avibactam with metronidazole in 1066 complicated intra-abdominal 1698 
infection, with the exclusion of a standardised set of highest mortality surgical 1699 
indications, again showed equivalence 202. On intention to treat analysis response rates 1700 
were 82.5% to the ceftazidime/avibactam-metronidazole combination and 84.9% to 1701 
meropenem. There was no difference in patient outcome in the combination arm if a 1702 
ceftazidime-resistant strain of Enterobacteriaceae was present or absent. Only 1 case of 1703 
C. difficile was recognised in either arm of the study. A RCT of ceftazidime/ avibactam 1704 
and metronidazole against meropenem of 333 patients largely with patients with 1705 
complicated UTI, but with some patients treated for intra-abdominal infections, all with 1706 
infections with ceftazidime-resistant Enterobacteriaceae or P. aeruginosa showed 91% 1707 
response rates at a test of cure visit 203. None of these patients were infected with 1708 
carbapenemase-producing strains. 1709 
Evidence 1710 
Ceftazidime/avibactam has similar efficacy to carbapenems in abdominal and 1711 
complicated UTI, the former requiring combination of ceftazidime/avibactam with 1712 
metronidazole.   1713 
Evidence level: 1+ 1714 
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Although clinical experience is limited in MDR GNB largely to ceftazidime-resistant 1715 
organisms in complicated urinary tract infection, it would be expected to be effective 1716 
when OXA-48 producing MDR GNB cause infection.  1717 
Evidence level: 4 1718 
Clinical experience against Klebsiella spp. producing KPC-carbapenemase is limited but 1719 
ominously efficacy is only some 60% with resistance emerging in 10% of treated 1720 
patients. 1721 
Evidence level: 2+ 1722 
Recommendations 1723 
 Could use ceftazidime/avibactam as an alternative to carbapenems for infection 1724 
with ESBL- and AmpC- producing Enterobacteriaceae but alternatives may be 1725 
cheaper 1726 
Grading: Conditional recommendation for  1727 
 Evaluate further ceftazidime/avibactam use alone or in combination when non-1728 
MBL carbapenemase-producing organisms cause infection. KPC-3 producing 1729 
Klebsiella spp. are vulnerable to mutations in the enzyme causing resistance  1730 
Grading: Recommendation for research and possibly conditional 1731 
recommendation for use restricted to trials 1732 
 Do not use for treating infection with anaerobes or bacteria producing MBLs: 1733 
these are resistant  1734 
Grading: Strong recommendation against 1735 
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7.4 Ceftolozane/tazobactam 1736 
Ceftolozane is an oxyimino-cephalosporin that has been combined with tazobactam. 1737 
Ceftolozane/tazobactam is active against many Gram-negative organisms, including 1738 
Enterobacteriaceae and P. aeruginosa 193, 204, 205. It is active against P. aeruginosa isolates 1739 
that are resistant to standard agents such as ceftazidime because of derepressed AmpC 1740 
β-lactamases or upregulated efflux. In terms of MIC, ceftolozane is the most active β-1741 
lactam against P. aeruginosa, with resistance (MIC >4 mg/L EUCAST) largely confined to 1742 
those with metallo-β-lactamases or unusual ESBLs such as VEB and GES types. 1743 
MIC50/90 values against 310 multi-drug resistant isolates of P. aeruginosa were 1744 
2/8mg/L 205. Activity against Acinetobacter spp. is variable 193. Ceftolozane/tazobactam 1745 
has in vitro activity against Enterobacteriaceae producing ESBLs including most TEM, 1746 
SHV, and CTX-M types  205-207. Since oxyimino-cephalosporins are stable to the inhibitor-1747 
resistant OXA-1 enzyme, ceftolozane is not compromised by co-production of this 1748 
enzyme in CTX-M-15 producing Enterobacteriaceae as happens with 1749 
piperacillin/tazobactam, Activity is less against ESBL-producing Klebsiella spp., possibly 1750 
owing to high ESBL levels arising from production of additional SHV enzymes 208. 1751 
Activity against Enterobacteriaceae with copious AmpC enzyme is variable, but many 1752 
Enterobacter spp. with derepressed AmpC are resistant. The combination has no activity 1753 
against strains with MBLs (NDM-1, IMP, and VIM) or against those with KPC 1754 
carbapenemases. Ceftazidime-resistant strains with OXA-48-like enzymes are mostly 1755 
resistant: ceftazidime-susceptible OXA-48 producers are susceptible to 1756 
ceftolozane/tazobactam (D.M. Livermore –unpublished data).  1757 
Ceftolozane/tazobactam therefore has potentially different uses from 1758 
ceftazidime/avibactam and should not be used in infections due to AmpC- or KPC-1759 
producing Enterobacteriaceae. The absence of clinical comparisons of 1760 
piperacillin/tazobactam and ceftolozane/tazobactam mean that choices must be made 1761 
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on in vitro grounds. The apparent enhanced activity of ceftolozane/tazobactam against 1762 
strains that co-produce the enzyme OXA-1, including the internationally prevalent E. 1763 
coli ST131 lineage, needs full laboratory and clinical verification but may make this drug 1764 
more likely to produce clinical cure. Caution on clinical outcome is necessary because of 1765 
the potential, as with ceftazidime/avibactam, for superinfection with C. difficile. 1766 
Ceftolozane activity against P. aeruginosa including ceftazidime-resistant strains in vitro 1767 
may offer clinical advantages where MDR Pseudomonas infections are a problem such 1768 
as in cystic fibrosis 209 but this needs confirmation in a clinical trial. Optimal dosing in 1769 
cystic fibrosis needs to be established but the drug’s pharmacokinetics appears to be the 1770 
same as in unaffected patients 210. 1771 
Ceftolozane/tazobactam is licensed, at present, for complicated intra-abdominal 1772 
infection and complicated urinary tract infection 211. In a prospective, randomised, 1773 
double-blind trial, 993 hospitalised patients with complicated intra-abdominal infection 1774 
received either ceftolozane/tazobactam (1.5g 8h IV) plus metronidazole, or meropenem 1775 
(1g 8h IV) for 4–14 days 212. Non-inferiority was demonstrated overall and MIC was not 1776 
related to outcome. In fifty patients an ESBL-producing organism was isolated. In these 1777 
patients, the clinical cure rate was 95.8% (23/24) in the ceftolozane/tazobactam plus 1778 
metronidazole group and 88.5% (23/26) in the meropenem group. In patients with 1779 
CTX-M-14/15 ESBL-producing Enterobacteriaceae, clinical cure was observed in 13 of 1780 
13 (100%) and 8 of 11 (72.7%) patients, respectively. A double-dummy, double-blinded 1781 
RCT compared ceftolozane/tazobactam against levofloxacin in 1083 patients with 1782 
complicated UTI 213. Patients received ceftolozane /tazobactam (1.5g iv 8h) or 1783 
intravenous levofloxacin (750mg od iv). The majority of participants (82%) had 1784 
pyelonephritis. Overall, ceftolozane/tazobactam was found to be non-inferior in clinical, 1785 
and superior in microbiological, outcome to levofloxacin therapy. In the intention to 1786 
treat population, 20 (2·7%) of 731 Gram-negative pathogens were resistant to 1787 
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ceftolozane/tazobactam at baseline, whereas 195 (26·7%) of 731 were resistant to 1788 
levofloxacin. Two (0·3%) of 594 of E. coli isolates were resistant to 1789 
ceftolozane/tazobactam and 144 (24·2%) of 594 were resistant to levofloxacin. For 1790 
patients with levofloxacin-resistant uropathogens (based on CLSI criteria) clinical cure 1791 
was seen in 90 (90·0%) of 100 patients in the ceftolozane/tazobactam group compared 1792 
(surprisingly) with 86 (76·8%) of 112 in the levofloxacin group. In patients with ESBL-1793 
producing uropathogens, cure with ceftolozane/tazobactam was 55 (90·2%) of 61 1794 
compared with 42 (73·7%) of 57 for levofloxacin (95% CI 2·6–30·2). Treatment choice 1795 
in complicated UTI and pyelonephritis involving MDR GNB between 1796 
piperacillin/tazobactam, carbapenems, ceftolozane/tazobactam, temocillin or 1797 
ceftazidime-avibactam depends on the bacteria present and their patterns of 1798 
susceptibility. 1799 
Evidence 1800 
Ceftolozane/tazobactam is not active against CPE strains, excepting ceftazidime-1801 
susceptible OXA-48-producers, but otherwise, when combined with metronidazole, is 1802 
non-inferior to meropenem in intra-abdominal infection 1803 
Evidence level: 1+ 1804 
 Ceftolozane/tazobactam is non-inferior to intravenous levofloxacin in complicated UTI 1805 
including those caused by ESBL-producing E. coli (most of which are resistant to 1806 
levofloxacin) 1807 
Evidence level: 2-Ceftolozane/tazobactam is the most active β-lactam in vitro against P. 1808 
aeruginosa 1809 
Evidence level: 4 1810 
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Recommendations 1811 
 Use ceftolozane/tazobactam to treat susceptible P. aeruginosa infections 1812 
resistant to ceftazidime  1813 
Grading: Conditional recommendation for 1814 
 Conduct clinical trials in P. aeruginosa infections in cystic fibrosis 1815 
Grading: Recommendation for research and possibly conditional 1816 
recommendation for use restricted to trials 1817 
 Use ceftolozane- tazobactam as an alternative to carbapenems to treat urinary or 1818 
intra-abdominal infection involving ESBL-producing E. coli. Caution may be 1819 
needed when treating infection due to ESBL-producing Klebsiella spp. owing to a 1820 
higher resistance rate. 1821 
Grading: Conditional recommendation for 1822 
 Do not use for infections due to AmpC- or carbapenemase- producing 1823 
Enterobacteriaceae or MBL/ESBL- producing P. aeruginosa.    1824 
Grading: Strong recommendation against 1825 
7.5 Aztreonam 1826 
Aztreonam is labile to AmpC and ESBL enzymes. It is stable to MBLs and OXA-48–like 1827 
carbapenemases but most Enterobacteriaceae with these enzymes also express ESBLs 1828 
or AmpC which confer resistance 214, 215. Isolates with MBLs or OXA 48 and no ESBL- or 1829 
AmpC- production may be susceptible (those with OXA-48 alone are likely also to be 1830 
susceptible to ceftazidime and ceftolozane/tazobactam). At EUCAST breakpoints (S <=1, 1831 
R >16) most P. aeruginosa are intermediate in susceptibility and the drug is usually less 1832 
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active than ceftazidime or ceftolozane/tazobactam except against MBL-producers 1833 
resistant to all other β-lactams which may be intermediate (rarely susceptible) to 1834 
aztreonam. 1835 
An aztreonam-avibactam combination is in Phase 11 development. This creates a 1836 
combination with very promising activity against Enterobacteriaceae with MBLs, OXA-1837 
48, AmpC, ESBLs and other β-lactamases (including AmpC, OXA-1 and CTX-M class)214, 1838 
215 216 .  1839 
Evidence 1840 
Aztreonam is not active against Gram-negative bacteria producing ESBLs, AmpC or KPC 1841 
carbapenemase; it is only moderately active against P. aeruginosa.  1842 
Evidence level: 4 1843 
It is stable to MBLs but strains possessing these often have ESBL or AmpC as well 1844 
resulting in resistance. Similar limitations apply to strains with OXA-48-like enzymes.  1845 
Evidence level; 3 1846 
Combination with a β-lactamase inhibitor such as avibactam would potentially make 1847 
aztreonam useful against MBLs (NDM, IMP and VIM)-producing bacteria that also have 1848 
ESBLS or Amp C enzymes. 1849 
Evidence level: 4 1850 
Recommendations 1851 
 Do not use aztreonam alone empirically if MDR GNB or Gram-positive or 1852 
anaerobic pathogens are suspected. 1853 
Grading: Strong recommendation against 1854 
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 Do not use aztreonam for CTX-M ESBL- or AmpC- producing bacteria even if 1855 
these appear susceptible in vitro  1856 
Grading: Strong recommendation against 1857 
 Use aztreonam for MBL- or OXA-48- producing strains if it is certain that they do 1858 
not produce ESBLs or AmpC 1859 
Grading: Conditional recommendation for  1860 
 Research usefulness of aztreonam in combination with avibactam for bacteria 1861 
producing MBLs with ESBL/AmpC enzymes and for those with other 1862 
carbapenemases. 1863 
Grading: Recommendation for research 1864 
7.6 Cefepime  1865 
Cefepime is not available in the UK. It appeared to be active in vitro against ESBL-1866 
producing Enterobacteriaceae especially when the old NCCLS-CLSI breakpoint of 1867 
=<8mg/l was used. A retrospective, case-controlled study compared the clinical and 1868 
microbiologic responses for 10 infections due to ESBL-producing Klebsiella spp. and E. 1869 
coli from a non-urinary source with 20 matched controls receiving cefepime for non-1870 
ESBL strains. Four patients with ESBL-producers had strains that were resistant to 1871 
cefepime by broth microdilution MIC, one of whom responded: Three of the remaining 1872 
six with strains then regarded as susceptible (NCCLS-CLSI breakpoint MIC =<8mg/l), 1873 
failed on treatment Patients receiving cefepime for infection with ESBL-producing 1874 
bacteria were 9.7 times more likely to have an unsuccessful clinical and microbiological 1875 
response than those with non-ESBL-producing bacteria 217. A randomised evaluator-1876 
controlled trial of ICU patients compared cefepime with imipenem for the treatment of 1877 
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hospital acquired pneumonia. The failure rate was 31% in the cefepime group 1878 
compared with 0% in the imipenem group. Cefepime MICs of 2-4mg/l, then interpreted 1879 
as susceptible by the NCCLS_(CLSI) breakpoint of =<8mg/l but now regarded as 1880 
susceptible dose-dependent by CLSI and intermediate by EUCAST criteria were noted in 1881 
strains from treatment failures 218. A retrospective case-control study of cefepime-1882 
susceptible bacteraemia caused by ESBL-producers in the period 20012-7 compared 30 1883 
day mortality amongst 17 patients treated with cefepime versus 161 cases treated with 1884 
a carbapenem 219. Mortality in the cefepime group was 58.8% versus 16.8% for 1885 
carbapenem treatment and, in multi variate analysis cefepime treatment was strongly 1886 
associated with mortality (OR, 9.9; 95% CI, 2.8-319; p 0.001). Mortality with cefepime in 1887 
definitive treatment also related to MIC being 16.7% (1/6) in those with an 1888 
MIC=<1mg/l, 45% (5/11) in those with an MIC of 2-8mg/l and 100% (4/4) in those 1889 
with an MIC of =>16mg/L 220. In a retrospective study of 305 adults with monomicrobial 1890 
Enterobacter cloacae infections, those with MICs of 4-8mg/l (i.e. with CLSI dose-1891 
dependent susceptibility and straddling the EUCAST I/R breakpoint) had significantly 1892 
higher mortality than those treated with carbapenem 71.4% vs. 18.2% (= 0.045) 14. Fifty 1893 
eight percent of strains in the cefepime-treated group produced an ESBL in addition to 1894 
AmpC. In those definitively treated with cefepime, ESBL-production (16/40 vs. 3/32 1895 
p=0.006) and susceptible dose-dependent strains (10/16 vs. 9/56 p=<0.001) were 1896 
independently associated on multivariate analysis with increased mortality 14. ESBL 1897 
production was more frequent in those strains with cefepime MICs of 4-8 mg/l (32/36 1898 
compared with 61/138 with MIC=<2mg/l p=<0.001). Mortality was not reduced even 1899 
when high dose regimens (2g 8h iv) were used. Mortality in infections due to ESBL non-1900 
producers (with median MICs of 0.5mg/l) treated with definitive cefepime was similar 1901 
to those who received definitive carbapenem therapy (9/56 vs. 16/72 p=0.5). This 1902 
study demonstrates the efficacy of cefepime against the presumptive AmpC producer E. 1903 
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cloacae but only in the absence of additional ESBL-production or absence of MIC 1904 
>2mg/L Nevertheless, in another retrospective study between 2005 and 2007, of 1905 
bacteraemia due to ESBL-producing pathogens, receipt of empirical cefepime alone 1906 
(n=43) was associated with increased mortality compared with cefepime 1907 
combination(n=69) or carbapenem combination (n=44) regimens: mortality was 1908 
unlinked to MIC being 5/13 with those with organisms MIC=<2mg/L, 2/6 with MICs of 4 1909 
or 8mg/L and 10/24 with MICs =>16mg/:L 221.  1910 
The concept of susceptible dose dependent isolates of Enterobacteriaceae was 1911 
suggested by CLSI In order to maximise cefepime use and spare carbapenems but these 1912 
findings suggest this is unwise A recent systematic review did not support the use of 1913 
cefepime in empirical therapy of critically-ill patients when ESBL-producing E coli or 1914 
Klebsiella sp. infection is suspected. Even in patients with ESBL strains susceptible to 1915 
cefepime (≤2mg/l CLSI; < 1mg/L EUCAST), treatment failure can be seen 220.  1916 
Evidence 1917 
Cefepime has a higher failure rate in treatment of infections due to ESBL-producing GNB 1918 
than carbapenems unless cefepime MICs were =<1mg/L    1919 
Evidence level: 2+ 1920 
Bacteraemias due to E. cloacae strains without ESBLs and with MIC =>2mg/l <8mg/L 1921 
can be successfully treated with cefepime  1922 
Evidence level 2+ 1923 
 Recommendations 1924 
 Could use cefepime to treat infection caused by ESBL- or Amp-C-producing 1925 
bacteria if susceptible to the EUCAST breakpoint of MIC =<1mg/L 1926 
Accepted manuscript 77 
Grading: Conditional recommendation for 1927 
 Do not use cefepime even at increased dose for isolates with i) MIC of 2-8 mg/l 1928 
(CLSI “susceptible dose dependent”) or ii) MIC 2-4mg/L (EUCAST intermediate, 1929 
or iii) strains that produce both AmpC and ESBLs. 1930 
Grading: Strong recommendation against  1931 
 Do not use cefepime to treat infection caused by carbapenemase-producing 1932 
Enterobacteriaceae.  1933 
Grading: Strong recommendation against 1934 
7.7 Cefoxitin 1935 
Cefoxitin, the original parenteral cephamycin, was developed by Merk and is now a 1936 
generic. It is no longer available in Europe but has several suppliers in the USA. 1937 
Cefoxitin was licensed at the same time as second-generation cephalosporins like 1938 
cefuroxime but differs in having activity against gut Bacteroides sp. but minimal activity 1939 
against Haemophilus influenzae. Cefoxitin is on the list of forgotten antibiotics that may 1940 
be useful against MDR GNB 222. It is active against ESBL-producing E. coli but is not 1941 
active against AmpC-inducible species of Enterobacteriaceae e.g. Enterobacter spp., 1942 
Citrobacter freundi, Serratia spp., Morganella morganii and Providencia stuartii, nor 1943 
against P. aeruginosa. Cefoxitin differs from temocillin (which has a 6-alpha methoxy 1944 
group corresponding to the 7-alpha methoxy group of cefoxitin) in having activity 1945 
against Gram-positive bacteria including penicillin-susceptible Streptococcus 1946 
pneumoniae and methicillin-susceptible Staphylococcus aureus, which may be 1947 
advantageous if a urinary infection is diagnosed but the patient actually has infection 1948 
due to these organisms elsewhere. 1949 
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EUCAST no longer cites MIC breakpoints but BSAC had a breakpoint of S<8mg/L and 1950 
resistant >8mg/L Typical MICs for E. coli and Klebsiella sp. are slightly below this level 1951 
meaning that small reductions in susceptibility can confer resistance. These can arise by 1952 
reductions in permeability or, (in E. coli only) by mutation in promoter or attenuator 1953 
sequences for ampC. Cefoxitin resistance is very common in the Middle East, India and 1954 
China. In a multicentre study of 1762 isolates from urinary infection in the Asia-Pacific 1955 
region 50.3% of strains were resistant to cefoxitin 223 . Resistance also occurs in E. coli 1956 
and Klebsiella sp., from plasmid-mediated Amp-C production. Porin loss combined with 1957 
other mechanisms of β-lactam resistance such as ESBL-production is described as 1958 
emerging during treatment of some Klebsiella infections (See 6.3.3 & 6.7).  1959 
 Cefoxitin is used in selective media for C. difficile and would be expected to trigger 1960 
infection with this pathogen. In one recent study antibiotic prophylaxis with cefoxitin 1961 
was an independent risk factor for C. difficile infection 224. The absolute frequency at 1962 
which this will occur relative to other antibiotics is not known. 1963 
In murine models of pyelonephritis cefoxitin was effective against an OXA-1- and CTX-1964 
M-15- producing transconjugant E. coli 225 and in combination with fosfomycin 1965 
prevented selection for fosfomycin-resistant mutants 226. Only one human trial of 1966 
cefoxitin against current ESBL-producers has been reported. In this 2015 French study 1967 
largely of urinary and catheter-related bacteraemia 30/33 patients responded in the 1968 
first 48 hours and 20/24 evaluable patients at follow-up. Six microbiological failures 1969 
were documented with emergence of resistance in 2 patients with Klebsiella infection 1970 
227. A pharmacological model suggests 1 h. infusion of 2g four times daily would be 1971 
effective 228.  1972 
Although cefoxitin appears active against CTXM-15-producing E. coli and Klebsiella spp., 1973 
it lacks temocillin’s activity against strains with copious inducible, derepressed 229 or 1974 
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plasmid-mediated, AmpC. Cefoxitin may be more prone than temocillin to select C. 1975 
difficile 230. Temocillin unlike cefoxitin has no Gram-positive spectrum so in empirical 1976 
use in the elderly where it is not clear if the urinary tract or the chest/skin is the source 1977 
of infection, it may need supplementation with another antibiotic. It is not clear if 1978 
cefoxitin’s reintroduction would offer any sustainable or competitive advantage apart 1979 
from its carbapenem-sparing capacity as its four-times daily intravenous dosing makes 1980 
it only usable in inpatient treatment not OPAT.   1981 
Evidence: 1982 
Cefoxitin is an intravenous cephamycin antibiotic, formerly licensed in the UK. 1983 
Inducible, derepressed or plasmid-mediated AmpC-production confers resistance as 1984 
does porin loss, especially in association with ESBL-production. Nevertheless, in vitro, 1985 
animal and human studies indicate activity against ESBL-producing strains of E. coli and 1986 
Klebsiella spp. Treatment can be complicated by emergence of resistance due to porin 1987 
loss.  1988 
Grading: Level 3. 1989 
Recommendations  1990 
 Could use as a carbapenem-sparing agent for infections caused by CTX-M-15-1991 
producing E. coli but is only suitable for inpatient use not OPAT because of the 1992 
short serum half-life. Narrower Gram-negative spectrum than temocillin so less 1993 
suitable for empirical use in UTI. 1994 
Grading: Recommendation for research and possibly conditional 1995 
recommendation for use restricted to trials 1996 
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7.8 Temocillin 1997 
Temocillin is a semi-synthetic 6-alpha-methoxy derivative of ticarcillin that is highly 1998 
stable to most β-lactamases except MBLs (e.g. IMP, NDM, and VIM) and OXA-48-like 1999 
enzymes. It lacks activity against anaerobes, Gram positive bacteria and most Gram-2000 
negative non-fermenters such as P. aeruginosa and Acinetobacter spp. It retains in vitro 2001 
activity against ESBL- and AmpC-producing Enterobacteriaceae 231, 232, and some KPC-2002 
producing E. coli and Klebsiella pneumoniae 233, and Burkholderia cepacia complex 234. It 2003 
is active against Enterobacteriaceae strains whose AmpC –production is stably 2004 
derepressed 235. No EUCAST breakpoint for susceptibility to the drug has yet been 2005 
published but the BSAC had a systemic value of S <8, R>8mg/L MICs for temocillin of 2006 
KPC-producing bacteria are in the range of 4-32mg/L (mode 16mg/L).In a lethal mouse 2007 
model of intra-abdominal infection using strains of KPC producing E. coli temocillin was 2008 
effective against KPC-2 236. Temocillin has poor activity against carbapenem-resistant 2009 
isolates of Enterobacteriaceae lacking carbapenemases – presumptively due to porin 2010 
loss 237. This antibiotic has no activity against OXA-48 or MBL-producing strains 238. 2011 
Caution is also needed in predicting results of treatment of systemic infections from in 2012 
vitro susceptibility and further trials of temocillin alone at defined and possibly greater 2013 
doses than the licensed 2g twice daily are necessary. Outcomes should be correlated 2014 
with MIC.  2015 
At present, clinical studies are limited to non-comparative series. The largest multi-2016 
centre study (non-randomised retrospective case series) involved 92 patients who were 2017 
treated with at least 3 days of therapy 239. Urinary tract and bacteraemia (42 episodes 2018 
each) were the most frequent indications followed by hospital acquired pneumonia. 2019 
Dosages of ≥4g/day, rather than 1g twice daily, were associated with improved 2020 
outcome. Patients with strains producing Amp C or ESBL enzymes responded 2021 
microbiologically in 23/27 or 18/22 cases in respectively UTI or bacteraemia. Higher 2022 
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dosage regimens, including 2g three times daily and 6g by continuous infusion and use 2023 
in veno-venous haemofiltration are reported in the literature with suggestions that 2024 
these improve efficacy 240.In a retrospective case review of bacteraemia caused by KPC 2025 
producing Enterobacteriacae, 14/14 patients treated either alone or in combination 2026 
with temocillin survived, whereas 6/30 treated similarly with tigecycline  died 241. Two 2027 
studies have been published on the use of temocillin in cystic fibrosis patients with B. 2028 
cepacia complex and sometimes P. aeruginosa. Both were retrospective non-2029 
randomised audits the first showing equivalence of combinations of temocillin with 2030 
tobramycin versus other agents with tobramycin against B. cenoepacia and the second 2031 
showing that 18/32 courses of temocillin resulted in improvement in the patient’s 2032 
infection 242, 243. 2033 
Evidence 2034 
Temocillin at a dose of 2g twice daily is an effective and well tolerated drug for urinary 2035 
tract infection with AmpC- or ESBL-producing bacterial infection. 2036 
Evidence Level: 3 2037 
Although in vitro work suggests activity against many KPC-producing bacteria, there is 2038 
little published clinical evidence to support this. Respiratory infections, including cystic 2039 
fibrosis infections with Burkholderia cepacia, and other sites of systemic infection 2040 
requires further clinical trials.  2041 
Evidence Level: 4       2042 
Recommendations 2043 
 Use alone for UTIs and associated bacteraemia caused by AmpC- or ESBL- 2044 
producing Enterobacteriaceae. 2045 
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Grading: Conditional recommendation for  2046 
 Continuous infusion or thrice-daily dosing may be desirable for systemic 2047 
infections with ESBL- or Amp-C producing bacteria  2048 
Grading: recommendation: for research and possible conditional 2049 
recommendation for use restricted to trials 2050 
 Could use for UTIs with KPC-producing Enterobacteriaceae but not for OXA-48 2051 
or MBL-producers, on basis of published in-vitro data. 2052 
Grading: Recommendation for research and possible conditional 2053 
recommendation for use restricted to trials 2054 
7.9 Ampicillin/sulbactam 2055 
Sulbactam has in vitro microbiological activity against some strains of A. baumannii, 2056 
including some carbapenem-resistant lineages. Microbiological studies showed that 2057 
sulbactam alone (without ampicillin) was active against these bacteria 244.  In an 2058 
uncontrolled study, forty-two patients with infections caused by multi-drug –resistant 2059 
A. baumannii were treated with sulbactam or ampicillin/sulbactam. Eighteen received 2060 
sulbactam alone and 24 received ampicillin/sulbactam; no difference in cure rate was 2061 
observed between the two groups. Another study compared ampicillin/sulbactam to 2062 
colistin therapy in a retrospective review of patients who had nosocomial infections 2063 
caused by carbapenem-resistant Acinetobacter spp. from 1996 to 2004 245. Eighty-two 2064 
patients received polymyxins and 85 were treated with ampicillin/sulbactam. The 2065 
authors concluded that ampicillin/sulbactam appeared to be more efficacious than 2066 
polymyxins. More generally, and predictably, multivariate analysis found that 2067 
prognostic factors for in-hospital mortality were older age, septic shock and higher 2068 
APACHE II score. A small retrospective non-blinded trial compared treatment with 2069 
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ampicillin-sulbactam to imipenem and tried also to address the benefit of combining 2070 
ampicillin/sulbactam with colistin. There was no difference in outcome 246, 247. Two 2071 
small RCTs have tried to assess differences in dosing regimens and efficacy compared 2072 
with colistin 248, 249. Overall the evidence base is poor and interpretation is difficult 2073 
without consideration of the MIC for the organism. In context sulbactam MICs for most 2074 
UK isolates of carbapenem-resistant A. baumannii are 16-32mg/L implying poor rates of 2075 
susceptibility (D.M. Livermore, unpublished data). 2076 
Evidence 2077 
Ampicillin/sulbactam appears effective in treating infections due to some carbapenem-2078 
resistant, Acinetobacter spp. but many isolates in the UK have relatively high sulbactam 2079 
MICs.  2080 
Evidence level:  3  2081 
Recommendations 2082 
 Could use against some carbapenem-resistant apparently sulbactam-susceptible 2083 
A. baumannii isolates, Caution needed in the UK because of a higher range of 2084 
MICs. Absence of a breakpoint prevents categorisation as susceptible/resistant. 2085 
Grading: Conditional recommendation for 2086 
7.10 Co-amoxiclav  2087 
Co-amoxiclav is a combination of the broad-spectrum amoxicillin with the beta-2088 
lactamase inhibitor clavulanic acid. Co-amoxiclav is known to select for 2089 
Enterobacteriaceae resistant to the clavulanate component as well as amoxicillin in the 2090 
gastrointestinal flora 250. Co-amoxiclav has been successfully used to treat urinary tract 2091 
infections due to ESBL-producers, as described in case reports and an observational 2092 
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study 251, 252. The cure rate among 37 patients with cystitis treated with co-amoxiclav 2093 
was 93% for those with susceptible isolates (minimum inhibitory concentration ≤8 2094 
mg/L) and 56% for those with intermediate or resistant isolates (minimum inhibitory 2095 
concentration ≥16 mg/L) (P=0.02)251. The study was performed in Spain, where many 2096 
ESBL-producers have CTX-M-14 enzyme; in the UK more have CTX-M-15 and many of 2097 
these co-produce OXA-1, an inhibitor-resistant penicillinase, raising co-amoxiclav MICs 2098 
to the intermediate or resistant range. Furthermore MIC determinations were done 2099 
with a β-lactam: β-lactamase inhibitor ratio of 2:1 and higher MICs would likely be 2100 
obtained using the fixed clavulanate concentration of 2 mg/L now advocated by 2101 
EUCAST. The outcomes for bacteraemias treated with co-amoxiclav or 2102 
piperacillin/tazobactam have been reviewed and the findings are discussed in the 2103 
section on piperacillin/tazobactam 253. 2104 
Evidence 2105 
These studies suggest that co-amoxiclav is effective in lower UTIs caused by ESBL-2106 
producing bacteria but efficacy was only reliably predicted in strains where these 2107 
organisms were fully susceptible in vitro and lacked co-production of OXA-1 β-2108 
lactamase. 2109 
Evidence level:   3 2110 
Recommendations 2111 
 Use for lower UTI due to known ESBL-producing bacteria only if current isolates, 2112 
or, if using empirically, recent isolates, are fully susceptible. 2113 
Grading: Conditional recommendation for 2114 
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7.11 Piperacillin/tazobactam 2115 
Different susceptibility standards are used worldwide and so correlations of mortality 2116 
with in-vitro susceptibility cannot be reliably transferred between countries. EUCAST 2117 
regards more isolates as resistant than CLSI. Some countries such as the UK have a 2118 
higher prevalence of Enterobacteriaceae with CTX-M-15 and, in E. coli, OXA-1 β-2119 
lactamase and these are more resistant than the CTX-M-14 ESBL producers circulating, 2120 
for example, in Spain. This may critically affect the validity of evidence collected from 2121 
different laboratories and hospitals about the adequacy of these combinations against 2122 
ESBL-producing bacteria.  2123 
The use of piperacillin/tazobactam for treating bacteraemias caused by ESBL-producing 2124 
bacteria remains consequently contentious. One recent retrospective analysis of 331 2125 
patients in a US hospital with bacteraemia due to ESBL-producing bacteria suggested 2126 
carbapenems were superior to piperacillin/tazobactam 254. One hundred three (48%) 2127 
patients received piperacillin/tazobactam empirically and 110 (52%) received 2128 
carbapenems empirically. The adjusted risk of death was 1.92 times higher for patients 2129 
receiving empiric piperacillin/tazobactam compared with empiric carbapenem therapy. 2130 
Another retrospective study of bacteraemic patients with ESBL-producing P. mirabilis 2131 
compared the outcomes of patients treated by piperacillin/tazobactam or a carbapenem 2132 
for at least 48 hours 255. Forty-seven patients with available clinical data were studied of 2133 
whom 34 were included. Only 11% of strains were imipenem susceptible but MICs of 2134 
the drug for Proteeae typically cluster around the breakpoint. The overall 30-day 2135 
mortality rate was 29.8%. 3/21 patients treated with carbapenems (all imipenem) died 2136 
within 30 days (all in hospital) versus 4/13 treated with piperacillin-tazobactam – a 2137 
non-significant difference. Furthermore, among those treated by 2138 
piperacillin/tazobactam, the mortality rate was lower in those infected by the isolates 2139 
with lower piperacillin/tazobactam MICs (≤0.5/4 mg/L) when compared with isolates 2140 
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with MICs of ≥1/4 mg/L (0/7 versus 3/5; P = 0.045). A study of 39 episodes of 2141 
bacteraemia due to ESBL-producing E. coli from Spain found a statistically significant 2142 
reduction in 30 day mortality in infections from non-urinary sources if the MIC ≤ 2 2143 
mg/L (0/11) compared with those strains with higher MIC (7/17)256. This suggests that 2144 
even the current EUCAST breakpoints (S<8mg/L, R>16mg/L) are too high to give 2145 
guidance on clinical response. An analysis of patients with bacteraemias due to ESBL-2146 
producing E. coli was performed to assess the efficacy of combinations of 2147 
piperacillin/tazobactam or co-amoxiclav compared with carbapenems 253. Mortality in 2148 
patients treated with such BL/BLI combinations or carbapenem was compared in two 2149 
cohorts: empirical therapy and definitive therapy. Mortality rates at day 30 for those 2150 
treated with BL/BLI versus carbapenems were 9.7% versus 19.4% for empirical 2151 
therapy and 9.3% versus 16.7% for definitive therapy respectively. After adjustment for 2152 
confounders, no association was found between either empirical therapy or definitive 2153 
therapy and increased mortality. The study suggested that co-amoxiclav and 2154 
piperacillin/tazobactam may be suitable alternatives to carbapenems for treating 2155 
patients with bacteraemias due to ESBL-E coli but only in the minority that were 2156 
susceptible in vitro. The study was not randomized, and confounding due to 2157 
unmeasured variables may have occurred. This retrospective observational study has 2158 
been repeated on a multi-national basis and extended to 627 patients with results that 2159 
BL/BLI combinations were statistically as effective as carbapenems in empirical and 2160 
directed therapy against ESBL-producing Gram-negative bacteraemia 257 A subset of 2161 
207 patients had their ESBL genes of their pathogens examined by PCR:42 were 2162 
identified as CTX-M-15, 27 as CTX-M-1, 31 CTX-M-14 and 18 as CTX-M-9. No details 2163 
were given of response rates in relation to the presence of specific resistance genes and 2164 
co-production of OXA enzymes was not sought.  In another study co-amoxiclav and 2165 
piperacillin/tazobactam susceptibility of the bacteria causing bacteraemia, particularly 2166 
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for E. coli ST131, were not correlated: 51% of the isolates also had OXA-1 and 90% of 2167 
isolates were reported susceptible to piperacillin/tazobactam versus 26% susceptible 2168 
to co-amoxiclav by CLSI criteria 258. Such discrepancies with different BL/BLI may relate 2169 
to whether the EUCAST or CLSI breakpoints are used as the MICs for many isolates with 2170 
a combination of CTX-M-15 and OXA-1 enzymes cluster around 16mg/L. The 2171 
relationship of the BL/BLI used and its MIC for infecting strain to efficacy in lower UTIs 2172 
(where urinary concentrations are higher than in serum) or bacteraemia needs to be 2173 
established. More generally, individual drug/inhibitor combinations must be separately 2174 
studied for efficacy, and related to both the β-lactamase genes present and in vitro 2175 
susceptibility. As American commentators have pointed out 259, it is important to note 2176 
the dosing regimen when considering response to piperacillin-tazobactam of many 2177 
ESBLs. Many Spanish studies used piperacillin-tazobactam at 4.5g 6-hourly not the 2178 
usual licensed UK dose of 4.5g 8- hourly. With β-lactams increasing the time above the 2179 
MIC substantially decreases mortality 260. It is possible that more frequent dosing would 2180 
achieve this. More materially this can be achieved with continuous infusion, albeit with 2181 
higher daily drug dosage (which might breach targets to reduce use) and could be 2182 
considered to increase efficacy of piperacillin-tazobactam. It cannot be anticipated with 2183 
biliary excretion whether this will change selection pressure for superinfecting 2184 
organisms or C. difficile in the gastrointestinal flora.  2185 
A retrospective case review of empirical treatment of bacteraemia caused by ESBL-2186 
producing E. coli or ESBL-producing Klebsiella sp. showed a mortality rate of 18/70 2187 
(25.7%) when patients received carbapenems. If they received piperacillin/tazobactam 2188 
8/44 (18.2%) died if the strain retrospectively was susceptible by CLSI criteria but 3/6 2189 
died if the strain was resistant or intermediate Similarly, if they received co-amoxiclav 2190 
3/40 (7.5%) died if the strain retrospectively was susceptible by CLSI criteria but 10/27 2191 
Accepted manuscript 88 
(37%) died if the strain was resistant or intermediate261  piperacillin/tazobactam. Data 2192 
on the genotypes of the ESBL producers present was not provided.  2193 
The findings of all these studies cannot be simply applied to the UK where many ESBL-2194 
producing strains are more resistant than CTX-M-14 as they co-produce CTX-M-15 and 2195 
OXA-1 β-lactamases, with the latter enzyme compromising susceptibility to 2196 
piperacillin/tazobactam. Variable dosing further complicates the picture. 2197 
Piperacillin/tazobactam is commonly used to treat infections caused by P. aeruginosa. A 2198 
retrospective cohort study of bacteraemic patients showed that in 34 episodes of 2199 
bacteraemia caused by strains with a MIC of 32 or 64 mg/L to piperacillin/tazobactam , 2200 
the 30-day mortality was significantly greater than controls given other appropriate 2201 
therapy 262. At the time, CLSI defined strains as susceptible if they had an MIC of 2202 
<64mg/L whereas EUCAST, then as now, has a breakpoint for susceptibility of <= 2203 
16+4mg/L and for resistance >16+4mg/L 2204 
Evidence 2205 
Could use piperacillin/tazobactam in some blood stream infections where ESBL-2206 
producers appear susceptible in vitro but mortality may be higher than with 2207 
carbapenems.  2208 
Evidence level 2- 2209 
Mortality when piperacillin/tazobactam is used in blood stream infection due to ESBL-2210 
producing Enterobacteriaceae without regard to in vitro susceptibility appears higher 2211 
than with carbapenems. 2212 
Evidence level 2+ 2213 
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In vitro susceptibilities by EUCAST and CLSI recommendations on what is a susceptible 2214 
organism differ for Enterobacteriaceae but only two-fold. There is no good analysis of 2215 
the impact of this difference in relation to i) strain MIC ii) clinical outcome of infections 2216 
at different sites and iii) different ESBL genotypes 2217 
Evidence level: 4  .  2218 
Breakpoints for piperacillin/tazobactam against Enterobacteriaceae have changed with 2219 
time. Better outcomes may be seen with isolates much more susceptible (MIC <=2mg/L) 2220 
than the currently agreed piperacillin/tazobactam Enterobacteriaceae breakpoints 2221 
(EUCAST Sensitive if MIC<=8+4mg/L resistant if MIC>16+4mg/LCLSI Sensitive if MIC 2222 
<=16+4mg/l/, resistant if MIC >=128+4mg/L.  2223 
Evidence level: 3 2224 
Recommendations 2225 
 Use for infections with known ESBL-producing bacteria only if current isolates, 2226 
or, if using empirically, isolates from the recent past, are fully susceptible. 2227 
Grading: Conditional recommendation for 2228 
 Consider definitive use of piperacillin/tazobactam to treat infections caused by P. 2229 
aeruginosa if susceptible by EUCAST standards.  2230 
Grading: Conditional recommendation for 2231 
7.12 Aminoglycosides 2232 
Parenteral broad-spectrum aminoglycosides are potentially important carbapenem-2233 
sparing drugs for infections due to MDR-GNB. Three such antibiotics, gentamicin, 2234 
tobramycin and amikacin remain available in the UK following withdrawal of netilmicin 2235 
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and sisomicin. These antibiotics have intrinsic activity against all P. aeruginosa, 2236 
Acinetobacter spp. and Enterobacteriaceae but plasmid-borne resistance (and 2237 
chromosomal resistance in Providencia spp. and Serratia spp.) now limits their 2238 
spectrum. Resistance is mostly due to i) bacterial aminoglycoside-modifying enzymes 2239 
which acetylate, phosphorylate or adenylate vulnerable hydroxyl or amino groups or ii) 2240 
to 16s ribosomal methyltransferases which alter the binding site for aminoglycosides. 2241 
The latter mechanism produces pan-resistance to aminoglycosides except the 2242 
veterinary product apramycin 263. By contrast, the vulnerability of aminoglycosides to 2243 
modifying enzymes varies, with amikacin inactivated by fewer enzymes than 2244 
gentamicin or tobramycin 264. Initially aminoglycoside-modifying enzymes were 2245 
restricted to certain species but integron and transposon carriage have mediated their 2246 
wide dissemination.  2247 
Amikacin evades AAC (3) and AAC (2’) enzymes but remains vulnerable to AAC (6’)-I as 2248 
does tobramycin. AAC(6’)-1b-cr arose from AAC(6’)-1b by the substitutions Trp102Arg 2249 
and Asp179Tyr and can acetylate ciprofloxacin (not levofloxacin) as well as 2250 
aminoglycosides causing deactivation. This enzyme, formerly rare in the UK 265 is 2251 
commonly found in E. coli ST131. Amikacin MICs typically are raised to just below the 2252 
susceptible breakpoint. Such reductions nevertheless may be important since efficacy of 2253 
aminoglycosides is proportional to the ratio of peak concentration to MIC 266. EUCAST 2254 
currently suggests that reports on isolates with this enzyme are edited to amikacin-2255 
resistant but this is under review. In contrast to other common aminoglycoside 2256 
modifying enzymes AAC (6’)-1 spares gentamicin. Aminoglycoside-nucleotidyl 2257 
transferases (ANT-6, ANT-9, ANT-4’, ANT-2”, and ANT-3”) do not confer amikacin 2258 
resistance nor – except APH (3)-V1 which is mostly confined to A. baumannii, do 2259 
aminoglycoside phospho-transferases in Gram-negative species. 2260 
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Overall resistance rates to gentamicin in community-onset E. coli bacteraemia in 2012-2261 
2014 was 8.6%. This is a similar figure to the 8.7% resistance rate to 2262 
piperacillin/tazobactam in community-onset cases. Such data must be considered when 2263 
empirically treating probable Gram-negative bacteraemia of likely urinary or unknown 2264 
origin 94. In the 1980s, parenteral aminoglycoside therapy rarely selected for resistant 2265 
Enterobacteriaceae in the gut flora 267 but oral aminoglycosides given for selective 2266 
digestive decontamination in haematological malignancy frequently did so 268 and 2267 
continued to do so over a 20 year period once resistance emerged, even when combined 2268 
with oral colistin 269.  2269 
There is limited surveillance of the genotypic distribution of aminoglycoside-modifying 2270 
enzymes except in specific strains and in those with other resistances (e.g. ESBL-2271 
producers). Little is known of travel associations beyond those to gentamicin and 2272 
tobramycin (but to a lesser extent amikacin) associated with acquisition of ESBL- or 2273 
carbapenemase producers for which there are clear travel links 270.  2274 
Aminoglycoside activity against P. aeruginosa varies between patients with cystic 2275 
fibrosis where aminoglycosides continue to be heavily used and patients with other 2276 
comorbidities. Resistance due to efflux pumps and permeability defects are common, as 2277 
well as aminoglycoside-modifying enzymes. Tobramycin which has greater intrinsic 2278 
activity than gentamicin against this species (off-setting its lower activity against 2279 
Enterobacteriaceae) and which causes less toxicity than gentamicin, continues to be the 2280 
aminoglycoside most likely to remain active. A recent meta-analysis continues to 2281 
suggest that use of β-lactam aminoglycoside combinations in the absence of cystic 2282 
fibrosis offers no statistically significant advantage in terms of outcome compared with 2283 
use of an active β-lactam alone 271.  2284 
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A new aminoglycoside plazomicin (ACHN 490, Achaeogen)272, 273 274 has completed 2285 
clinical trials. This evades modification by almost all aminoglycoside modifying enzymes 2286 
except the AAC(2’) chromosomal enzymes of Providencia spp. It is however 2287 
compromised by the plasmid mediated ArmA and Rmt 16S ribosomal 2288 
methyltransferases which are currently rare in UK MDR GNB except in 2289 
Enterobacteriaceae strains producing NDM-1 carbapenemase 263 or OXA-23 2290 
carbapenemase-producing A. baumannii which have spread globally over the last 10 2291 
years. 2292 
Aminoglycosides have a narrow margin between being effective and toxic to the 2293 
auditory and vestibular apparatus or to the kidneys. They fell from favour as broader –2294 
spectrum β-lactams were developed. For acceptably safe use, intervals between doses 2295 
are increased usually to a minimum of once daily but with doses related to renal 2296 
clearance and MIC and the presumption of a post-antibiotic effect. If the dosage is based 2297 
on the patient’s weight it is possible, using a nomogram, to model the likely blood 2298 
concentration at varying intervals after the dose. Measuring plasma levels between 6 2299 
and 14 hours after the dose, usually now by immunoassay, and relating these levels on 2300 
to the nomogram permits more precise dosing intervals than by measuring renal 2301 
function. Nomograms for gentamicin and tobramycin at doses of 7mg/kg 275 and 2302 
5mg/Kg 276 in adults have been constructed and their use is associated with a low 2303 
incidence of detected ototoxicity (3/2184 cases in the former). The dosage 2304 
recommendation for amikacin is 15mg/kg/day reflecting that, amikacin MICs are 2 to 4 2305 
fold higher than gentamicin MICs for susceptible strains. Much higher incidences of 2306 
toxicity with all aminoglycosides are well recorded and it is still common to encounter 2307 
in the UK deficiencies in i) weight-related dosage ii) dosage interval especially if there is 2308 
renal impairment, iii) measuring levels in every case, and iv) taking blood for assay at 2309 
the correct interval after dosage and recording both the time of administration and time 2310 
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of sample collection to enable later interpretation of assay results by other staff. 2311 
Validation of expected and achieved serum levels has been undertaken for 7mg/kg dose 2312 
but not 5mg/kg doses which are based on exclusion of some patients considered in the 2313 
former study. There is no validated nomogram for amikacin 277 and immunoassays for 2314 
this antibiotic are not widely available on automated immunoassay platforms. There are 2315 
no trial data on amikacin use in E. coli ST131. Vestibular toxicity with all 2316 
aminoglycosides commonly presents after the drug has stopped and the patient has left 2317 
hospital 278, 279. Toxicity can occur after normal courses of 5 daily doses or even a single 2318 
dose 278. Auditory toxicity is initially often subclinical requiring audiograms to detect. 2319 
The true incidence of toxicity is difficult to determine. Renal toxicity can be measured by 2320 
quantitative renal function tests or qualitative urinary renal tubular enzymes. These 2321 
critical steps to safe use as determined by case follow-up after the patient has left 2322 
hospital, have not yet been assessed for plazomicin although there are no described 2323 
cases of toxicity yet in clinical trials. In older studies before the adoption of once daily 2324 
regimens and weight-related dosage, auditory toxicity appears to have been commoner 2325 
with amikacin than gentamicin whilst vestibular toxicity rates were not significantly 2326 
different 280: toxicity was commoner with increasing age paralleling a decline in renal 2327 
function 281. This creates an issue, insofar as infections with MDR GNB and ESBL-2328 
producers occur more frequently among those aged over 65 years and especially over 2329 
75 years of age. It is noteworthy that one recent Scottish national intervention in 2330 
surgery as part of targeted antimicrobial stewardship measures to reduce the incidence 2331 
of C. difficile by 30% in 2 years was to substitute use of gentamicin for cephalosporins in 2332 
prophylaxis in surgery. In Tayside, a interrupted time series with segmented regression 2333 
in 7666 patients undergoing orthopaedic surgery (excluding fractured neck of 2334 
femur),where 2 doses of flucloxacillin 1G and one dose of 4mg/Kg gentamicin were 2335 
substituted for cefuroxime was performed. An unacceptable 94% increase in acute 2336 
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kidney injury in gentamicin-treated patients occurred and the gentamicin use was 2337 
stopped 282. Patients undergoing implant surgery had a mean age of 71 years and 36% 2338 
had received non-steroidal anti-inflammatory drugs in the last year and 38% received a 2339 
diuretic which are known cofactors for gentamicin nephrotoxicity but this was adjusted 2340 
for in the study. One year mortality was higher in the acute kidney injury group (20.8% 2341 
vs. 8.2%). There was no association of acute kidney injury in a further 4816 patients in 2342 
other surgical specialties where gentamicin was substituted. It is not certain whether 2343 
the effect was due to gentamicin, flucloxacillin, or the combination or whether all 2344 
patients additionally received gentamicin bone cement. 2345 
Evidence: 2346 
Aminoglycosides retain activity against a similar proportion of Enterobacteriaceae to 2347 
piperacillin/tazobactam (8.6-8.7%). However approximately 50% of ESBL-producing E. 2348 
coli in the UK are resistant to gentamicin and more to tobramycin. 2349 
Evidence level: 3 2350 
Overall resistance rates to amikacin are lower than to gentamicin and tobramycin in the 2351 
UK. However bacteria producing AAC(6’) are usually amikacin resistant and bacteria 2352 
producing the AAC(6’)-1b-cr enzymes including many E. coli ST131 often have reduced 2353 
amikacin susceptibility. Strains producing NDM-carbapenemase often carry 16S 2354 
ribosomal methyltransferases which confer high-level pan-resistance to 2355 
aminoglycosides including amikacin and plazomicin. 16S ribosomal methyltransferases 2356 
are also frequent in UK A. baumannii.  2357 
Evidence level: 3 2358 
Plazomicin, a new aminoglycoside evades almost all aminoglycoside-modifying 2359 
enzymes but is inactive if 16s ribosomal methyltransferases are present. It has recently 2360 
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completed a phase 3 RCT with superiority to meropenem in complicated UTI so far 2361 
reported only in a press release. 2362 
Evidence level: 3 2363 
Historically parenteral aminoglycosides rarely proved selective for resistance among 2364 
Enterobacteriaceae in the faecal flora. However, because of resistance linkage and 2365 
carriage on transposons and integrons aminoglycoside resistance may be selected by 2366 
use of other antibiotics.  2367 
Evidence level 3 2368 
Evidence from travel-associated ESBL-producers suggests that aminoglycoside-2369 
resistance may also be travel-associated. The co-carriage of 16S ribosomal 2370 
methyltransferases by strains with NDM-carbapenemase linked to the Indian sub-2371 
continent is noteworthy. 2372 
Evidence level: 3 2373 
The narrow therapeutic index of aminoglycosides demands attention to the detail of 2374 
weight-related dosing and frequency of doses, collection of blood at an appropriate time 2375 
for assays, and the careful interpretation of antibiotic assays by nomograms. These 2376 
actions are essential for adequately safe management of patients treated with 2377 
gentamicin and tobramycin. Similar modern safety measures are likely to be necessary 2378 
for amikacin and plazomicin but nomograms are not, and assays may not be, widely 2379 
available.  2380 
Evidence level: 4 2381 
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When strains are susceptible and safety measures are well-organised and reviewed in 2382 
hospitals, gentamicin and tobramycin are useful carbapenem-sparing agents for 2383 
definitive treatment. 2384 
Evidence level: 4 2385 
Recommendations 2386 
 Could use gentamicin empirically in the UK if the likelihood of MDR GNB is low. 2387 
Grading Conditional recommendation for 2388 
 Could use gentamicin as a carbapenem sparing agent for urinary, intra-2389 
abdominal and bacteraemic infections due to ESBL-producing E. coli when 2390 
susceptibility is confirmed but do not use empirically if the risk of MDR GNB is 2391 
raised 2392 
Grading: Conditional recommendation for. 2393 
 Could use gentamicin in combinations for urinary, intra-abdominal and 2394 
bacteraemic infections due to gentamicin-susceptible KPC-producing Klebsiella 2395 
spp. if strain is resistant to colistin and meropenem (See Section 7.18). 2396 
Gradingl: Conditional recommendation for 2397 
 Use once daily dosage of gentamicin if no renal impairment followed by 2398 
measurement of levels 6 to 14 hours post dose and adjust repeat dosage by 2399 
reference to the appropriate 7mg/kg or 5mg/kg nomogram. Consider increased 2400 
risks of toxicity if there is co-administration of nephrotoxic or ototoxic drugs. 2401 
Grading: Strong recommendation for. 2402 
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 Avoid tobramycin for MDR Enterobacteriaceae because of risk of resistance due 2403 
to AAC (6’)1 and AAC (6’)-1b-cr 2404 
Grading: Conditional recommendation against 2405 
 Use tobramycin in preference to other aminoglycosides for susceptible 2406 
Pseudomonas infection 2407 
Grading: Conditional recommendation for 2408 
 Use once daily dosage of tobramycin if no renal impairment followed by 2409 
measurement of levels 6 to 14 hours post dose and adjust repeat dosage by 2410 
reference to nomogram.  2411 
Grading: Strong recommendation for 2412 
 Modernise use of amikacin, which has improved activity, with development of 2413 
validated nomograms. Ensure assays are readily available before repeat doses 2414 
and consider, because of the risks of toxicity, the practicality of monitoring with 2415 
audiograms.  2416 
Gradingl: Conditional recommendation for. 2417 
7.13 Polymyxins 2418 
The polymyxins are a group of five chemically different bactericidal antibiotics 2419 
(polymyxins A to E). Only polymyxin B and polymyxin E (colistin) have been used in 2420 
clinical practice. Intravenously administered colistin methane sulphonate is most 2421 
widely used, and requires conversion in the body to the active colistin molecule.  2422 
Polymyxins have a wide spectrum of activity against Gram-negative organisms, 2423 
including most Enterobacteriaceae, A. baumannii, P. aeruginosa and S. maltophilia, but 2424 
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are inactive against B. cepacia, Proteus spp., Providencia spp., Morganella spp. and 2425 
Serratia marcescens. Resistance to colistin occurs in some P. aeruginosa isolates283 but 2426 
remains rare and almost exclusive to cystic fibrosis isolates. Acquired colistin resistance 2427 
is generally rare but has become common in K. pneumoniae in Italy. Colistin 2428 
heteroresistance is defined as the emergence of resistance to colistin in a subpopulation 2429 
of an otherwise susceptible (MIC of ≤2 mg/L) population 284. This may be related to 2430 
exposure to suboptimal polymyxin concentrations. Detection of resistance or hetero-2431 
resistance is difficult,506 and is reviewed elsewhere.507   2432 
Etest®, disc diffusion, Microscan®285 and VITEK2® detections methods are currently 2433 
unreliable,286 and data for Phoenix® are only published for Acinetobacter baumannii. A 2434 
comparison of BMD was made with VITEK2®, Sensititre™ and Etest® using a collection 2435 
of 76 Enterobacteriaceae, including 21 MCR-1 positive strains.508 Both Etest® and 2436 
VITEK2® performed poorly against BMD with very major error (VME) rates of 12% 2437 
(ETest®) and 36% (VITEK2®) for colistin.508 Poor performance of both Phoenix® and 2438 
VITEK2® with substantial under reporting of resistance has been reported when using 2439 
these systems for testing Acinetobacter baumanii.509   2440 
The difficulty of detecting colistin resistance in routine laboratories was evident in a 2441 
recent US study.287 Resistance to gentamicin was rarer and tigecycline resistance 2442 
commoner in colistin-resistant isolates. Colistin resistance was associated with 2443 
increased hospital mortality. Most colistin resistance is chromosomally mediated, 2444 
involving various mutations that modulate two component regulatory systems (e.g. 2445 
pmrAB, phoPQ and its negative regulator mgrB in the case of K. pneumoniae), leading to 2446 
modification of lipid A with moieties such as phosphoethanolamine or 4-amino-4-2447 
arabinose, or in rare instances to total loss of the lipopolysaccharide 288. Of concern is 2448 
the recent reporting of plasmid-mediated polymyxin-resistance lipid A-modifying 2449 
enzymes (MCR-1 and 2) that confer resistance in Enterobacteriaceae 24. MCR-1 was first 2450 
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found in China but is now being detected worldwide mainly in Enterobacteriaceae of 2451 
animal origin but also in occasional human isolates. It remains much rarer than 2452 
mutational resistance. China plans to stop use of 8000 tons of colistin in animal feed 2453 
from April 2017. A recent study shows mcr-1 genes are very widespread (50-100%) in 2454 
chicken in hatcheries, commercial farms and supermarkets and a slaughterhouse in 2455 
Shandong, Although testing of hatcheries was negative, NDM-carbapenemase-producing 2456 
E. coli were recovered from 21.8% of samples; 23% of carbapenem-resistant E. coli 2457 
tested MCR-1 positive and multiple sequence types and NDM subtypes were found289. 2458 
There are widespread reports of MCR-1 in the European (including UK) food-chain.510  2459 
Synergy studies suggested many years ago 290-294 that polymyxins, trimethoprim and 2460 
sulphonamides might be useful together in therapy and these studies need repeating 2461 
with other agents and newer strains.  2462 
Pharmacokinetic and pharmacodynamic data have been limited, particularly in critically 2463 
ill patients. Polymyxins were developed before the advent of contemporary drug 2464 
evaluation. Colistin methanesulfonate is an inactive pro-drug converted in vivo to the 2465 
active drug and different brands may produce different concentrations of active drug. 2466 
Data suggested drug concentrations are very variable and dosing in excess of data-sheet 2467 
recommendations may be required commonly on the basis of pharmacokinetic 2468 
parameters 295. Recently the FDA and European medicines agency have made new, but 2469 
different, recommendations for intravenous colistin in patients with various degrees of 2470 
renal function. These have been assessed using data from 162 adult critically ill patients 2471 
with varying renal function. A comparison showed that adequate serum levels with 2472 
impaired renal function were more likely to be attained with European guidelines and a 2473 
later paper suggests that in the critically ill target concentrations are difficult to achieve 2474 
if creatinine clearance =>80ml/min/1.73m2. 296, 297. Data are also now available on the 2475 
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implications of haemodialysis 298. Therapeutic drug monitoring is advisable, if available 2476 
and depends critically on maintaining stability of the drug in separated plasma. 2477 
Colistin can be given intravenously, or in respiratory infection via the aerosol route 2478 
(typically in patients with CF; either alone or combined with IV administration), or 2479 
intrathecal.  2480 
Polymyxin B or colistin sulphate can be given orally as a non-absorbed major 2481 
component of selective digestive decontamination regimens. Selective digestive 2482 
decontamination has been widely used for general infection prevention in neutropenia 2483 
and intensive care. Polymyxins orally were widely added in haematology to 2484 
aminoglycosides, trimethoprim-sulfamethoxazole 299 or ciprofloxacin 269 to prevent 2485 
emergence of resistance and in intensive care units to parenteral cephalosporins and 2486 
oral tobramycin 300. Recent findings that colistin resistance is difficult to detect 2487 
accurately and it’s frequency is usually underestimated, the clear emergence in China 2488 
and elsewhere of plasmid mediated resistance and the emergence of colistin resistance 2489 
in KPC-producing Klebsiella spp. in Italy, China and the USA imply that it can no longer 2490 
be relied on to prevent emergence of resistant strains in patients who have strains that 2491 
are already frequently resistant to the drugs it was added to protect. Use of colistin in all 2492 
patients in such a unit might well become a mechanism now for selection for XDR GNB 2493 
or indeed pan-drug resistant MDR GNB in the critical care and haematology units where 2494 
it is used. This is an enduringly controversial area 301 which we do not have space to 2495 
fully review but such selection of colistin resistance in ESBL-producing Klebsiella spp. in 2496 
an ICU has already been reported 302. We consider continued use of colistin-containing 2497 
decontamination regimens should be reviewed urgently within specialties 303and at the 2498 
local level, and in our judgement is now unwise.  2499 
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Clinical reports and reviews of experience with colistin are relatively encouraging, with 2500 
side effects (principally nephrotoxicity and neurotoxicity) observed less often than 2501 
expected from historical data 304-309. These studies are summarized in Table 6. In Italy 2502 
strict rules for the use of colistin are advocated to stop the spread of colistin resistant 2503 
KPC-producing Klebsiella spp., which have increased three fold in 4 years among 2504 
bacteraemic patients. A case-control study of this guidance showed associations of 2505 
resistance with previous colistin therapy, previous colonization or infection with KPC-2506 
producing Klebsiella spp., and a Charlson comorbidity score >3 (all of which were 2507 
associated with mortality) and also with neutropenia and >3 hospitalisations 310. 2508 
The addition of aerosolized to IV colistin has been compared with IV colistin alone for 2509 
the treatment of VAP in several studies. Korbila and colleagues demonstrated an 2510 
improvement in outcome with the addition of aerosolized colistin 311 but no benefit was 2511 
demonstrated in another study 312. Both had methodological flaws. NICE has recently 2512 
reviewed the usefulness of aerosolised colistin or tobramycin dry powders in patients 2513 
with cystic fibrosis and concluded there were some patients who would benefit from 2514 
colistin dry powder with cost reduction 313. 2515 
Polymyxin B is more toxic than colistin (polymyxin E) but has the advantage of not 2516 
requiring subject-variable conversion to an active form, A recent retrospective cohort 2517 
study compared 45 patients with P. aeruginosa bacteraemia treated with polymyxin B at 2518 
a median dose of 141+/-54 mg/day usually in 2 divided doses: 11 received 2519 
>200mg/day. Eighty eight patients were treated with a comparator (typically a β-2520 
lactam). The in-hospital mortality was 66% in the arm treated with polymyxin B versus 2521 
28% for those treated with a comparator, even when matched for mechanical 2522 
ventilation and sepsis score suggesting polymyxin B was inferior 314. This was 2523 
regardless of dosing regimens. A higher dose (≥200mg/day) of polymyxin B was found 2524 
to be associated with reduced mortality but increased renal impairment in another 2525 
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retrospective cohort study 315. We do not recommend use of polymyxin B in the light of 2526 
these results. 2527 
 Combinations including colistin are more effective than monotherapy in treating K. 2528 
pneumoniae carbapenemase (KPC) infections (See 7.18) 316, 317. 2529 
Nephrotoxicity and neurotoxicity are the principal side effects associated with 2530 
parenteral administration of polymyxins. The toxicity demonstrated in earlier studies 2531 
was almost certainly related to lack of understanding of the drug’s PK/PD and the use of 2532 
inappropriate doses 318. Studies now suggest that age, high doses, prolonged courses, 2533 
concomitant vancomycin, hypoalbuminaemia and non-steroidal anti-inflammatory 2534 
drugs, are independent risk factors for nephrotoxicity 319, 320 and it is likely that other 2535 
nephrotoxic drug are also associated. Monitoring renal function closely is essential for 2536 
patients receiving colistin. Recent expert opinion suggests the risk benefit ratio should 2537 
be carefully considered with strategies applied to reduce toxicity321. There is no 2538 
information on the dose-relationship of reversible neurotoxicity or encephalopathy: in a 2539 
recent large paediatric series they occurred in 2% of patients 322  2540 
There are gaps in our knowledge about these agents. Although they were developed 2541 
some seventy years ago . they have only recently been used extensively. Much of the 2542 
current knowledge is summarised in the Prato consensus report 323.  2543 
Dosing of intravenous colistin remains contentious. In adult cystic fibrosis (CF) patients, 2544 
colistin is typically given at a standard dose of 2MU 8-hourly. However, evidence is 2545 
emerging that higher-dose regimens may be more appropriate in the ICU setting (with 2546 
therapeutic drug monitoring: to target a peak of 5-15mg/L and a trough of 2-6mg/L). A 2547 
recent study of significant infections caused by a range of MDR GNB suggested that a 2548 
loading dose of 9MU followed by 4.5MU twelve hourly reduced in renal impairment was 2549 
effective (23/28 responses) and resulted in a reversible mild renal injury in only 5 2550 
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patients 324. Further clinical and PK/PD studies are required to confirm appropriate 2551 
regimens including in relation to a loading dose, combination therapy and the need for 2552 
monitoring. In the meantime European medicines agency guidance should be followed. 2553 
Evidence 2554 
Colistin is effective in treatment of infections caused by MDR GNB with low mortality at 2555 
higher-than-previous, but well-controlled dosage. 2556 
Evidence level: 3  2557 
The role of loading doses of colistin, monitoring of serum levels and optimal 2558 
combination therapy are inadequately researched. 2559 
Evidence level: 4  2560 
Use of aerosolized colistin dry powder has recently been accepted by NICE in cystic 2561 
fibrosis. 2562 
Evidence level: 3 2563 
Use of aerosolized colistin dry powder in ventilator-associated pneumonia as an 2564 
addition to intravenous chemotherapy appears useful. 2565 
Evidence level: 3 2566 
The dose-relationship of colistin nephrotoxicity and the rarer neurotoxicity and 2567 
encephalopathy, require investigation. 2568 
Evidence level: 4 2569 
Recommendations 2570 
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 Reserve intravenous polymyxins for infections due to susceptible multi-resistant 2571 
strains and preferably used in combination with other agents.   2572 
Grading: Conditional recommendation for 2573 
 Give careful consideration to use of higher dosage regimens in critically ill 2574 
patients. 2575 
Grading: Conditional recommendation for 2576 
 Closely monitor renal function especially in the elderly, those receiving high 2577 
intravenous doses for prolonged periods and those on concomitant nephrotoxic 2578 
agents e.g. aminoglycosides.   2579 
Grading: Strong recommendation for 2580 
 Reconsider use of polymyxins in selective digestive decontamination regimens as 2581 
these agents are now important last therapeutic options against carbapenemase-2582 
producing Enterobacteriaceae and are more threatened by resistance than 2583 
previously appreciated. 2584 
Grading: Good practice point 2585 
 Need research on optimal rapid and practical methods of susceptibility testing 2586 
outside intrinsically resistant groups such as Proteeae and Serratia spp. 2587 
Grading: Recommendations for research 2588 
 Aerosolised colistin dry powder should be used in cystic fibrosis according to 2589 
NICE guidelines. Use in combination in ventilator-associated pneumonia may be 2590 
considered pending further trials without methodological flaws. 2591 
Grading: Conditional recommendation for 2592 
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7.14 Fluoroquinolones 2593 
Fluoroquinones suppress susceptible Enterobacteriaceae in the intestinal flora and also 2594 
select for quinolone-resistant MDR GNB 250 131. Such suppression has been used in 2595 
neutropaenic patients alone or with colistin 269. The continued efficacy of this 2596 
combination in suppression and non-selection of resistance to either agent needs re-2597 
establishing, with the increasing recognition of colistin resistance which may well 2598 
emerge alongside existing quinolone-resistance. Prophylaxis with quinolones alone in 2599 
neutropenia against susceptible bacteraemia seems effective even when quinolone-2600 
resistance levels in the treated population reach a high level. Trials of withdrawing 2601 
prophylaxis have been reported and show problematic increases in Gram-negative 2602 
bacteraemia (See 6.5.) 2603 
Fluoroquinolones (intravenous and oral) may be suitable for complicated urinary tract 2604 
infections due to ESBL-producing Enterobacteriaceae if there is no resistance in vitro: 2605 
however most ESBL-producing strains in the UK are resistant to fluoroquinolones 2606 
including ciprofloxacin and levofloxacin. Furthermore quinolone resistance without 2607 
ESBL production is now frequent, particularly in the multiple resistant if not MDR E. coli 2608 
ST131 89. Newer quinolones in development are unlikely to provide substantial 2609 
additional benefits over ciprofloxacin for infections due to Gram-negative pathogens. 2610 
Three observational clinical studies have assessed the relative merits of quinolones and 2611 
carbapenems for serious infections due to ESBL-producing organisms 181, 325, 326. Two of 2612 
these found that carbapenems were superior to quinolones, although most strains were 2613 
quinolone susceptible, whereas one study found equivalent effectiveness. 2614 
Fluoroquinolones have been used to treat infections caused by S. maltophilia; however 2615 
resistance is not uncommon so combination with one or more of: 2616 
trimethoprim/sulfamethoxazole, ceftazidime, or tigecycline has been proposed 327. 2617 
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These combinations have not been shown to offer any advantages over 2618 
trimethoprim/sulfamethoxazole alone.  2619 
A wide range of resistance mechanisms exist: high-level resistance almost always 2620 
involves mutations in the genes encoding subunits of the target-enzymes, DNA gyrase 2621 
and topoisomerase 1V (gyrA and parC respectively), but reduced susceptibility can arise 2622 
from plasmid-acquired genes e.g. aac (6’)-1b-cr, oqxAB, qnrA, etc.  or via up-regulation of 2623 
outer-membrane efflux pumps and porin loss 328.  2624 
Evidence 2625 
Quinolones are effective in treatment of complicated urinary tract infection caused by 2626 
susceptible ESBL- producing Gram-negative bacteria, but resistance is common limiting 2627 
their usefulness. 2628 
Evidence level: 2+     2629 
Recommendations 2630 
 Could use orally to treat UTI caused by MDR GNB that are susceptible   2631 
Grading: Conditional recommendation for 2632 
7.15 Tigecycline and eravacycline 2633 
Tigecycline is a semisynthetic glycylglycine derivative of minocycline and like other 2634 
tetracyclines is bacteriostatic. 329. The main determinant of acquired plasmid-mediated, 2635 
resistance to older tetracyclines in Gram-negative bacteria, namely active efflux by Tet 2636 
pumps is overcome by steric hindrance by a large substituent group. Tigecycline has in 2637 
vitro activity against most Enterobacteriaceae except Proteeae i.e. Proteus spp., 2638 
Providencia spp. and Morganella morganii. MICs for A. baumannii (including many 2639 
carbapenem resistant strains) and S. maltophilia are low (mostly 0.25-2mg./L) but, 2640 
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there are no break points or convincing efficacy studies. In common with other 2641 
tetracyclines, tigecycline lacks useful activity against P. aeruginosa. . Tigecycline is 2642 
vulnerable to the chromosomal resistance–nodulation–cell division (RND) multi-drug 2643 
efflux pumps, including MexXY–OprM of P. aeruginosa, and the AcrAB pump found in 2644 
Proteus mirabilis which explains the intrinsic resistance of these species 330, 331.  2645 
Whilst tigecycline-resistant isolates of Enterobacteriaceae have been described from 2646 
treatment naïve patients, another potential problem is the development of resistance 2647 
during treatment of infections with Enterobacteriaceae and Acinetobacter spp. by the 2648 
mutational up-regulation of RND pumps, but the frequency is unclear particularly when 2649 
used in combination  332-336. Use of tigecycline is an independent predictor of emergence 2650 
of tigecycline resistance when treating multi-resistant K. pneumoniae infection 337. 2651 
Further studies are required, possibly including different dosing regimens and in 2652 
combination with other agents. Tigecycline has a potential to favour superinfections by 2653 
P. aeruginosa, Proteeae 338 and sometimes Klebsiella spp. 339 337; again, these aspects 2654 
require further investigation.  2655 
Subject to the earlier caveat about the lack of breakpoints, tigecycline has in vitro 2656 
activity against S. maltophilia, and susceptibility rates of >87% have been reported 340. 2657 
However there is little clinical experience with the drug in treating infections caused by 2658 
this organism. 2659 
Intravenous tigecycline is licensed for the treatment of complicated skin and soft tissue 2660 
infections and complicated intra-abdominal infections 341, 342. However, the US FDA 2661 
issued a warning describing an increased mortality risk with its use when compared 2662 
with other drugs343, 344. The highest risk was in patients treated for ventilator-associated 2663 
pneumonia, which was not a licensed indication. However even in FDA approved uses 2664 
there was a higher risk of death among patients given tigecycline compared with those 2665 
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given other antibacterial drugs 345, 346. There are no RCTs comparing tigecycline with 2666 
polymyxins, fosfomycin, sulbactam and other antibiotics against infections due to MDR 2667 
GNB, alone or in combinations 347.  Several meta-analyses examine the efficacy and 2668 
safety of tigecycline in general (not just against MDR GNB) and these reported 2669 
conflicting findings. One very recent analysis reviews the earlier studies and includes a 2670 
number of new trials. Clinical success rates were lower than comparator for hospital-2671 
acquired pneumonia and diabetic foot infection, with increased gastrointestinal adverse 2672 
events and higher all-cause mortality probably due to reduced efficacy 348.  2673 
Further work on tigecycline is needed, as its efficacy in ventilator associated pneumonia 2674 
might be improved using higher doses (i.e. 200 mg initial and then 100 mg twice daily): 2675 
an increase in adverse events was not seen with this regimen349 . Tigecycline in 2676 
combination with other antibiotics (e.g. carbapenems and polymyxins) is a potentially 2677 
valuable approach for infections caused by carbapenemase-producing Klebsiella spp., as 2678 
shown by Tumbarello et al. (2012).350  In this retrospective cohort study largely of 2679 
infections due to strains with KPC-3 carbapenemase 9/19 patients survived on 2680 
tigecycline monotherapy, 0/11 on colistin monotherapy and 16/23 with tigecycline and 2681 
colistin combinations. Two comparisons of monotherapy and combination therapy for 2682 
infections with carbapenemase-producing Klebsiella spp. give further survival data on 2683 
monotherapy: survival was respectively 71/116 for tigecycline and 70/132 for colistin 2684 
316 and 16/27 for tigecycline and 12/22 for colistin 351. 2685 
Whilst the in vitro data supports use of tigecycline in respiratory infection there is poor 2686 
correlation between the laboratory results and clinical outcome 334, 352, 353.  2687 
Eravacycline is a novel intravenous fluorocycline with a similar spectrum to tigecycline. 2688 
It showed non-inferiority to ertapenem in a Phase 3 trial of complicated intra-2689 
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abdominal infection but failed to show non-inferiority to levofloxacin in an iv/oral 2690 
switch Phase 3 trial of complicated UTI 354-356. 2691 
Evidence 2692 
The role of tigecycline remains uncertain in the treatment of infections due to MDR 2693 
GNB. 2694 
Evidence level: 1-      2695 
Recommendations 2696 
 Could use tigecycline in combination in the treatment of multi-resistant soft 2697 
tissue and intra-abdominal infections  2698 
Grading: Conditional recommendation for 2699 
 Use alone in hospital-acquired respiratory infections is unlicensed and not 2700 
advised with licensed dosing as outcomes are not clearly satisfactory in 2701 
Acinetobacter and MDR GNB infections.  2702 
Grading: Conditional recommendation against  2703 
 Use in combinations in hospital-acquired respiratory infections: precise 2704 
combinations depend on the antibiotic-susceptibility of the MDR GNB causing 2705 
the infection. 2706 
Grading: Recommendation for research and possibly conditional 2707 
recommendation for use restricted to trials 2708 
 Use higher-than licensed dosing such as 100mg twice daily for infections due to 2709 
MDR GNB in critical care 2710 
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Grading: Conditional recommendation for 2711 
 Investigate if higher dosing counters the unexpectedly high mortality seen even 2712 
in infections due to strains apparently susceptible in vitro.  2713 
Grading: Recommendation for research and possibly conditional 2714 
recommendation for use restricted to trials 2715 
7.16 Fosfomycin 2716 
Fosfomycin, a strongly hydrophilic phosphonic acid (unrelated to aminoglycoside or 2717 
macrolide antibiotics), inhibits the addition of phosphoenol-pyruvate to N-acetyl-2718 
glucosamine in synthesis of the bacterial cell wall. Fosfomycin MICs of E. coli vary from 2719 
1-4mg/L : those for Klebsiella spp. are higher at 2-64mg/L. EUCAST breakpoints for both 2720 
IV and oral formulations are S ≤32mg/L, R >32mg/L, available for E. coli only. 2721 
Morganella morganii and Bacteroides spp. are inherently resistant and activity against P. 2722 
aeruginosa is controversial, particularly in combination, although MICs=>128mg/L. The 2723 
drug is otherwise very broad in its spectrum. Fosfomycin was active against 72% of 2724 
Enterobacteriaceae resistant to carbapenems in a German study 357. In vitro testing with 2725 
discs required the addition of Glucose-6-phosphate to the disc. In this study there were 2726 
22% major discrepancies between agar dilution in medium containing glucose-6-2727 
phosphate and disc or E-test testing and it is not clear if glucose-6-phosphate was 2728 
present in discs and MIC gradient strips, an area for quality control development.  There 2729 
are similarly no published details on the reliability of automated susceptibility testing 2730 
methods.  2731 
Fosfomycin trometamol is used as an oral treatment for patients with uncomplicated 2732 
lower UTI due to fosfomycin-susceptible organisms resistant to first line agents. At the 2733 
conventional dosage of 3g on a single occasion this oral formulation gives an adequate 2734 
urinary concentration for 2 days (see 9.3.). An earlier oral product was a calcium salt 2735 
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only 30-40% of which was absorbed: this gave peak plasma levels of 7 to 9mg/L 4 hours 2736 
after a 3g dose. The trometamol salt which replaced this is better absorbed (60% 2737 
bioavailable) reaching peak plasma levels of 32mg/L 2 hours after a 3g dose. ).   2738 
Experience with IV fosfomycin disodium (not a trometamol formulation) is limited in 2739 
the UK where it has only recently been introduced specifically for treatment of infection 2740 
with multi-resistant bacteria. It has been more widely used elsewhere in Europe. The 2741 
intravenous sodium salt reaches levels of 25mg/L after a 1G dose. A very early single 2742 
open comparison of 38 patients with acute pyelonephritis showed that 7 days of 2743 
intravenous fosfomycin 2g six hourly achieved only a 44% response rate 358; the authors 2744 
therefore concluded the drug had no role in pyelonephritis: the oral trometamol salt has 2745 
never been examined for pyelonephritis. Intravenous dosage with MDR GNB is now 2746 
usually at 24g/day in 3 divided doses but dosage reduction is needed in renal 2747 
impairment as the drug is exclusively renally excreted, unchanged. The formulation has 2748 
a high sodium load and the most frequently encountered side effect is hypokalaemia 2749 
(26% patients) 359. Fosfomycin exhibits excellent penetration into tissue after an 2750 
intravenous dose as it is a small (138 Da), molecule with negligible protein binding; it 2751 
also has a long serum half-life of between 4 – 8 hours 360.  2752 
A prospective salvage study of 11 ICU patients with serious infections caused by 2753 
carbapenem-resistant K. pneumoniae reported an all-cause mortality of 2/11, although 2754 
analysis of the claimed successes is complicated because 6 patients were also treated 2755 
with colistin and 3 with gentamicin 361. A larger outcome study of 48 patients (mainly 2756 
VAP) infected with KPC-producing K. pneumoniae and to a lesser extent, VIM-producing 2757 
P. aeruginosa reported clinical success when fosfomycin was used mainly in 2758 
combination with colistin or tigecycline in 54.2% patients and 28-day all-cause 2759 
mortality of 37.5% 362. Of 15 patients with colistin-, tigecycline- aminoglycoside- and 2760 
carbapenem- resistant KPC-producing Klebsiella infection (one with an additional 2761 
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carbapenem-resistant P. aeruginosa) 9 responded to fosfomycin combinations and in 8 2762 
microbiological eradiation was achieved. 2763 
The use of intravenous fosfomycin has been reviewed extensively. Clinical cure was 2764 
described in 1242 of 1529 (81.2%) of patients overall (for both Gram-positive and 2765 
Gram-negative pathogens) 363. Most of the Gram-negative infections in this series were 2766 
due to P. aeruginosa, (which most would regard as resistant), but also included 2767 
infections due to Enterobacter spp., Klebsiella spp., E. coli, Proteus spp. and S. typhi. Most 2768 
patients also received concomitant antibiotics, so again interpretation is difficult. A wide 2769 
variety of infections were treated and fosfomycin was well tolerated. Despite in vitro 2770 
resistance to fosfomycin, most patients with infections caused by P. aeruginosa 2771 
improved although this may reflect concomitant antibiotics. 2772 
Further detailed studies of the parenteral form used alone in single indications (such as 2773 
urinary tract infection, and ventilator-associated pneumonia are required to establish 2774 
its relative efficacy and usefulness for specific MDR GNB. Similarly in combination 2775 
therapy comparisons of specific combinations are required.  2776 
Evidence 2777 
Further details and regimens for the oral formulation are given in 9.6.3. 2778 
The parenteral formulation may be a valuable treatment alternative for infections due 2779 
to MDR GNB including carbapenemase- and MBL- producing strains. However, further 2780 
detailed comparative trial experience is necessary to determine its optimal use. 2781 
Evidence level: 3   2782 
Recommendations 2783 
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 Consider parenteral fosfomycin, probably in combination, as part of salvage 2784 
treatment for susceptible MDR GNB: clear indications for use are not yet 2785 
established. 2786 
Grading: Conditional recommendation for.  2787 
 Need comparative clinical trials to establish optimal indications for, and optimal 2788 
use of, parenteral fosfomycin, a potential drug of last resort against MDR GNB.  2789 
Grading: Recommendation for research and possibly conditional recommendation 2790 
for use restricted to trials. 2791 
7.17 Trimethoprim/sulfamethoxazole 2792 
Trimethoprim/sulfamethoxazole (available as intravenous and oral formulations) has in 2793 
vitro activity against Stenotrophomonas maltophilia340 and some less frequently 2794 
encountered non-fermenting Gram-negative bacilli (e.g. Achromobacter spp., Alcaligenes 2795 
spp., Burkholderia spp., Chryseobacterium spp. and Elizabethkingia spp.)364. These species 2796 
have inherent resistance to most other antibiotics and often produce MBLs. 2797 
Stenotrophomonas sp. typically have similar percentage susceptibility at the CLSI 2798 
breakpoint to sulphonamides alone and trimethoprim/sulfamethoxazole but are 2799 
resistant to trimethoprim alone. The combination has greater in-vitro potency than 2800 
either trimethoprim or sulfamethoxazole. A similar comment applies to Achromobacter 2801 
spp. and with few exceptions to Alcaligenes spp. Chryseobacterium spp. and 2802 
Elizabethkingia spp..364 These genera are susceptible to trimethoprim and more strains 2803 
of these genera and Burkholderia spp. are more susceptible to trimethoprim/ 2804 
sulfamethoxazole than either component alone364 . The clinical use of sulphonamides 2805 
alone against non-fermenters has not been explored and the combination of 2806 
trimethoprim/sulfamethoxazole is usually used in S. maltophilia infections and for 2807 
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simplicity, against those due to these other unusual species. Problems occur with disc 2808 
susceptibility testing of S. maltophilia and there are few data on the performance of 2809 
automated susceptibility systems. Trailing endpoints are frequent and results vary with, 2810 
the temperature of incubation and the susceptibility testing medium used. Occasional 2811 
resistance to trimethoprim/sulfamethoxazole is not well understood in these non-2812 
fermenters but resistance to trimethoprim-sulfamethoxazole caused via the sulI gene 2813 
has been described repeatedly in S. maltophilia365. A recent systematic review suggested 2814 
that some strains of Acinetobacter spp. are susceptible to trimethoprim-2815 
sulfamethoxazole and that use against this genus can be guided by in vitro testing366. 2816 
However over half the UK strains of A. baumannii show high level resistance 364. 2817 
Evidence 2818 
Trimethoprim/sulfamethoxazole has wide in vitro activity against S, maltophilia, 2819 
Achromobacter spp., Alcaligenes spp., Burkholderia spp., Chryeobacterium spp. and 2820 
Elizabethkingia spp. Susceptibility testing methods for these organisms are not well 2821 
established but some S. maltophilia have resistance to trimethoprim and 2822 
sulfamethoxazole. Carbapenem resistance is inherent to most of these species.  2823 
Evidence level: 3 2824 
Recommendations 2825 
 Use in treatment of infections due to susceptible S. maltophilia and consider in 2826 
infections due to Achromobacter spp., Alcaligenes spp., Burkholderia spp., 2827 
Chryeobacterium spp. and Elizabethkingia spp.   2828 
Grading: Conditional recommendation for 2829 
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7.18 Intravenous combination therapy for infections due to carbapenemase-2830 
producers 2831 
Although results of RCTs will be available, most of the current evidence for advantage of 2832 
combination therapy for carbapenem-resistant infections derives from observational 2833 
studies and reports mainly focus on severely-ill patients or those where the pathogen 2834 
has reduced sensitivity to colistin 367. An international working group report 2835 
recommended combination including a carbapenem as optimal treatment but only in 2836 
settings where NDM carbapenemases are infrequent 368. However, retrospective studies 2837 
are liable to bias in that investigators have no control over antibiotic use.  2838 
Different studies and reviews of combination therapy have reached contradictory 2839 
conclusions. One systematic review identified that evidence for combination treatment 2840 
was poor quality and inherently biased, being based on small observational studies with 2841 
heterogeneity of i) antibiotic choice and activity against responsible pathogens, ii) 2842 
antibiotic dosage and iii) severity of illness 369. These authors concluded that any benefit 2843 
in outcome between monotherapy with colistin and combination of colistin with other 2844 
agents (aminoglycoside, tigecycline, carbapenem or rifampicin) was uncertain. There 2845 
were methodological problems in the studies reviewed. Another systematic review 370 2846 
which lacked quality assessments likewise found only observational studies with 2847 
marked heterogeneity, and suggested no proven benefit in terms of mortality between 2848 
combination treatment and monotherapy except for three more homogenous studies 2849 
exclusively of bacteraemias due to KPC-producing Klebsiella spp. in critically ill patients 2850 
which are worth detailed consideration 350, 371, 372.  2851 
Firstly, Tumbarello et al. (2012) in a 3-centre retrospective cohort study found 16/23 2852 
patients survived with tigecycline and colistin combinations and 12/14 with colistin-2853 
tigecycline-carbapenem combinations compared with 11/22 with colistin monotherapy 2854 
and 10/19 with tigecycline monotherapy.350 Secondly, Qureshi et al. (2012)371 in a 2-2855 
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centre retrospective cohort study showed that 3/7 receiving polymyxin monotherapy, 2856 
1/5 receiving tigecycline monotherapy, 2/4 receiving carbapenem monotherapy and 2857 
2/3 other antibiotics as monotherapy survived 28 days compared with 5/6 receiving 2858 
colistin combinations and 6/6 receiving tigecycline combinations. Thirdly, Zarkotou et 2859 
al (2011)372 noted 3/7 survivals with colistin, 3/5 with tigecycline and 0/1 on 2860 
carbapenem, all as monotherapy, compared with 9/9 receiving combined tigecycline 2861 
and colistin, 3/3 receiving tigecycline and carbapenems and 8/8 among those treated 2862 
with other combinations . Two studies of bacteraemias involving VIM-1-producers 2863 
considered in this review produced even less interpretable results. A third systematic 2864 
review of polymyxin treatment found mortality at 30 days was lower in patients given 2865 
combination treatment 373. A 2017 systematic review and meta-analysis favours 2866 
combination use of polymyxins 374. 2867 
Given this background, conclusions from further individual on-RCT studies must be 2868 
interpreted with caution, but some support combination treatment. A larger 2869 
retrospective cohort study of 661 infections caused by KPC-carbapenemase-producing 2870 
strains of K. pneumoniae reported improved survival in patients treated with two or 2871 
more active drugs versus those given monotherapy 316 . Mortality at 14 days in 2872 
bacteraemias with an unknown or non-urinary source was 52.8% with monotherapy 2873 
and 34.1% with combination treatment. A similar result with 49.1% and 24.8% 2874 
mortality respectively was seen with lower respiratory tract infection. There was no 2875 
significant difference in bacteraemias from a known urinary source. Overall death rates 2876 
on monotherapy were 62/132 (47%) with colistin, 45/116(39%) with tigecycline, 2877 
and28/70 (40%) with gentamicin. With two drug therapy mortality was 38/134 (28%) 2878 
and with three drug therapy 67/217 (31%). Only the use of meropenem in a 2879 
combination produced a statistically significant improvement to 54/205 (26%). Use of 2880 
meropenem was associated with lower mortality only if the MIC ≤8 mg/L as was the 2881 
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case for 37% of the isolates. Colistin resistance was significantly associated with 2882 
increased mortality. Overall combinations including tigecycline, colistin and 2883 
meropenem were associated with the lowest mortality (12.5% OR 0.11 95%CI 0.02-2884 
0.69). Epidemiologically overall colistin, tigecycline and gentamicin resistance rates 2885 
were 11%, 9% and 6% in 2010 but by 2014 were 21%, 27% and 25%.  2886 
A further review including some previously reviewed studies, suggested superiority of 2887 
combination- over mono-therapy with mortality rates of 27.4% vs. 38.7% respectively. 2888 
Again carbapenem-containing regimens had the lowest mortality (18.8%)and this was 2889 
associated with isolates that were not resistant by the EUCAST breakpoint 375. Similar 2890 
findings were reported in a retrospective observational study of 205 bacteraemias 2891 
caused by carbapenemase-producing K. pneumoniae 351. Combination therapy was 2892 
associated with a lower mortality rate of 27% compared with 44% for monotherapy, 2893 
11/27 with tigecycline, 10/22 with colistin, and 7/12 with carbapenems. The difference 2894 
in mortality was most marked in the more severe cases. Furthermore, mortality with a 2895 
carbapenem-containing combination was 19.3% (6/31) compared with 30.6% (22/72) 2896 
without a carbapenem (5/16 in those treated with tigecycline and colistin alone). 2897 
Mortality on carbapenem-containing regimens in this study was lower only if the 2898 
carbapenem MIC was <=8mg/L The authors comment that 40% of isolates with MICs by 2899 
Etest <=8 were found resistant by automated machines. These studies suggest i) that 2900 
KPC-carbapenemase –producing Klebsiella spp. commonly appear meropenem 2901 
susceptible in vitro and ii) that treatment combinations containing conventionally-2902 
dosed carbapenems are advisable in such cases with lower MICs.  2903 
Much higher doses of meropenem by continuous infusion can also be used (See 7.1.). 2904 
This extends the MIC range of strains that can be treated. Continuous infusion therapy 2905 
of meropenem with doses up to 13.2G daily with levels optimised by therapeutic drug 2906 
monitoring when used in combinations (mainly with colistin and tigecycline), were 2907 
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associated with 73% clinical cures in patients with KPC-producing K. pneumoniae with 2908 
MIC >16<64 mg/L 376. These are better outcomes in treatment of more-resistant KPC-2909 
producing Klebsiella than apparent in earlier studies of these more resistant KPC-2910 
producing Klebsiella. Direct comparisons have not been made including comparison 2911 
with high-dose continuous infusion meropenem alone. The application of this approach 2912 
to other carbapenem-resistant isolates with MICs within the attainable range has not 2913 
been assessed. 2914 
Anecdotal reports suggest double carbapenem combinations of ertapenem plus either 2915 
meropenem or doripenem can be effective as last resort treatment for infections due to 2916 
K. pneumoniae producing KPC carbapenemase but not those with NDM enzymes. This is 2917 
perhaps because ertapenem binds tightly to the KPC enzyme, acting as an inhibitory 2918 
substrate and thereby protects the meropenem or doripenem 377, 378. 2919 
In cases where the Klebsiella spp. strain was resistant to colistin and carbapenems, the 2920 
use of gentamicin in combination with various agents was independently associated 2921 
with reduced mortality in a retrospective cohort study 379  . However this was in the 2922 
epidemiological context of a clonal K. pneumoniae ST512 (CC258) lineage with a KPC 2923 
enzyme. This lineage commonly has the AAC (6’)-1b enzyme; which confers resistance 2924 
to amikacin but largely spares gentamicin; it is unlikely to be true for isolates with NDM 2925 
carbapenemases, which mostly have Arm A or Rmt ribosomal methyltransferases, 2926 
conferring high level resistance to all standard aminoglycosides, including gentamicin 2927 
and plazomicin. Plazomicin might have a future role with non-NDM-producing, 2928 
gentamicin-resistant strains. 2929 
Evidence for efficacy of tigecycline in combination largely derives from observational 2930 
studies but microbiological cure rates with monotherapy are lower than clinical cure 2931 
rates and mortality rates are high. Pooled results from 5 observational studies 2932 
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suggested a clinical response rate of 77% (567/733) for all patients and 81% (329/408) 2933 
for tigecycline monotherapy in the treatment of complicated intra-abdominal infection 2934 
380. Another review of five observational studies of uncomplicated soft tissue and intra-2935 
abdominal infection with tigecycline similarly found monotherapy was effective 381. 2936 
These studies contain no data on response by resistances present and studies were with 2937 
the licensed dose of 50mg twice daily. 2938 
In an open label RCT of treatment of ventilator-associated or hospital-acquired 2939 
pneumonia caused by multi-drug-resistant Acinetobacter spp. addition of rifampicin to 2940 
colistin did not affect 30-day mortality or length of hospital stay, but was associated 2941 
with a higher rate of microbiological eradication 382. A retrospective observational study 2942 
of 251 blood-stream infections treated with colistin or, colistin-sulbactam, colistin-2943 
carbapenem or another colistin combination reached the similar conclusion that 2944 
mortality was not affected but microbiological eradication was higher with combination 2945 
treatment 383. Another observational study of 101 patients with MDR Acinetobacter 2946 
infections did not show any improvement in mortality rates for combination therapy 2947 
(e.g. colistin plus tigecycline or carbapenem plus tigecycline) over a single agent 2948 
(usually colistin) but the group size in this study was small 384. 2949 
In the case of multi-drug-resistant Pseudomonas infections a prospective cohort study 2950 
showed no outcome advantage in combination versus monotherapy 385. Combination 2951 
therapy with aminoglycosides did not reduce the development of resistance 386. 2952 
Fosfomycin in combination with tigecycline or colistin was effective in 54% of 48 2953 
patients with infections with MDR GNB, some of which had Pseudomonas infection 362. 2954 
The recent introduction of ceftazidime/avibactam and the possibilities of using this in 2955 
treatment may change the need to use combination treatment for some KPC or 2956 
ceftazidime-resistant OXA-48 carbapenemase-producing strains.   2957 
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Evidence 2958 
Two of four systematic reviews do not show a benefit of combination therapy over 2959 
monotherapy.   2960 
Evidence level 2++ 2961 
In infections with KPC-carbapenemase producing Klebsiella spp., combination therapy 2962 
including meropenem is associated with lower mortality than colistin monotherapy if 2963 
the meropenem MIC is <8mg/L but this was not the case with strains with higher MICs 2964 
unless continuous infusion therapy with higher than licensed doses was used (See 7.1). 2965 
Combinations with other agents such as tigecycline or an aminoglycosides to which 2966 
carbapenemase-producing strains are susceptible also seem advantageous but only the 2967 
expected results of a new RCT will resolve this. 2968 
Evidence Level 3 2969 
Paul et al (2014)369 detail the hazards of bias in favour of combination therapy that arise 2970 
without an RCT. Data from a subset with bacteraemia with Klebsiella spp. Producing 2971 
KPC-carbapenemases  in the second systematic review performed by Falagas et al 2972 
(2014) 370 suggests that in treatment of carbapenem-resistant Enterobacteriaceae 2973 
infection, colistin used in combination with other agents is associated with a lower 2974 
mortality than colistin alone and this is also a finding in the review of Ni et al (2015)373.  2975 
Evidence level: 1+ 2976 
The evidence that tigecycline combinations, including other antibiotics active against 2977 
Enterobacteriaceae, are more effective than tigecycline alone in intra-abdominal 2978 
infections is poor 2979 
Evidence level: 1- 2980 
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Ertapenem in combination with meropenem may be effective as salvage therapy for 2981 
infections with KPC-carbapenemase-producers but the evidence is very weak.  2982 
Evidence level: 3 2983 
In treatment of multi-drug resistant Acinetobacter respiratory infections, addition of 2984 
rifampicin to colistin does not affect 30 day mortality.  2985 
Evidence level: 1+ 2986 
Recommendations 2987 
 Use colistin with meropenem to treat susceptible KPC-producing Klebsiella 2988 
infection if the meropenem MIC is <=8mg/L and consider higher meropenem 2989 
dose by continuous infusion if the MIC is >8 and =<32mg/L  2990 
Grading: Conditional recommendation for 2991 
 Consider colistin with aminoglycosides or tigecycline in infections with strains 2992 
producing other carbapenemases or KPC strains which are susceptible to these 2993 
agents but resistant to meropenem    2994 
Grading: Conditional recommendation for 2995 
 Consider if ceftazidime/avibactam should be used with a carbapenem or colistin 2996 
to treat infections with KPC3-producers based on latest evidence at the time of 2997 
use. 2998 
Grading: recommendation for research and possibly conditional 2999 
recommendation for use restricted to trials. 3000 
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8 Oral agents for secondary/tertiary care treatment 3001 
8.1 Mecillinam and Pivmecillinam 3002 
Pivmecillinam (the oral form of mecillinam) can be considered alone as oral therapy for 3003 
lower UTI caused by AmpC producing Enterobacteriaceae. The antibiotic is not active 3004 
against carbapenemase producers. It has been suggested as active against ESBL-3005 
producing E. coli. Patients with infections with such strains referred from the 3006 
community for intravenous treatment with carbapenems might be considered for oral 3007 
follow-on therapy with pivmecillinam alone for UTI because of mecillinam’s apparent 3008 
activity in vitro. However, additional measures are desirable and this oral treatment is 3009 
dealt with under community use. (See 9.4 for more detail). Patients should be carefully 3010 
monitored both clinically and microbiologically if pivmecillinam is prescribed alone in 3011 
hospital for infections involving ESBL-producers as treatment failure is a risk.  3012 
8.2 Cefixime and oral cephalosporins 3013 
 Cefixime is an oral third-generation cephalosporin, which has been used as an oral 3014 
switch for patients with pyelonephritis. Among uropathogenic Enterobacteriaceae, it is 3015 
not active alone against ESBL-producing E. coli because of their multiple resistances 3016 
including quinolones 387 but is useful if ESBL-producing organisms or CPE are not 3017 
present. Cefixime could be used in combination with co-amoxiclav against ESBL-3018 
producing Enterobacteriaceae as supported by in vitro data 388. Data from 3019 
transconjugant E. coli further suggests cefixime plus clavulanate is effective against 3020 
strains producing CTX-M-15 enzyme which has higher cefixime MICs than strains 3021 
producing CTX-M-9 enzyme 389. Other oral cephalosporins including cefdinir, ceftibuten, 3022 
and cefpodoxime also showed synergy with clavulanate whereas sulbactam was less 3023 
effective as a potentiator. Cefixime, with or without clavulanate, was not active against 3024 
AmpC-producing organisms nor would it be expected to be active against CPE. 3025 
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Consequently cefixime-co-amoxiclav combinations should not be used against 3026 
cephalosporin-resistant organisms without tests to distinguish AmpC and ESBL 3027 
production. No clinical trials of cefixime together with clavulanate or 3028 
amoxicillin/clavulanate against ESBL-producing E. coli have been published. Cefixime is 3029 
detectable in faeces after administration. Other cephalosporins e.g. cephalexin which 3030 
are fully absorbed, are not detectable in faeces and less frequently provoke C. difficile 3031 
may be better partners for clavulanate, although in vitro data to support this 3032 
combination are lacking 105. Synergy in vitro between cephalosporins and mecillinam 3033 
because of their different target penicillin-binding proteins is likely and synergy of 3034 
cephalexin with fosfomycin (earlier known as alafosfalin or fosfonomycin), another cell-3035 
wall active antibiotic is also recorded 390. 3036 
Evidence 3037 
Cefixime with clavulanate, which is not available commercially, in vitro, has reliable 3038 
activity against ESBL-producing E. coli and Klebsiella spp. (not Enterobacter spp. where 3039 
AmpC will cause resistance). Cefixime is not useful alone against MDR GNB and no 3040 
clinical studies with oral cephalosporins and clavulanate or amoxicillin/clavulanate 3041 
have been published.  3042 
Evidence level: 3 3043 
Recommendations 3044 
 Do not use cefixime or other oral cephalosporins alone for treating infections 3045 
caused by ESBL-, AmpC- or carbapenemase-producing Enterobacteriaceae.   3046 
Grading: Conditional recommendation against 3047 
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 Oral cephalosporins need clinical trials with clavulanate (alone or with 3048 
amoxicillin) against ESBL-producing E. coli UTI.  3049 
Grading: Recommendation for research and possibly conditional 3050 
recommendation for use restricted to trials 3051 
8.3 What are the recommended antibiotics for community care,   3052 
 including care homes? 3053 
Most MDR GNB infections encountered in the community involve the urinary tract. As 3054 
described earlier, ESBL-producing isolates of Enterobacteriaceae are a significant and 3055 
growing problem, whereas there are few community infections in the UK involving CPE. 3056 
There are no published randomized controlled trials of antibiotic treatment of UTIs due 3057 
to ESBL-producing organisms in the community or care homes. Recommendations must 3058 
rely on observational studies of ESBL-producing GNB, or randomized controlled trials of 3059 
effectiveness of antibiotics against UTIs caused by GNB lacking ESBLs. 3060 
8.4 What are the risk factors for patients with UTIs caused by MDR GNB  in the 3061 
UK? 3062 
In order to help the assessment of patients we review risk factors for MDR GNB and 3063 
suitable oral agents for acute uncomplicated and complicated UTI. Prospective and 3064 
retrospective epidemiological studies identified several risk factors for carriage of 3065 
ESBL-producing E. coli 99, 136, 184, 391-393 394.395 Patients are at increased risk if they have:  3066 
• recurrent UTI  3067 
• persistent urinary symptoms after an initial antibiotic,  3068 
• over 7 days hospital admission in the last 6 months,  3069 
• residence in a care home 3070 
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• recent travel and especially healthcare in a country with increased 3071 
antimicrobial resistance. Details of countries where prevalence is 3072 
currently high are given in 8.5. 3073 
• previously known UTI (within a year) caused by bacteria resistant to 3074 
amoxicillin-clavulanate, cephalosporins or quinolone or recent treatment 3075 
with these agents 396. 3076 
There is no UK data validating an Italian scoring system devised and tested in 2009 for 3077 
carriage of ESBL-producing bacteria on admission to hospital or incorporating 3078 
information on travel, overseas healthcare in the previous 2 years or migration. The 3079 
Italian scoring system identifies risk based on hospitalisation within the previous 12 3080 
months OR 5.69 (95% CI 2.94-10.99), transfer from another healthcare facility OR 5.61 3081 
(95% CI 1.65-19.08), Charlson comorbidity score >4 OR3.80 (95% CI 1.90-7.59), β-3082 
lactam or fluoroquinolone prescription within the previous 3 months OR 3.68 (95%CI 3083 
1.96-6,91, recent urinary catheterization OR 3.52 (95%CI 1.96-6.91) and age >70 years 3084 
OR 3.20 (95%CI 1.79-5.70)99 . This model of risk factors has been re-assessed in the US 3085 
to see if it can be used to realistically restrict the need for carbapenem treatment to an 3086 
identifiable high risk subgroup 397. In the US evaluation, risk factors for community-3087 
onset clinical infection involving MDR GNB diagnosed within 48 h. of admission were: 3088 
hospitalization OR 2.63 (95%CI 1.323-5.41), inter-hospital transfer OR5.30 (95%CI 3089 
2.67-10.71), urinary catheterization OR 6.89(95%CI 3.62-13.38), β-lactam or quinolone 3090 
prescription OR 3.47 (95% CI 1.91-6.41) and additionally immunosuppression in the 3091 
preceding 3 months 2.34 (95% CI 1.14-4.8). Age over 70 was not a risk factor but age 3092 
was not examined as a continuous variable. In this model, the sensitivity and specificity 3093 
were >=94% and <=65% for scores of 3 or below and <=58% and >=95% for scores of 8 3094 
or above. Urinary catheterization was also a risk factor in a Spanish study 398. A further 3095 
paired US retrospective case-control studies compared infections with CTX-M ESBL 3096 
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producing E. coli infections with E. coli lacking CTX-M enzymes to uninfected controls; 3097 
carbapenemase-producers were excluded. Patients with infections with CTX-M-3098 
producers were more likely to be male, have dementia or dependency, have higher 3099 
Charlson median scores, receive H2 antagonists, and have exposure to health-care 3100 
settings 393. Recent antibiotics did not differ between the two groups except that 3101 
trimethoprim/sulfamethoxazole use was commoner in the non CTX-M-producing group. 3102 
Exposure to immunosuppressives was also commoner in the CTX-M group. A similar 75-3103 
77% of strains were present within 48 h. of admission. When patients with strains 3104 
producing CTX-M-ESBLs were compared with controls, the former had a higher 3105 
incidence of comorbidity (Charlson score =>5),and were more often resident in nursing 3106 
homes with greater exposure to healthcare and more indwelling urinary catheters. They 3107 
were more likely to be receiving H2 antagonists or proton pump inhibitors and to have 3108 
exposure to oxyimino cephalosporins within the last 3 months.  3109 
Evidence 3110 
Quoted rates of resistance in the community are biased to an unknown extent by 3111 
infection occurring shortly after hospital discharge, care home cross-infection, an excess 3112 
of treatment failures represented in the samples tested and an unknown proportion of 3113 
patients with risk factors and recent antibiotic use.  3114 
Evidence level: 2- 3115 
UK surveillance suggests MDR GNB remain uncommon in community UTIs with few 3116 
carbapenemase producers.  3117 
Evidence level: 3 3118 
Empirical antibiotic choice for lower urinary tract infection can be guided by the 3119 
presence of established risk factors for a multi-resistant organism.  3120 
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Evidence level: 2+   3121 
Predictive models have been established in Italy and the USA for ESBL-producing E. coli 3122 
infections and colonisation on admission to hospital but these have not been validated 3123 
in the UK nor do they consider travel-, migration-, or household-associated risks. 3124 
Evidence level: 2+ 3125 
Recommendations 3126 
 In younger women with acute uncomplicated UTI, only consider MDR GNB in 3127 
choosing empirical treatment if there are risk factors or recent foreign travel to 3128 
countries where such strains are highly prevalent.  3129 
Grading: Strong recommendation for 3130 
 If the defined risk factors for MDR GNB are present avoid cephalosporins, 3131 
quinolones, trimethoprim and co-amoxiclav in treatment of lower UTIs unless 3132 
the pathogens are confirmed to be susceptible. 3133 
Grading: Strong recommendation against 3134 
 Building on previous work, predictive scoring should be developed in the UK for 3135 
the presence of ESBL-producing E. coli in primary care and on admission to 3136 
hospital to restrict the need to prescribe carbapenems and other antimicrobial 3137 
agents generally active against ESBL-producing organisms. 3138 
Grading: Strong recommendation for. 3139 
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9 Which oral antibiotics are preferred for use in treating uncomplicated UTIs 3140 
due to MDR GNB in the community? 3141 
9.1 Trimethoprim 3142 
Due to increasing resistance trimethoprim is no longer the suggested first-line empirical 3143 
therapy for post menopausal women and older men in Public Health England guidance 3144 
and nitrofurantoin is advised instead. In Wales trimethoprim remained until 2016 the 3145 
suggested first-line empirical therapy for uncomplicated UTI in the community except 3146 
for the elderly and for patients who have received antibiotics in the preceding 3 months.  3147 
Following advice to decrease trimethoprim use, an 86% reduction in trimethoprim use 3148 
was seen in a Swedish region (hospitals and community) from 2004-2006 with a 3149 
compensatory increase in nitrofurantoin, pivmecillinam and ciprofloxacin use. This 3150 
programme resulted in no overall change in trimethoprim resistance. Before the 3151 
intervention trimethoprim resistance was more prevalent in E. coli phylogroups A, B1 3152 
and D than in phylogroup B2 strains, although rates were high in ST131 which belongs 3153 
to phylogroup B2.There was a marked change after the intervention in the distribution 3154 
of resistance between phylogroups and associated sequence types with an increase in 3155 
the trimethoprim resistance in phylogroup B2 (including ST131) and a decrease in 3156 
trimethoprim resistance in phylogroup A and B1 strains (which seldom cause 3157 
extraintestinal infection) and to a lesser extent in phylogroup D. Trimethoprim 3158 
resistance was associated with a change in prevalence of dfrA1. Resistance to other 3159 
antibiotics, including those substituted for trimethoprim increased in phylogroup A and 3160 
B1 strains. 118 Amongst 273 urine isolates of E. coli collected in 2006 versus the same 3161 
number collected in 2004, strains of ST69 (which includes the former clonal group A), 3162 
ST12 and unusual strains became more prevalent increasing respectively from 4.8 to 3163 
8.1%, from 2.6 to 4.8% and from 42 to 51%. By contrast strains of ST131, ST127, and 3164 
ST80 declined in prevalence from 4.8 to 2.2%, 8.1 to 3.7% and 5.1% to 1.1%. There 3165 
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were statistically significant increases in trimethoprim resistance rates in the strains of 3166 
ST131 and ST127. This would suggest that in types ST131 and ST127 susceptible 3167 
strains were eliminated by the antibiotics substituted for trimethoprim (quinolones, 3168 
pivmecillinam and nitrofurantoin) but because of resistance linkage trimethoprim 3169 
resistance increased in these sequence types. Information is lacking on ST80. The 3170 
increase in strains ST69 and ST12 suggests they may have been selected by the 3171 
antibiotics substituted for trimethoprim but it is not clear which antibiotics would have 3172 
this effect as these STs are usually only resistant to ampicillin and in the case of ST69 3173 
trimethoprim. In a structured survey of extraintestinal strains from US veterans in 2011 3174 
quinolone-resistant ST131 accounted for 78% of quinolone resistant strains which 3175 
comprised 29% of reported strains overall. It accounted for 56% of trimethoprim 3176 
resistant strains and 52% of quinolone and trimethoprim resistant strains 399. This 3177 
suggests that quinolones have the potential to select against trimethoprim susceptible 3178 
ST131 strains, decreasing in the Swedish intervention study the overall prevalence at 3179 
that time but potentially selecting for later increased prevalence of the ST131. Thus, 3180 
because of resistance linkage, community-wide change in use of a single antibiotic may 3181 
unpredictably change the epidemiology and the prevalence of antibiotic resistance in 3182 
more pathogenic phylogroups. It cannot be assumed that risk factors for multi-3183 
resistance, or the likelihood of success with an antibiotic in reinfection or recurrent 3184 
infection will stay the same after abandonment of trimethoprim as a first line agent. 3185 
This aspect of change needs urgent study. 3186 
Trimethoprim-resistant strains are much more frequently resistant to amoxicillin than 3187 
trimethoprim-susceptible strains and this is a feature of ST69. Trimethoprim resistance 3188 
rates in ESBL-producing E. coli in 2010 in the West Midlands were between 86% and 3189 
92% depending on whether the strain was not, or was, ST131. Ciprofloxacin resistance 3190 
is also usual in these strains 93. Trimethoprim consequently is a poor choice for patients 3191 
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with treatment failures on amoxicillin with, or without, clavulanate, cephalosporins or 3192 
quinolones who require an urgent prescription before samples can be tested for 3193 
antibiotic susceptibilities. 3194 
More generally, trimethoprim should not be used as empirical treatment for UTI if there 3195 
are risk factors for an antibiotic resistant bacterium unless i) susceptibility has been 3196 
confirmed in the previous month ii) there are no new risk factors for resistance, and iii) 3197 
there have been no treatment failure with trimethoprim. In the absence of resistance, 3198 
trimethoprim attains excellent bacteriological cure, two-weeks after completion of 3199 
treatment, 94% of women using a 3-day course achieved bacteriological cure compared 3200 
with 97% of those using a 10-day course (n =135) 400.  3201 
Evidence: 3202 
Trimethoprim use has not been explored as a risk factor for MDR GNB infection but 3203 
resistance is common generally and very common in ESBL-producing bacteria. 3204 
Trimethoprim is no longer recommended as a first line antibiotic choice for post 3205 
menopausal women and older men with UTI and has little place in treatment of 3206 
infection due to MDR GNB.   3207 
Evidence level: 3 3208 
3 day courses are almost as effective as longer courses in bacteriological cure of 3209 
susceptible infections. 3210 
Evidence level: 1+ 3211 
Recommendations: 3212 
 Do not use trimethoprim in treating MDR GNB or treatment failures with other 3213 
agents unless in vitro-susceptibility has been demonstrated.  3214 
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Grading: Strong recommendation against 3215 
 Do not use trimethoprim to treat lower UTIs as a first line agent if ≥ 50 years old. 3216 
Only consider use if there are no risk factors for resistance, or confirmed, in vitro 3217 
susceptibility 3218 
Grading: Conditional recommendation against 3219 
9.2 Nitrofurantoin 3220 
Nitrofurantoin is widely used for acute uncomplicated UTI in the community, and is 3221 
now the recommended first line treatment in England. It attains only low 3222 
concentrations in renal tissue and the blood stream and should not be used if 3223 
pyelonephritis or bacteraemia is suspected: treatment may fail if used for ascending 3224 
infection 401. Nitrofurantoin resistance is inherent in Proteus spp., Morganella morganii, 3225 
Providencia spp. and Serratia spp. and the drug may not be effective in the alkaline urine 3226 
produced by urease-producing bacteria such as these and possibly Staph saprophyticus, 3227 
which is apparently susceptible in vitro but also produces large amounts of urease. 3228 
Nitrofurantoin resistance is very common in CPE 120. 3229 
In early studies nitrofurantoin had a minimal effect on rectal flora and a recent 3230 
metagenomics study supports this 402, 403. Resistant strains of E. coli and increased 3231 
numbers of Proteeae may be detected in the faecal flora 404, 405 but UTIs breaking 3232 
through prophylaxis in recurrent infection are usually due to strains that remain 3233 
susceptible unlike the situation with trimethoprim 404, 405. Recurrent UTIs after 3234 
nitrofurantoin treatment of ESBL-producing E. coli may reflect relapse or recurrent 3235 
infection arising from persistent carriage in the gastrointestinal flora: these possibilities 3236 
cannot easily be distinguished. Frequent recurrence of UTI due to ESBL strains may 3237 
justify using an alternative antibiotic regimen such as fosfomycin, or amoxicillin-3238 
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clavulanate with pivmecillinam, with a greater theoretical chance of changing the 3239 
gastrointestinal flora, which may act as the source for reinfection. 3240 
If a patient has a reduced glomerular filtration rate, urinary concentrations of 3241 
nitrofurantoin may be too low to be effective. eGFR frequently declines with age, on 3242 
average by between 6 and 9ml/min/1.73m2 per decade. Around half of women over 75 3243 
years and men over 85 years have an eGFR under 60mL/min/1.73m2 which used to be 3244 
the lower limit for use of nitrofurantoin 401. In a cohort study of lower UTI in 21,317 3245 
women treated with nitrofurantoin and 7926 treated with trimethoprim, there was no 3246 
greater risk of nitrofurantoin treatment failure in patients with creatinine clearance of 3247 
30-50ml/min; however the risk of pulmonary adverse events was significantly 3248 
increased with creatinine clearance <50ml/min (HR 4.1, 95% of CI.31-13.09) 406. In 3249 
2014, and in the context of increasing antibiotic resistance to trimethoprim the UK, the 3250 
Medicine and Healthcare Regulatory Agency reviewed the evidence for use of 3251 
nitrofurantoin in reduced renal function407. They concluded on evidence 401, 406 that the 3252 
eGFR below which nitrofurantoin should not be used could be lowered to 45 3253 
ml/min/1.73m2. The MHRA further stated that a short course (3 to 7 days) may be used 3254 
with caution in patients with an eGFR of 30 to 44 ml/min/1.73m2; but only advocates 3255 
prescribing in such patients for lower UTIs with suspected or proven multi-drug 3256 
resistant pathogens when the benefits of nitrofurantoin are considered to outweigh the 3257 
risks of side effects. Long term or repeated courses of nitrofurantoin are associated with 3258 
severe pulmonary fibrosis 408. Nevertheless 219 courses of prophylaxis for one year for 3259 
recurrent UTI in normal patients were not associated with a single case so this 3260 
unwanted effect may be rare under controlled conditions where the drug is very 3261 
effective 405 .  Nitrofurantoin is poorly tolerated by some patients, but the modified 3262 
release form has fewer side effects 409. When used in this formulation an open RCT over 3263 
20 years ago (n = 538) found that nitrofurantoin had equivalent clinical cure rates to 3264 
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trimethoprim/sulfamethoxazole and trimethoprim (both given for 7 days) in a group of 3265 
patients with acute uncomplicated lower UTI409. The rate of gastrointestinal adverse 3266 
effects was similar between groups (7-8%). At this time the rates of nitrofurantoin 3267 
resistance across all pathogens isolated was 3.9% whereas the rate of trimethoprim 3268 
resistance was 12.5%. Trimethoprim- but not nitrofurantoin-resistance is now far 3269 
commoner.  3270 
A recent review and meta-analysis suggested nitrofurantoin had a similar clinical cure 3271 
rate to comparators but with a 5- rather than 3-day course for nitrofurantoin 3272 
apparently producing better cure rates 410. However 5 day and 3 day courses have not 3273 
been directly compared in adequate numbers and Public Health England has not 3274 
recommended 5 day courses. We consider in MDR GNB UTI that course lengths should 3275 
be those that produce the best rates of bacteriological cure. There is no convincing 3276 
evidence that shorter courses are equivalent to longer courses specifically in MDR GNB 3277 
infections nor that the risk of serious unwanted effects is increased with longer courses . 3278 
Whether such longer course lengths should be used more generally for nitrofurantoin is 3279 
therefore unresolved.  Unwanted effects in the systematic review were mainly 3280 
gastrointestinal and no pulmonary events were reported although this may reflect short 3281 
follow up periods 410. There are no specific studies of nitrofurantoin in UTI caused by 3282 
ESBL-producing organisms, but UTIs that are susceptible to nitrofurantoin have a 3283 
similar response rate irrespective of ESBL-production. However ESBL-producing 3284 
members of the E coli ST131 clone which are common in the UK and elsewhere often 3285 
have urinary virulence factors that are associated with recurrence, infection of the 3286 
upper urinary tract and bacteraemia 411 and when infection reaches the upper tract 3287 
nitrofurantoin is ineffective. Nitrofurantoin resistance has appeared in this sequence 3288 
type (See 6.3.4). Further comparative studies in UTIs due to ESBL-producing E. coli are 3289 
needed. 3290 
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Evidence:  3291 
Nitrofurantoin is effective in lower, uncomplicated UTI and resistance rates remains low 3292 
in E. coli although new plasmid-mediated mechanisms of resistance are now described. 3293 
Mechanisms of acquired resistance in the UK, including in travellers, have not been 3294 
recently studied. Resistance is intrinsic in Proteus spp. and Serratia spp..  3295 
Evidence level: 1+ 3296 
There is usually no change in faecal Enterobacteriaceae during or immediately after use. 3297 
Breakthrough infection, when the drug is used prophylactically, remains susceptible 3298 
unlike with trimethoprim.  3299 
Evidence level: 3 3300 
Nitrofurantoin’s activity is reduced in alkaline urine. 3301 
Evidence level: 4 3302 
Use of nitrofurantoin in moderate renal impairment, as seen with increasing age, has 3303 
been controversial, but unrestricted use down to an eGFR of >45mL/min may be 3304 
acceptable.  3305 
Evidence level: 1+ 3306 
Use in moderate renal impairment or in long term/repeated courses may be associated, 3307 
albeit rarely with serious pulmonary unwanted effects.  3308 
Evidence level: 3 3309 
Five-day not 3-day courses are recommended for susceptible ESBL-producing E. coli. 3310 
Evidence level: 1+  3311 
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Recommendations: 3312 
 Could use nitrofurantoin for 5 days to treat uncomplicated, lower urinary tract 3313 
infections with nitrofurantoin-susceptible MDR E. coli (not Proteeae or P. 3314 
aeruginosa).  3315 
Grading: Strong recommendation for 3316 
 Do not use repeatedly if there is moderate renal impairment, or in long-term 3317 
courses, as these are associated with rare unwanted pulmonary effects. 3318 
Grading: Conditional recommendation against 3319 
  Use alternative agents if there are repeated recurrences with MDR GNB but do 3320 
not anticipate the emergence of resistance in E. coli infections on a single 3321 
recurrence as selection for resistant strains in the urine or faecal flora is rare. 3322 
Grading: Conditional recommendation for 3323 
 Need comparative studies of nitrofurantoin and other active antimicrobials in 3324 
patients with ESBL-producing E. coli and Klebsiella spp. 3325 
Grading: Recommendation for research and possibly conditional 3326 
recommendation for use restricted to trials. 3327 
9.3 Fosfomycin trometamol 3328 
Fosfomycin has not been widely used in the UK, where the oral form was available 3329 
between Feb 1994 and 1996 was thereafter withdrawn and not marketed for nearly 3330 
two decades until 2013. Its use elsewhere in Europe has been associated with clinical 3331 
success in lower UTIs. Fosfomycin suppresses Enterobacteriaceae in the faecal flora of 3332 
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60% of patients by day 3 after a single dose but this rapidly drops to 30% at days 10 to 3333 
14: in contrast, nitrofurantoin does not suppress these organisms 403. 3334 
Oral fosfomycin should be administered while fasting or 2 or 3 hours before meals, as 3335 
food can slow its absorption, leading to lower concentrations in the urine 412. Oral 3336 
fosfomycin is licensed solely for the treatment of uncomplicated cystitis. A single oral 3337 
dose of 3 grams results in a plasma C max of 22-32 mg/L and a urine maximum 3338 
concentration (Umax )  of 1053-445mg/L413 The urinary concentration remains 3339 
inhibitory for E. coli for at least 48 hours. In elderly patients with a mean GFR of 3340 
40mL/min concentrations after 24 hours exceeded those reported for healthy young 3341 
subjects but there was considerable variation in excretion rates 414.  3342 
Treatment with a 3g single dose of fosfomycin trometamol was associated with clinical 3343 
success rates (defined as the resolution of symptoms after treatment) between 77.8% 3344 
and 94.2% in four observational studies (some complicated and some receiving >1 3345 
dose) of treatment of lower UTI due to multi-resistant bacteria 415. Oral fosfomycin 3346 
trometamol has been used successfully for prophylaxis of pyelonephritis in patients 3347 
with asymptomatic bacteriuria (ASB) in pregnancy, and there are reports of its use, 3348 
sometimes in combination, in chronic prostatitis. The use and kinetics of fosfomycin has 3349 
recently been extensively reviewed following its re-introduction to Canada 413. 3350 
Evidence 3351 
Fosfomycin is effective and well tolerated in treatment of UTI but the oral drug has only 3352 
been studied in lower UTI.  3353 
Evidence level: 2++ 3354 
Plasmid- and chromosomally-mediated resistance has emerged in populations where 3355 
fosfomycin is widely used. 3356 
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Evidence level: 2-   3357 
Recommendations 3358 
 Use in the treatment of lower UTI due to MDR Enterobacteriaceae. Oral 3359 
formulation available. Useful for infections with ESBL-producers or 3360 
carbapenemase producers . No trials of oral formulation for upper UTI. 3361 
Grading: Strong recommendation for 3362 
 Carry out ongoing local and national surveillance of use and resistance because 3363 
of previous emergence of bacterial resistance in populations and the drug’s 3364 
potential as an important parenteral agent.  3365 
Grading: Strong recommendation for 3366 
9.4 Mecillinam and Pivmecillinam 3367 
Pivmecillinam is an oral inactive ester and prodrug that is converted to 3368 
microbiologically active mecillinam, penicillin, after intestinal absorption. Mecillinam 3369 
has in vitro activity against most Enterobacteriaceae (including those with copious 3370 
AmpC and some with ESBLs), but innate resistance occurs in Proteus spp., Morganella 3371 
morganii, Providencia spp., some Serratia spp., and most non-fermenters including 3372 
Acinetobacter spp. and P. aeruginosa. Mecillinam has no activity against enterococci or S. 3373 
saprophyticus.  3374 
 Some TEM and SHV ESBLs confer clear resistance416 389 and an inoculum effect on 3375 
testing is common for other ESBL producers 417. In one study of ESBL-producing E. coli 3376 
the MIC50 by agar dilution was 1mg/L with an inoculum of 104 cfu/spot but the MIC90 3377 
was 4mg/L 418. Experiments with E. coli transconjugants showed that mecillinam MICs 3378 
rose to 8mg/L when CTX-M-15 or -3 were present but only to 0.25-0.5mg/L with CTX-3379 
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M-9 or -14. Combination with clavulanate reduced all mecillinam MICs for ESBL 3380 
producers (except SHV-4) to <=4mg/L at high inocula and <=2mg/L with usual light 3381 
inocula389. In another study of combination with clavulanate 418 47/48 ESBL producers, 3382 
were susceptible to mecillinam. Most of these produced CTX-M-3 (found in N. Ireland) 3383 
not the commoner CTX-M-15 enzymes usual in England, Wales, and Scotland. There was 3384 
no difference between the MICs for transconjugants producing CTX-M-3 and -15 in the 3385 
earlier study. Synergy with clavulanate was detected in 40-60.4% of ESBL-producing 3386 
isolates depending on the method of assessment. When a high inoculum was used, there 3387 
was a marked inoculum effect raising the MIC of mecillinam alone but not mecillinam 3388 
plus clavulanate. This study needs to be repeated with E. coli ST131 strains producing 3389 
CTX-M-15 enzyme and also often OXA-1 which is not inhibited by clavulanate but said to 3390 
have little activity against mecillinam  3391 
Mutants resistant to mecillinam by non-ESBL mechanisms can readily be obtained by 3392 
laboratory selection. These show mutations in many different cellular functions 68. 3393 
However, a recent study of mecillinam-resistant clinical isolates found them all to have 3394 
mutations leading to inactivation of the cysB gene. Reduced cysteine biosynthesis 3395 
results in accumulation of the transcriptional regulator guanosine 3’-diphosphate 5’-3396 
diphosphate (ppGpp) so that the mecillinam targeted PBP2 becomes non-essential 419. 3397 
Addition of cysteine to the growth medium in vitro reversed the resistance to 3398 
mecillinam for such mutants raising possible issues with regard to current in vitro 3399 
testing media. 3400 
Mecillinam is inactive against Enterobacteriaceae with KPC enzymes but some 3401 
published data suggest in vitro activity against isolates with OXA-48-like enzymes 68, 389 3402 
and even some with NDM-1 enzymes, as reflected in an MIC50 of 4mg/L for NDM 3403 
carbapenemase-producing E. coli 420 although this low value is disputed by others (D.M. 3404 
Livermore, unpublished data).  3405 
Accepted manuscript 139 
Pivmecillinam at 200mg three time daily only produces sustained inhibition in Monte 3406 
Carlo simulations if  the mecillinam MIC is <= to 0.25mg/l suggesting a higher dose or 3407 
lower EUCAST breakpoint may be required respectively to produce and predict clinical 3408 
response 421. 3409 
Pivmecillinam is used mainly for lower urinary tract infection, where it has similar 3410 
short-term symptomatic efficacy to amoxicillin and trimethoprim/sulfamethoxazole if 3411 
organisms are susceptible 422, 423 and also to norfloxacin in 3- or 7- day regimens 424. 3412 
Seven-day pivmecillinam regimens are associated with more frequent clinical success 3413 
than 3-day regimens 425. Pivmecillinam prophylaxis in children with vesicoureteric 3414 
reflux markedly reduced faecal E. coli and urinary breakthrough with E. coli; unlike 3415 
nitrofurantoin, breakthrough infection with enterococci was common, reflecting 3416 
different in vitro resistance 426. Urinary concentrations are very high 427.  3417 
Clinical trials of pivmecillinam against ESBL-producing Enterobacteriaceae are limited 3418 
to case series. In one small trial pivmecillinam was used alone with 30/39 patients 3419 
receiving 400mg three times daily and 9/39 receiving 200mg three times daily. Dosage 3420 
did not affect clearly the cure rates regardless of whether the UTI was complicated. 3421 
Twenty eight patients were noted to have calculi, prostatic hypertrophy or urinary 3422 
catheters (i.e. complicated UTI) and 6 of these were bacteriological failures. Two other 3423 
bacteriological failures were seen among the remaining 11 patient. Bacteriological cure 3424 
was attained in 31/39 (79% overall), but five relapsed; clinical cure was attained in 3425 
16/19 patients but the rest were lost to follow-up 428. There is no theoretical, trial or 3426 
practise evidence to support a regimen with a loading dose of 400mg followed by 3427 
200mg three times daily which has been recommended in the UK as a compromise429. A 3428 
population-based Norwegian study of pivmecillinam treatment of community-acquired 3429 
UTIs examined the impact of MICs and ESBL-production in E. coli: it is not clear this was 3430 
restricted to uncomplicated lower UTIs for which, alone, pivmecillinam is licensed 430. A 3431 
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total of 343 patients were included, of whom 158 (46%) were treated with 3432 
pivmecillinam. Eighty-one patients had infections caused by ESBL producing E. coli, and 3433 
41 (51%) received pivmecillinam as the primary treatment usually at a dose of 200mg 3434 
three times daily for at least 7 days. Mecillinam MICs were higher for ESBL-producers 3435 
than non-producers: 68% of strains had CTX-M Group 1 enzymes (including CTX-M-15) 3436 
and 28% had Group 9 enzymes (including CTX-M-9 and -14). Treatment failure was 3437 
(atypically) defined as a new antibiotic prescription appropriate for UTI within two 3438 
weeks of the initial therapy or failure to clinically improve. Clinical treatment failure 3439 
with pivmecillinam was observed in 18 (44%) of patients infected by ESBL-producing 3440 
strains and in 16 (14%) of patients with ESBL non-producing strains Mecillinam MICs 3441 
for isolates from treatment failures (n=34, 18 ESBLs) averaged 2mg/L (range 1-4mg/L) 3442 
compared with MICs of <1mg/L for all isolates from treatment successes (n=124, 23 3443 
ESBLs). Treatment failures occurred in 50% of cases with mecillinam MICs of 2mg/L 3444 
rising to 63% at MICs of 4mg/L This compares with a EUCAST breakpoint of S=<8mg/L, 3445 
R>8mgL for mecillinam, again suggesting inadequate levels or too high a breakpoint. 3446 
Multivariate analysis showed that ESBL status (odds ratio (OR) 3.2, 95% confidence 3447 
interval (CI) 1.3-7.8, p = 0.009) and increased MIC of mecillinam (OR 2.0 for each 3448 
doubling value of MIC, CI 1.4-3.0, p<0.001) were associated with pivmecillinam 3449 
treatment failure. Treatment failure rates above 25% were associated with mecillinam 3450 
MICs >=2mg/L for ESBL-producers and >4mg/L for isolates lacking ESBL. From the 3451 
transconjugant study cited earlier it is likely that UK CTX-M-15 producing isolates will 3452 
be in this more resistant category and will respond poorly if pivmecillinam is used 3453 
alone. This study must be seen also in the context of the earlier studies on the doses 3454 
necessary to achieve adequate urinary concentrations.  3455 
There has been controversy over whether studies should be repeated with higher doses 3456 
such as 400mg three times daily but a more effective action to improve cure rates may 3457 
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be combined use of a 200mg three times daily regimen together with 3458 
amoxicillin/clavulanate at 375mg three times daily. We recommend this combination if 3459 
oral pivmecillinam follow-on therapy is prescribed following hospital or OPAT iv 3460 
treatment for UTI involving an ESBL-producer. Co-administration of 3461 
amoxicillin/clavulanate may not only provide efficacy via inhibition of ESBL but also 10- 3462 
to 100- fold bactericidal synergy by combining amoxicillin’s action on PBP1 and 3 and 3463 
mecillinam’s action on PBP2 431. 3464 
Future use of co-amoxiclav, rather than clavulanate without amoxicillin, in combination 3465 
with mecillinam is partly supported by a high quality double-blind multicentre RCT of 3466 
mecillinam and ampicillin-congeners without clavulanate in pyelonephritis in 1995, in 3467 
the era before CTX-M enzymes. Equivalent results to cefotaxime/cefadroxil were 3468 
achieved with an oral switch from parenteral mecillinam (no longer available) and 3469 
ampicillin to pivmecillinam (at 400 mg three times daily) plus an oral ampicillin 3470 
prodrug, suggesting that synergy of amoxicillin and pivmecillinam potentially would be 3471 
clinically useful in follow-on therapy for pyelonephritis. In modern circumstances, 3472 
including against ESBL-producers, this efficacy might be restored by protecting both 3473 
mecillinam and amoxicillin by using them with clavulanate. A clinical success rates of 3474 
93% for pivmecillinam as against 53% with pivampicillin in a study in 1986 of 3475 
pyelonephritis suggests the drug has activity in the upper urinary tract 432. However, it 3476 
is important to note that clinical trials of the combination of amoxicillin/clavulanate 3477 
with pivmecillinam have never been undertaken in pyelonephritis, and pivmecillinam 3478 
has no license for pyelonephritis.  3479 
Further clinical comparative studies with outcome data are urgently required for 3480 
pivmecillinam, with and without clavulanate (probably administered as 3481 
amoxicillin/clavulanate), for both complicated (including upper urinary tract) and 3482 
lower urinary tract infection against ESBL producers. Amoxicillin/clavulanate unlike 3483 
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clavulanate alone is available and licensed for upper UTI. These trials would determine 3484 
pivmecillinam’s role and its potential to reduce the need for hospitalisation or OPAT 3485 
admissions to administer IV agents active against ESBL-producers. 3486 
Pivmecillinam is claimed to have a minimal effect on the intestinal and vaginal flora of 3487 
the host with little selection for resistant bacteria, vaginal Candida or C. difficile 433. 3488 
However, the earlier study of 426 suggests it markedly reduces faecal E. coli at least in 3489 
children. In an in vitro human gut model, it did not elicit C. difficile germination, 3490 
proliferation or toxin production; suggesting that superinfection with this pathogen 3491 
should be rare if the drug is used alone 434. Clinical studies with pivmecillinam-3492 
amoxicillin/clavulanate regimens should include studies on persistence of ESBL-3493 
producing E. coli gut colonisation and new infections with C. difficile.  3494 
Overall there are uncertainties about how pivmecillinam should best be used in the 3495 
modern era. The drug has very valuable potential and these uncertainties need 3496 
resolution by large clinical trials which are now urgent. Selection for resistant strains 3497 
(such as SHV-producers) in the interim would be unfortunate and for this reason we 3498 
await further substantive trials and action and do not include its use alone in our 3499 
general recommendations.  3500 
Evidence: 3501 
Pivmecillinam is a prodrug for mecillinam and is the sole oral β-lactam (excluding 3502 
tebipenem and faropenem which are available only in Asia) with some activity against 3503 
ESBL- and AmpC-producing organisms. It has a European license, and is widely and 3504 
effectively used for lower UTI in some countries. Parenteral mecillinam has been 3505 
manufactured in the past but is now unavailable. 3506 
Evidence level: 2++  3507 
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Pivmecillinam has no published clinical trials against CPE and in vitro activity appears 3508 
poor or non-existent. 3509 
Evidence level: 4 3510 
Urinary levels following doses of 200mg three times daily are inadequate to inhibit 3511 
some ESBL-producing MDR GNB including some with CTX-M-15 considered susceptible 3512 
by the current EUCAST breakpoint (S=<8mg/L). 3513 
Evidence level: 3 3514 
Failure rates with 200mg three times daily pivmecillinam used alone against lower UTIs 3515 
due to ESBL-producing E. coli are too high to recommend regular use in such infections. 3516 
A higher dose, 400mg three times daily, has been proposed but there is no convincing 3517 
evidence to show it is more effective Comparative studies with fosfomycin have not 3518 
been reported but there are no suggestions of such ESBL-related failures in existing 3519 
fosfomycin studies in the absence of resistance.  3520 
Evidence level: 3 3521 
There are inadequate trial data to support the use of pivmecillinam in Klebsiella 3522 
infection especially where the strain responsible produces ESBLs 3523 
Evidence level: 4 3524 
In vitro evidence and early trials of combination with ampicillin or pivampicillin suggest 3525 
that a useful measure to increase efficacy would be combination with amoxicillin as well 3526 
as clavulanate (See below). 3527 
Evidence level: 2+ 3528 
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In vitro studies suggest that clavulanate (available clinically only as 3529 
amoxicillin/clavulanate) would protect mecillinam from destruction by ESBLs and 3530 
lower its MICs for Enterobacteriaceae. If pivmecillinam is prescribed as follow-on to 3531 
OPAT or in-patient treatment, use of the combination is recommended. 3532 
Evidence level: 3 3533 
 Clinical trials of pivmecillinam alone versus pivmecillinam with amoxicillin/clavulanate 3534 
in lower UTI would be in the public interest. These should be sized to give information 3535 
on efficacy against ESBL-producing bacteria and should include studies on the bowel-3536 
flora and associated recurrence rates and C. difficile. If results of combination treatment 3537 
are satisfactory consideration should be given to trials in upper UTI including economic 3538 
assessment against OPAT treatment. Comparative trials with nitrofurantoin or 3539 
fosfomycin trometamol for MDR GNB lower UTI are also required.  3540 
Evidence level: 4  3541 
Recommendations 3542 
 Consideration should be given to reducing the mecillinam EUCAST breakpoint 3543 
for classification of susceptibility 3544 
Grading: Conditional recommendation for 3545 
 Treat lower UTI due to ESBL-negative E. coli with pivmecillinam at 200mg three 3546 
times daily: do not use for infections caused by Proteeae, Klebsiella or 3547 
Pseudomonas. Some ESBL-producing E. coli respond, but efficacy is poor against 3548 
CTX-M-15 enzyme producers: dosing at 400mg three times daily may be no more 3549 
effective. Consider combination of the 200mg dose with 375mg 3550 
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amoxicillin/clavulanate for follow on to parenteral therapy for such infections in 3551 
hospital or OPAT. 3552 
Grading: Conditional recommendation for 3553 
 Requires clinical comparative trials in UTI in the public interest in i) alone or 3554 
together with amoxicillin/clavulanate for UTI involving ESBL-producing 3555 
organisms including particularly those producing CTX-M-15 enzymes ii) in 3556 
uncomplicated lower UTI generally compared with fosfomycin trometamol and 3557 
nitrofurantoin as the relative advantages of these drugs have not been directly 3558 
compared by industry over the least 10 years as MDR GNB have become more 3559 
problematic. 3560 
Grading: Recommendation for research and possibly conditional 3561 
recommendation for use restricted to trials 3562 
10 Managing urinary tract infection 3563 
10.1 Diagnosis and the need for treatment or prophylaxis 3564 
Because UTIs are the major group of infections due to antibiotic-resistant Gram 3565 
negative infections in primary care, we have chosen to make specific recommendations 3566 
about their diagnosis and about specific antibiotic stewardship.   3567 
 Good practice in differentiating urinary infections from other infections and 3568 
asymptomatic bacteriuria is vital to reduce the unnecessary use of antibiotics. When 3569 
clinical variables were examined in a  validation study435, of a previously derived 3570 
predictive dipstick rule-based on having nitrite or both leucocytes and blood, 436 the positive 3571 
predictive value for urinary infection was 82% for women with all three of cloudy urine, 3572 
dysuria, and nocturia. The negative predictive value for urinary infection was 67% 3573 
when none of these three features was 436present. When individual clinical features 3574 
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were considered alone, cloudy urine or dysuria was predictive of UTI, but nocturia or 3575 
smelly urine was not 435, which brings into question its value in the assessment above of 3576 
the combination of cloudy urine, dysuria and nocturia. In women aged 17-70 years with 3577 
uncomplicated UTI, the negative predictive value when nitrite, leucocytes, and blood are 3578 
ALL negative was 76% 435. The positive predictive value for having nitrite alone or 3579 
nitrite together with either blood or leucocytes was 92% 435. A systematic review of 3580 
diagnostic studies found that the presence of vaginal discharge or vaginal irritation 3581 
reduced the probability of urinary infection to 20-30% 437.  3582 
Several different studies have shown the prevalence of asymptomatic bacteriuria is 3583 
about 6% in men and 16% of women aged over 65 years 438 and is higher in older age 3584 
groups and in the institutionalized elderly. In a cohort study, 1173 elderly female 3585 
residents without catheters in care homes were followed for 9 years with urine cultures 3586 
every six months439  No relationship was found between ever having had asymptomatic 3587 
bacteriuria and death after adjusting for covariates (hazard ratio, 1.10; CI, 0.78 to 1.55). 3588 
The death rate in the group who never had asymptomatic bacteriuria was similar to 3589 
those who had bacteriuria but either received no treatment or were treated (P > 0.2) 439.  3590 
The lack of benefit in treating asymptomatic bacteriuria was confirmed in another 3591 
smaller study: neither mortality nor the frequency of symptomatic episodes was 3592 
reduced, but for every three women with asymptomatic bacteriuria in a care home 3593 
given antibiotics (the type was not specified in this study), one experienced adverse 3594 
effects (such as rash or GI symptoms) 440. Cumulatively, 3-6% of people acquire 3595 
bacteriuria per day of urinary catheterisation even with best practice for insertion and 3596 
care of the catheter, and therefore many older people with long term catheters have 3597 
bacteriuria 441, 442. Intermittent catheterisation is associated with a lower incidence of 3598 
asymptomatic bacteriuria than long-term catheterisation 443.  Catheterised patients 3599 
should only receive antibiotic treatment when they are systemically symptomatic to 3600 
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reduce the risk of colonisation by antibiotic resistant bacteria 441, 442. Differentiating 3601 
urinary tract infection from asymptomatic bacteriuria can be particularly challenging in 3602 
elderly patients with dementia as they cannot always describe their symptoms. A 3603 
positive urine culture or dipstick test will not differentiate between UTI and ASB 439. 3604 
Patients with asymptomatic bacteriuria may have white blood cells in the urine just as 3605 
in true infection. In older patients including those with dementia, diagnosis should be 3606 
based on a full clinical assessment, including vital signs.  3607 
A Canadian randomized controlled trial of a diagnostic and treatment algorithm for UTI 3608 
implemented in care homes, using a multifaceted approach, reduced antibiotics for 3609 
urinary indications by 31%, compared with control care homes, with no increase in 3610 
hospital admissions or mortality 444. Patients were considered for antibiotic treatment 3611 
based primarily on presence of fever greater than 37.9˚C or 1.5˚C increase above 3612 
baseline on at least two occasions over last 12 hours and one or more signs of UTI444 3613 
The full algorithm used is shown in Figure 5. Fewer courses of antibiotics for suspected 3614 
urinary tract infections per 1000 resident days were prescribed in the intervention 3615 
nursing homes than in control care homes (1.17 versus 1.59 courses per 1000 resident 3616 
days). Antimicrobials for suspected UTI represented 28.4% of all courses of drugs 3617 
prescribed in the intervention nursing homes compared with 38.6% prescribed in the 3618 
control care homes (weighted mean difference – 9.6%, − 16.9% to –2.4%). No 3619 
significant difference was found in admissions to hospital or mortality between the 3620 
study arms. 3621 
In recurrent UTI, deciding whether to give prophylaxis is a balance between the benefits 3622 
of reducing symptomatic relapse and pyelonephritis versus side effects and the risks of 3623 
selecting antibiotic resistance. Guidance is based on a systematic review of 19 trials. 3624 
Nightly prophylaxis in non-pregnant women with recurrent urinary infection showed 3625 
that prophylaxis reduced the relative risk of having one microbiological recurrence by 3626 
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five- fold (0.21) (95% CI 0.13 to 0.34), giving number needed to treat of 1.85 over 6–3627 
12 months445 However, adverse effects occurred, particularly following nitrofurantoin, 3628 
and 30% of women did not adhere to treatment. Any benefit was lost as soon as the 3629 
prophylaxis stopped. Post-coital antibiotics were equally effective to nightly prophylaxis 3630 
445, 446. Previous studies before the rise in resistance showed the same effect with 3631 
postcoital single-dose cephalexin when used for recurrent urinary infection in 3632 
pregnancy 447.  If recurrence is not too frequent it may be better to provide the patient 3633 
with standby nitrofurantoin, to take as soon as symptoms occur; this approach was 3634 
shown to result in less use of antibiotics and intuitively should result in less antibiotic 3635 
resistance. Studies with cephalexin before the rise of ESBLs showed a slight increase in 3636 
use with post coital cephalexin offset considerably by antibiotics used in treatment of 3637 
UTI recurrences448. The offset needs to be taken into account in individual patients if 3638 
standby nitrofurantoin is used. Prophylaxis, if used, can usually be stopped after a year 3639 
without a resumption of the recurrences 405 and there are now European guidelines that 3640 
this review should be made at 6 months 449. The increase in trimethoprim resistance 3641 
makes prophylaxis with this drug less suitable than it was and prolonged nitrofurantoin 3642 
is associated with an increased risk of unwanted pulmonary damage, although this is 3643 
rare. Patients on prophylaxis for >6months should be reviewed. If the patient wishes to 3644 
continue with a prophylactic regimen, consideration should be given in advance as to 3645 
which antibiotic would be appropriately substituted for trimethoprim, nitrofurantoin or 3646 
indeed ciprofloxacin (which can also be used in prophylaxis), if resistance develops or a 3647 
breakthrough infection occurs. Persisting with an agent where breakthrough with a 3648 
resistant strain has occurred will be ineffective. Cranberry juice prophylaxis is less 3649 
effective in preventing breakthrough infection but cotrimoxazole generates more 3650 
multiple resistance in breakthrough strains 450. Prophylaxis with beta-lactam antibiotics 3651 
commonly selects for resistant Enterobacteriaceae in the faecal flora and is not 3652 
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recommended 451. There are relevant studies of prophylaxis after symptomatic UTI in 3653 
infants which show similar problems with emergence of resistance on continuous 3654 
prophylactic antibiotics, including resistance to cephalosporins due to ESBL-production 3655 
452, 511 3656 
NICE notes that prophylactic antibiotics given at catheter change or insertion do not 3657 
reduce infections in those with neurological conditions and recommends that they 3658 
should not be used 453: such use for any indication contributes to pressure on 3659 
emergence of resistance and should be avoided. NICE recommends that clinicians 3660 
should consider antibiotic prophylaxis at change of catheter for patients who:  3661 
i) have a history of symptomatic urinary tract infection after catheter change or  3662 
ii) experience trauma during catheterisation (frank haematuria after catheterisation or 3663 
two or more attempts of catheterisation). Placement of an incontinence implant is also 3664 
an indication for short term prophylaxis but the recent insertion of an orthopaedic 3665 
implant is not. 3666 
Evidence 3667 
Specific symptoms and signs hitherto accepted as characteristic of urinary infection 3668 
have different predictive values.  3669 
Evidence level: 1+ 3670 
In women with uncomplicated urinary infection the highest positive predictive value for 3671 
strip testing was for having nitrite alone or nitrite with either positive leucocyte 3672 
esterase or blood.  3673 
Evidence level 1+ 3674 
There is no patient benefit in treating asymptomatic bacteriuria 3675 
Evidence level: 1+ 3676 
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Using an algorithm based on fever and at least one sign of urinary infection reduces the 3677 
number of antibiotic prescriptions in nursing homes 3678 
Evidence level: 3 3679 
Treatment or prophylaxis with antibiotics in catheterised patients increases 3680 
colonisation by antibiotic-resistant strains. 3681 
Evidence level: 1+ 3682 
Prophylactic antibiotics given short-term at catheter change or insertion do not reduce 3683 
infections but are indicated with specific criteria of i) traumatic catherisation, ii) 3684 
previous severe symptomatic infection on catheter change, or iii) to cover placement of 3685 
a urinary continence implant.  3686 
Evidence level: 4.  3687 
In recurrent UTI, antibiotic prophylaxis is very effective whether given daily (Evidence 3688 
level 1++) or post coitally (Evidence level 1+) but an alternative is to consider pre-3689 
prescribed standby antibiotics to take at the onset of symptoms.  3690 
Evidence level 4.  3691 
If prophylaxis is used and effective it should be usually restricted to six-months 3692 
prescription, 3693 
Evidence level 3  3694 
Previous resistances, or breakthrough of resistant isolates on prophylaxis should 3695 
preclude use of an agent and consideration should be given to unwanted effects with 3696 
long courses and what antibiotic would be chosen for breakthroughs.  3697 
Evidence level 4  3698 
Recommendations 3699 
 Always consider the positive and negative predictive value of specific symptoms 3700 
before sending urine for culture or starting antibiotics for a UTI. Use dipstick 3701 
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tests, if no catheter is present, to confirm the diagnosis, before prescribing 3702 
especially when symptoms are mild or not localized. 3703 
Grading: Strong recommendation for 3704 
 For an elderly patient, do NOT send urine for culture or start empirical 3705 
antibiotics unless there are specific symptoms or signs of UTI and none 3706 
elsewhere. Use the algorithm in Figure 5 to decide whether to do this in elderly 3707 
patients especially in those with dementia 3708 
Grading: Conditional recommendation for 3709 
 Do not prescribe antibiotics in asymptomatic bacteriuria (ASB) in the elderly 3710 
with, or without, an indwelling catheter.   3711 
Grading: Strong recommendation for 3712 
 Avoid antibiotic prophylaxis for urinary catheter insertion or changes unless 3713 
there is previous history of symptomatic UTI with the procedure, insertion of 3714 
incontinence implant, or trauma at catheterization.  3715 
Grading: Conditional recommendation for 3716 
 To reduce recurrent UTI, consider firstly, the option of pre-prescribed standby 3717 
antibiotics to take when symptoms begin, rather than daily or post-coital 3718 
antibiotic prophylaxis. 3719 
Grading: Conditional recommendation for 3720 
 Where prophylaxis is used successfully for recurrent infection in adults limit use 3721 
to six months. 3722 
Grading: conditional recommendation for 3723 
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10.2 Choosing a suitable antibiotic 3724 
Choosing an antibiotic to which an uropathogen is susceptible, is important as UTI 3725 
symptoms resolve more slowly when an inappropriate antibiotic is given 454. All 3726 
patients should be given advice on when to seek further medical advice, i.e. if their 3727 
symptoms worsen (even if, after taking antibiotics, on the same day) or do not improve 3728 
after several days. Treating patients with infections due to MDR GNB in the community 3729 
is a challenge as oral antimicrobial treatment is preferred. ESBL-producing bacteria are 3730 
generally resistant to trimethoprim, ciprofloxacin, amoxicillin and cephalosporins; 3731 
susceptibility to amoxicillin/clavulanate is variable and interpretation by the laboratory 3732 
is affected by different breakpoints used formerly by BSAC, and currently by EUCAST, or 3733 
CLSI. 3734 
Local community antibiotic guidance should be informed by national and local 3735 
surveillance data. An algorithm on choices based on the individual agents discussed is 3736 
given in Figure 4.  Choosing between fosfomycin, pivmecillinam and nitrofurantoin is 3737 
difficult as there are no direct comparisons of these three antibiotics in infections due to 3738 
ESBL-producing organisms. High failure rates with pivmecillinam may be due to the 3739 
precise ESBL present and not using the drug in combination with 3740 
amoxicillin/clavulanate, or possibly inadequate dosage: optimal ways to use the drug 3741 
now in the UK have not been proven. In urinary infections due to non-ESBL-producing 3742 
organisms nitrofurantoin for 3, or5 days (or 7 days, which is not significantly different 3743 
from the results of a 5 day course) 410 and a single dose of fosfomycin have similar 3744 
efficacy 455, 456.  3745 
In a systematic review of the length of antibiotic treatment for acute uncomplicated 3746 
urinary infection before the rise in prevalence of ESBL-producing Enterobacteriaceae, 3747 
therapy for 3 days, delivered in the case of fosfomycin trometamol by a single 3g dose, 3748 
Accepted manuscript 153 
was similarly effective to prolonged therapy in achieving symptomatic cure for 3749 
cystitis.512  However, in this systematic review, bacteriological failure rates in the 3750 
subgroup of trials where the same antibiotic was used in both short and long treatment 3751 
arms of the trial, were higher in the short duration arms (RR 1.37, 95% CI 1.07 to 1.74, P 3752 
= 0.01).  After a single dose of fosfomycin high concentrations are usually maintained in 3753 
the urine for 2 days. This is usually curative in uncomplicated UTI in women, but for 3754 
infection due to confirmed ESBL-producers, or in males, a second dose on the third day 3755 
has been suggested to promote bacteriological cure 457. On the same basis 5 not 3 days 3756 
nitrofurantoin would be recommended for confirmed ESBL-producing bacteria and 7 3757 
days for pivmecillinam regimens. Although frequently used as an end-point in 3758 
regulatory trials, it is uncertain if bacteriological cure immediately after treatment is of 3759 
any long term clinical or bacteriological significance in patients with UTIs involving 3760 
MDR GNB but the precautionary principle of adequate elimination of infections with 3761 
MDR GNB would suggest regimens for best bacteriological cure should be followed in 3762 
such cases. Eight studies in the systematic review included pivmecillinam at various 3763 
doses and durations. An analysis of E. coli strains from persistent or relapsed infection 3764 
after pivmecillinam showed an increased frequency of phylogenetic group B2 (which 3765 
includes ST131) and showed that when matched by virulence factors 7 days treatment 3766 
was preferable to 3 days therapy because it was less likely to be followed by persistence 3767 
or relapse 458.  Studies of urinary infection with strains producing the CTX-M-15-ESBL 3768 
suggest that pivmecillinam alone at 200mg three times daily is inadequate treatment. In 3769 
vitro studies suggesting use with amoxicillin/clavulanate have not been followed by 3770 
clinical trials.  3771 
Based on evidence collected before the spread of ESBL-producing strains nitrofurantoin 3772 
(100mg twice daily) should be given for 3 or 5, not 7, days for fully susceptible strains. 3773 
No trials of nitrofurantoin 100mg twice daily with ESBL-producing strains have been 3774 
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published although the antibiotic is widely used. Efficacy, relapse/recurrence rates or 3775 
incidence of spread to the upper urinary tract or blood stream are all uncertain and no 3776 
studies have been published on the emergence of resistance during or after treatment 3777 
or in relapses. MDR Klebsiella spp., but not E. coli, are commonly resistant to 3778 
nitrofurantoin but the mechanisms for resistance in the UK have not been investigated 3779 
recently. 3780 
Evidence 3781 
Local community antibiotic guidance on empirical treatment of urinary infection should 3782 
be informed by national and local surveillance data.  3783 
Evidence level: 4 3784 
In lower uncomplicated UTI where risk factors for MDR GNB are present these four 3785 
treatment options can be used rather than trimethoprim: 3786 
Fosfomycin trometamol 3787 
Evidence level: 2+              3788 
Nitrofurantoin (unless patients eGFR is less than 45 ml/min/1.73m2).     3789 
Evidence level: 2+ 3790 
Pivmecillinam but in vitro and clinical data suggest this is less successful than a) and b) 3791 
for ESBL-producing bacteria likely to be present in the UK. 3792 
Evidence level: 3           3793 
Another other relevant antibiotic if the causative organism is confirmed as susceptible. 3794 
Evidence level: 4 3795 
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Recommendations 3796 
 Inspect up-to-date national and local antibiotic surveillance when compiling local 3797 
antibiotic guidelines on treatment of UTI. 3798 
Grading: Strong recommendation for  3799 
 If there are risk factors for MDR GNB or previous presence of MDR GNB and the 3800 
patient is symptomatic, send a urine specimen for culture and susceptibility 3801 
testing  3802 
Grading: Strong recommendation for 3803 
 Always inform the patient or their carer(s) on what to look out for and how to re-3804 
consult if symptoms worsen or do not improve as community-onset E. coli 3805 
bacteraemias of urinary origin are increasing  3806 
Grading: Strong recommendation for 3807 
 Use fosfomycin, or nitrofurantoin or as third-line choice pivmecillinam, guided 3808 
where possible i) by susceptibility testing and ii) by this guideline’s 3809 
recommendation on choice, combinations, dosing and duration, for 3810 
uncomplicated lower urinary tract infection where MDR GNB are suspected.  3811 
Grading: Strong recommendation for 3812 
 Use nitrofurantoin for 5 days with MDR GNB. Alternatively use fosfomycin 3813 
trometamol 3g orally as single dose, and repeat on third day only if MDR GNB are 3814 
confirmed to improve bacteriological cure. Pivmecillinam at 200mg three times 3815 
daily for 7 days may be a third line choice but consider combination use with 3816 
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amoxicillin/clavulanate. Clinical trial results on pivmecillinam for MDR GNB in 3817 
the UK are urgently required. . 3818 
Grading: Conditional recommendation for  3819 
10.3 Treatment of pyelonephritis and complicated UTI caused by MDR Gram-3820 
negative bacteria 3821 
Whenever resistant pathogens are anticipated, it is essential to send a urine specimen 3822 
for culture and susceptibility testing before empirical treatment and such specimens 3823 
will be useful in this condition even if resistant pathogens are not anticipated. As 3824 
nitrofurantoin, pivmecillinam and oral fosfomycin are currently considered 3825 
inappropriate in suspected or confirmed pyelonephritis, intravenous ertapenem 3826 
(unlicensed in Europe for this indication) should be given in an Outpatient Parenteral 3827 
Antibiotic Therapy setting to treat patients with pyelonephritis confirmed or suspected 3828 
to be caused by ESBL-producing pathogens that are resistant to trimethoprim and 3829 
quinolones 163, 164. If the patient requires admission to hospital meropenem or, 3830 
depending on costs and local policy, ceftolozane/tazobactam or temocillin should be 3831 
given for infection due to ESBL-producing strains. Piperacillin/tazobactam may be 3832 
considered if the isolate has been shown to be susceptible. Amikacin might be 3833 
considered but activity may be impaired if AAC (6’)-1b-cr is produced. In practise 3834 
strains with this enzyme may be reported as either susceptible or resistant and the 3835 
enzyme cannot easily be detected: no trials of amikacin use against such strains have 3836 
been reported. Measuring amikacin levels promptly and adjusting doses is less likely to 3837 
be easily supportable than use of gentamicin but the latter is unsuitable for infection 3838 
with ESBL-producers unless susceptibility is known.   3839 
Ceftazidime/avibactam or non- β-lactam agents in combination perhaps with 3840 
meropenem should be considered for infections with CPE- See Figure 4. Temocillin may 3841 
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have a place for more susceptible strains with KPC-carbapenemases but this has not 3842 
been established by trials: it does not have a role against strains with MBLs or OXA-48 3843 
like carbapenemases. Such factors and choices are important when empirically treating 3844 
pyelonephritis caused by probable or confirmed MDR GNB as this may be complicated 3845 
by bacteraemia 94.  3846 
If a patient with pyelonephritis due to ESBL-producing bacteria has penicillin or 3847 
cephalosporin-hypersensitivity, there are two alternative strategies. Firstly meropenem 3848 
can be given despite a risk of cross-allergenicity that is now thought to be largely 3849 
hypothetical. In this case caution must be exercised with appropriate drugs ready to 3850 
treat any severe acute reaction. This seems to be safe 154 . Alternatively urgent 3851 
susceptibility tests by automated methods should be performed. Depending on any 3852 
previous results for the patient’s isolates, intravenous gentamicin or amikacin (which 3853 
has more auditory than vestibular toxicity but a lower resistance rate than gentamicin) 3854 
may initially be used until a less toxic antibiotic can be identified from the concurrent 3855 
susceptibility testing. Trimethoprim, ciprofloxacin or co-amoxiclav can be used in 3856 
pyelonephritis if the pathogen is known to be susceptible (or a susceptible organism has 3857 
been isolated in the preceding month with a satisfactory therapeutic response). A 3858 
retrospective cohort study of community onset acute pyelonephritis due to ESBL- 3859 
producing E. coli compared 85 patients receiving carbapenems with 67 receiving other 3860 
agents to which the infecting bacterium was susceptible in vitro. There was no 3861 
difference in rates of clinical or microbiological failure 459. A randomized double-blind 3862 
controlled trial showed that 7 days of ciprofloxacin 500 mg twice daily was as effective 3863 
as 14 days trimethoprim/sulfamethoxazole against susceptible organisms. However 3864 
trimethoprim and quinolone resistance are now common and therefore none of these 3865 
agents remain suitable for empirical use in pyelonephritis 460. The substitution of OPAT 3866 
Accepted manuscript 158 
therapy for oral antibiotic use in early pyelonephritis has not been costed in its effects 3867 
on services. 3868 
Evidence 3869 
Pending antibiotic susceptibility testing, patients at increased risk of MDR GNB and 3870 
suspected of pyelonephritis or complicated UTIs (i.e. indwelling catheter, recent urinary 3871 
instrumentation, renal stones, prostatic obstruction, diabetes, immunosuppression, 3872 
pregnancy, functional or anatomical urological abnormality 437 can be treated 3873 
empirically with:  3874 
a) outpatient intravenous therapy with ertapenem. 3875 
Evidence level: 2+ 3876 
b) admission for i) intravenous meropenem, temocillin, or ceftolozane/tazobactam 3877 
if infected by ESBL-producing E. coli or Klebsiella spp., ii) intravenous fosfomycin 3878 
and colistin with or without meropenem, or ceftazidime/avibactam therapy if 3879 
infected by a susceptible carbapenemase-producer. 3880 
Evidence level: 1+ 3881 
If hypersensitive to penicillin treat with meropenem with caution or gentamicin 3882 
(if no past evidence of resistance) or amikacin 3883 
Evidence level: 4 3884 
c. Trimethoprim, ciprofloxacin or co-amoxiclav if urine testing shows an 3885 
organism that was susceptible in the preceding month and there has been no 3886 
history of clinical failure.    3887 
Evidence level: 1+ 3888 
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Recommendations 3889 
 In pyelonephritis always collect a urine sample before treatment. MDR GNB are 3890 
unlikely to respond to oral treatment so consider risk factors for an MDR isolate 3891 
including travel. Use an active oral agent only if the patient is well enough and if 3892 
known to have had ciprofloxacin-, trimethoprim-, or co-amoxiclav-susceptible 3893 
MDR GNB in last month.  3894 
Grading: Conditional recommendation for 3895 
 If the patient has pyelonephritis and risk factors for MDR GNB, start, if 3896 
hospitalisation not required, empirical intravenous therapy with ertapenem if 3897 
OPAT therapy available. This will treat ESBL and Amp-C producing 3898 
Enterobacteriaceae. If the patient needs hospitalisation, or OPAT is not available, 3899 
admit for meropenem, temocillin or ceftolozane/tazobactam if no evidence of 3900 
CPE organism. If the patient is penicillin-hypersensitive then the hospital may 3901 
use amikacin or meropenem, or if only susceptible isolates in the past, 3902 
gentamicin. If carbapenem-resistant bacteria are, or have been, present, base 3903 
treatment on susceptibility testing of recent or current isolates.  3904 
Grading: Strong recommendation for 3905 
10.4 What is the threshold level of resistance for changing the choice of empirical 3906 
treatment for urinary tract infections? 3907 
Most patients with UTI are treated empirically, particularly in a first episode of lower 3908 
UTI. Failure of empirical therapy particularly in complicated UTI (e.g., pyelonephritis) is 3909 
a common source of Gram-negative bacteraemia where increased 30-day mortality is 3910 
associated with ineffective empirical therapy 256, 461 though maybe only in patients with 3911 
sepsis syndrome. The probability of ineffective empirical therapy would be predicted to 3912 
increase as the proportion of ESBL-producing, or carbapenem-resistant, bacteria rise. 3913 
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Older narrower spectrum antibiotics may be recommended for empirical use in order to 3914 
slow the emergence of resistance. One group of authors asserts that the right of future 3915 
patients to come to less harm outweighs the right of the present patient to share in 3916 
decisions on antibiotic treatment 462 but this is a view many do not share. There is no 3917 
agreement within the Working Party on the threshold resistance rate to an antibiotic 3918 
that would justify substitution of other agents, nor on the degree to which routine 3919 
laboratory testing of submitted samples overestimates the “true” resistance rate 463. 3920 
Rates of 20% have been suggested as justifying a change of empirical treatment in UTI.  3921 
Confounders are i) that resistance rates are affected by duplicates within the series 3922 
including when infection control sampling is intensive 464,ii) a bias towards performing 3923 
culture and susceptibility only for difficult/unresponsive cases iii) by sequential testing 3924 
second-line agents only for resistant strains according to local laboratory policy 117 and 3925 
iv) differences in breakpoints between laboratories. These sources of variation may 3926 
justify central susceptibility testing of all UTI from sentinel groups of GPs in regions for 3927 
national surveillance purposes or requirements for national notification and annual 3928 
updating of method changes and assessment of their effects 465. Local and regional and 3929 
variations exist in resistance rates for ESBLs as demonstrated by regional and national 3930 
surveys. Quinolone resistance rates in E. coli are below 20% in most reported 3931 
susceptibility surveys but resistance in bacteraemia is associated with increased 3932 
mortality and with the ST131 group of strains which have an unrivalled ability to 3933 
acquire other resistances. The risk of selection for resistance with a switch from 3934 
trimethoprim leads us not to recommend their widespread use.  3935 
When the probability of bacteraemia associated arising from UTI rises, a lower 3936 
threshold for altering normal treatment to cover a resistant strain is needed owing to 3937 
the greater risk to the individual patient. A threshold of <5% resistance may be 3938 
appropriate for higher risk situations. 3939 
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 Evidence 3940 
There are no accurate current figures on the prevalence of antibiotic resistance in UTI. 3941 
Routine clinical data are subject to sample bias. These probably lead to overestimated 3942 
resistance.  3943 
Evidence level: 2- 3944 
A threshold of 20% true resistance has been suggested as an indication to change “first 3945 
line” empirical treatment of lower UTI. A lower threshold of, perhaps, 5% is appropriate 3946 
when the risk of the patient becoming bacteraemic is increased. The Working Party 3947 
consider that, in the absence of accurate national resistance surveillance these, or 3948 
similar thresholds, presently can only be applied at a local laboratory level with i) 3949 
careful de-duplication ii) precisely understood testing policies and iii) consistent local 3950 
methodology. 3951 
Evidence level: 4 3952 
Recommendations 3953 
 Locally assess the true rate of resistance and determine from this when changes 3954 
to guideline recommendations for empirical therapy in UTI are necessary 3955 
including recommendations where the risk of antibiotic-resistant bacteraemia is 3956 
high.  3957 
Grading: Conditional recommendation for  3958 
 Personalise empirical chemotherapy for each patient by considering current 3959 
features of bacteraemia, risk factors for antibiotic resistance and past 3960 
susceptibility testing including the presence of MDR GNB in the patient or unit.  3961 
Grading: Conditional recommendation for  3962 
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11 What effect does good antibiotic stewardship have on rates of MDR GNB? 3963 
11.1 The impact of good antibiotic stewardship in secondary/tertiary care 3964 
facilities 3965 
The evidence base and practice of antibiotic stewardship in the UK has been recently 3966 
promulgated in the Public Health England “Guidelines for Antimicrobial Prescribing and 3967 
Stewardship Competencies” 466 and the guidance from NICE (National Institute for 3968 
Health and are excellence) Guideline 15: Antimicrobial stewardship: systems and 3969 
processes for effective antimicrobial medicine use 467. This report will focus on aspects 3970 
of stewardship that pertain to MDR GNB: more general aspects can be found also in the 3971 
above sources. A Cochrane systematic review showed that interventions to reduce 3972 
excessive antibiotic prescribing to hospital inpatients might reduce antimicrobial 3973 
resistance and that interventions to increase effective prescribing can improve clinical 3974 
outcome 468. Of the 89 studies cited to 2009 (reporting 95 interventions), 56 were 3975 
interrupted time series (ITS), 25 were RCTs, 5 were controlled before-after studies 3976 
(CBAs) and three were controlled clinical trials (CCTs). The reporting of outcomes was 3977 
very variable (only 13/25 RCTs reported on mortality and only 5 on readmissions) 3978 
complicating comparative assessment of studies. Interventions that enhanced the 3979 
quality of prescribing in patients (defined softly as prescribing in accordance with 3980 
guidelines) with any infection had no effect on mortality whereas interventions to 3981 
increase compliance with evidence-based guidelines in community-acquired 3982 
pneumonia, usually due to Gram-positive Streptococcus pneumoniae, was associated 3983 
with reduced mortality. Reducing prescribing for all indications, determined as 3984 
excessive by reference to evidence-based guidelines, was associated with increased re-3985 
admission but not with increased mortality or length of stay. Restrictive and persuasive 3986 
interventions were associated with improved prescribing outcomes based on median 3987 
outcome effect (proportion of subjects with an improvement or change in antibiotic 3988 
selection, dose, route or duration versus control). Multifaceted interventions were 3989 
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common but not necessarily more effective than simple interactions. Most (80/95, 84%) 3990 
of the interventions targeted the antibiotic prescribed (choice of antibiotic, timing of 3991 
first dose and route of administration). The remaining 15/95 interventions aimed to 3992 
change exposure of patients to antibiotics by targeting the decision to treat or the 3993 
duration of treatment. Only nine studies reported the effect of interventions on 3994 
colonization or infection with antibiotic-resistant Gram-negative bacteria. Seven of 3995 
these were ITSs, with a median effect size of 47% 469-474.  3996 
Although most studies reported >25% reduction in colonisation/infection with resistant 3997 
Gram-negative bacteria, the confidence intervals were wide and in two studies the 3998 
effects were not statistically significant 471, 475 and one crossover study of cycling 3999 
empirical gentamicin, ceftazidime, and piperacillin/tazobactam showed an unintended 4000 
increase of 39% in colonization with GNB resistant to any of the target drugs 476. One 4001 
cluster CCT in neonatal units, showed, as intended, a reduction from baseline in 4002 
colonization/infection of 68% by cefotaxime-resistant organisms, predominantly E. 4003 
cloacae, when the initial empirical treatment was penicillin and tobramycin rather than 4004 
ampicillin-cefotaxime 477. This study, the only one of the nine to report on mortality, 4005 
showed a small increase in mortality when penicillin and tobramycin was substituted 4006 
for cefotaxime ampicillin in matched neonatal units. A 2017 update of this Cochrane 4007 
review 478 concluded that there was still no statistically significant evidence that 4008 
antibiotic stewardship reduced multiple antibiotic resistance although the impact on C. 4009 
difficile is undoubted. Additionally this updated unwanted effects from stewardship 4010 
interventions including an aminoglycoside substitution producing acute kidney 4011 
injury282 (See 7.12) and studies where there was consequent delay in instituting 4012 
antibiotics. Furthermore some studies reported a disruption of interaction between 4013 
physicians and infection specialists as guidelines were used more frequently. 4014 
Nevertheless an editorial on this review called for stewardship to be adopted in every 4015 
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health care institution479. One must now consider the homogeneity and quality of local 4016 
hospital guidelines given guideline compliance is being used as a criterion of good 4017 
stewardship. 4018 
In the 2013 Cochrane review468, 11 studies of attempts to reduce excessive prescribing, 4019 
reported data on mortality with no significant overall effect seen (and this continued to 4020 
be the case in the 2017 revision).513  Interestingly one of the interrupted time-series 4021 
studies examined the impact of a switch from penicillin and gentamicin to penicillin and 4022 
amikacin in a neonatal unit with gentamicin-resistant E. cloacae infections and showed 4023 
a reduction in gentamicin-resistant E. cloacae but an increase is E. aerogenes and 4024 
enterococci 474.  4025 
Kaki et al. produced another systematic review of antibiotic stewardship programmes, 4026 
limited to the critical care unit 480. These included three RCTs, three ITSs, and 18 4027 
uncontrolled before-and-after studies. Introduction of various antibiotic stewardship 4028 
interventions led to 11% to 38% reductions in antimicrobial defined daily doses/1000 4029 
patient-days (except in a single study that found an increase of 6%), and lower total 4030 
antimicrobial costs. Stewardship programmes led to shorter average duration of 4031 
antibiotic therapy, less inappropriate use and fewer antibiotic-related adverse events. 4032 
They also found some reductions in antimicrobial resistance rates extending beyond six 4033 
months.  4034 
A meta-analysis of 52 ITS was used to compare restrictive versus persuasive 4035 
interventions 468. Restrictive interventions had significantly greater impact on 4036 
prescribing outcomes at one month (32%), 95% CI 2-61%, P=0.03) and on microbial 4037 
outcomes at 6 months (53%, 95% CI 31-75%, P=0.001) but there were no significant 4038 
differences at 12 or 24 months. Clinical outcome data were limited with 11 studies 4039 
reporting on all-cause mortality but with no defined time-boundary, 4 studies showed 4040 
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increased mortality, 7 found decreased mortality giving a non-significant overall 4041 
effect(0.92 95%CI 0.81-1.06 P=0.25). 4042 
In the USA, the Department of Veterans Affairs recently commissioned a systematic 4043 
review of antimicrobial stewardship programmes (ASP) 481, 482. The key findings have 4044 
been published and the reader is referred to these publications for details 483, 484. To 4045 
avoid duplication, the VA systematic review only included papers meeting their 4046 
eligibility criteria but not included in the 2013 Cochrane review. The review reported 4047 
mixed results for clinical/microbial outcomes and overall improvement in prescribing. 4048 
Because (i) few studies of different interventions reported each outcome, (ii) of 4049 
inconsistency across studies and (iii) medium/high risk of bias, the strength of evidence 4050 
for all clinical outcomes was low: no single antimicrobial stewardship programme was 4051 
found to be superior but amongst studies since 2000 the greatest body of evidence of 4052 
effectiveness was for decreasing inappropriate or increasing appropriate antibiotic use. 4053 
Effects were seen across all species of Gram-negative bacteria and broad-spectrum 4054 
antimicrobials. 4055 
There are individual studies of high quality. Introduction of a stewardship programme 4056 
in one US hospital reduced the use of broad spectrum agents, and was associated with a 4057 
reduction in hospital-acquired infections caused by MDR GNB from 37% to 8% over 6 4058 
years 485. Similarly resistance in P. aeruginosa declined when state guidelines on 4059 
stewardship were implemented using a computerized programme in an Australian ICU 4060 
486. In another study in Israel, a carbapenem-restriction policy was used as part of a 4061 
successful infection control strategy also including emergency department flagging of 4062 
colonized or infected patients, building an isolation facility, eradication of clusters, 4063 
environmental and personnel hand cultures, with rectal screening of 8376 patients. This 4064 
was effective in controlling an outbreak of carbapenem-resistant Klebsiella pneumoniae. 4065 
Although there was a significant reduction in meropenem use, prescription of colistin 4066 
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rose 487. Restriction of use of some antibiotics may need, or lead to, use of a diversity of 4067 
other agents and even introduction of newly available antibiotics or appropriate use of 4068 
older agents. These aspects also need to be subject to stewardship with appropriate 4069 
actions in responsible bodies within hospitals and reporting to users. This can be 4070 
complex and time-consuming. Some effective interventions are simple, for example, a 4071 
high-quality study compared 8- and 15-day antibiotic treatment of ventilator-associated 4072 
pneumonia (n=401) and did not find any difference in mortality or unfavourable 4073 
outcome. Patients who received 8 day treatment had significantly less emergence of 4074 
MDR pathogens (42% versus 62% p=0.04) but had a higher recurrence rate if they 4075 
initially had non-fermenting organisms as pathogen (40.6% versus 25.4% risk 4076 
difference 15.2% (CI 3.9%-26.6%).488  4077 
Effective antibiotic stewardship requires the use of timely bacterial antimicrobial 4078 
susceptibility testing. Relatively simple phenotypic tests, such as a comprehensive 4079 
antibiogram by automated methods, screening for resistance in bacteraemia isolates by 4080 
direct disc testing,514 double disc diffusion tests for ESBL, and biochemical 4081 
carbapenemase detection can provide useful information for treatment and infection 4082 
control purposes.515  Automated diagnostic tests for bacterial identification (e.g. MALDI-4083 
ToF) and PCR-based resistance gene detection (e.g. Cepheid® for carbapenemase and 4084 
ESBL detection) can provide even more detailed information within the same day for 4085 
MDR GNB. More rapid susceptibility methods for resistance detection are being 4086 
developed. Further information may be found in recent reviews.515-518  4087 
This information together with promptly administered appropriate antibiotics is likely 4088 
to improve prognosis. All UK laboratories should have access to phenotypic and basic 4089 
genotypic methods described above within their resources. As a performance measure, 4090 
overall time elapsed from sample collection to administration of treatment appropriate 4091 
to the bacterial susceptibility can and should be assessed and repeatedly audited 4092 
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against what could best be achieved with modern methods. Particular attention should 4093 
be paid to MDR GNB as defined either for community or hospital originating strains. 4094 
Audit of outcomes associated with bacteraemia provides an objective measure of the 4095 
appropriateness of antimicrobial treatment, particularly for MDR GNB. 4096 
The deployment of antibiotic stewardship programmes is variable, as shown by a 4097 
survey of 660 hospitals in 67 countries 489. This study included the first data from sites 4098 
in Asia, Africa and South America, many with considerable problems with MDR GNB. 4099 
There is an urgent need for the adoption of an international antibiotic stewardship 4100 
timetable. 4101 
Evidence 4102 
Up-to-date local resistance and outcome surveillance data are needed to inform 4103 
guidelines on empirical antibiotic advice and must be persuasive to medical and nursing 4104 
staff, to all prescribers and to pharmacists advising on guidelines. 4105 
Evidence level: 4 4106 
Interventions intended to decrease prescribing that is excessive (by reference to 4107 
guidelines) for specific antibiotics have been associated with reductions in both 4108 
colonisation and infections caused by carbapenem, aminoglycoside or cephalosporin-4109 
resistant bacteria but this is not a consistent finding across all stewardship initiatives 4110 
Evidence level: 2++ 4111 
Restrictive rather than persuasive prescribing interventions cause a significant short- 4112 
term change in prescribing and there is scanty evidence that they may contribute to 4113 
reductions in the prevalence of resistant GNB. Persuasive prescribing interventions 4114 
should also be used and are as effective over a 1- to 2- year period 4115 
Evidence level: 2++ 4116 
Clinical outcome data on infections that is linked to antibiotic prescribing should be 4117 
collected as well as data on resistance and prescriptions of antimicrobials to ensure 4118 
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stewardship approaches do not degrade outcomes, and ensure high and consistent 4119 
standards between hospitals. 4120 
Evidence level: 2++ 4121 
Audit and feedback should be used to reduce antimicrobial use in hospitals. Local and 4122 
national advice on which antibiotics to prescribe are a useful standard against which to 4123 
conduct audit and to explore clinical and microbiological outcomes 4124 
Evidence level: 4 4125 
Recommendations 4126 
 Provide an on-going antimicrobial stewardship programme in all care settings, 4127 
based on resistance rates, with audit of compliance with guidelines, surveillance 4128 
of outcomes, and active feedback.  4129 
Grading: Strong recommendation for 4130 
 Use restrictive prescribing policies to acutely reduce the incidence of infection, 4131 
or colonization, with MDR GNB; thereafter, maintain persuasive and restrictive 4132 
approaches and monitor that gains persist. 4133 
Grading: Strong recommendation for 4134 
 Identify through horizon scanning, and make available, new antimicrobials that 4135 
may be required to treat MDR GNB. Monitor their use through formulary/drug 4136 
and therapeutics committees.   4137 
Grading: Conditional recommendation for 4138 
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11.2 The national monitoring of good antibiotic stewardship in    4139 
 secondary/tertiary care facilities 4140 
Antibiotic therapy differs from other treatment in man in being directed against diverse 4141 
and frequently unknown organisms and in exercising selection for resistant organisms, 4142 
these change the potential target for drug action and may then cause infection either in 4143 
the same or other patients. Treatment options for infections due to MDR GNB are 4144 
restricted and failure to deploy appropriate treatment in these infections may be 4145 
associated with a poor outcome whereas excessive use of a single agent in a hospital or 4146 
unit is more likely to select for superinfection caused by resistant organisms. The 4147 
clinical governance of antibiotic policies therefore is a balance between treatment of the 4148 
individual and management of the community’s antibiotic armamentarium. 4149 
Antibiotic use and the prevalence of MDR GNB are now widely monitored in 4150 
communities and hospitals but (i) monitoring use does not indicate whether use was 4151 
appropriate, and (ii) monitoring the accumulative prevalence of resistant strains is no 4152 
guide to the incidence rate of new cases caused by MDR GNB. Root cause analysis of 4153 
individual cases is burdensome and very complex if it is intended to relate to outcome. 4154 
It also runs the risk of bias with regard to outcome unless the proportions of resistant or 4155 
susceptible organisms that are examined match the overall population. It does not 4156 
produce reliable statistically comparable data between institutions to support good 4157 
practice. Nevertheless, such comparisons were used with MRSA bacteraemia and C. 4158 
difficile in the past in the UK but these are acute events unlike chronic prevalence of 4159 
antibiotic resistant strains. 4160 
Clinical trials early in a product’s availability offer guidance on efficacy against 4161 
susceptible organisms and with some agents, an indication of potential for selection for 4162 
resistance. However, antibiotic efficacy is not usually sustained as resistance emerges, 4163 
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and unlike other classes of drug, early clinical trials become less relevant with the 4164 
passage of time. Anticipating when empirical therapy should include coverage against 4165 
MDR GNB is difficult but is a key part of local guidelines. Recommendations that i) limit 4166 
use of broad spectrum drugs such as carbapenems, or ii) which reserve particular 4167 
agents for patients with MDR GNB present in infections that have a potential high 4168 
mortality, need also to consider the potential hazard of poor clinical outcomes.  4169 
Despite assistance from other professions, deployment of infection and microbiology 4170 
specialists into surveillance and away from patient care is frequent, and mundane tasks 4171 
in surveillance employing specialists should be reduced to a minimum, without 4172 
compromising excessively data quality. Routine national reporting systems on 4173 
bacteraemia in the UK should be routinely linked to public health date of death data 4174 
held nationally for each person by the Office for National Statistics as has been 4175 
described in one study restricted to E. coli bacteraemia 102. Such linked information 4176 
should be fed back annually to, and within, individual hospitals and summarized 4177 
findings provided to hospitals to enable comparisons of performance. Incidence and 4178 
mortality rates in bacteraemia at the local level would provide key assurance on the 4179 
prevention of systemic infections and the quality of outcomes. If these data on outcome 4180 
were provided by patient, it would provide a focus to examine and attempt to reduce, 4181 
the increasing incidence of bacteraemias and their associated mortality. Further these 4182 
data would ensure locally that overall and specific audit could be made of the antibiotic 4183 
resistance in organisms and the antibiotics actually deployed to treat serious infections 4184 
that they caused. Added to existing data, such audit and source information could 4185 
nationally and locally identify locations where there is high mortality either in primary 4186 
or secondary/tertiary care enabling appropriate investigation and action to be taken 4187 
locally. A crucial foundation has already been organized in England and Scotland via 4188 
mandatory reporting of bacteraemia data for E. coli which specifically includes, inter 4189 
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alia, data on community or hospital onset, and nursing home residency entered locally 4190 
by laboratories. In England laboratories voluntarily and automatically (via computer 4191 
links) submit antibiotic susceptibility data for 82% (54,301/66,512 over 2 years) of 4192 
cases of E. coli bacteraemia reported by the mandatory programme, which does not, 4193 
itself capture susceptibility data. This could be built upon to deliver local and nationally 4194 
useful data on outcome by antibiotic resistance 94. Furthermore, this process should be 4195 
expanded to capture mortality information on other important bacteraemias e.g. 4196 
Klebsiella spp. where prevalence is increasing and resistance is a major global threat or 4197 
indeed to all bacteraemias.  Reduction in the absolute number of associated deaths from 4198 
bacteraemia may well involve changes other than in chemotherapy provided audit 4199 
suggests chemotherapy is actively employed and appropriate. This requires 4200 
multidisciplinary joint engagement and clinical management expertise in the 4201 
community quite as much as in hospital to avoid sepsis and improve its management.  A 4202 
decrease in prevalence of bacteraemia and multi-drug-resistance within such infections 4203 
is one aspect of this. Quantitative reduction in the number of deaths, and not changes in 4204 
the comparative position of hospitals and communities in their respective peer groups 4205 
should be the focus. 4206 
Bacteraemias should be, assigned reliably as being of community, wider healthcare or 4207 
hospital onset so that responsibility can be assigned and accepted for performance by 4208 
relevant commissioning groups, public health services and hospitals. Whilst the date of 4209 
sampling of bacteraemia can be recorded, patients may become colonized by the 4210 
causative bacterium much earlier and the exact timing of acquisition usually cannot be 4211 
proven from existing laboratory records. IT coordination and shared responsibility 4212 
across the health economy is needed to access the last date of discharge from hospital, 4213 
which may be a practical proxy for date of colonization in cases of apparent community 4214 
acquisition that are actually hospital-acquired. Where care does not involve transfer to a 4215 
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tertiary centre and the patient is not being admitted to multiple hospitals in a 4216 
conurbation, such information should already be available in many localities but non-4217 
automated extraction is time consuming. It is important for securing improvement that 4218 
the bacteria isolated from bacteraemias can be related to likely acquisition in hospital, 4219 
wider healthcare or community and not simply to onset in hospital or community and 4220 
that responsibility for resistant strains falls accurately on hospitals or community 4221 
commissioners of healthcare. Targeting reductions in MDR GNB in potentially life-4222 
threatening infection is problematic because of variations between community 4223 
populations in ethnic origin associated apparently with antibiotic resistance such as 4224 
ESBL-production 4, 137.  For this reason a simple process of commissioned reduction in 4225 
resistance may be unachievable in some communities and their associated hospitals.   4226 
Residence in a nursing home is a marker of healthcare acquisition, not general 4227 
community acquisition, and nursing-home patients should be separately and reliably 4228 
categorized. Dates of hospital discharge of patients admitted from nursing homes may 4229 
be relevant to intervention if the patient has moved between the nursing home and 4230 
hospital recently – say within the last 2 years. 4231 
Tertiary and international referral in some hospitals (including referrals from armed 4232 
forces  deployed overseas 490) even if the hospitals are not formally categorized as 4233 
specialist hospitals may also skew their resistance profile towards multiple resistance 4234 
491, 492 so it is important to keep a balance between recognizing that this may be a reason 4235 
for high resistance rates and ensuring that such resistant strains should be, as they 4236 
always have been, a target for effective infection control.  Again for this reason targeting 4237 
antibiotic resistance reduction appropriately within a national context, may be more 4238 
straightforward if it is directed at a local level. 4239 
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Dates of collection of blood cultures, as recorded in laboratory computer systems, may 4240 
be distorted by entry of default dates of registration on Monday mornings after 4241 
submission of samples from Friday night on wards. There is no information on the 4242 
frequency of this problem but it is time-consuming to retrospectively correct or 4243 
prospectively avoid. An interval of <3 days since admission, is recommended for 4244 
defining ‘community onset’ as more practical than the 48 hour limit suggested 4245 
internationally and probably without important consequence, if permitted. This should 4246 
be investigated if the mandatory programme is expanded as recommended. Laboratory 4247 
data should not be reported multiple times and should utilize as little manual entry as 4248 
possible and hospital trusts should ensure the automated transfer of data from 4249 
laboratory systems to monitoring bodies. Information transfer should be frequent. 4250 
However in the presence of good infection control and absence of an ongoing MDR GNB 4251 
outbreak, annual batch processing of mortality linkage and annual central audit should 4252 
be adequate in most hospitals for governance monitoring of hospitals and this would be 4253 
adequate to support changes to infection management including antibiotic policy 4254 
(which are seldom made more frequently). Not only good performance in reducing 4255 
antibiotic use but also in better-than- average performance in bacteraemia reduction 4256 
and better outcomes in bacteraemia (including that which is antibiotic resistant) should 4257 
be rewarded. 4258 
Such laboratory-based extended surveillance of all bacteraemias would address (i) the 4259 
diversity of organisms and, at a local level, the match to antibiotics prescribed (which 4260 
itself could be centrally reported, if pharmacy systems and laboratory systems are 4261 
linked by patient/NHS number and then ordered by concatenated patient/NHS number 4262 
and reversed Julian date) ii) the usual, but not invariable, progression in antibiotic 4263 
resistance rates. (iii) the need for organisations to make changes to prescribing policy 4264 
with document control, feedback to clinicians and corporate responsibility of CCGs and 4265 
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hospitals for infection management. To address bacterial species- and resistance-4266 
specific aspects in any locality, analysis (including trend analysis) of data cumulated 4267 
over 5 years may be needed to avoid problems with small numbers of some pathogens. 4268 
Individual hospitals need more local as well as the existing national data to 4269 
systematically analyse, explain and address unsatisfactory outcomes. The already 4270 
striking increase in incidence of E. coli bacteraemia often in patients being admitted 4271 
from the community will probably increase further, with better ascertainment of sepsis. 4272 
Commissioning attention needs to be paid to the appropriateness of prior 4273 
chemotherapy (i.e. for UTIs in the community) to attempt to reduce such rising 4274 
incidence and associated mortality. Owing to the rise of MDR GNB, central monitoring 4275 
of, and action on, informatics is required in all hospitals. Collation of information is 4276 
required to explain clinical and resistance outcomes by patients and to plan action in 4277 
hospital and community onset cases. Early Warning Scores, which are required for such 4278 
analysis, are frequently now available on computerised systems to monitor vital signs. 4279 
Separate patient-based prescribing systems record the date of prescription and 4280 
antibiotics given. Laboratory data systems record (i) the date of collection of the first 4281 
positive blood culture for an organism-episode from a patient, and (ii) the organism and 4282 
its antimicrobial susceptibilities. These data sets should be linked electronically along 4283 
with, from hospital patient administration systems, the admission date, the date of last 4284 
hospital discharge and place of residence (i.e. home or residential care). Early Warning 4285 
Scores of 6 or more within 3 days of the bacteraemia indicate a poorer prognosis in 4286 
bacteraemia but this data is continuously collected and may be difficult to link as single 4287 
values.  The most difficult area to address is usually the unequivocal assessment of 4288 
outcome. Mortality is associated with poor functional state and co-morbidities, which 4289 
may link to age and have been assessed automatically from computerized discharge 4290 
records of diagnoses (ICD or Diagnosis-related group codes) in the US 493 and France 494. 4291 
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Defining mortality at a point less than 30 days after bacteraemia could tighten linkages 4292 
to resistance and inappropriate prescribing, and should be studied. Acute renal injury is 4293 
also a useful outcome measure as is subsequent development of C. difficile infection 4294 
within 28 days. Sometimes these linkages can be made expediently without linking 4295 
systems by exporting data and linking it in data bases or spreadsheets but the 4296 
mechanics of this should not be dependent directly and solely on infection specialists, 4297 
although they must advise on what should be done. 4298 
Quality and commissioning organisations should ensure hospitals are collecting and 4299 
analysing all such data to explain and improve their results in the treatment of serious 4300 
infections uch as bacteraemias not just those with MDR GNB. Particular scrutiny of year-4301 
on-year improvement in outcome of bacteraemia and reduction in prevalence according 4302 
to onset in hospital or the community is needed both in CCGs and hospitals. Application 4303 
of enhanced definitions of place of likely acquisition together with the working party’s 4304 
definitions of multi-resistance as applied to hospitals and the community and within the 4305 
context of the local communities population make-up, may explain the reasons for, and 4306 
sometimes enable multi-facetted action on, problematic multiple resistance as a whole 4307 
health economy approach. . Hospital-, community-healthcare and community-onset 4308 
bacteraemia therefore require separate analysis.  4309 
Evidence 4310 
Key components of an effective antimicrobial stewardship programme are consistent 4311 
effort and audit of outcome by specialists with full communication and support from 4312 
electronic prescribing/laboratory and clinical records. Computerised systems can and 4313 
should be integrated. Also required are full accountability of responsible organisations 4314 
for occurrence of serious infections, and the outcomes of treating them. Accurate 4315 
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information is required on serious infections with MDR GNB but must not be assessed in 4316 
isolation. 4317 
Evidence level: 2+  4318 
Hospital or community antibiotic use (by DDDs, or perhaps better in the context of 4319 
resistance selection, number of patients exposed to each agent), should be reviewed 4320 
locally together with antibiotic resistance data. These data sets are available from 4321 
pharmacy and microbiology systems respectively. Audit on compliance with local 4322 
guidelines can be undertaken, but this provides no assurance on clinical outcome in 4323 
severe infections: these require comparison with performance of other similar 4324 
institutions and analysis to ensure the quality of care. 4325 
Evidence level: 2++ 4326 
Extended surveillance of bacteraemia with appropriate record linkage both centrally 4327 
and in the hospital would provide clinical outcome assurance in the most severe 4328 
infections and also a means of comparing improvement in hospitals and communities. 4329 
Further this would lead to a sharp focus on improvements to antibiotic guidance, usage 4330 
and infection control  4331 
Evidence level: 2+ 4332 
Recommendations 4333 
 Ensure production of local guidelines for empirical and definitive antibiotic use, 4334 
regularly updated for community-, wider healthcare-, and hospital- onset 4335 
infections, and audit compliance with these. 4336 
Grading: Conditional recommendation for   4337 
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 Integrate hospital IT to deliver annually linked data for each bacteraemia, 4338 
including patient demographics, whether the bacteraemias onset was in the 4339 
community, wider healthcare or hospital, antibiotic resistances of isolates, 4340 
antibiotics prescribed, and maximum early warning score or occurrence of septic 4341 
shock, and, if possible, defined time-limited (not admission-limited) mortality. 4342 
Use these integrated data to review the adequacy of treatment of infection in 4343 
communities and hospitals  4344 
Grading: Good practice recommendation 4345 
 Central public health departments or the Chief Medical Officers should receive 4346 
bacteraemia data from the jurisdictions of trusts and CCGs or equivalent primary 4347 
care organisations. Annually, either peripherally or centrally they should ensure 4348 
computerized record linkage to give dates of death to be added to, organism, 4349 
specific antibiotic resistance and pattern, date of collection, nursing home 4350 
residency, optionally local records on last hospital discharge before bacteraemia. 4351 
This data should be made available, for open interrogation and downloading, 4352 
with rolling cumulative data within the health service. They should ensure 4353 
information findings on mortality rate are categorized by locality (separately for 4354 
hospitals and for community with associated separate wider healthcare data). 4355 
Grading: Strong recommendation for 4356 
 Make publicly available tabulated incidence and outcome data for bacteraemia 4357 
giving hospital onset data by region and hospital, and for community and wider 4358 
healthcare outcome data by CCG or equivalent primary care organisation. 4359 
Correlate this data with similar analysed and tabulated annual data on total 4360 
antibiotic use and organism and antibiotic resistance in clinical infections. 4361 
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Grading: Good practice recommendation  4362 
 Continuously monitor bacteraemia outcomes and antibiotic resistance by 4363 
organism and devise improvement programmes to both, locally and 4364 
appropriately within health economies.   4365 
Grading: Good practice recommendation 4366 
 Consider central production of unbiased national or regional data on true 4367 
resistance rates in community-onset localized or systemic infections to guide 4368 
national community antibiotic recommendations.  4369 
Grading: Strong recommendation for 4370 
11.3 Antibiotic stewardship in the community and care homes to reduce MDR 4371 
Gram-negative infections 4372 
Several RCTs in the UK communities have shown that multifaceted interventions that 4373 
included i) general practice staff education and ii) education of the patient through 4374 
improving communication during the doctor-patient consultation have improved 4375 
prescribing 495, 496. There have also been several Cochrane reviews that included studies 4376 
in hospitals, but which should be transferable to the community and care homes, aiming 4377 
to improve antibiotic prescribing. In one Cochrane review, restrictive interventions 4378 
(selective reporting of laboratory susceptibilities, formulary restriction, and antibiotic 4379 
policy change strategies) had a greater effect in the short term in reducing use of broad 4380 
spectrum antibiotics than persuasive interventions (distribution of educational 4381 
materials; educational meetings; local consensus processes; educational outreach visits; 4382 
local opinion leaders; reminders provided verbally, on paper or on computer; audit and 4383 
feedback). However both were equally effective in controlling antibiotic use and 4384 
antimicrobial resistance after 6 months 468. In a separate Cochrane review, printed 4385 
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educational materials alone had an effect on the practice of healthcare professionals and 4386 
patient health outcomes 497. Based on seven RCTs and 54 outcomes, the median 4387 
absolute risk difference in categorical practice outcomes was 0.02 when printed 4388 
educational materials were compared with no intervention (range from 0 to +0.11) 497. 4389 
Other Cochrane reviews show multifaceted interventions are more effective. Moreover, 4390 
interventions that are based on cognitive theories and consider personal attitudes, 4391 
subjective norms and perceived behavioural controls (confidence and other barriers) 4392 
are more likely to be successful, e.g., posters raise awareness and change subjective 4393 
norms but are ineffective when used alone.  4394 
In an audit and feedback process, an individual’s professional practice or performance is 4395 
measured and then compared with professional standards or targets. The results of this 4396 
comparison are then fed back to the individual. In general practices this will probably 4397 
be via the medicine manager, local GP prescribing champions or in collaboration with 4398 
local microbiologists. The aim is to encourage the individual to follow professional 4399 
standards 498. A Cochrane review considered 82 comparisons from 49 studies of any 4400 
health care interventions in which audit and feedback was core and evaluated effects on 4401 
professional practice. 498.There was a median 4.3% increase in healthcare professionals’ 4402 
compliance with desired practice (interquartile range (IQR) 0.5% to 16%) when i) 4403 
baseline performance was low, ii) the source was a supervisor or colleague iii) it was 4404 
provided more than once, iv) it was delivered in both verbal and written formats, and v) 4405 
when it included both explicit targets and an action plan. In addition, the effect size 4406 
varied based on the clinical behaviour targeted by the intervention 498. An RCT 4407 
evaluating a multifaceted intervention in English general practice aimed at improving 4408 
antibiotic prescribing included feedback of practice level data on antibiotic prescribing 4409 
and resistance: this led to a 4.2% fall in total antibiotic use 495. In some parts of the UK, 4410 
audit with action plans, and intense infection control measures, have been associated 4411 
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with falls in quinolones and cephalosporin use and resistance 4, 499. Incentives attached 4412 
to action plans can be very effective but, without personal attitude changes, the change 4413 
may reverse when the incentive is reduced 500. Any audit indicators need to be well 4414 
monitored, as implementation of an effective multiple-intervention strategy achieved no 4415 
reduction of antibiotic prescription rates when deployed at a larger scale in general 4416 
practice: the authors attributed the failure to a less tight monitoring of the intervention 4417 
and audit 501. It is necessary to demonstrate by further study, that such interventions 4418 
can be effective at practice or hospital unit/hospital level.  4419 
Relevant outcomes, which should be monitored, include mortality from systemic 4420 
infections such as bacteraemia, hospital admission, emergency room attendance, 4421 
requirement for outpatient parenteral antibiotic therapy, re-consultation in person or 4422 
by telephone, time-limited re-prescription of antibiotics and microbiological and clinical 4423 
persistence of infection. 4424 
Evidence 4425 
Restrictive and persuasive interventions are equally effective in controlling antibiotic 4426 
use and antimicrobial resistance and a multi-faceted approach is most effective 4427 
Evidence level: 1+  4428 
Audit and feedback interventions result in an increase in healthcare professionals’ 4429 
compliance with desired practice 4430 
Evidence level; 1++ 4431 
Local and national surveillance data are needed to determine appropriate empirical 4432 
antibiotic guidelines. 4433 
Evidence level: 3   4434 
Collection and analysis of outcome data is important in assessment of measures needed 4435 
to improve the management of infection and to reduce the increase in antibiotic use and 4436 
resistance. 4437 
Accepted manuscript 181 
Evidence level 2+  4438 
Recommendations 4439 
 Use persuasive and restrictive interventions to reduce the total antibiotic 4440 
consumption, particularly broad-spectrum antibiotics in the, community and 4441 
care homes. 4442 
Grading: Strong recommendation for 4443 
 Provide and use active feedback of monitoring to prescribers, and nursing staff 4444 
ensuring optimization of clinical, microbiological, and antimicrobial prescribing 4445 
outcomes. Use audit and feedback to reduce inappropriate antimicrobial use in 4446 
the community and wider healthcare. 4447 
Grading: Strong recommendation for 4448 
 Review outcome data linked to antibiotic prescribing to improve quality of care 4449 
in the community and care homes. 4450 
Grading: Conditional recommendation for 4451 
12 Conclusions 4452 
The selection of antibiotics for the treatment of infections caused by Gram-negative 4453 
bacteria (GNB) has always been difficult. Following the introduction of the first 4454 
antibiotics with activity against GNB such as tetracycline, chloramphenicol and 4455 
streptomycin, introduced in the late 1940's, resistance in E. coli causing urinary tract 4456 
infection was observed at rates of 5-10% as early as 1953 502. Subsequently it emerged 4457 
that Enterobacteriaceae can exchange and re-assort antibiotic resistance genes with 4458 
great ease via plasmids, transposons, integrons and other mobile, or potentially mobile, 4459 
genetic elements. This meant that resistances to antimicrobials no longer being used 4460 
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were easily and stably maintained as the relevant resistance genes commonly become 4461 
linked to, and compromise, antibiotics that remain in use. These linked resistances 4462 
became transferable to a wider and more versatile range of strains.  4463 
As each class of new agent was introduced so resistance negated its reliable empirical 4464 
use for the treatment of serious sepsis and also undermined any future reliance on the 4465 
older agents. This is exemplified in the UK by the rise of plasmid mediated TEM beta-4466 
lactamase conferring resistance to ampicillin in the 1960's, aminoglycoside modifying 4467 
enzymes conferring gentamicin resistance in the 1970's, extended spectrum TEM and 4468 
SHV beta-lactamases conferring cephalosporin resistance in the 1980's  and beginning 4469 
in the 1990s CTX-M ESBLs, DNA gyrase mutations, and dihydrofolate reductases 4470 
conferring resistance to third generation cephalosporins, fluoroquinolones and 4471 
trimethoprim, respectively . We are now facing a similar process with carbapenems and 4472 
polymyxins.  4473 
The bacterial ability to maintain older resistances may undermine any benefit from the 4474 
introduction of more resolute antibiotic stewardship. Over-reliance on stewardship as 4475 
the sole strategy for reducing MDR GNB may not be productive although reductions in 4476 
antibiotic use if they are substantial enough to reduce selection in the human microflora 4477 
for resistant strains are welcome. Use of a diversity of agents focused to proven 4478 
bacterial infection may be more important than restricting 478 entirely the use of certain 4479 
antibiotics and classes. Empirical prescribing based on generic clinical diagnoses will 4480 
also need to be safely reduced.  4481 
Because of widely differing usage of antibiotics active against GNB in both medicine and 4482 
agriculture in different parts of the globe since the 1980's we have created widely 4483 
differing rates of occurrence of MDR GNB in these different locations and in some cases 4484 
between food animals and man. Furthermore the increasing recognition of restricted 4485 
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extraintestinal pathogens in different species suggests that animal husbandry quality 4486 
and control of these strains may be variable. Higher rates of MDR GNB pose therapeutic 4487 
problems for those countries. In addition over the last decade the movement of people, 4488 
goods and food has resulted in countries such as the UK meeting unpredictable and 4489 
alarming appearances of MDR GNB by importation 49. Imported food-producing animals 4490 
from overseas founder stock, and foodstuffs, need to be free of important antibiotic 4491 
resistance in Gram negative bacilli to just as great an extent as returned travellers for 4492 
biosecurity and as a foundation for enhanced antimicrobial stewardship. 4493 
In order to produce relevant guidelines for the empirical treatment of infections caused 4494 
by MDR GNB an understanding of the local epidemiology and susceptibility patterns is 4495 
essential. The unpredictability of horizontal gene transfer and nosocomial spread may 4496 
necessitate specific guidelines being produced for individual hospitals/communities. 4497 
The present guideline has attempted to assess the relative clinical efficacy of different 4498 
agents. We have found very few good quality clinical trials to support treatment 4499 
regimens, particularly for licensed older agents, formerly little-used, that have been re-4500 
introduced into regular use. Finding much more rapidly a mechanism to address this 4501 
deficit in trials is an important overarching research objective as the existing pattern of 4502 
industry-sponsored initial regulatory trials fails to address the need. 4503 
It is self-evident that selection of antibiotic treatment based on susceptibility testing is 4504 
the optimum strategy for treating infections caused by MDR GNB. The initiative to 4505 
develop and deploy molecular and rapid phenotypic susceptibility testing methods will 4506 
help refine antibiotic usage. Any additional expense must be funded within the 4507 
healthcare system for these to be introduced. Risk factor, rule-based prescribing for 4508 
MDR GNB is unlikely to be sufficiently predictive alone for the reasons outlined above 4509 
but risk-assessment of travel, household spread, and screening on admission to 4510 
hospitals needs urgent improvement. However we have attempted to present an 4511 
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evidence base and suggestions to support the development of local prescribing policies 4512 
and possibly for the future application of such technologies and overall improvement in 4513 
outcomes.  4514 
Over-reliance on empirical piperacillin/tazobactam, and for treatment failure 4515 
meropenem, has and will drive selection for resistance to these agents, and UK health 4516 
policy is attempting to contain this upsurge in usage. For patients presenting with 4517 
serious sepsis convincingly caused by GNB and in the absence of prior exposure to 4518 
healthcare in countries/hospitals with endemic carbapenemase producing 4519 
Enterobacteriaceae, carbapenems remain the best empirical therapy with early and 4520 
embedded shift to alternative definitive treatment. The overall prevalence of resistance 4521 
in E. coli alone to piperacillin-tazobactam or gentamicin (approximately 10%) is the 4522 
basis for this superiority of carbapenems although factors such as aminoglycoside 4523 
toxicity and C. difficile risk must be considered. Combinations of these agents or 4524 
cephalosporins without β-lactamase inhibitors increase antibiotic use and are unlikely 4525 
to produce adequate activity against ESBLs because of resistance linkage. Algorithms for 4526 
predicting accurately presence of ESBLs need urgent validation in the UK health service 4527 
so piperacillin/tazobactam or gentamicin can be safely used to provide Gram-negative 4528 
cover in their absence, and cephalosporin-BLI combinations in their presence thus 4529 
diversify antibiotic use in serious infections within a stewardship framework. Use of 4530 
piperacillin/tazobactam or existing licensed aminoglycosides as empirical therapy 4531 
where ESBL-producing strains are prevalent such as after overseas travel or 4532 
hospitalisation, in communities where such travel has been frequent, and hospital or 4533 
nursing home exposure is unwise. Historical evidence suggests these agents continue to 4534 
be appropriate for sepsis if these risk factors are not implicated.  4535 
In England, use of the Commissioning for Quality and Innovation (CQUIN) payments 4536 
framework (or public health control of institutions and community healthcare) needs to 4537 
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be sensitive to the requirement to have safe effective antibiotics to use in sepsis caused 4538 
by non-MDR GNB which remain the majority of GNB causing serious infections in UK 4539 
hospitals. The role and utility of the latest generation of BL/BLI combinations is yet to 4540 
fully emerge. The early reports of emergence of resistance to ceftazidime-avibactam in 4541 
KPC-3-producing carbapenem resistant Enterobacteriaceae is extremely ominous 503.  4542 
Nevertheless, at the moment new BL/BLIs and fosfomycin offer the only immediate new 4543 
help to treat the latest MDR GNB particularly for carbapenemase producers and ESBL-4544 
producing GNB. Further development of BLI combinations for oral use is an urgent need 4545 
in primary care.  4546 
Initiatives are being put in place to address the paucity of new agents but they will take 4547 
time to give results which are by no means inevitable. A greater emphasis in 4548 
communities should be given to the better use of existing treatments for effective 4549 
treatment of complicated and upper UTI with prevention of bacteraemia and in 4550 
hospitals to an auditable improved outcome in well-defined groups of patients with life-4551 
threatening Gram-negative infections such as bacteraemia. This effort should match the 4552 
attention given to reducing inappropriate use of wide-spectrum agents for less 4553 
important infections and should ensure that reductions in antibiotic use are appropriate 4554 
and do not adversely affect patients. Computerised support to spare infection 4555 
professional time is necessary locally for surveillance of bacteraemia to focus attention 4556 
on improvements in performance in life-threatening infection.  4557 
Greater research and deployment efforts in the area of very rapid diagnostics to guide 4558 
immediate prescribing are needed. In the healthcare environment stopping spread of 4559 
infection with MDR GNBs is of paramount importance and such infection control 4560 
measures have been dealt with comprehensively in another working-party publication3.  4561 
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The greatest long-term threat arises from the fundamental epidemiology of GNB, with 4562 
their large faecal reservoirs in both humans and food animals leading to dissemination 4563 
into the environment 21. This leads to unpredictable acquisition by individuals with high 4564 
rates of commensal carriage and subsequent infection. Not only antibiotic control in 4565 
man but parallel control of use of the same agents in food animals is important. This is 4566 
exemplified by use of colistin, mequindox and fosfomycin 504 in food animals in China 4567 
and other parts of the world, and consequent emergence of plasmid-mediated colistin, 4568 
nitrofurantoin and fosfomycin resistance mediated by mcr-1, oqxAB and modified 4569 
nitroreductases, and fosA as discussed previously (See 6.3.4). The close association of 4570 
NDM MBL with connections with the Indian sub-continent is likely to change with the 4571 
demonstration of this carbapenemase in poultry, farm workers, flies and wild birds in 4572 
Shandong, China. 289. Practical measures to contain human importations of 4573 
carbapenemases but also assessment and potentially prevention of any spread in 4574 
foodstuffs are urgent at this early stage. Variations in the prevalence of MDR GNB in 4575 
different localities and cultural backgrounds even within the UK need to be further 4576 
explored and considered in empirical therapy. Separate effects of migration, travel, 4577 
household cross- colonization/infection and food consumption need to be rapidly 4578 
studied to make risk assessments practical and effective. 4579 
Internationally, public health hygiene measures to reduce faecal oral transmission such 4580 
as clean water initiatives and sewerage and irrigation systems to prevent transmission 4581 
are of major importance. Food stuffs including imports should be regulated for the 4582 
presence of GNB resistant to third-generation cephalosporins, quinolones and possibly 4583 
in the future carbapenems. Failure to address these under-recognised threats will undo 4584 
our ability to treat infections caused by MDR GNB.  If we do not control human and 4585 
agricultural use of antibiotics and the spread of MDR GNB from faeces back into humans 4586 
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and food animals as a consistent multi-faceted, global-scale, public-health programme, 4587 
we will suffer greatly. 4588 
13 Further research and development 4589 
Without consideration of the research needed for new compounds and formulations in 4590 
the antibiotic pipeline, there are numerous areas which require research with a 5 year 4591 
horizon for completion. 4592 
 Diagnostic tests and or serum markers should be formally and comprehensively 4593 
assessed for safety and efficacy as aids in deciding when to start and stop 4594 
antimicrobial treatment, particularly in critically ill patients and those with 4595 
haematological malignancies.  4596 
 Develop and introduce new cheap, rapid, and preferably bedside, diagnostic tests 4597 
for important multiple antibiotic resistant organisms in urine and blood. 4598 
 Undertake RCT studies of antimicrobial agents (both new and old) in the 4599 
treatment of Gram-negative infection in areas where multi-resistance is likely 4600 
e.g. admissions unit, critical care and urology in hospitals and in treatment of 4601 
infections due to ESBL-producing bacteria in the community. Identified research 4602 
areas in this guideline include 4603 
a. Use of continuous infusion meropenem at dose determined by nomogram 4604 
if infection with KPC-carbapenemase –producing Klebsiella with MIC of 4605 
>8<64mg/L. 4606 
b. Use of temocillin for non-urinary infections with trials to establish their 4607 
optimal dosage 4608 
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c. Use of temocillin alone, or in combination, in UTIs caused by 4609 
Enterobacteriaceae with KPC-enzyme. 4610 
d. Use of ceftazidime/avibactam alone when non-MBL carbapenemase-4611 
producing organisms cause infection in comparison with alternatives, 4612 
including combination therapy. 4613 
e. Use of ceftolozane/tazobactam in P. aeruginosa infections in cystic 4614 
fibrosis 4615 
f. In vitro and in vivo research to identify the usefulness of aztreonam in 4616 
combination with avibactam for infections due to Enterobacteriaceae 4617 
with MBLs and other carbapenemases. 4618 
g. Research into the role of loading doses of colistin, monitoring of serum 4619 
levels and optimal combination therapy.  4620 
h. Research into use of polymyxin-containing and non-containing selective 4621 
digestive decontamination regimens and the prevalence of newly 4622 
identified polymyxin resistance mechanisms 4623 
i. Optimal rapid and practical methods of colistin susceptibility testing 4624 
outside intrinsically resistant species such as Proteeae and Serratia spp. 4625 
j. Higher dosing studies with tigecycline to investigate if the unexpectedly 4626 
high mortality in infections with strains that are apparently susceptible in 4627 
vitro, can be reduced 4628 
k. Optimal use of high dose tigecycline in combinations in hospital-acquired 4629 
respiratory infections 4630 
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l. Specific system-based and resistance-mechanism-based indications for 4631 
use of parenteral fosfomycin, in infections due to MDR GNB. 4632 
m. Cefixime (or other oral cephalosporin) with clavulanate (alone or with 4633 
amoxicillin) against ESBL-producing E. coli UTI.  4634 
n. Nitrofurantoin versus fosfomycin trometamol versus pivmecillinam (with 4635 
or without amoxicillin/clavulanate) in patients with ESBL-producing E. 4636 
coli and Klebsiella spp. 4637 
o. Use of meropenem, or temocillin or ceftolozane/tazobactam in 4638 
community onset pyelonephritis where hospitalisation is required and 4639 
where MDR GNB excluding CPE are, or are likely to be, present. These 4640 
studies should include assessment of meropenem or aminoglycosides if 4641 
the patient describes penicillin-hypersensitivity. 4642 
 Undertake surveillance in both the hospital and community populations, and 4643 
households of newly detected colonised individuals, for incidence of known 4644 
mechanisms of resistance and the emergence of novel resistance mechanisms to 4645 
currently used antimicrobials. Link this surveillance to travel, prior 4646 
hospitalisation as in-patient, or residential healthcare. 4647 
 Develop new models of licensing and funding of antimicrobials for treating MDR 4648 
GNB infections. Develop non-microbial therapies for MRGNB (e.g. phage, 4649 
antibacterial peptides, etc.) 4650 
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Table 1. Summary of recommendations for stakeholders including prescribers 4691 




Central public health departments or the Chief Medical Officers should receive bacteraemia 
data from the jurisdictions of trusts and CCGs or equivalent primary care organisations 
bacteraemia data in their localities. Annually, either peripherally or centrally they should 
ensure computerized record linkage to give dates of death. They should ensure information is 
categorized by locality (separately for hospitals and for community with associated separate 
wider healthcare data), date of onset or acquisition, organism, specific antibiotic resistance and 
pattern, the mortality rate, This data should be made available, for open interrogation, with 
rolling cumulative data within the health service.   
Strong for 
 Make publicly available tabulated incidence and outcome data for bacteraemia giving hospital 
onset data by region and hospital, and for community and wider healthcare onset data by CCG 
or equivalent primary care organisations. Correlate this data with similar analysed and 
tabulated annual data on total antibiotic use and organisms and antibiotic resistance in clinical 
infections.  
Good practise 
 Consider central production of unbiased national or regional data on true resistance rates in 






Continuously monitor bacteraemia outcomes and antibiotic resistance by organism and devise 
improvement programmes to both, locally and appropriately within health economies.   
Good practise 
 Provide and use active feedback of monitoring to prescribers, and nursing staff ensuring 
optimization of clinical, microbiological, and antimicrobial prescribing outcomes. Use audit and 
feedback to reduce inappropriate antimicrobial use in the community and wider healthcare. 
Conditional for 
 Use persuasive and restrictive interventions to reduce the total antibiotic consumption, 
particularly broad-spectrum antibiotics in the, community and care home setting. 
Strong 
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 Ensure production of local guidelines for empirical and definitive antibiotic use, regularly 






Provide an on-going antimicrobial stewardship programme in all care settings, based on 
resistance rates, with audit of compliance with guidelines, surveillance of outcome, and active 
feedback. 
Strong 
 Identify through horizon scanning, and make available, and make available new antimicrobials 
that may be required to treat MDR GNB. Monitor use through formulary/drug and therapeutics 
committees.  
Conditional for 
 Use restrictive prescribing policies to acutely reduce the incidence of infection or colonisation 
with MDR GNB; thereafter, maintain persuasive and restrictive approaches and monitor that 
gains persist. 
Strong for 
 Integrate hospital IT to deliver annually linked data for each bacteraemia, including patient 
demographics, whether the bacteraemias onset was in the community, wider healthcare or 
hospital, antibiotic resistances of isolate, antibiotics prescribed, and maximum early warning 
score or occurrence of septic shock, and if possible defined time-limited (not admission-
limited) mortality. Use these integrated data to review the adequacy of treatment of infection in 






Inspect up-to-date national and local antibiotic surveillance when compiling local antibiotic 
guidelines on treatment of UTI. Follow local guidance on what antibiotics to prescribe,  
Strong for 
 For an elderly patient, do NOT send urine for culture or start empirical antibiotics unless there 
are specific symptoms or signs of UTI and none elsewhere. Use the algorithm in Figure 5 to 
decide whether to do this in elderly patients especially in those with dementia 
Conditional for 
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 Do not prescribe antibiotics in asymptomatic bacteriuria (ASB) in the elderly with, or without, 
an indwelling catheter.  
Strong for 
 Always consider the positive and negative predictive value of specific symptoms before sending 
urine for culture or starting antibiotics for a UTI. Base decision on when to prescribe (whatever 
the age) primarily on symptoms. Use dipstick tests, if no catheter is present, to confirm the 
diagnosis, before prescribing especially when symptoms are mild or not localized. 
Strong for 
 If there are risk factors for MDR GNB or previous presence of MDR GNB and the patient is 
symptomatic, send a urine specimen for culture and susceptibility  
Strong for 
 Building on previous work, predictive scoring should be developed for the presence of ESBL-
producing E. coli in primary care and on admission to hospital to restrict the need to prescribe 
carbapenems and other antimicrobial agents generally active against ESBLs 
Strong for 
 Need to quantify risks of infection with/ carriage of, extraintestinal pathogenic E. coli and of 
Klebsiella sp. resistant to all antibiotics and relate to time since travel to countries with high 
prevalence of MDR GNB and incorporate in risk assessments for clinical infection with MDR 
GNB in the community and on admission to hospital to guide therapy 
Strong for 
 If defined risk factors for MDR GNB are present avoid cephalosporins, quinolones, 
trimethoprim and co-amoxiclav in treatment of lower UTIs unless the pathogens are confirmed 
to be susceptible. 
Strong for 
 Personalise empirical chemotherapy for each patient by considering current features of 
bacteraemia, risk factors for antibiotic resistance and past susceptibility testing including the 
presence of MDR GNB in the patient, hospital unit, nursing home, or community. 
Conditional for 
 In pyelonephritis always collect a urine sample before treatment. MDR GNB are unlikely to 
respond to oral treatment so consider risk factors for MDR GNB including travel. Use an active 
oral agent only if patient is well enough and if known to have had ciprofloxacin-, trimethoprim-, 
or co-amoxiclav-susceptible MDR GNB in last month. 
Conditional for 
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 If the patient has pyelonephritis and risk factors for MDR GNB, start, if hospitalisation not 
required, empirical intravenous therapy with ertapenem if OPAT therapy available. This will 
treat ESBL and Amp-C producing Enterobacteriaceae. If hospitalisation required for this or 
OPAT not available, admit for meropenem, temocillin or ceftolozane/tazobactam if no evidence 
of CPE organism. If the patient is penicillin-hypersensitive then the hospital may use amikacin 
or meropenem, or if only susceptible isolates in the past, gentamicin. If carbapenem-resistant 
bacteria are, or have been, present, base treatment on susceptibility testing of recent or current 
isolates.  
Strong for 
 Locally assess the true rate of resistance and determine from this when changes to guideline 
recommendations for empirical therapy for UTI in guidelines are necessary including 





Always inform the patient or their carer(s) on what to look out for and how to reconsult if 
symptoms worsen or do not improve as community-onset E. coli bacteraemias of urinary origin 
are increasing  
Strong for 
 In younger women with acute uncomplicated UTI, only consider MDR GNB in choosing 
empirical treatment if there are risk factors See Section 9.3.1. or recent foreign travel to 
countries where such strains are highly prevalent.  
Strong for 
 Use fosfomycin, nitrofurantoin or pivmevillinam, guided where possible i) by susceptibility 
testing and ii) by this guideline’s recommendation on choice, dosing and duration, for 
uncomplicated lower urinary tract infection where MDR GNB are suspected.  
Strong for 
 Use nitrofurantoin for 5 days with MDR GNB. Alternatively use fosfomycin trometamol 3g 
orally as single dose, and repeat on third day only if MDR GNB confirmed to improve 
bacteriological cure. Pivmecillinam alone at 200mg three times daily for 7 days may be a third 
line choice but consider combination use with amoxicillin/clavulanate depending on clinical 
trial results at the time. 
Conditional for 
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 Review outcome data linked to antibiotic prescribing to improve quality of care in the 
community and care homes 
Conditional for 
 To reduce recurrent UTI, consider firstly, the option of pre-prescribed standby antibiotics to 
take when symptoms begin, rather than daily or post-coital antibiotic prophylaxis. Where 
prophylaxis is used successfully for recurrent infection in adults limit use to six months.  
Conditional for 
 Avoid antibiotic prophylaxis for urinary catheter insertion or changes unless there is previous 

















Accepted manuscript 197 
Table 2 Summary recommendations for specific antibiotics 4706 
 4707 
  4708 
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Amikacin Modernise use of amikacin, which has improved activity, with development of 
validated nomograms. Ensure assays are readily available before repeat doses and 
consider, because of the risks of toxicity, the practicality of monitoring with 
audiograms. 
Conditional for 
Amoxicillin/clavulanate Use for lower UTI due to known ESBL-producing bacteria only if current isolates, 
or if using empirically, recent isolates, are fully susceptible. 
Conditional for 
Ampicillin/sulbactam Could use against some carbapenem-resistant apparently sulbactam-susceptible 
A. baumannii isolates, Caution needed in the UK because of a higher range of MICs. 
Absence of a breakpoint prevents categorisation as susceptible/resistant. 
Conditional for 
Aztreonam Do not use aztreonam alone empirically if MDR GNB or Gram-positive or 
anaerobic pathogens are suspected 
Strong against 
Do not use aztreonam for CTX-M ESBL- or AmpC- producing bacteria even if these 
appear susceptible in vitro  
Strong against 
Use aztreonam for MBL- or OXA-48- producing strains if it is certain that they do 
not produce ESBLs or AmpC 
Strong for 
Research usefulness of aztreonam in combination with avibactam for bacteria 




Cefepime Could use cefepime to treat infection caused by ESBL- or Amp-C-producing 
bacteria if susceptible to the EUCAST breakpoint of MIC =<1mg/L 
Conditional for 
Do not use cefepime even at increased dose for isolates with i) MIC of 2-8 mg/l 
(CLSI “susceptible dose dependent”) or ii) MIC 2-4mg/L (EUCAST intermediate, or 
iii) strains with stable derepression of AmpC or iv) strains that produce both 
AmpC and ESBLs. 
Strong against 
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Do not use cefepime to treat infection caused by carbapenemase-producing 
Enterobacteriaceae 
Strong against 
Cefixime and other oral 
cephalosporins  
Do not used for treating infection caused by ESBL, AmpC and carbapenemase-
producing Enterobacteriaceae 
Conditional 
Cefoxitin Confirmation needed of its usefulness as a carbapenem-sparing agent for in-
patients to empirically treat urinary infection or use definitively for infections 
caused by CTX-M-15-producing E. coli: its short serum half-life means it is 




Ceftazidime Use ceftazidime for susceptible infections with P. aeruginosa including quinolone- 
or some imipenem- resistant strains 
Strong for 
Do not use ceftazidime to treat infections due to ESBL-or AmpC-producing 
Enterobacteriaceae or CPE (other than OXA-48 producers), even if in vitro tests 
suggest the isolate is susceptible 
Conditional 
against 
Ceftazidime/avibactam Could use ceftazidime/avibactam as an alternative to carbepenems for infection 
with ESBL- and AmpC- producing Enterobacteriaceae but alternatives may be 
cheaper 
Conditional for 
Evaluate further ceftazidime/avibactam use alone or in combination when non-
MBL carbapenemase-producing organisms cause infection. KPC-3 producing 
Klebsiella are vulnerable to mutations in the enzyme causing resistance  
Research and 
trials  
Consider if ceftazidime/avibactam should be used with a carbapenem or colistin 
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Do not use for treating infection with anaerobes or bacteria producing MBLs: 
these are resistant 
Strong against 
Ceftolozane/tazobactam  Use ceftolozane/tazobactam to treat susceptible infections with P. aeruginosa 
resistant to ceftazidime 
Conditional for 
Conduct clinical trials in P. aeruginosa infections in cystic fibrosis Research and 
trials 
Use ceftolozane- tazobactam as an alternative to carbapenems to treat urinary or 
intra-abdominal infection involving ESBL-producing E. coli. Caution may be 
needed when treating infections with ESBL-producing Klebsiella spp. owing to a 
higher resistance rate. 
Conditional for 
Do not use for infections due to AmpC- or carbapenemase- producing 
Enterobacteriaceae or MBL/ESBL- producing P. aeruginosa. 
Strong against 
Ertapenem Use ertapenem to treat serious infections with ESBL and AmpC-producing 
Enterobacteriaceae. 
Strong for 
Apply antibiotic stewardship to use of all carbapenems to minimize the risk of 
developing resistance either by acquisition of carbapenemase-producing strains 
or by porin loss. 
Strong for 
Preferred carbapenem for outpatient antibiotic treatment (OPAT) of susceptible 
infections  in view of the once daily dosing regimen 
Conditional for 
Fluoroquinolones Could use orally to treat UTI caused by MDR GNB that are susceptible Conditional for 
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Fosfomycin Use in the treatment of lower UTI due to MDR Enterobacteriaceae. Oral 
formulation available is  useful for  ESBL producers after repeated recurrence 
after nitrofurantoin and potentially for carbapenemase-producers 
Conditional for 
Consider dosage and trials of oral formulation for upper UTI Research and 
trials 
Consider parenteral fosfomycin, probably in combination, as part of salvage 
treatment for susceptible MDR GNB: clear indications for use are not yet 
established. Potential drug of last resort 
Research and 
trials 
Need comparative clinical trials to establish optimal indications for, and optimal 
use of, oral and parenteral drug.  
Research and 
trials 
Carry out ongoing local and national surveillance of use and resistance because of 
previous emergence of bacterial resistance in populations and the drug’s potential 
as an important parenteral agent. 
Strong for 
Gentamicin Could use gentamicin empirically in the UK if the likelihood of MDR GNB is low. Conditional for 
Could use gentamicin as a carbapenem sparing agent for urinary, intra-abdominal 
and bacteraemic infections due to ESBL-producing E. coli when susceptibility is 




Could use gentamicin in combinations for urinary, intra-abdominal and 
bacteraemic infections due to gentamicin-susceptible KPC-producing Klebsiella 
spp. if strain is resistant to colistin and meropenem (See Section 7.18). 
Conditional for 
Use once daily dosage of gentamicin or tobramycin if no renal impairment, 
followed by measurement of levels 6 to 14 hours post dose and adjust repeat 
dosage by reference to the appropriate 7mg/kg or 5mg/kg nomogram. Consider 
Strong for 
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increased risks of toxicity if there is co-administration of nephrotoxic or ototoxic 
drugs 
Imipenem & Meropenem Use meropenem or imipenem or ertapenem to treat serious infections with ESBL 
and AmpC-producing Enterobacteriaceae. 
Strong for 
Apply antibiotic stewardship to use of all carbapenems to minimize the risk of 
developing resistance either by acquisition of carbapenemase-producing strains 
or, with ertapenem, by porin loss.    
Strong for 
Do not use imipenem to treat susceptible Pseudomonas infections Conditional for 
Introduce in the UK mandatory reporting of meropenem- or imipenem- resistant 
Enterobacteriaceae from all anatomical sites and specimens. 
Strong for 
Test all meropenem- or imipenem- resistant isolates of Enterobacteriaceae 
immediately for the precise level of resistance and for an indication of the 
responsible class of carbapenemase.                                                                                                                                                                                                                                                                                                                                                             
Submit to agreed reference laboratories to determine susceptibility to a wide 
range of potentially active agents including, as appropriate, colistin, 
ceftazidime/avibactam, temocillin, aminoglycosides, fosfomycin and tigecycline. 
Strong for 
Consider use of continuous infusion meropenem in combination at dose 
determined by nomogram if infection with KPC-carbapenemase –producing 
Klebsiella with MIC of >8 & <64mg/L. 
Research and 
trials 
Nitrofurantoin Could use nitrofurantoin for 5 days to treat uncomplicated, lower urinary tract 
infections with nitrofurantoin-susceptible MDR E. coli (not Proteeae or P. 
aeruginosa). 
Strong for 
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Do not use repeatedly if there is moderate renal impairment 
(eGFR<45mks/min/1.73m2.), or in long-term courses, as these are associated 
with rare unwanted pulmonary effects. 
Conditional 
against 
Use alternative agents if there are repeated recurrences with MDR GNB but do not 
anticipate the emergence of resistance in E. coli infections on a single recurrence 
as selection for resistant strains in the urine or faecal flora is rare 
Conditional for 
Need comparative studies of nitrofurantoin and other active antimicrobials in 
patients with ESBL-producing E. coli and Klebsiella spp 
Research and 
trials 
Piperacillin/tazobactam Use for infections with known ESBL-producing bacteria only if current isolates, or, 
if using empirically, isolates from the recent past, are fully susceptible by EUCAST 
criteria. 
Conditional for 
Consider definitive use of piperacillin/tazobactam to treat infections caused by P. 
aeruginosa if susceptible by EUCAST criteria. 
Conditional for 
Pivmecillinam Consideration should be given to reducing the mecillinam EUCAST breakpoint for 
classification of susceptibility 
Conditional for 
Treat lower UTI due to ESBL-negative E. coli with pivmecillinam at 200mg three 
times daily: do not use for infections caused by Proteeae, Klebsiella or 
Pseudomonas. 
Conditional for 
Some ESBL-producing E. coli respond, but efficacy is poor against CTX-M-15 & 
OXA-1 enzyme producers: dosing at 400mg three times daily may be no more 
effective. Consider combination of the lower dose with 375mg three times daily 
amoxicillin/clavulanate for follow on to parenteral therapy for such infections in 
hospital or OPAT. 
Conditional for 
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Requires clinical comparative trials in the public interest i) alone or together with 
amoxicillin/clavulanate for UTIs due to ESBL-producing organisms including 
particularly those producing CTX-M-15 enzymes ii) in uncomplicated lower UTI 
generally against fosfomycin trometamol and nitrofurantoin as the relative 
advantages of these drugs have not been directly compared over the last 10 years 
as MDR GNB have become more problematic. 
Trials and 
research 
Polymyxins(including colistin)  Reserve intravenous colistin for infections due to polymyxin susceptible but 
multiresistant bacteria and preferably use in combination with other agents. 
Conditional for 
Give careful consideration to use of higher dosage regimens in critically ill 
patients 
Conditional for 
Use colistin with meropenem to treat susceptible KPC-producing Klebsiella spp. if 
the meropenem MIC is <=8mg/L and consider higher meropenem dose by 
continuous infusion if the MIC is >8 and =<32mg/L. 
Conditional for 
Consider colistin with aminoglycosides or tigecycline in infections with strains 
producing KPC or other carbapenemases, which are susceptible to these but 
resistant to meropenem with MIC>32mg/L.  
Conditional for 
Closely monitor renal function especially in the elderly, those receiving high 
intravenous doses for prolonged periods and those on concomitant nephrotoxic 
agents e.g. aminoglycosides   
Strong for 
Reconsider use of polymyxins in selective digestive decontamination regimens as 
these agents are now important last therapeutic options .against carbapenemase-
producing Enterobacteriaceae and are more threatened by resistance than 
previously appreciated 
Good practise 
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Need research on optimal rapid and practical methods of susceptibility testing 
outside intrinsically resistant groups such as Proteeae and Serratia spp. 
Research and 
trials 
Aerosolised colistin dry powder should be used in cystic fibrosis according to 
NICE guidelines Use in combination in ventilator-associated pneumonia may be 
considered pending further trials without methodological flaws. 
Conditional for 
Temocillin Use alone for UTIs and associated bacteraemia caused by AmpC- or ESBL- 
producing Enterobacteriaceae. 
Conditional for 
Continuous infusion or thrice-daily dosing may be desirable for systemic 
infections with ESBL- or Amp-C producing bacteria. 
Research and 
trials 
Could use for UTIs with KPC-producing Enterobacteriaceae but not for OXA-48 or 
MBL-producers, on basis of published in-vitro data. 
Research and 
trials 
Tigecycline Could use tigecycline in combination in the treatment of multiresistant soft tissue 
and intra-abdominal infections 
Conditional for 
Use alone in hospital-acquired respiratory infections is unlicensed and not 
advised as outcomes with current dosing are not clearly satisfactory in 
Acinetobacter and MDR GNB infections.  
Conditional 
against 
Use in combinations in hospital-acquired respiratory infections: precise 




Use higher-than licensed dosing such as 100mg twice daily for infections due to 
MDR GNB in critical care 
Conditional for 
Investigate if higher dosing counters the unexpectedly high mortality seen even in 
infections due to strains apparently susceptible in vitro. 
Research and 
trials 
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4713 Tobramycin Avoid tobramycin for MDR Enterobacteriaceae because of risk of resistance due to 
AAC (6’)1 and AAC (6’)-1b-cr 
Conditional 
against 
Use tobramycin in preference to other aminoglycosides for susceptible 
Pseudomonas infection 
Conditional for 
Use once daily dosage of tobramycin if no renal impairment followed by 
measurement of levels 6 to 14 hours post dose and adjust repeat dosage by 
reference to nomogram. 
Strong for 
Trimethoprim Do not use trimethoprim in treating MDR GNB or treatment failures with other 
agents unless in vitro-susceptibility has been demonstrated.  
Strong against 
Do not use trimethoprim to treat lower UTIs as a first line agent. Only consider 
use if there are norisk factors for resistance, or confirmed, in vitro susceptibility 
Conditional 
against 
Trimethoprim/sulfamethoxazole Use in treatment of infections due to susceptible S. maltophilia and consider in 
infections due to Achromobacter spp., Alcaligenes spp., Burkholderi spp., 
Chryeobacterium spp. and Elizabethkingia spp. 
Conditional for 
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Table 3 Levels of evidence for intervention studies 1  4714 
1++ High-quality meta-analyses, systematic reviews of RCTs or RCTs with a 
very low risk of bias 
1 + Well-conducted meta-analyses, systematic reviews or RCTs with a low 
risk of bias 
1 - Meta-analyses, systematic reviews or RCTs with a high risk of bias* 
2++ High-quality systematic reviews of case–control or cohort studies. 
High-quality case–control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is 
causal.  
Interrupted time series with a control group: (i) there is a clearly 
defined point in time when the intervention occurred; and (ii) at least 
three data points before and 
three data points after the intervention 
2+  Well-conducted case–control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship is 
causal OR Controlled before–after studies with two or more 
intervention and control sites 
2- Case–control or cohort studies with a high risk of confounding or bias 
and a significant risk that the relationship is not causal. 
Interrupted time series without a parallel control group: 
(i) There is a clearly defined point in time when the intervention 
occurred; and (ii) at least three data points before and three data points 
after the intervention. Controlled before–after studies with one 
intervention and one control site 
3 Non-analytic studies (e.g. uncontrolled before–after studies, case 
reports, case series) 
4 Expert opinion. Legislation 
*Studies with an evidence level of ‘1-‘and ‘2-‘should not be used as a basis for making a 4715 
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recommendation. 4716 
RCT randomised controlled trial. 4717 
  4718 
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Table 4 Grading of Recommendations 11 .  4719 
 Recommendation 
Undesirable consequences clearly 
outweigh 
desirable consequences 
Strong recommendation against 
Undesirable consequences probably 
outweigh 
desirable consequences 
Conditional recommendation against 
Balance between desirable and 
undesirable consequences is closely 
balanced or uncertain. 
Recommendation for research and 
possibly 
conditional recommendation for use 
restricted to 
trials 
Desirable consequences probably 
outweigh 
undesirable consequences 
Conditional recommendation for 
Desirable consequences clearly outweigh 
undesirable consequences 
Strong recommendation for 
  4720 
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Table 5 Stability of various β-lactam antibiotics and different inhibitor activities against important β-lactamases found in MDR GNB 4721 
  Enterobacteriaceae Acinetobacter Burkholderia Pseudomonas 






ESBL OXA-1 OXA-48 KPC IMP/VIM/NDM native 
OXA-
23/24/58 native native 






inhibited Not inhibited   Not inhibited     






inhibited Not inhibited   Not inhibited     
tazobactam 
Not 






inhibited Not inhibited   Not inhibited     
avibactam Inhibited Inhibited Inhibited Inhibited ? Inhibited InhibitedX Not inhibited   Not inhibited     
β-lactam                         











piperacillin Labile* Labile Labile Labile Labile Labile Labile Labile 
Acquired R 
near 
universal Labile Variable Active 
ceftazidime Labile* Labile Labile Labile Stable Stable Labile Labile 
Acquired R 
near 
universal Labile Variable Active 
meropenem/imipenem Stable Stable Stable Stable Stable Labile Labile Labile Active Labile Variable Active 
ertapenem 
Moderately 
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 + except Morganella morganii          
 
*May appear active if AmpC is inducible, as induce weakly 
X Inhibition not reliable with KPC3        
4722 
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Table 6 Studies of the efficacy of Colistin 4724 
Study  No of 
patients 
Conditions treated Pathogens Duration 
(mean) 
Outcome 
Levin 1999305 59 VAP 33%; UTI 20%; 
BSI 15%; CNS 8% 
A. baumannii 65%; 
P. aeruginosa 35%  
12 days 58% success overall. Worst in 
pneumonia group (25%) 
Garnacho-Montero et al. 
2003304 
21 VAP 100% A. baumannii 100% 14 days 57% success 
Linden et al. 2003306 23 VAP 78%; BSI 35%; 
Intra-abdominal 26% 
P. aeruginosa 100% 17 days 61% favourable 
Markou et al. 2003307 24 VAP 63%; Catheter 
related 12%; 
Meningitis 4% 
A. baumannii 24%; 
P. aeruginosa 76%  
13.5 days 73% success 
Michalopoulos et al. 2005308  43 VAP 73%; BSI 33% A. baumannii 19%; 
P. aeruginosa 81% 
18.6 days 69% clinical cure 
Reina et al. 2005309  55 VAP 53%; UTI 18%; 
BSI 16% 
A. baumannii 65%; 
P. aeruginosa 35%  
13 days 15% cure on day 6 of treatment 
Koomanachaie et al 2007505   78 VAP 58%; BSI 10% A. baumannii 91%; 
P. aeruginosa 9% 
12 days 81% clinical response 
VAP ventilator associated pneumonia 4725 
UTI urinary tract infection#BSI bloodstream infection 4726 
CNS central nervous system  4727 
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Figure 1 Flow chart of systematic review 4728 
Records identified through 
database searching 



























 Additional records identified 
through other sources 
N = 1 
Records after duplicates removed 
N = 2385 
Records screened 
N = 2385 
Records excluded 
N = 1902 
Full-text articles 
assessed for eligibility 
N = 2523 
Full-text articles 
excluded, with reasons 
N = 440 
 
Full-text articles not 
retrieved 
N = 6 
Studies included in 
qualitative synthesis 
N = 49 
Studies included in 
quantitative synthesis 
(meta-analysis) 
N = 0 
Full-text articles 
assessed for eligibility in 
September 2014 
N = 114 
Studies included in 
qualitative synthesis in 
September 2014 
N = 16 



















Figure 2 – Carbapenemase-producing Enterobacteriaceae submitted to and 4729 
confirmed by PHE-AMRHAI-Colindale from Laboratories in England. 4730 
Courtesy of Dr Katie Hopkins, Public Health England 4731 
In a national context, a regional non PHE centre in an area of KPC endemicity became 4732 
active in 2014 and did not submit or report isolates 4733 
   4734 
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Figure 3 Suggested algorithm for the treatment of MDR Gram negative bacteria 4735 
admitted to UK hospitals 4736 
Figure 4 Suggested algorithm for the treatment of UTI in the UK community 4737 
likely to be due to MDR GNB. 4738 
  4739 
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Temocillin (if urinary) 
Oral follow-on if mecillinam S 
Pivmecillinm with 
amoxicillin/clavulanate 
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healthcare in high risk country according 












Colistin & meropenem 
(2G three times daily  if 
past S or unknown) 
Add 100mg twice daily 
tigecycline if unknown. 
If R consider adding 
continuous meropenem 












Patient requires hospital 
admission 
 
eGFR >45ml/min/1.73 m 2 
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1Not nitrofurantoin if pyelonephritis or eGFR <45ml/min. or Age <50 years 4740 
2Caution re prolonged/frequently repeated courses 4741 
3 Not fosfomycin if pyelonephritis 4742 
4 Unlike co-amoxiclav, 1st gen cephalosporins, fosfomycin, and pivmecillinam 4743 
ciprofloxacin is generally active against Proteus vulgaris, Morganella and Providencia.  4744 
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Figure 5: Diagnostic algorithm for ordering urine cultures and starting antibiotics 4745 
if positive for nursing home residents in the intervention arm in the Loeb trial. 4746 
(Loeb 2005) 444 4747 
 4748 
 4749 
*Respiratory symptoms include increased shortness of breath, increased cough, 4750 
increased sputum production, new pleuritic chest pain. Gastrointestinal symptoms 4751 
include nausea or vomiting, new abdominal pain, new onset of diarrhoea. Skin and soft 4752 
tissue symptoms include new redness, warmth, swelling, purulent drainage. 4753 
¥ >37.9˚C (100˚F) or 1.5˚C (2.4˚F) above baseline on two occasions over last 12 hours  4754 
B Stop antibiotics if urine culture is negative or no pyuria is present  4755 
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Appendix 1 – Glossary 
AmpC β-lactamases: clinically important cephalosporinases encoded by the 
chromosomes of many Enterobacteriaceae or (less often) by plasmids. High-level 
expression confers resistance to penicillins (except temocillin), cephalosporins (except 
cefepime), aztreonam and penicillin- β-lactamase inhibitor combinations. 
Antimicrobial: A substance that kills or inhibits the growth of microorganisms. This 
includes antibiotics and totally synthetic compounds. 
Bacteraemia: The presence of micro-organisms in the blood stream 
β-lactamases: Enzymes produced by some bacteria that confer resistance to β-lactam 
antibiotics such as penicillins and cephalosporins, by breaking down the central 
structure of the antibiotic. 
Carbapenemases: These are β-lactamases that inactivate carbapenems such as 
meropenem; most also attack and confer resistance to penicillins and cephalosporins  
CBA – (Controlled before and after study) is a more limited assessment than interrupted 
time series because it does not contain an initial pre-study period to examine 
underlying trends not a post-study period to assess the sustainability of trend, A cross-
over study design may exclude bias due to sequential change, 
CCG: Clinical Commissioning Group. This is a locality based authority in England 
responsible for primary care services and placing financial contracts with local hospitals 
for specific services 
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CQUIN: NHS England Commissioning for Quality and Innovation payments framework, 
to encourage care providers to share and continually improve how care is delivered and 
to achieve transparency and overall improvement in healthcare. 
Cluster randomized controlled clinical trial. This is a trial where groups of individuals 
rather than individuals are randomized to treatment. This complex study design may 
reduce the chances of one patient’s treatment having an effect on detection of effects in 
a patient randomized to a different treatment in the dame environment. 
Colonization: Situation whereby microorganisms establish themselves in a particular 
environment, such as a body surface, without producing disease 
Community-acquired: infection that is acquired outside of hospitals.  
Community-onset or community-associated: usually defined as infection or colonization 
detected in an outpatient or within 48 hours of hospital admission. Recommended to 
permit extension to 72hours 
CCT – (Controlled clinical trial) A ckinical trial where there is a comparative arm that is 
not randomized. 
ESBL (extended-spectrum β-lactamase): β-Lactamases that attack cephalosporins with 
an oxyimino side chain, for example, cefotaxime, ceftriaxone, ceftazidime, ceftolozane as 
well as the oxyimino-monobactam aztreonam. Unlike AmpC -lactamases (q.v.) they are 
inhibited by clavulanic acid and tazobactam and unlike carbapenemases (q.v.) they do 
not attack carbapenems. Avibactam inhibitis them and AmpC -lactamases. 
Healthcare – associated (acquired) : infection or colonization detected in an in-patient 
more than 48 hours after hospital admission or in a resident of a nursing (or 
residential) home.Recommended to permit extension to 72hours  
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Hospital-onset or Hospital–associated (-acquired): infection or colonization detected in 
an inpatient more than 48 hours after hospital admission. Recommended to permit 
extension to 72 hours. 
IMP carbapenemase (of MBL class) prevalent particularly in Asia and Australia 
sometimes in association with a second carbapenemase (blaKPC) gene 
Infection: Invasion by and multiplication of pathogenic microorganisms in the body, 
producing tissue injury and disease, requiring treatment. 
ITS – (Interrupted time series). A series of sequential cases where an intervention is 
made in the middle of the study as in before and after studies but additional time 
periods before and after the two comparative periods are included to give information 
omn prior trends and sustainability. studied. There may be further interventions in the 
series similarly studied.  
KPC Klebsiella pneumoniae carbapenemase-producing bacteria are drug-resistant Gram 
negative bacilli which spread rapidly and cause significant morbidity and mortality. 
They are the most prevalent carbapenemase producers encoded by the blaKPC gene, 
which can be found in other Gram negative species. 
MBL (Metallo β-lactamase) producing Gram negative bacteria use a Zn2+ ion in 
expressing resistance to carbapenems and other B-lactams 
MDR GNB – (Multi-drug resistant Gram-negative bacteria) are defined as bacteria 
resistant to at least three different antibiotic classes or susceptible to only one or two 
classes.  
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NDM New Delhi metallo β-lactamase is a carbapenemase located on a mobile genetic 
element blaNDM-1 and is found on plasmids of various sizes. It is found in various species 
making outbreaks more difficult to identify.  
OXA-48 carbapenemases hydrolyze penicillins at a high level but carbapenems at a low 
level sparing broad spectrum cephalosporins and are no susceptible to β-lactamase 
inhibitors. Recogniition in the laboratory can be difficult. The gene blaOXA-48 is carried on 
a transposon and can be in a plasmid or chromosome. 
Outbreak: at least two similar (i.e. not distinct) cases related in time and place  
Porins: These are proteins that span the outer membrane of Gram-negative bacteria and 
mycobacteria forming pores that allow the entry of small water-soluble molecules, 
including antibiotics. 
RCT (randomised controlled trial). Trials where patient allocation to the control and 
test arms of the study are allocated at random. They can be open label where treating 
physicians know which arm a patient has been allocated to or blinded where this is not 
the case. The latter is less likely to be subject to bias. 
VIM MBL is a carbapenemase predominantly found in Pseudomonas aeruginosa but  
found in Enterobacteriaceae as well. The genes blaVIM are located on mobile integrons .  
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Appendix 2 Remit scope and related NICE guidelines 
Joint BSAC/HIS/BIA Working Party on Multi-resistant Gram-negative bacteria 
2.1. Guideline title 
Treatment of MDR Gram-negative bacteria – report from a Joint Working Party 
Short title: Treatment of Multi-Drug-Resistant Gram negative bacteria  
2.2. Clinical need for the guideline 
Epidemiology 
There are a rising number of MDR Gram-negative infections across community and 
hospital care and the dual problems of finding an appropriate antibiotic and 
preventing spread.  
APRHAI has recently produced brief guidelines on infection control and treatment 
options for these infections.  
There is significant interest attracted by the May 2010 BSAC conference examining 
the dearth of new antibiotics effective against Gram-negative bacteria. 
The Department of Health’s recognised that whilst control of MRSA and C difficile 
has been relatively successful, Gram-negative infections have continued to increase. 
Consequent to this is the surveillance subcommittee of APRHAI recommendation 
that E. coli bacteraemia be included in mandatory surveillance.  
Current practice 
Members of BSAC and HIS, with the knowledge of the Councils of each, have been 
discussing the issues surrounding the recent increase in infections with multi-
resistant Gram-negative bacteria in UK hospitals.  
Following discussions and consideration of the forthcoming APRHAI report we now 
believe it an appropriate time to set up a Joint Working Party to look at making 
authoritative recommendations both for treatment and prevention of transmission 
of these infections. 
2.3. The remit 
To examine and make recommendations both for treatment and prevention of 
transmission of multi-drug-resistant (MDR) Gram-negative infections, resulting in 
the publication of guidelines on: 
 current epidemiology and infection control issues; and 
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 therapeutic issues and antibiotic guidance for treating infections 
caused by MDR Gram-negative bacteria. 
For the purposes of this Working Party, the remit will mainly include infections in 
critical and non-critical care patients in secondary care. However, the same general 
principles would apply in community settings, particularly in areas where 
inappropriate treatment is encouraging selection. Consideration will be given to 
laboratory testing and susceptibility testing, although only screening and 
confirmatory tests available in a general microbiology laboratory. The use of 
antibiotic combinations in the therapy of infections will be considered, both 
parenteral and oral agents. 
2.4. The Guideline 
The guideline development process is described on the NICE website and 
reproduced in Appendix 3. The Working Party will follow the SIGN process when 
developing guidance including the hosting of a national stakeholder meeting as part 
of the national stakeholder consultation process.  
2.5. The Scope 
Defines what the guideline will and will not examine and what the guideline 
developers will consider. The scope is based on the referral from the three Societies 
and is the final scope. 
2.5.1. Population Groups that will be covered 
a) Adults 
Particular consideration given to patients of 65 years and older, and people at high 
risk of acquiring multi-resistant bacteria such as those requiring care in hospital 
settings 
b) Children over 1 month old 
2.5.2. Key clinical issues that will be covered 
a) Antimicrobial treatment of MDR Gram-negative infections 
b) Antimicrobial stewardship 
c) Epidemiology 
d) Surveillance 
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e) Infection prevention: standards, hand and environmental hygiene, organizational 
structures 
Clinical situations that will not be covered include: 
Cystic fibrosis 
Community outbreaks 
2.5.3. Infections that will be covered  
Those caused by the following organisms 
Escherichia coli, Klebsiella spp. including Klebsiella pneumoniae, Enterobacter spp., 
Pseudomonas aeruginosa, Acinetobacter spp., Proteus spp., Serratia spp., Citrobacter 
freundii, Morganella morgani 
Sexually transmitted infections, Helicobacter ssp.  Salmonella ssp. and some 
anaerobes are Gram-negative and are increasingly resistant, but were excluded 
because relevant public health control actions are substantially different or they 
have not been researched.  
2.5.4. Antibiotics that will be considered 
Standard antibiotics currently in use such as most cephalosporins, coamoxiclav, 
piperacillin/tazobactam quinolones, temocillin (pivmecillinam is the oral 
formulation of mecillinam 
Old antibiotics that have been re-introduced: such as aminoglycosides (including 
gentamicin and amikacin), colistin, fosfomycin, nitrofurantoin 
Recently developed antibiotics: tigecycline, cefepime, new B-lactam-B-lactamase 
inhibitor combinations and carbapenems or those new agents at preliminary stages 
of testing. 
2.5.5. Healthcare settings 
All settings in which NHS care is received 
2.6. Main outcomes 
Outputs will be the production of guidelines, which will be approved via a process of 
national consultation. The intention is to inform and guide practice but also to 
highlight areas where more research is needed. The following will be produced and 
published as indicated: 
Current epidemiology and infection control issues – Journal of Hospital Infection 
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Therapeutic issues and antibiotic guidance for treating infections caused by multi-
resistant Gram-negatives – Journal of Antimicrobial Chemotherapy 
In addition, it is expected that each Journal will carry a leading article or review 
article on the guidance that is published by the joint societies. 




Prevention of transmission 
Cleaning and environment 
2.8. Economic aspects 
Developers will take into account both clinical and cost effectiveness when making 
recommendations involving a choice between alternative interventions. 
Failure to implement the recommendations would result in greater costs in terms of 
life expectancy or quality. Screening and isolation will result in significant cost 
pressures where this is not currently practised, but these costs are set against 
reduced transmission and fewer cases needing antibiotic treatment. Prolonged 
isolation can have adverse effects on a patient’s psychological health, so may have 
additional unexpected costs.  
2.9. Patient Representation and Equality  
Patient representatives are invited to all meetings and involved in the writing and 
drafting of the guidelines. As part of these discussions potential impacts on equality 
of groups sharing protected characteristics are considered and incorporated into the 
guidelines. Health inequalities associated with socioeconomic factors and with 
inequities in access for groups to healthcare and social care are considered and 
opportunities identified to improve health. 
2.10. Status 
 2.10.1 Scope 
This is the final scope. 
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2.10.2 Timing 
The development of the guideline recommendation began in July 2011. 
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Appendix 3 Guideline development process 
3.1. Guidance document 
Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. 
Revised edition. Edinburgh: Healthcare Improvement Scotland; 2014. Available at: 
http://www.sign.ac.uk [last accessed April 2017]. 
3.2. Related NICE guidance 
National Institute for Health and Care Excellence. Infection: prevention and control of 
healthcare-associated infections in primary and community care. NICE Clinical 
Guideline 139. London: NICE; 2012. Last updated: February 2017. Available at: 
http://www.nice.org.uk/guidance/cg139 [ last accessed April 2017]. 
 
National Institute for Health and Care Excellence. .Antimicrobial stewardship: 
prescribing antibiotics. London:  NICE; Published date: January 2015 Last 
updated: January 2017. Available at: 
https://www.nice.org.uk/advice/ktt9/chapter/evidence-context [ last accessed July 
2017] 
 
National Institute for Health and Care Excellence. .Urinary Tract Infection in Adults. 
London:  NICE; Quality standard [QS90] Published date: June 2015. Available at: 
https://www.nice.org.uk/guidance/qs90/chapter/introduction 
 
NICE approved guideline: Wilson AP, Livermore DM, Otter JA, et al. Prevention and 
control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint 
Working Party. J Hosp Infect 2016; 92 Suppl 1: S1-S44. Available at : 
http://www.journalofhospitalinfection.com/article/S0195-6701(15)00314-X/pdf 
3.3. Process followed 
The subject was identified by the Scientific Development Committee of the Healthcare 
Infection Society in February 2011 and approved by HIS in May 2011. The BSAC Council 
agreed a similar proposal at the same time. BIA Council agreed to join in September 
2011. The members were chosen to reflect the range of stakeholders and not limited to 
members of the three Societies. The questions were decided at the first meeting of the 
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Group in November 2011 from issues presented to the members and patient 
representatives by staff and patients in the preceding months. Each was debated by the 
Group before adoption. Enhance Reviews was paid for the serach and data extraction. 
Working Party members were not paid except for travel expenses. 
3.4. Conflict of Interests 
Conflicts of interest were registered at the outset and renewed during the process. They 
are stated in the Transparency declaration of the Report. In the event of a potential 
conflict being identified, the Working Party agreed that the member should not 
contribute to the section affected. With one exception, no interests were declared that 
required any actions and this related to the infection control paper produced by the 
working party. 
3.5. PICO  
Patients: All patient groups were included. The guideline is careful not to make 
recommendations which may prejudice clinical care based on gender, age, ethnicity or 
socio-economic status.  
Interventions: interventions were identified in the literature to generate intervention 
specific recommendations 
Comparisons: comparisons between intervention and standard management were 
used;  
Outcomes were objective referring to length of hospital stay, mortality, rate of 
acquisition or infection.  
3.6. Systematic Review Questions: Infection Control 
1. What is the definition of Multidrug Resistant Gram-negative bacilli?  
2. What Gram-negative bacilli cause infection control problems? 
3. What are the relative contributions of community and hospital acquisition? 
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4. What is the evidence for reservoir and spread of mulitresistant Gram-negatives 
in Care Homes and secondary care? 
5. What is the role of agricultural use of sewage and antibiotic treatment in 
veterinary practice in spreading ESBL? 
6. What insights has national E. coli bacteraemia surveillance provided? 
7. What is the role for screening in patients and staff? 
8. What organisms should screening include? 
9. Who, how and when to screen patients for Multidrug Resistant Gram-negative 
bacilli? 
10. What can be done concerning patients unable to consent to a rectal swab? 
11. How frequently does screening need to be performed? 
12. Is there evidence for effective interventions on positive patients i.e. can carriage 
be cleared?  
13. Selective decontamination: Why is it not used? Is there a role? 
14. When should the environment be sampled? 
15. What is the evidence that respiratory equipment contributes to transmission? 
16. What national surveillance is performed and how should it be developed? 
17. What is the evidence that sensor taps contribute to transmission? 
18. Is there any cleaning method more effective than others at removing the 
Multidrug Resistant Gram-negative bacilli from the environment? 
19. What is the evidence that infection control precautions prevent transmission? 
20.  Are standard infection control measures sufficient to stop transmission?  
21. What are the minimum standards to stop spread in public areas, primary care or 
care homes?  
22. Is there evidence for high/low risk areas within a healthcare facility? 
23. Are there any organisational structures within a healthcare facility that play a 
role in the successful control of multi-resistant Gram-negative bacilli? 
24. How should we undertake local screening, why is it important and how should it 
be interpreted? 
25. At what point should passive surveillance switch to active surveillance i.e. 
screening? 
26. What is the role of isolation in the care home/hospital settings? 
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Is there evidence of differences between organisms in respect of transmission, 
morbidity and mortality: 
3.7. Antimicrobial Chemotherapy -Systematic Review Questions 
1. What is the clinical importance of carbapenemases versus AmpC and CTX-M 
strains?  
2. What impact have returning travellers made on UK epidemiology? 
3. What is the global epidemiology of MDR-GNR? 
4. How do Multidrug Resistant Enterobacteriaceae differ from the non-fermenters 
in terms of their prevalence and associated resistance genes? 
5. What is the efficacy of carbapenems, mecillinam, temocillin, fosfomycin and 
colistin against specific pathogens? 
6. What are the recommended antibiotics for community/secondary/tertiary care? 
7. What is the threshold level of resistance for changing choice of empirical 






Appendix 4 Systematic Review 
4.1. Databases and Search terms Used 23/5/14i 
4.1.1. Databases 
The Cochrane Library; MEDLINE; EMBASE; CINAHL 
MeSH Terms See  4.2. 
Free text terms. See 4.2. 
Search Date: Medline 1946-2014; Embase 1980-2012; CINAHL (1984-2012) 
Search Results (Figure 1) 
Total number of articles located after duplicates removed = 2523 
Sift 1 Criteria 
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Abstract screening: Systematic review, primary research, infection relates to MDR 
Gram-negative infection, informs one or more review question 
Articles Retrieved 
Total number of studies selected = 597 
Sift 2 Criteria 
Full text confirms that the article is primary research (randomised controlled trial, non-
randomised controlled trials, controlled before and after studies, interrupted time 
series, case control study, case series, prospective cohort, systematic review; informs 
one or more of the review questions. 
Articles selected for appraisal (10 full text publications could not be retrieved) 
Total number of studies selected = 49 
Critical appraisal 
Articles presenting primary research or a systematic review and meeting the sift 
criteria were critically appraised by two reviewers using SIGN and EPOC criteria. 
Consensus was achieved through discussion 
Accepted and Rejected Evidence 
No meta analyses were available 
Accepted after critical appraisal 49 
Rejected after critical appraisal 0  
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4.2. Search 
4.2.1. CINAHL (January 1984-December 2012) 
 
#  Query  Results  
S83  S48 AND S82  275 
S82  S55 OR S56 OR S81  515,966 
S81  
S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or 
S67 or S68 or S69 or S70 or S71 or S72 or S73 or S74 or S75 or S76 or 
S77 or S78 or S79 or S80  
471,263 
S80  
TI ( (time points n3 over) or (time points n3 multiple) or (time points n3 
three) or (time points n3 four) or (time points n3 five) or (time points n3 
six) or (time points n3 seven) or (time points n3 eight) or (time points 
n3 nine) or (time points n3 ten) or (time points n3 eleven) or (time 
points n3 twelve) or (time points n3 month*) or (time points n3 hour*) 
or (time points n3 day*) or (time points n3 ‘more than’) ) or AB ( (time 
points n3 over) or (time points n3 multiple) or (time points n3 three) or 
(time points n3 four) or (time points n3 five) or (time points n3 six) or 
(time points n3 seven) or (time points n3 eight) or (time points n3 nine) 
or (time points n3 ten) or (time points n3 eleven) or (time points n3 
twelve) or (time points n3 month*) or (time points n3 hour*) or (time 
points n3 day*) or (time points n3 ‘more than’) )  
1,527 
S78  
TI ( multicentre or multicenter or multi-centre or multi-center ) or AB 
random*  
101,899 
S77  TI random* OR controlled  94,669 
S76  
TI ( trial or (study n3 aim) or ‘our study’ ) or AB ( (study n3 aim) or ‘our 
study’ )  
87,121 
S75  
TI ( pre-workshop or preworkshop or post-workshop or postworkshop 
or (before n3 workshop) or (after n3 workshop) ) or AB ( pre-workshop 
or preworkshop or post-workshop or postworkshop or (before n3 
workshop) or (after n3 workshop) )  
283 
S74  
TI ( demonstration project OR demonstration projects OR 
preimplement* or pre-implement* or post-implement* or 
postimplement* ) or AB ( demonstration project OR demonstration 
projects OR preimplement* or pre-implement* or post-implement* or 
postimplement* )  
1,290 
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S73  
(intervention n6 clinician*) or (intervention n6 community) or 
(intervention n6 complex) or (intervention n6 design*) or (intervention 
n6 doctor*) or (intervention n6 educational) or (intervention n6 family 
doctor*) or (intervention n6 family physician*) or (intervention n6 
family practitioner*) or (intervention n6 financial) or (intervention n6 
GP) or (intervention n6 general practice*) Or (intervention n6 hospital*) 
or (intervention n6 impact*) Or (intervention n6 improv*) or 
(intervention n6 individualize*) Or (intervention n6 individualise*) or 
(intervention n6 individualizing) or (intervention n6 individualising) or 
(intervention n6 interdisciplin*) or (intervention n6 multicomponent) or 
(intervention n6 multi-component) or (intervention n6 multidisciplin*) 
or (intervention n6 multi-disciplin*) or (intervention n6 multifacet*) or 
(intervention n6 multi-facet*) or (intervention n6 multimodal*) or 
(intervention n6 multi-modal*) or (intervention n6 personalize*) 
or(intervention n6 personalise*) or (intervention n6 personalizing) or 
(intervention n6 personalising) or (intervention n6 pharmaci*) or 
(intervention n6 pharmacist*) or (intervention n6 pharmacy) or 
(intervention n6 physician*) or (intervention n6 practitioner*) Or 
(intervention n6 prescrib*) or (intervention n6 prescription*) or 
(intervention n6 primary care) or (intervention n6 professional*) or 
(intervention* n6 provider*) or (intervention* n6 regulatory) or 
(intervention n6 regulatory) or (intervention n6 tailor*) or (intervention 
n6 target*) or (intervention n6 team*) or (intervention n6 usual care)  
23,198 
S72  
TI ( collaborativ* or collaboration* or tailored or personalised or 
personalized ) or AB ( collaborativ* or collaboration* or tailored or 
personalised or personalized )  
38,021 
S71  TI pilot  13,958 
S70  (MH ‘Pilot Studies’)  36,433 
S69  AB ‘before-and-after’  17,437 
S68  AB time series  1,670 
S67  TI time series  359 
S66  
AB ( before* n10 during or before n10 after ) or AU ( before* n10 during 
or before n10 after )  
32,982 
S65  
TI ( (time point*) or (period* n4 interrupted) or (period* n4 multiple) or 
(period* n4 time) or (period* n4 various) or (period* n4 varying) or 
(period* n4 week*) or (period* n4 month*) or (period* n4 year*) ) or AB 
( (time point*) or (period* n4 interrupted) or (period* n4 multiple) or 
(period* n4 time) or (period* n4 various) or (period* n4 varying) or 
(period* n4 week*) or (period* n4 month*) or (period* n4 year*) )  
51,050 
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S64  
TI ( ( quasi-experiment* or quasiexperiment* or quasi-random* or 
quasirandom* or quasi control* or quasicontrol* or quasi* W3 method* 
or quasi* W3 study or quasi* W3 studies or quasi* W3 trial or quasi* W3 
design* or experimental W3 method* or experimental W3 study or 
experimental W3 studies or experimental W3 trial or experimental W3 
design* ) ) or AB ( ( quasi-experiment* or quasiexperiment* or quasi-
random* or quasirandom* or quasi control* or quasicontrol* or quasi* 
W3 method* or quasi* W3 study or quasi* W3 studies or quasi* W3 trial 
or quasi* W3 design* or experimental W3 method* or experimental W3 
study or experimental W3 studies or experimental W3 trial or 
experimental W3 design* ) )  
12,758 
S63  TI pre w7 post or AB pre w7 post  9,367 
S62  MH ‘Multiple Time Series’ or MH ‘Time Series’  1,312 
S61  
TI ( (comparative N2 study) or (comparative N2 studies) or evaluation 
study or evaluation studies ) or AB ( (comparative N2 study) or 
(comparative N2 studies) or evaluation study or evaluation studies )  
11,680 
S60  
MH Experimental Studies or Community Trials or Community Trials or 
Pretest-Posttest Design + or Quasi-Experimental Studies + Pilot Studies 
or Policy Studies + Multicenter Studies  
34,567 
S59  
TI ( pre-test* or pretest* or posttest* or post-test* ) or AB ( pre-test* or 
pretest* or posttest* or ‘post test* ) OR TI ( preimplement*’ or pre-
implement* ) or AB ( pre-implement* or preimplement* )  
6,868 
S58  
TI ( intervention* or multiintervention* or multi-intervention* or 
postintervention* or post-intervention* or preintervention* or pre-
intervention* ) or AB ( intervention* or multiintervention* or multi-
intervention* or postintervention* or post-intervention* or 
preintervention* or pre-intervention* )  
151,748 
S57  (MH ‘Quasi-Experimental Studies’)  5,747 
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S56  
(TI (systematic* n3 review*)) or (AB (systematic* n3 review*)) or (TI 
(systematic* n3 bibliographic*)) or (AB (systematic* n3 bibliographic*)) 
or (TI (systematic* n3 literature)) or (AB (systematic* n3 literature)) or 
(TI (systematic* n3 review*)) or (AB (systematic* n3 review*)) or (TI 
(comprehensive* n3 literature)) or (AB (comprehensive* n3 literature)) 
or (TI (comprehensive* n3 bibliographic*)) or (AB (comprehensive* n3 
bibliographic*)) or (JN ‘Cochrane Database of Systematic Reviews’) or 
(TI (information n2 synthesis)) or (TI (data n2 synthesis)) or (AB 
(information n2 synthesis)) or (AB (data n2 synthesis)) or (TI (data n2 
extract*)) or (AB (data n2 extract*)) or (TI (medline or pubmed or 
psyclit or cinahl or (psycinfo not ‘psycinfo database’) or ‘web of science’ 
or scopus or embase)) or (AB (medline or pubmed or psyclit or cinahl or 
(psycinfo not ‘psycinfo database’) or ‘web of science’ or scopus or 
embase)) or (MH ‘Systematic Review’) or (MH ‘Meta Analysis’) or (TI 
(meta-analy* or metaanaly*)) or (AB (meta-analy* or metaanaly*))  
59,817 
S55  S49 OR S50 OR S51 OR S52 OR S53 OR S54  158,596 
S54  
TI ( ‘control* N1 clinical’ or ‘control* N1 group*’ or ‘control* N1 trial*’ or 
‘control* N1 study’ or ‘control* N1 studies’ or ‘control* N1 design*’ or 
‘control* N1 method*’ ) or AB ( ‘control* N1 clinical’ or ‘control* N1 
group*’ or ‘control* N1 trial*’ or ‘control* N1 study’ or ‘control* N1 
studies’ or ‘control* N1 design*’ or ‘control* N1 method*’ )  
1 
S53  TI controlled or AB controlled  68,638 
S52  TI random* or AB random*  117,418 
S51  
TI ( ‘clinical study’ or ‘clinical studies’ ) or AB ( ‘clinical study’ or ‘clinical 
studies’ )  
7,969 
S50  (MM ‘Clinical Trials+’)  10,670 
S49  
TI ( (multicent* n2 design*) or (multicent* n2 study) or (multicent* n2 
studies) or (multicent* n2 trial*) ) or AB ( (multicent* n2 design*) or 
(multicent* n2 study) or (multicent* n2 studies) or (multicent* n2 trial*) 
)  
8,917 
S48  S18 AND S21 AND S47  917 
S47  
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR 
S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR 
S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46  
16,726 
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S46  
TI ( (belcomycin or colicort or colimycin* or colisitin or colisticin or 
Colistin or colistine or colomycin or (coly n1 mycin) or colymicin or 
colymycin or coly-mycin or multimycin or (Polymyxin n1 E) or totazina) 
) OR AB ( (belcomycin or colicort or colimycin* or colisitin or colisticin 
or Colistin or colistine or colomycin or (coly n1 mycin) or colymicin or 
colymycin or coly-mycin or multimycin or (Polymyxin n1 E) or totazina) 
)  
171 
S45  (MH ‘Colistin’)  134 
S44  
TI ( ((amdinocillin n1 pivoxil) or (FL n1 ‘1039’) or FL1039 or fl1039 or 
FL-1039 or pivamdinocillin or Pivmecillinam or Selexid or coactabs or 
(ro n1 ‘109071’) or (ro10 n1 ‘9071’) or ro109071) ) OR AB ( 
((amdinocillin n1 pivoxil) or (FL n1 ‘1039’) or FL1039 or fl1039 or FL-
1039 or pivamdinocillin or Pivmecillinam or Selexid or coactabs or (ro 
n1 ‘109071’) or (ro10 n1 ‘9071’) or ro109071) )  
13 
S43  
TI ( ((Cephalosporanic n1 Acid*) or Cephalosporin* or Cefamandole or 
Cefoperazone or Cefazolin or Cefonicid or Cefsulodin or Cephacetrile or 
Cefotaxime or Cephalothin or Cephapirin or Cephalexin or Cefaclor or 
Cefadroxil or Cephaloglycin or Cephradine or Cephaloridine or 
Ceftazidime or Cephamycins or Cefmetazole or Cefotetan or Cefoxitin) ) 
OR AB ( ((Cephalosporanic n1 Acid*) or Cephalosporin* or Cefamandole 
or Cefoperazone or Cefazolin or Cefonicid or Cefsulodin or Cephacetrile 
or Cefotaxime or Cephalothin or Cephapirin or Cephalexin or Cefaclor or 
Cefadroxil or Cephaloglycin or Cephradine or Cephaloridine or 
Ceftazidime or Cephamycins or Cefmetazole or Cefotetan or Cefoxitin) )  
1,569 
S42  
TI ( (Axepim* or bmy 28142 or bmy28142 or BMY-28142 or Cefepim* or 
cefepitax or ceficad or cepimax or forzyn beta or maxcef or maxfrom or 
maxipime or Quadrocef) ) OR AB ( (Axepim* or bmy 28142 or 
bmy28142 or BMY-28142 or Cefepim* or cefepitax or ceficad or cepimax 
or forzyn beta or maxcef or maxfrom or maxipime or Quadrocef) )  
171 
S41  (MH ‘Cephalosporins+’)  2,105 
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S40  
TI ( (berkfurin or biofurin or chemiofuran or dantafur or f 30 or f30 or 
fua-med or furaben or furadantin* or furadantoin or furadina or 
furadoine or furadonin or furadonine or furalan or furanpur or 
furantocompren or furantoin* or furobactina or furofen or furophen or 
infurin or ituran or ivadantin or macrobid or macrodantin* or 
macrofuran or macrofurin or micofurantin* or mitrofuratoin or 
nephronex or nierofu or nifurantin or nifuryl or (nitro n1 macro) or 
nitrofuracin or nitrofuradantoin or nitrofurantine or nitrofurantoin* or 
nitrofurin or novofuran or nsc 2107 or nsc2107 or orafuran or parfuran 
or phenurin or (potassium n1 furagin) or ralodantin or trocurine or 
urantin or (uro n1 tablinen) or urodil or urodin or urofuran or urolong 
or urotablinen or uro-tablinen or urotoina or uvamin) ) OR AB ( 
(berkfurin or biofurin or chemiofuran or dantafur or f 30 or f30 or fua-
med or furaben or furadantin* or furadantoin or furadina or furadoine 
or furadonin or furadonine or furalan or furanpur or furantocompren or 
furantoin* or furobactina or furofen or furophen or infurin or ituran or 
ivadantin or macrobid or macrodantin* or macrofuran or macrofurin or 
micofurantin* or mitrofuratoin or nephronex or nierofu or nifurantin or 
nifuryl or (nitro n1 macro) or nitrofuracin or nitrofuradantoin or 
nitrofurantine or nitrofurantoin* or nitrofurin or novofuran or nsc 2107 
or nsc2107 or orafuran or parfuran or phenurin or (potassium n1 
furagin) or ralodantin or trocurine or urantin or (uro n1 tablinen) or 
urodil or urodin or urofuran or urolong or urotablinen or uro-tablinen 
or urotoina or uvamin) )  
325 
S39  
TI ( ((az n1 threonam) or azactam or azenam or azthreonam or 
aztreonam or (corus n1 ‘1020’) or dynabiotic or primbactam or SQ 
26,776 or sq 26,776 or sq 26776 or SQ-26,776 or sq26776 or sq-26776 
or urobactam) ) OR AB ( ((az n1 threonam) or azactam or azenam or 
azthreonam or aztreonam or (corus n1 ‘1020’) or dynabiotic or 
primbactam or SQ 26,776 or sq 26,776 or sq 26776 or SQ-26,776 or 
sq26776 or sq-26776 or urobactam) )  
96 
S38  (MH ‘Aztreonam’)  54 
S37  
TI ( (fosfocil or fosfocin or fosfocina or fosfomicin or fosfomycin or 
fosfonomycin or ‘mk 0955’ or mk 955 or mk0955 or mk955 or monuril 
or phosphomycin or phosphonomycin) ) OR AB ( (fosfocil or fosfocin or 
fosfocina or fosfomicin or fosfomycin or fosfonomycin or ‘mk 0955’ or 
mk 955 or mk0955 or mk955 or monuril or phosphomycin or 
phosphonomycin) )  
57 
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S36  
TI ( (akacin or akicin or amicacina or amicasil or amicin or amiglymide v 
or amikacin* or amikafur or amikalem or amikan or amikayect or amikin 
or amiklin or amikozit or amiktam or amitracin or amixin or amukin or 
apalin or bb k 8 or bb k8 or bbk 8 or bb-k 8 or bbk8 or bbk-8 or bb-k8 or 
biclin or biklin or biokacin or briclin or briklin or chemacin or cinmik or 
fabianol or gamikal or glukamin or kacinth-a or kanbine or kormakin or 
likacin or lukadin or miacin or mikasome or onikin or oprad or orlobin 
or pediakin or pierami or riklinak or savox or selaxa or selemycin or 
sulfate amikacin or tybikin or vs 107 or vs107 or yectamid) ) OR AB ( 
(akacin or akicin or amicacina or amicasil or amicin or amiglymide v or 
amikacin* or amikafur or amikalem or amikan or amikayect or amikin or 
amiklin or amikozit or amiktam or amitracin or amixin or amukin or 
apalin or bb k 8 or bb k8 or bbk 8 or bb-k 8 or bbk8 or bbk-8 or bb-k8 or 
biclin or biklin or biokacin or briclin or briklin or chemacin or cinmik or 
fabianol or gamikal or glukamin or kacinth-a or kanbine or kormakin or 
likacin or lukadin or miacin or mikasome or onikin or oprad or orlobin 
or pediakin or pierami or riklinak or savox or selaxa or selemycin or 
sulfate amikacin or tybikin or vs 107 or vs107 or yectamid) )  
342 
S35  (MH ‘Amikacin’)  140 
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S34  
TI ( (adelanin or alcomicin or apigent or apogen or apoten or azupel or 
bactiderm or biogaracin or bristagen or cidomycin or danigen or 
dermogen or dianfarma or dispagent or duragentam* or epigent or 
(frieso n1 gent) or garabiotic or garalone or garamicin* or garamycin or 
garbilocin or gencin or gendril or genoptic or genrex or gensumycin or 
gentabiotic or gentabiox or gentac or gentacidin or gentacin or gentacor 
or gentacycol or gentacyl or gentafair or gentagram or gentak or gental 
or gentaline or gentalline or gentalol or gentalyn or gentamax or 
gentame* or gentamicin* or gentamina or gentamycin* or gentamyl or 
gentamytrex or gentaplus or gentarad or gentasil or gentasol or 
gentasone or gentasporin or gentatrim or gentavet or genticin* or 
genticyn or gentiderm or gentimycin or gentocin or gentogram or 
gentomycin or genum or geomycine or gevramycin or g-mycin or 
gmyticin or g-myticin or grammicin or hexamycin or jenamicin or 
konigen or lacromycin or lisagent or martigenta or migenta or miragenta 
or miramycin or nichogencin or nsc 82261 or nsc82261 or obogen or 
ocugenta or ocu-mycin or oftagen or ophtagram or opthagen or optigen 
or opti-genta or ottogenta or pyogenta or refobacin or ribomicin or 
rigaminol or rocy gen or rovixida or rupegen or sagestam or sch 9724 or 
sch9724 or sedanazin or servigenta or skinfect or sulmycin or tangyn or 
u-gencin or versigen or yectamicina) ) OR AB ( (adelanin or alcomicin or 
apigent or apogen or apoten or azupel or bactiderm or biogaracin or 
bristagen or cidomycin or danigen or dermogen or dianfarma or 
dispagent or duragentam* or epigent or (frieso n1 gent) or garabiotic or 
garalone or garamicin* or garamycin or garbilocin or gencin or gendril 
or genoptic or genrex or gensumycin or gentabiotic or gentabiox or 
gentac or gentacidin or gentacin or gentacor or gentacycol or gentacyl or 
gentafair or gentagram or gentak or gental or gentaline or gentalline or 
gentalol or gentalyn or gentamax or gentame* or gentamicin* or 
gentamina or gentamycin* or gentamyl or gentamytrex or gentaplus or 
gentarad or gentasil or gentasol or gentasone or gentasporin or 
gentatrim or gentavet or genticin* or genticyn or gentiderm or 
gentimycin or gentocin or gentogram or gentomycin or genum or 
geomycine or gevramycin or g-mycin or gmyticin or g-myticin or 
grammicin or hexamycin or jenamicin or konigen or lacromycin or 
lisagent or martigenta or migenta or miragenta or miramycin or 
nichogencin or nsc 82261 or nsc82261 or obogen or ocugenta or ocu-
mycin or oftagen or ophtagram or opthagen or optigen or opti-genta or 
ottogenta or pyogenta or refobacin or ribomicin or rigaminol or rocy gen 
or rovixida or rupegen or sagestam or sch 9724 or sch9724 or sedanazin 
or servigenta or skinfect or sulmycin or tangyn or u-gencin or versigen 
or yectamicina) )  
993 
S33  (MH ‘Gentamicins’)  808 
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S32  
TI ( (Aminoglycosides or Anthracyclines or Aclarubicin or Daunorubicin 
or Plicamycin or Butirosin Sulfate or Sisomicin or Hygromycin B or 
Kanamycin or Dibekacin or Nebramycin or Metrizamide or Neomycin or 
Framycetin or Paromomycin or Ribostamycin or Puromycin or 
Spectinomycin or Streptomycin or Dihydrostreptomycin Sulfate or 
Streptothricins or Streptozocin) ) OR AB ( (Aminoglycosides or 
Anthracyclines or Aclarubicin or Daunorubicin or Plicamycin or 
Butirosin Sulfate or Sisomicin or Hygromycin B or Kanamycin or 
Dibekacin or Nebramycin or Metrizamide or Neomycin or Framycetin or 
Paromomycin or Ribostamycin or Puromycin or Spectinomycin or 
Streptomycin or Dihydrostreptomycin Sulfate or Streptothricins or 
Streptozocin) )  
1,269 
S31  (MH ‘Aminoglycosides+’)  6,215 
S30  
TI ( ((chinolone n1 derivative) or fluoroquinolones or (haloquinolone n1 
derivative) or ketoquinolines or oxoquinolines or quinolinones or 
quinolones) ) OR AB ( ((chinolone n1 derivative) or fluoroquinolones or 
(haloquinolone n1 derivative) or ketoquinolines or oxoquinolines or 
quinolinones or quinolones) )  
834 
S29  (MH ‘Quinolines+’) OR (MH ‘Antiinfective Agents, Quinolone+’)  4,842 
S28  
TI ( (tigecycline or (tbg n1 mino) or tygacil or gar 936 or gar936 or (tert 
n1 butylglycinamido*)) ) OR AB ( (tigecycline or (tbg n1 mino) or tygacil 
or gar 936 or gar936 or (tert n1 butylglycinamido*)) )  
208 
S27  
TI ( ((brl n1 ‘17421’) or brl17421 or (thiophenemalonamic n1 acid) or 
negaban or temocillin or temopen) ) OR AB ( ((brl n1 ‘17421’) or 
brl17421 or (thiophenemalonamic n1 acid) or negaban or temocillin or 
temopen) )  
10 
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S26  
TI ( (aclam or aktil or ambilan or amocla or amoclan or amoclav or 
amoksiklav or amolanic or amometin or (amox n1 clav) or amox-clav or 
(amoxi n1 plus) or (amoxNear/3clavulan*) or amoxiclav or amoxiclav-
bid or amoxiclav-teva or amoxsiklav or amoxxlin or (amoxycillin-
clavulanic n1 acid) or ancla or (auclatin n1 duo) or augamox or 
augmaxcil or augmentan or augmentin* or augmex or augpen or 
(augucillin n1 duo) or augurcin or ausclav or auspilic or bactiv or 
bactoclav or bioclavid or (brl n1 ‘25000’) or brl25000 or brl-25000 or 
cavumox or ciblor or (clacillin n1 duo) or clamax or clamentin or 
clamobit or clamonex or clamovid or clamoxin or (clamoxyl n1 duo*) or 
clarin-duo or clavamox or clavar or clavinex or clavodar or clavoxil or 
(clavoxilin n1 plus) or clavubactin or clavudale or clavulanate-
amoxicillin or clavulin or (clavulox n1 duo) or clavumox or (co n1 
amoxiclav) or (co n1 amoxyclav) or coamoxiclav or co-amoxiclav or 
coamoxyclav or (cramon n1 duo) or (croanan n1 duo) or curam or 
danoclav or (darzitil n1 plus) or e-moxclav or enhancin or fleming or 
fugentin or (fullicilina n1 plus) or gumentin or hibiotic or inciclav or 
klamonex or kmoxilin or lactamox or lansiclav or moxiclav or moxicle or 
moxyclav or natravox or nufaclav or palentin or quali-mentin or ranclav 
or spektramox or stacillin or suplentin or synermox or synulox or 
(velamox n1 cl) or vestaclav or viaclav or vulamox or xiclav or (zami n1 
‘8503’)) ) OR AB ( (aclam or aktil or ambilan or amocla or amoclan or 
amoclav or amoksiklav or amolanic or amometin or (amox n1 clav) or 
amox-clav or (amoxi n1 plus) or (amoxNear/3clavulan*) or amoxiclav or 
amoxiclav-bid or amoxiclav-teva or amoxsiklav or amoxxlin or 
(amoxycillin-clavulanic n1 acid) or ancla or (auclatin n1 duo) or 
augamox or augmaxcil or augmentan or augmentin* or augmex or 
augpen or (augucillin n1 duo) or augurcin or ausclav or auspilic or bactiv 
or bactoclav or bioclavid or (brl n1 ‘25000’) or brl25000 or brl-25000 or 
cavumox or ciblor or (clacillin n1 duo) or clamax or clamentin or 
clamobit or clamonex or clamovid or clamoxin or (clamoxyl n1 duo*) or 
clarin-duo or clavamox or clavar or clavinex or clavodar or clavoxil or 
(clavoxilin n1 plus) or clavubactin or clavudale or clavulanate-
amoxicillin or clavulin or (clavulox n1 duo) or clavumox or (co n1 
amoxiclav) or (co n1 amoxyclav) or coamoxiclav or co-amoxiclav or 
coamoxyclav or (cramon n1 duo) or (croanan n1 duo) or curam or 
danoclav or (darzitil n1 plus) or e-moxclav or enhancin or fleming or 
fugentin or (fullicilina n1 plus) or gumentin or hibiotic or inciclav or 
klamonex or kmoxilin or lactamox or lansiclav or moxiclav or moxicle or 
moxyclav or natravox or nufaclav or palentin or quali-mentin or ranclav 
or spektramox or stacillin or suplentin or synermox or synulox or 
(velamox n1 cl) or vestaclav or viaclav or vulamox or xiclav or (zami n1 
‘8503’)) )  
805 
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S25  
TI ( (cl 307579 or cl298741 or cl307579 or tazabactam or tazobac* or 
tazocel or tazocillin* or tazocin or tazomax or tazonam or tazopril or yp 
14 or yp14 or ytr 830 or ytr 830h or ytr830 or ytr830h or zosyn) ) OR 
AB ( (cl 307579 or cl298741 or cl307579 or tazabactam or tazobac* or 
tazocel or tazocillin* or tazocin or tazomax or tazonam or tazopril or yp 
14 or yp14 or ytr 830 or ytr 830h or ytr830 or ytr830h or zosyn) )  
247 
S24  
TI ( (acopex or avocin or cl 227,193 or Cl 227193 or cl 227193 or cl 
227193 or cl227,193 or Cl227193 or cl227193 or cl227193 or Cl-
227193 or cl-227193 or cypercil or hishiyaclorin or ivacin or pentcillin 
or pentocillin or picillin* or pipcil or pipera hameln or piperacil or 
piperacillin* or piperacin or pipera-hameln or pipercillin or piperilline 
or pipraci* or pipraks or pipril or piprilin or pitamycin or t 1220 or 
t1220 or t-1220 or taiperacillin) ) OR AB ( (acopex or avocin or cl 
227,193 or Cl 227193 or cl 227193 or cl 227193 or cl227,193 or 
Cl227193 or cl227193 or cl227193 or Cl-227193 or cl-227193 or 
cypercil or hishiyaclorin or ivacin or pentcillin or pentocillin or picillin* 
or pipcil or pipera hameln or piperacil or piperacillin* or piperacin or 
pipera-hameln or pipercillin or piperilline or pipraci* or pipraks or pipril 
or piprilin or pitamycin or t 1220 or t1220 or t-1220 or taiperacillin) )  
296 
S23  
TI ( (Carbapenem* or doripenem or ertapenem or Imipemide or 
Imipenem or Invanoz or Invanz or meropenem or Merrem or ‘MK 0787’ 
or MK0787 or MK-0787 or N Formimidoylthienamycin or N-
Formimidoylthienamycin or Penem or Ronem or S 4661 or S-4661 or SM 
7338 or SM-7338 or Thienamycin*) ) OR AB ( (Carbapenem* or 
doripenem or ertapenem or Imipemide or Imipenem or Invanoz or 
Invanz or meropenem or Merrem or ‘MK 0787’ or MK0787 or MK-0787 
or N Formimidoylthienamycin or N-Formimidoylthienamycin or Penem 
or Ronem or S 4661 or S-4661 or SM 7338 or SM-7338 or Thienamycin*) 
)  
974 
S22  (MH ‘Carbapenems+’)  559 
S21  S19 OR S20  14,473 
S20  (MH ‘Drug Resistance, Microbial+’)  14,182 
S19  
TI ( (multiresistant or (multi n1 resistan*)) ) OR AB ( (multiresistant or 
(multi n1 resistan*)) )  
604 
S18  
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 
OR S12 OR S13 OR S14 OR S15 OR S16 OR S17  
7,706 
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#  Query  Results  
S17  
TI ( ((bacillus n1 morgan*) or (bacterium n1 morgana) or (morganella 
n1 morgagni*) or (morganella n1 morganii) or (proteus n1 morgagni) or 
(proteus n1 morgana*) or (salmonella n1 morgana)) ) OR AB ( ((bacillus 
n1 morgan*) or (bacterium n1 morgana) or (morganella n1 morgagni*) 
or (morganella n1 morganii) or (proteus n1 morgagni) or (proteus n1 
morgana*) or (salmonella n1 morgana)) )  
20 
S16  
TI ( ((Citrobacter n1 freundii) or (bacterium n1 freundii) or (Escherichia 
n1 freundii)) ) OR AB ( ((Citrobacter n1 freundii) or (bacterium n1 
freundii) or (Escherichia n1 freundii)) )  
32 
S15  (MH ‘Citrobacter’)  40 
S14  TI Serratia OR AB Serratia  238 
S13  (MH ‘Serratia’) OR (MH ‘Serratia Infections’)  174 
S12  TI Proteus OR AB Proteus  257 
S11  (MH ‘Proteus’) OR (MH ‘Proteus Infections’)  118 
S10  
TI ( (Acinetobacter or mima or mimae or herellea or acinetobacterium) ) 
OR AB ( (Acinetobacter or mima or mimae or herellea or 
acinetobacterium) )  
889 
S9  (MH ‘Acinetobacter Infections’)  581 
S8  TI ‘p. aeruginosa’ OR AB ‘p. aeruginosa’  610 
S7  
TI ( ((bacillus n1 pyocyaneus) or (bacterium n1 (aeruginosum or 
pyocyaneum)) or (blue n1 apus) or (Pseudomonas n1 (aeruginosa or 
aureofaciens or pyoceaneus or pyocyanea or pyocyaneus))) ) OR AB ( 
((bacillus n1 pyocyaneus) or (bacterium n1 (aeruginosum or 
pyocyaneum)) or (blue n1 apus) or (Pseudomonas n1 (aeruginosa or 
aureofaciens or pyoceaneus or pyocyanea or pyocyaneus))) )  
1,855 
S6  




TI ( (‘k. pneumoniae’ or ‘b. friedlander’) ) OR AB ( (‘k. pneumoniae’ or ‘b. 
friedlander’) )  
200 
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#  Query  Results  
S4  
TI ( (klebsiella or Calymmatobacterium or (aerobacter n1 aerogenes) or 
((bacillus or bacterium) n1 pneumonia) or ((friedlaender or 
Friedlander) n1 bacillus) or (Hyalococcus n1 pneumonia) or 
Pneumobacillus) ) OR AB ( (klebsiella or Calymmatobacterium or 
(aerobacter n1 aerogenes) or ((bacillus or bacterium) n1 pneumonia) or 
((friedlaender or Friedlander) n1 bacillus) or (Hyalococcus n1 
pneumonia) or Pneumobacillus) )  
1,039 
S3  (MH ‘Klebsiella’) OR (MH ‘Klebsiella Infections’)  835 
S2  
TI ( (Eaggec or (escherichia n1 coli) or (e n1 coli) or (alkalescens-dispar 
n1 group) or (bacillus n1 escherichii) or (Coli n1 bacillus) or (Coli n1 
bacterium) or colibacillus or (colon n1 bacillus)) ) OR AB ( (Eaggec or 
(escherichia n1 coli) or (e n1 coli) or (alkalescens-dispar n1 group) or 
(bacillus n1 escherichii) or (Coli n1 bacillus) or (Coli n1 bacterium) or 
colibacillus or (colon n1 bacillus)) )  
2,914 
S1  (MH ‘Escherichia Coli’) OR (MH ‘Escherichia Coli Infections’)  2,983 
4.2.2. Cochrane Library (Issue 11, 2012) 
ID Search  
#1 MeSH descriptor: [Escherichia coli] explode all trees 
#2 (Eaggec or (escherichia near/1 coli) or (e near/1 coli) or (alkalescens-dispar 
near/1 group) or (bacillus near/1 escherichii) or (Coli near/1 bacillus) or (Coli near/1 
bacterium) or colibacillus or (colon near/1 bacillus)):ti,ab,kw (Word variations have 
been searched) 
#3 MeSH descriptor: [Klebsiella] explode all trees 
#4 (klebsiella or Calymmatobacterium or (aerobacter near/1 aerogenes) or 
((bacillus or bacterium) near/1 pneumonia) or ((friedlaender or Friedlander) near/1 
bacillus) or (Hyalococcus near/1 pneumonia) or Pneumobacillus):ti,ab,kw (Word 
variations have been searched) 
#5 k. pneumoniae or b. friedlander:ti,ab,kw (Word variations have been searched) 
#6 MeSH descriptor: [Enterobacter] explode all trees 
#7 (enterobacter or aerobacter):ti,ab,kw (Word variations have been searched) 
#8 MeSH descriptor: [Pseudomonas aeruginosa] explode all trees 
#9 ((bacillus near/1 pyocyaneus) or (bacterium near/1 (aeruginosum or 
pyocyaneum)) or (blue near/1 apus) or (Pseudomonas near/1 (aeruginosa or 
aureofaciens or pyoceaneus or pyocyanea or pyocyaneus))):ti,ab,kw (Word variations 
have been searched) 
#10 p. aeruginosa:ti,ab,kw (Word variations have been searched) 
#11 MeSH descriptor: [Acinetobacter] explode all trees 
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#12 (Acinetobacter or mima or mimae or herellea or acinetobacterium):ti,ab,kw 
(Word variations have been searched) 
#13 MeSH descriptor: [Proteus] explode all trees 
#14 Proteus:ti,ab,kw (Word variations have been searched) 
#15 MeSH descriptor: [Serratia] explode all trees 
#16 Serratia:ti,ab,kw (Word variations have been searched) 
#17 MeSH descriptor: [Citrobacter freundii] explode all trees 
#18 ((Citrobacter near/1 freundii) or (bacterium near/1 freundii) or (Escherichia 
near/1 freundii)):ti,ab,kw (Word variations have been searched) 
#19 MeSH descriptor: [Morganella morganii] explode all trees 
#20 ((bacillus near/1 morgan$) or (bacterium near/1 morgana) or (morganella 
near/1 morgagni$) or (morganella near/1 morganii) or (proteus near/1 morgagni) or 
(proteus near/1 morgana$) or (salmonella near/1 morgana)):ti,ab,kw (Word variations 
have been searched) 
#21 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
or #14 or #15 or #16 or #17 or #18 or #19 or #20  
#22 (multiresistant or (multi near/1 resistan$)):ti,ab,kw (Word variations have been 
searched) 
#23 MeSH descriptor: [Drug Resistance, Multiple] explode all trees 
#24 #22 or #23  
#25 MeSH descriptor: [Colistin] explode all trees 
#26 (belcomycin or colicort or colimycin$ or colisitin or colisticin or Colistin or 
colistine or colomycin or (coly near/1 mycin) or colymicin or colymycin or coly-mycin 
or multimycin or (Polymyxin near/1 E) or totazina):ti,ab,kw (Word variations have 
been searched) 
#27 MeSH descriptor: [Carbapenems] explode all trees 
#28 (Carbapenem$ or doripenem or ertapenem or Imipemide or Imipenem or 
Invanoz or Invanz or meropenem or Merrem or ‘MK 0787’ or MK0787 or MK-0787 or N 
Formimidoylthienamycin or N-Formimidoylthienamycin or Penem or Ronem or S 4661 
or S-4661 or SM 7338 or SM-7338 or Thienamycin$):ti,ab,kw (Word variations have 
been searched) 
#29 MeSH descriptor: [Piperacillin] explode all trees 
#30 (acopex or avocin or cl 227,193 or Cl 227193 or cl 227193 or cl 227193 or 
cl227,193 or Cl227193 or cl227193 or cl227193 or Cl-227193 or cl-227193 or cypercil 
or hishiyaclorin or ivacin or pentcillin or pentocillin or picillin$ or pipcil or pipera 
hameln or piperacil or piperacillin$ or piperacin or pipera-hameln or pipercillin or 
piperilline or pipraci$ or pipraks or pipril or piprilin or pitamycin or t 1220 or t1220 or 
t-1220 or taiperacillin):ti,ab,kw (Word variations have been searched) 
#31 (cl 307579 or cl298741 or cl307579 or tazabactam or tazobac$ or tazocel or 
tazocillin$ or tazocin or tazomax or tazonam or tazopril or yp 14 or yp14 or ytr 830 or 
ytr 830h or ytr830 or ytr830h or zosyn):ti,ab,kw (Word variations have been searched) 
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#32 MeSH descriptor: [Amoxicillin-Potassium Clavulanate Combination] explode all 
trees 
#33 (aclam or aktil or ambilan or amocla or amoclan or amoclav or amoksiklav or 
amolanic or amometin or (amox near/1 clav) or amox-clav or (amoxi near/1 plus) or 
(amoxNear/3clavulan$) or amoxiclav or amoxiclav-bid or amoxiclav-teva or amoxsiklav 
or amoxxlin or (amoxycillin-clavulanic near/1 acid) or ancla or (auclatin near/1 duo) or 
augamox or augmaxcil or augmentan or augmentin$ or augmex or augpen or (augucillin 
near/1 duo) or augurcin or ausclav or auspilic or bactiv or bactoclav or bioclavid or (brl 
near/1 ‘25000’) or brl25000 or brl-25000 or cavumox or ciblor or (clacillin near/1 duo) 
or clamax or clamentin or clamobit or clamonex or clamovid or clamoxin or (clamoxyl 
near/1 duo$) or clarin-duo or clavamox or clavar or clavinex or clavodar or clavoxil or 
(clavoxilin near/1 plus) or clavubactin or clavudale or clavulanate-amoxicillin or 
clavulin or (clavulox near/1 duo) or clavumox or (co near/1 amoxiclav) or (co near/1 
amoxyclav) or coamoxiclav or co-amoxiclav or coamoxyclav or (cramon near/1 duo) or 
(croanan near/1 duo) or curam or danoclav or (darzitil near/1 plus) or e-moxclav or 
enhancin or fleming or fugentin or (fullicilina near/1 plus) or gumentin or hibiotic or 
inciclav or klamonex or kmoxilin or lactamox or lansiclav or moxiclav or moxicle or 
moxyclav or natravox or nufaclav or palentin or quali-mentin or ranclav or spektramox 
or stacillin or suplentin or synermox or synulox or (velamox near/1 cl) or vestaclav or 
viaclav or vulamox or xiclav or (zami near/1 ‘8503’)):ti,ab,kw (Word variations have 
been searched) 
#34 ((brl near/1 ‘17421’) or brl17421 or (thiophenemalonamic near/1 acid) or 
negaban or temocillin or temopen):ti,ab,kw (Word variations have been searched) 
#35 (tigecycline or (tbg near/1 mino) or tygacil or gar 936 or gar936 or (tert near/1 
butylglycinamido$)):ti,ab,kw (Word variations have been searched) 
#36 MeSH descriptor: [Quinolones] explode all trees 
#37 ((chinolone near/1 derivative) or fluoroquinolones or (haloquinolone near/1 
derivative) or ketoquinolines or oxoquinolines or quinolinones or quinolones):ti,ab,kw 
(Word variations have been searched) 
#38 MeSH descriptor: [Aminoglycosides] explode all trees 
#39 (Aminoglycosides or Anthracyclines or Aclarubicin or Daunorubicin or 
Plicamycin or Butirosin Sulfate or Sisomicin or Hygromycin B or Kanamycin or 
Dibekacin or Nebramycin or Metrizamide or Neomycin or Framycetin or Paromomycin 
or Ribostamycin or Puromycin or Spectinomycin or Streptomycin or 
Dihydrostreptomycin Sulfate or Streptothricins or Streptozocin):ti,ab,kw (Word 
variations have been searched) 
#40 MeSH descriptor: [Gentamicins] explode all trees 
#41 (adelanin or alcomicin or apigent or apogen or apoten or azupel or bactiderm or 
biogaracin or bristagen or cidomycin or danigen or dermogen or dianfarma or 
dispagent or duragentam$ or epigent or (frieso near/1 gent) or garabiotic or garalone 
or garamicin$ or garamycin or garbilocin or gencin or gendril or genoptic or genrex or 
gensumycin or gentabiotic or gentabiox or gentac or gentacidin or gentacin or gentacor 
or gentacycol or gentacyl or gentafair or gentagram or gentak or gental or gentaline or 
gentalline or gentalol or gentalyn or gentamax or gentame$ or gentamicin$ or 
gentamina or gentamycin$ or gentamyl or gentamytrex or gentaplus or gentarad or 
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gentasil or gentasol or gentasone or gentasporin or gentatrim or gentavet or genticin$ 
or genticyn or gentiderm or gentimycin or gentocin or gentogram or gentomycin or 
genum or geomycine or gevramycin or g-mycin or gmyticin or g-myticin or grammicin 
or hexamycin or jenamicin or konigen or lacromycin or lisagent or martigenta or 
migenta or miragenta or miramycin or nichogencin or nsc 82261 or nsc82261 or 
obogen or ocugenta or ocu-mycin or oftagen or ophtagram or opthagen or optigen or 
opti-genta or ottogenta or pyogenta or refobacin or ribomicin or rigaminol or rocy gen 
or rovixida or rupegen or sagestam or sch 9724 or sch9724 or sedanazin or servigenta 
or skinfect or sulmycin or tangyn or u-gencin or versigen or yectamicina):ti,ab,kw 
(Word variations have been searched) 
#42 MeSH descriptor: [Amikacin] explode all trees 
#43 (akacin or akicin or amicacina or amicasil or amicin or amiglymide v or 
amikacin$ or amikafur or amikalem or amikan or amikayect or amikin or amiklin or 
amikozit or amiktam or amitracin or amixin or amukin or apalin or bb k 8 or bb k8 or 
bbk 8 or bb-k 8 or bbk8 or bbk-8 or bb-k8 or biclin or biklin or biokacin or briclin or 
briklin or chemacin or cinmik or fabianol or gamikal or glukamin or kacinth-a or 
kanbine or kormakin or likacin or lukadin or miacin or mikasome or onikin or oprad or 
orlobin or pediakin or pierami or riklinak or savox or selaxa or selemycin or sulfate 
amikacin or tybikin or vs 107 or vs107 or yectamid):ti,ab,kw (Word variations have 
been searched) 
#44 MeSH descriptor: [Fosfomycin] explode all trees 
#45 (fosfocil or fosfocin or fosfocina or fosfomicin or fosfomycin or fosfonomycin or 
‘mk 0955’ or mk 955 or mk0955 or mk955 or monuril or phosphomycin or 
phosphonomycin):ti,ab,kw (Word variations have been searched) 
#46 MeSH descriptor: [Aztreonam] explode all trees 
#47 ((az near/1 threonam) or azactam or azenam or azthreonam or aztreonam or 
(corus near/1 ‘1020’) or dynabiotic or primbactam or SQ 26,776 or sq 26,776 or sq 
26776 or SQ-26,776 or sq26776 or sq-26776 or urobactam):ti,ab,kw (Word variations 
have been searched) 
#48 MeSH descriptor: [Nitrofurantoin] explode all trees 
#49 (berkfurin or biofurin or chemiofuran or dantafur or f 30 or f30 or fua-med or 
furaben or furadantin$ or furadantoin or furadina or furadoine or furadonin or 
furadonine or furalan or furanpur or furantocompren or furantoin$ or furobactina or 
furofen or furophen or infurin or ituran or ivadantin or macrobid or macrodantin$ or 
macrofuran or macrofurin or micofurantin$ or mitrofuratoin or nephronex or nierofu or 
nifurantin or nifuryl or (nitro near/1 macro) or nitrofuracin or nitrofuradantoin or 
nitrofurantine or nitrofurantoin$ or nitrofurin or novofuran or nsc 2107 or nsc2107 or 
orafuran or parfuran or phenurin or (potassium near/1 furagin) or ralodantin or 
trocurine or urantin or (uro near/1 tablinen) or urodil or urodin or urofuran or urolong 
or urotablinen or uro-tablinen or urotoina or uvamin):ti,ab,kw (Word variations have 
been searched) 
#50 MeSH descriptor: [Cephalosporins] explode all trees 
#51 ((Cephalosporanic near/1 Acid$) or Cephalosporin$ or Cefamandole or 
Cefoperazone or Cefazolin or Cefonicid or Cefsulodin or Cephacetrile or Cefotaxime or 
Cephalothin or Cephapirin or Cephalexin or Cefaclor or Cefadroxil or Cephaloglycin or 
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Cephradine or Cephaloridine or Ceftazidime or Cephamycins or Cefmetazole or 
Cefotetan or Cefoxitin):ti,ab,kw (Word variations have been searched) 
#52 MeSH descriptor: [Amdinocillin Pivoxil] explode all trees 
#53 ((amdinocillin near/1 pivoxil) or (FL near/1 ‘1039’) or FL1039 or fl1039 or FL-
1039 or pivamdinocillin or Pivmecillinam or Selexid or coactabs or (ro near/1 ‘109071’) 
or (ro10 near/1 ‘9071’) or ro109071):ti,ab,kw (Word variations have been searched) 
#54 #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or 
#36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or 
#48 or #49 or #50 or #51 or #52 or #53  
#55 #21 and #24 and #54 (21) 
 
4.2.3. Embase (January 1980 to December 1012) 
1 exp Escherichia coli/ (255846) 
2 (Eaggec or (escherichia adj coli) or (e adj coli) or (alkalescens-dispar adj group) or 
(bacillus adj escherichii) or (Coli adj bacillus) or (Coli adj bacterium) or colibacillus or 
(colon adj bacillus)).ti,ab. (240749) 
3 exp Klebsiella/ (30199) 
4 (klebsiella or Calymmatobacterium or (aerobacter adj aerogenes) or ((bacillus or 
bacterium) adj pneumonia) or ((friedlaender or Friedlander) adj bacillus) or 
(Hyalococcus adj pneumonia) or Pneumobacillus).ti,ab. (22836) 
5 (‘k. pneumoniae’ or ‘b. friedlander’).ti,ab. (5513) 
6 exp Enterobacter/ (12784) 
7 (enterobacter or aerobacter).ti,ab. (9700) 
8 exp Pseudomonas aeruginosa/ (55073) 
9 ((bacillus adj pyocyaneus) or (bacterium adj (aeruginosum or pyocyaneum)) or (blue 
adj apus) or (Pseudomonas adj (aeruginosa or aureofaciens or pyoceaneus or 
pyocyanea or pyocyaneus))).ti,ab. (43474) 
10 ‘p. aeruginosa’.ti,ab. (17572) 
11 exp Acinetobacter/ (12028) 
12 (Acinetobacter or mima or mimae or herellea or acinetobacterium).ti,ab. (10917) 
13 exp Proteus/ (14447) 
14 Proteus.ti,ab. (10461) 
15 exp Serratia/ (9507) 
16 Serratia.ti,ab. (7407) 
17 exp Citrobacter freundii/ (1778) 
18 ((Citrobacter adj freundii) or (bacterium adj freundii) or (Escherichia adj 
freundii)).ti,ab. (1675) 
19 exp Morganella morganii/ (1134) 
Accepted manuscript 296 
20 ((bacillus adj morgan$) or (bacterium adj morgana) or (morganella adj morgagni$) 
or (morganella adj morganii) or (proteus adj morgagni) or (proteus adj morgana$) or 
(salmonella adj morgana)).ti,ab. (804) 
21 or/1-20 (396800) 
22 (multiresistant or (multi adj resistan$)).ti,ab. (5599) 
23 exp multidrug resistance/ (29629) 
24 22 or 23 (33705) 
25 exp Colistin/ (8049) 
26 (belcomycin or colicort or colimycin$ or colisitin or colisticin or Colistin or colistine 
or colomycin or (coly adj mycin) or colymicin or colymycin or coly-mycin or multimycin 
or (Polymyxin adj E) or totazina).ti,ab. (3104) 
27 exp Carbapenems/ (4745) 
28 (Carbapenem$ or doripenem or ertapenem or Imipemide or Imipenem or Invanoz or 
Invanz or meropenem or Merrem or ‘MK 0787’ or MK0787 or MK-0787 or N 
Formimidoylthienamycin or N-Formimidoylthienamycin or Penem or Ronem or S 4661 
or S-4661 or SM 7338 or SM-7338 or Thienamycin$).ti,ab. (18086) 
29 exp Piperacillin/ (14822) 
30 (acopex or avocin or cl 227,193 or Cl 227193 or cl 227193 or cl 227193 or cl227,193 
or Cl227193 or cl227193 or cl227193 or Cl-227193 or cl-227193 or cypercil or 
hishiyaclorin or ivacin or pentcillin or pentocillin or picillin$ or pipcil or pipera hameln 
or piperacil or piperacillin$ or piperacin or pipera-hameln or pipercillin or piperilline or 
pipraci$ or pipraks or pipril or piprilin or pitamycin or t 1220 or t1220 or t-1220 or 
taiperacillin).ti,ab. (6462) 
31 exp Amoxicillin-Potassium Clavulanate Combination/ (23616) 
32 (aclam or aktil or ambilan or amocla or amoclan or amoclav or amoksiklav or 
amolanic or amometin or (amox adj clav) or amox-clav or (amoxi adj plus) or (amox 
adj3 clavulan$) or amoxiclav or amoxiclav-bid or amoxiclav-teva or amoxsiklav or 
amoxxlin or (amoxycillin-clavulanic adj acid) or ancla or (auclatin adj duo) or augamox 
or augmaxcil or augmentan or augmentin$ or augmex or augpen or (augucillin adj duo) 
or augurcin or ausclav or auspilic or bactiv or bactoclav or bioclavid or (brl adj ‘25000’) 
or brl25000 or brl-25000 or cavumox or ciblor or (clacillin adj duo) or clamax or 
clamentin or clamobit or clamonex or clamovid or clamoxin or (clamoxyl adj duo$) or 
clarin-duo or clavamox or clavar or clavinex or clavodar or clavoxil or (clavoxilin adj 
plus) or clavubactin or clavudale or clavulanate-amoxicillin or clavulin or (clavulox adj 
duo) or clavumox or (co adj amoxiclav) or (co adj amoxyclav) or coamoxiclav or co-
amoxiclav or coamoxyclav or (cramon adj duo) or (croanan adj duo) or curam or 
danoclav or (darzitil adj plus) or e-moxclav or enhancin or fleming or fugentin or 
(fullicilina adj plus) or gumentin or hibiotic or inciclav or klamonex or kmoxilin or 
lactamox or lansiclav or moxiclav or moxicle or moxyclav or natravox or nufaclav or 
palentin or quali-mentin or ranclav or spektramox or stacillin or suplentin or synermox 
or synulox or (velamox adj cl) or vestaclav or viaclav or vulamox or xiclav or (zami adj 
‘8503’)).ti,ab. (11598) 
33 exp Quinolones/ (101072) 
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34 ((chinolone adj derivative) or fluoroquinolones or (haloquinolone adj derivative) or 
ketoquinolines or oxoquinolines or quinolinones or quinolones).ti,ab. (15677) 
35 exp Aminoglycosides/ (10599) 
36 (Aminoglycosides or Anthracyclines or Aclarubicin or Daunorubicin or Plicamycin or 
Butirosin Sulfate or Sisomicin or Hygromycin B or Kanamycin or Dibekacin or 
Nebramycin + or Metrizamide or Neomycin or Framycetin or Paromomycin or 
Ribostamycin or Puromycin or Spectinomycin or Streptomycin or Dihydrostreptomycin 
Sulfate or Streptothricins or Streptozocin).ti,ab. (56708) 
37 exp Gentamicins/ (70647) 
38 (adelanin or alcomicin or apigent or apogen or apoten or azupel or bactiderm or 
biogaracin or bristagen or cidomycin or danigen or dermogen or dianfarma or 
dispagent or duragentam$ or epigent or (frieso adj gent) or garabiotic or garalone or 
garamicin$ or garamycin or garbilocin or gencin or gendril or genoptic or genrex or 
gensumycin or gentabiotic or gentabiox or gentac or gentacidin or gentacin or gentacor 
or gentacycol or gentacyl or gentafair or gentagram or gentak or gental or gentaline or 
gentalline or gentalol or gentalyn or gentamax or gentame$ or gentamicin$ or 
gentamina or gentamycin$ or gentamyl or gentamytrex or gentaplus or gentarad or 
gentasil or gentasol or gentasone or gentasporin or gentatrim or gentavet or genticin$ 
or genticyn or gentiderm or gentimycin or gentocin or gentogram or gentomycin or 
genum or geomycine or gevramycin or g-mycin or gmyticin or g-myticin or grammicin 
or hexamycin or jenamicin or konigen or lacromycin or lisagent or martigenta or 
migenta or miragenta or miramycin or nichogencin or nsc 82261 or nsc82261 or 
obogen or ocugenta or ocu-mycin or oftagen or ophtagram or opthagen or optigen or 
opti-genta or ottogenta or pyogenta or refobacin or ribomicin or rigaminol or rocy gen 
or rovixida or rupegen or sagestam or sch 9724 or sch9724 or sedanazin or servigenta 
or skinfect or sulmycin or tangyn or u-gencin or versigen or yectamicina).ti,ab. (23700) 
39 exp Amikacin/ (28644) 
40 (akacin or akicin or amicacina or amicasil or amicin or amiglymide v or amikacin$ or 
amikafur or amikalem or amikan or amikayect or amikin or amiklin or amikozit or 
amiktam or amitracin or amixin or amukin or apalin or bb k 8 or bb k8 or bbk 8 or bb-k 
8 or bbk8 or bbk-8 or bb-k8 or biclin or biklin or biokacin or briclin or briklin or 
chemacin or cinmik or fabianol or gamikal or glukamin or kacinth-a or kanbine or 
kormakin or likacin or lukadin or miacin or mikasome or onikin or oprad or orlobin or 
pediakin or pierami or riklinak or savox or selaxa or selemycin or sulfate amikacin or 
tybikin or vs 107 or vs107 or yectamid).ti,ab. (9841) 
41 exp Fosfomycin/ (5561) 
42 (fosfocil or fosfocin or fosfocina or fosfomicin or fosfomycin or fosfonomycin or ‘mk 
0955’ or mk 955 or mk0955 or mk955 or monuril or phosphomycin or 
phosphonomycin).ti,ab. (2386) 
43 exp Aztreonam/ (10567) 
44 ((az adj threonam) or azactam or azenam or azthreonam or aztreonam or (corus adj 
‘1020’) or dynabiotic or primbactam or SQ 26,776 or sq 26,776 or sq 26776 or SQ-
26,776 or sq26776 or sq-26776 or urobactam).ti,ab. (3245) 
45 exp Nitrofurantoin/ (9724) 
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46 (berkfurin or biofurin or chemiofuran or dantafur or f 30 or f30 or fua-med or 
furaben or furadantin$ or furadantoin or furadina or furadoine or furadonin or 
furadonine or furalan or furanpur or furantocompren or furantoin$ or furobactina or 
furofen or furophen or infurin or ituran or ivadantin or macrobid or macrodantin$ or 
macrofuran or macrofurin or micofurantin$ or mitrofuratoin or nephronex or nierofu or 
nifurantin or nifuryl or (nitro adj macro) or nitrofuracin or nitrofuradantoin or 
nitrofurantine or nitrofurantoin$ or nitrofurin or novofuran or nsc 2107 or nsc2107 or 
orafuran or parfuran or phenurin or (potassium adj furagin) or ralodantin or trocurine 
or urantin or (uro adj tablinen) or urodil or urodin or urofuran or urolong or 
urotablinen or uro-tablinen or urotoina or uvamin).ti,ab. (3412) 
47 exp Cephalosporins/ (150937) 
48 (Axepim$ or bmy 28142 or bmy28142 or BMY-28142 or Cefepim$ or cefepitax or 
ceficad or cepimax or forzyn beta or maxcef or maxfrom or maxipime or 
Quadrocef).ti,ab. (2995) 
49 exp tazobactam/ (3045) 
50 (cl 307579 or cl298741 or cl307579 or tazabactam or tazobac$ or tazocel or 
tazocillin$ or tazocin or tazomax or tazonam or tazopril or yp 14 or yp14 or ytr 830 or 
ytr 830h or ytr830 or ytr830h or zosyn).ti,ab. (3809) 
51 exp temocillin/ (499) 
52 ((brl adj ‘17421’) or brl17421 or (thiophenemalonamic adj acid) or negaban or 
temocillin or temopen).ti,ab. (236) 
53 exp tigecycline/ (3876) 
54 (tigecycline or (tbg adj mino) or tygacil or gar 936 or gar936 or (tert adj 
butylglycinamido$)).ti,ab. (1970) 
55 exp cefepime/ (9948) 
56 ((Cephalosporanic adj Acid$) or Cephalosporin$ or Cefamandole or Cefoperazone or 
Cefazolin or Cefonicid or Cefsulodin or Cephacetrile or Cefotaxime or Cephalothin or 
Cephapirin or Cephalexin or Cefaclor or Cefadroxil or Cephaloglycin or Cephradine or 
Cephaloridine or Ceftazidime or Cephamycins or Cefmetazole or Cefotetan or 
Cefoxitin).ti,ab. (45983) 
57 exp pivmecillinam/ (685) 
58 ((amdinocillin adj pivoxil) or (FL adj ‘1039’) or FL1039 or fl1039 or FL-1039 or 
pivamdinocillin or Pivmecillinam or Selexid or coactabs or (ro adj ‘109071’) or (ro10 
adj ‘9071’) or ro109071).ti,ab. (280) 
59 or/25-58 (349366) 
60 21 and 24 and 59 (4969) 
61 (review or review,tutorial or review, academic).pt. (1901059) 
62 (systematic$ adj5 review$).tw,sh. (70959) 
63 (systematic$ adj5 overview$).tw,sh. (869) 
64 (quantitativ$ adj5 review$).tw,sh. (15516) 
65 (quantitativ$ adj5 overview$).tw,sh. (203) 
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66 (quantitativ$ adj5 synthesis$).tw,sh. (2716) 
67 (methodologic$ adj5 review$).tw,sh. (3414) 
68 (methodologic$ adj5 overview$).tw,sh. (238) 
69 (integrative research review$ or research integration).tw. (94) 
70 (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (96394) 
71 (meta synthesis or meta synthesis or metasynthesis).tw,sh. (238) 
72 (meta-regression or meta regression or metaregression).tw,sh. (2242) 
73 (synthes$ adj3 literature).tw. (1448) 
74 (synthes$ adj3 evidence).tw. (3583) 
75 integrative review.tw. (604) 
76 data synthesis.tw. (8747) 
77 (research synthesis or narrative synthesis).tw. (547) 
78 (systematic study or systematic studies).tw. (7413) 
79 systematic comparison$.tw. (1183) 
80 comprehensive review$.tw. (6873) 
81 critical review.tw. (11216) 
82 quantitative review.tw. (488) 
83 structured review.tw. (492) 
84 realist review.tw. (34) 
85 realist synthesis.tw. (12) 
86 review.ti. (264011) 
87 systematic$ literature review$.tw. (3464) 
88 ‘systematic review’/ (55637) 
89 ‘systematic review (topic)’/ (2885) 
90 meta analysis/ (67746) 
91 ‘meta analysis (topic)’/ (5552) 
92 (synthes$ adj2 qualitative).tw. (428) 
93 (systematic adj2 search$).tw. (7848) 
94 systematic$ literature research$.tw. (102) 
95 (review adj3 scientific literature).tw. (833) 
96 (literature review adj2 side effect$).tw. (10) 
97 (literature review adj2 adverse effect$).tw. (2) 
98 (literature review adj2 adverse event$).tw. (6) 
99 (evidence-based adj2 review).tw. (1915) 
100 critical analysis.tw. (5559) 
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101 (review$ adj10 (papers or trials or trial data or studies or evidence or 
intervention$ or evaluation$ or outcome$ or findings)).tw. (248295) 
102 review.ti. (264011) 
103 metanaly$.tw. (316) 
104 letter.pt. (800258) 
105 editorial.pt. (417835) 
106 104 or 105 (1218093) 
107 or/61-103 (2212977) 
108 107 not 106 (2200787) 
109 (clin$ adj2 trial).mp. (968683) 
110 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (190403) 
111 (random$ adj5 (assign$ or allocat$)).mp. (101920) 
112 randomi$.mp. (613392) 
113 crossover.mp. (59181) 
114 exp randomized-controlled-trial/ (334017) 
115 exp double-blind-procedure/ (112280) 
116 exp crossover-procedure/ (35737) 
117 exp single-blind-procedure/ (16758) 
118 exp randomization/ (60197) 
119 or/109-118 (1282139) 
120 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or 
complex or DESIGN$ or doctor? or educational or family doctor? or family physician? or 
family practitioner? or financial or GP or general practice? or hospital? or impact? or 
improv$ or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or 
multi-component or multidisciplin$ or multi-disciplin$ or multifacet$ or multi-facet$ or 
multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or 
pharmacist? or pharmacy or physician? or practitioner? or prescrib$ or prescription? or 
primary care or professional$ or provider? or regulatory or regulatory or tailor$ or 
target$ or team$ or usual care)).ab. (175033) 
121 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? 
or provider? or physician? or nurse? or nursing or doctor?).ti,hw. (1363115) 
122 demonstration project?.ti,ab. (2081) 
123 (pre-post or ‘pre test$’ or pretest$ or posttest$ or ‘post test$’ or (pre adj5 
post)).ti,ab. (78013) 
124 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 
workshop)).ti,ab. (673) 
125 trial.ti. or ((study adj3 aim?) or ‘our study’).ab. (724065) 
126 (before adj10 (after or during)).ti,ab. (394152) 
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127 (time points adj3 (over or multiple or three or four or five or six or seven or eight 
or nine or ten or eleven or twelve or month$ or hour? or day? or ‘more than’)).ab. 
(10006) 
128 pilot.ti. (43036) 
129 (multicentre or multicenter or multi-centre or multi-center).ti. (34428) 
130 random$.ti,ab. or controlled.ti. (819713) 
131 review.ti. (264011) 
132 *experimental design/ or *pilot study/ or quasi experimental study/ (5205) 
133 (‘quasi-experiment$’ or quasiexperiment$ or ‘quasi random$’ or quasirandom$ or 
‘quasi control$’ or quasicontrol$ or ((quasi$ or experimental) adj3 (method$ or study 
or trial or design$))).ti,ab. (105122) 
134 or/120-133 (3341084) 
135 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or 
animal tissue/ or animal cell/ or nonhuman/ (18985259) 
136 human/ or normal human/ or human cell/ (14037258) 
137 135 and 136 (14004971) 
138 135 not 137 (4980288) 
139 (‘time series’ adj2 interrupt$).ti,ab. (922) 
140 134 not (138 or 139) (2996658) 
141 108 or 119 or 140 (5157863) 
142 and 141 (1860) 
4.2.4. Medline (January 1946 to December 2012) 
1 exp Escherichia coli/ (224545) 
2 (Eaggec or (escherichia adj coli) or (e adj coli) or (alkalescens-dispar adj group) or 
(bacillus adj escherichii) or (Coli adj bacillus) or (Coli adj bacterium) or colibacillus or 
(colon adj bacillus)).ti,ab. (226847) 
3 exp Klebsiella/ (13720) 
4 (klebsiella or Calymmatobacterium or (aerobacter adj aerogenes) or ((bacillus or 
bacterium) adj pneumonia) or ((friedlaender or Friedlander) adj bacillus) or 
(Hyalococcus adj pneumonia) or Pneumobacillus).ti,ab. (18345) 
5 (‘k. pneumoniae’ or ‘b. friedlander’).ti,ab. (3902) 
6 exp Enterobacter/ (5504) 
7 (enterobacter or aerobacter).ti,ab. (8130) 
8 exp Pseudomonas aeruginosa/ (30232) 
9 ((bacillus adj pyocyaneus) or (bacterium adj (aeruginosum or pyocyaneum)) or (blue 
adj apus) or (Pseudomonas adj (aeruginosa or aureofaciens or pyoceaneus or 
pyocyanea or pyocyaneus))).ti,ab. (35984) 
10 ‘p. aeruginosa’.ti,ab. (14103) 
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11 exp Acinetobacter/ (5262) 
12 (Acinetobacter or mima or mimae or herellea or acinetobacterium).ti,ab. (8005) 
13 exp Proteus/ (8091) 
14 Proteus.ti,ab. (9496) 
15 exp Serratia/ (5505) 
16 Serratia.ti,ab. (6720) 
17 exp Citrobacter freundii/ (438) 
18 ((Citrobacter adj freundii) or (bacterium adj freundii) or (Escherichia adj 
freundii)).ti,ab. (1361) 
19 exp Morganella morganii/ (133) 
20 ((bacillus adj morgan$) or (bacterium adj morgana) or (morganella adj morgagni$) 
or (morganella adj morganii) or (proteus adj morgagni) or (proteus adj morgana$) or 
(salmonella adj morgana)).ti,ab. (601) 
21 or/1-20 (360253) 
22 (multiresistant or (multi adj resistan$)).ti,ab. (3949) 
23 exp drug resistance, multiple/ (21763) 
24 22 or 23 (24405) 
25 exp Colistin/ (2107) 
26 (belcomycin or colicort or colimycin$ or colisitin or colisticin or Colistin or colistine 
or colomycin or (coly adj mycin) or colymicin or colymycin or coly-mycin or multimycin 
or (Polymyxin adj E) or totazina).ti,ab. (2346) 
27 exp Carbapenems/ (6668) 
28 (Carbapenem$ or doripenem or ertapenem or Imipemide or Imipenem or Invanoz or 
Invanz or meropenem or Merrem or ‘MK 0787’ or MK0787 or MK-0787 or N 
Formimidoylthienamycin or N-Formimidoylthienamycin or Penem or Ronem or S 4661 
or S-4661 or SM 7338 or SM-7338 or Thienamycin$).ti,ab. (11771) 
29 exp Piperacillin/ (2035) 
30 (acopex or avocin or cl 227,193 or Cl 227193 or cl 227193 or cl 227193 or cl227,193 
or Cl227193 or cl227193 or cl227193 or Cl-227193 or cl-227193 or cypercil or 
hishiyaclorin or ivacin or pentcillin or pentocillin or picillin$ or pipcil or pipera hameln 
or piperacil or piperacillin$ or piperacin or pipera-hameln or pipercillin or piperilline or 
pipraci$ or pipraks or pipril or piprilin or pitamycin or t 1220 or t1220 or t-1220 or 
taiperacillin).ti,ab. (4319) 
31 (cl 307579 or cl298741 or cl307579 or tazabactam or tazobac$ or tazocel or 
tazocillin$ or tazocin or tazomax or tazonam or tazopril or yp 14 or yp14 or ytr 830 or 
ytr 830h or ytr830 or ytr830h or zosyn).ti,ab. (2217) 
32 exp Amoxicillin-Potassium Clavulanate Combination/ (1914) 
33 (aclam or aktil or ambilan or amocla or amoclan or amoclav or amoksiklav or 
amolanic or amometin or (amox adj clav) or amox-clav or (amoxi adj plus) or (amox 
adj3 clavulan$) or amoxiclav or amoxiclav-bid or amoxiclav-teva or amoxsiklav or 
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amoxxlin or (amoxycillin-clavulanic adj acid) or ancla or (auclatin adj duo) or augamox 
or augmaxcil or augmentan or augmentin$ or augmex or augpen or (augucillin adj duo) 
or augurcin or ausclav or auspilic or bactiv or bactoclav or bioclavid or (brl adj ‘25000’) 
or brl25000 or brl-25000 or cavumox or ciblor or (clacillin adj duo) or clamax or 
clamentin or clamobit or clamonex or clamovid or clamoxin or (clamoxyl adj duo$) or 
clarin-duo or clavamox or clavar or clavinex or clavodar or clavoxil or (clavoxilin adj 
plus) or clavubactin or clavudale or clavulanate-amoxicillin or clavulin or (clavulox adj 
duo) or clavumox or (co adj amoxiclav) or (co adj amoxyclav) or coamoxiclav or co-
amoxiclav or coamoxyclav or (cramon adj duo) or (croanan adj duo) or curam or 
danoclav or (darzitil adj plus) or e-moxclav or enhancin or fleming or fugentin or 
(fullicilina adj plus) or gumentin or hibiotic or inciclav or klamonex or kmoxilin or 
lactamox or lansiclav or moxiclav or moxicle or moxyclav or natravox or nufaclav or 
palentin or quali-mentin or ranclav or spektramox or stacillin or suplentin or synermox 
or synulox or (velamox adj cl) or vestaclav or viaclav or vulamox or xiclav or (zami adj 
‘8503’)).ti,ab. (9184) 
34 ((brl adj ‘17421’) or brl17421 or (thiophenemalonamic adj acid) or negaban or 
temocillin or temopen).ti,ab. (179) 
35 (tigecycline or (tbg adj mino) or tygacil or gar 936 or gar936 or (tert adj 
butylglycinamido$)).ab,ti. (1161) 
36 exp Quinolones/ (33277) 
37 ((chinolone adj derivative) or fluoroquinolones or (haloquinolone adj derivative) or 
ketoquinolines or oxoquinolines or quinolinones or quinolones).ti,ab. (11055) 
38 exp Aminoglycosides/ (122582) 
39 (Aminoglycosides or Anthracyclines or Aclarubicin or Daunorubicin or Plicamycin or 
Butirosin Sulfate or Sisomicin or Hygromycin B or Kanamycin or Dibekacin or 
Nebramycin + or Metrizamide or Neomycin or Framycetin or Paromomycin or 
Ribostamycin or Puromycin or Spectinomycin or Streptomycin or Dihydrostreptomycin 
Sulfate or Streptothricins or Streptozocin).ti,ab. (52288) 
40 exp Gentamicins/ (16678) 
41 (adelanin or alcomicin or apigent or apogen or apoten or azupel or bactiderm or 
biogaracin or bristagen or cidomycin or danigen or dermogen or dianfarma or 
dispagent or duragentam$ or epigent or (frieso adj gent) or garabiotic or garalone or 
garamicin$ or garamycin or garbilocin or gencin or gendril or genoptic or genrex or 
gensumycin or gentabiotic or gentabiox or gentac or gentacidin or gentacin or gentacor 
or gentacycol or gentacyl or gentafair or gentagram or gentak or gental or gentaline or 
gentalline or gentalol or gentalyn or gentamax or gentame$ or gentamicin$ or 
gentamina or gentamycin$ or gentamyl or gentamytrex or gentaplus or gentarad or 
gentasil or gentasol or gentasone or gentasporin or gentatrim or gentavet or genticin$ 
or genticyn or gentiderm or gentimycin or gentocin or gentogram or gentomycin or 
genum or geomycine or gevramycin or g-mycin or gmyticin or g-myticin or grammicin 
or hexamycin or jenamicin or konigen or lacromycin or lisagent or martigenta or 
migenta or miragenta or miramycin or nichogencin or nsc 82261 or nsc82261 or 
obogen or ocugenta or ocu-mycin or oftagen or ophtagram or opthagen or optigen or 
opti-genta or ottogenta or pyogenta or refobacin or ribomicin or rigaminol or rocy gen 
or rovixida or rupegen or sagestam or sch 9724 or sch9724 or sedanazin or servigenta 
or skinfect or sulmycin or tangyn or u-gencin or versigen or yectamicina).ti,ab. (19829) 
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42 exp Amikacin/ (3372) 
43 (akacin or akicin or amicacina or amicasil or amicin or amiglymide v or amikacin$ or 
amikafur or amikalem or amikan or amikayect or amikin or amiklin or amikozit or 
amiktam or amitracin or amixin or amukin or apalin or bb k 8 or bb k8 or bbk 8 or bb-k 
8 or bbk8 or bbk-8 or bb-k8 or biclin or biklin or biokacin or briclin or briklin or 
chemacin or cinmik or fabianol or gamikal or glukamin or kacinth-a or kanbine or 
kormakin or likacin or lukadin or miacin or mikasome or onikin or oprad or orlobin or 
pediakin or pierami or riklinak or savox or selaxa or selemycin or sulfate amikacin or 
tybikin or vs 107 or vs107 or yectamid).ti,ab. (7140) 
44 exp Fosfomycin/ (1378) 
45 (fosfocil or fosfocin or fosfocina or fosfomicin or fosfomycin or fosfonomycin or ‘mk 
0955’ or mk 955 or mk0955 or mk955 or monuril or phosphomycin or 
phosphonomycin).ti,ab. (1779) 
46 exp Aztreonam/ (1233) 
47 ((az adj threonam) or azactam or azenam or azthreonam or aztreonam or (corus adj 
‘1020’) or dynabiotic or primbactam or SQ 26,776 or sq 26,776 or sq 26776 or SQ-
26,776 or sq26776 or sq-26776 or urobactam).ti,ab. (2333) 
48 exp Nitrofurantoin/ (2253) 
49 (berkfurin or biofurin or chemiofuran or dantafur or f 30 or f30 or fua-med or 
furaben or furadantin$ or furadantoin or furadina or furadoine or furadonin or 
furadonine or furalan or furanpur or furantocompren or furantoin$ or furobactina or 
furofen or furophen or infurin or ituran or ivadantin or macrobid or macrodantin$ or 
macrofuran or macrofurin or micofurantin$ or mitrofuratoin or nephronex or nierofu or 
nifurantin or nifuryl or (nitro adj macro) or nitrofuracin or nitrofuradantoin or 
nitrofurantine or nitrofurantoin$ or nitrofurin or novofuran or nsc 2107 or nsc2107 or 
orafuran or parfuran or phenurin or (potassium adj furagin) or ralodantin or trocurine 
or urantin or (uro adj tablinen) or urodil or urodin or urofuran or urolong or 
urotablinen or uro-tablinen or urotoina or uvamin).ti,ab. (2721) 
50 exp Cephalosporins/ (35352) 
51 (Axepim$ or bmy 28142 or bmy28142 or BMY-28142 or Cefepim$ or cefepitax or 
ceficad or cepimax or forzyn beta or maxcef or maxfrom or maxipime or 
Quadrocef).ti,ab. (1916) 
52 ((Cephalosporanic adj Acid$) or Cephalosporin$ or Cefamandole or Cefoperazone or 
Cefazolin or Cefonicid or Cefsulodin or Cephacetrile or Cefotaxime or Cephalothin or 
Cephapirin or Cephalexin or Cefaclor or Cefadroxil or Cephaloglycin or Cephradine or 
Cephaloridine or Ceftazidime or Cephamycins or Cefmetazole or Cefotetan or 
Cefoxitin).ti,ab. (35099) 
53 exp Amdinocillin Pivoxil/ (199) 
54 ((amdinocillin adj pivoxil) or (FL adj ‘1039’) or FL1039 or fl1039 or FL-1039 or 
pivamdinocillin or Pivmecillinam or Selexid or coactabs or (ro adj ‘109071’) or (ro10 
adj ‘9071’) or ro109071).ti,ab. (237) 
55 or/25-54 (246506) 
56 21 and 24 and 55 (3195) 
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57 exp clinical trial/ (706293) 
58 exp randomized controlled trials/ (85563) 
59 exp double-blind method/ (118498) 
60 exp single-blind method/ (17086) 
61 exp cross-over studies/ (30990) 
62 randomized controlled trial.pt. (342334) 
63 clinical trial.pt. (476450) 
64 controlled clinical trial.pt. (85694) 
65 (clinic$ adj2 trial).mp. (552367) 
66 (random$ adj5 control$ adj5 trial$).mp. (443104) 
67 (crossover or cross-over).mp. (59003) 
68 ((singl$ or double$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (162179) 
69 randomi$.mp. (509202) 
70 (random$ adj5 (assign$ or allocat$ or assort$ or reciev$)).mp. (150717) 
71 or/57-70 (968331) 
72 (review or review,tutorial or review, academic).pt. (1758734) 
73 (systematic$ adj5 review$).tw,sh. (40365) 
74 (systematic$ adj5 overview$).tw,sh. (663) 
75 (quantitativ$ adj5 review$).tw,sh. (3684) 
76 (quantitativ$ adj5 overview$).tw,sh. (153) 
77 (quantitativ$ adj5 synthesis$).tw,sh. (1107) 
78 (methodologic$ adj5 review$).tw,sh. (2696) 
79 (methodologic$ adj5 overview$).tw,sh. (180) 
80 (integrative research review$ or research integration).tw. (78) 
81 meta-analysis as topic/ (12608) 
82 (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (62359) 
83 (meta synthesis or meta synthesis or metasynthesis).tw,sh. (215) 
84 (meta-regression or meta regression or metaregression).tw,sh. (1650) 
85 meta-analysis.pt. (37918) 
86 (synthes$ adj3 literature).tw. (1070) 
87 (synthes$ adj3 evidence).tw. (2956) 
88 integrative review.tw. (583) 
89 data synthesis.tw. (6328) 
90 (research synthesis or narrative synthesis).tw. (463) 
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4.3.Clinical Review Tables 
4.3.1. Antibiotic stewardship 
  
 


























To assess the effect of an intensiﬁed 
intervention, that included active 
surveillance, on the incidence of 





Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: data from medical 
records of all patients who acquired 
CRKP infection 
 
















1. Enhanced national infection 
control programme: contact 
precautions were used for the 
care of all patients with CRKP 
colonization or infection; the 
prevalence of colonization or 
infection was reported daily, and 
this information was mailed to 
the hospital management and 
the national coordinator; and 
patients infected with CRKP had 
their names entered into a 
database so that they could be 
identified at hospital re-
admission 
2. Active surveillence 
programme: obtaining rectal 
culture samples from patients 
hospitalized in ICUs and in step-
down units, at admission to the 
unit and once weekly until the 
patient was discharged 
 
Length of pre-intervention: 17 
months prior 
Length of post-intervention: 
19 months following 
Infection control 
Before the intervention, the 
incidence of clinical infection with 
CRKP had increased 6.42-fold to 
6.93 cases per 10,000 patient-days 
 
After an enhanced infection control 
and active surveillance programme 
was introduced, the incidence of 
clinical infection reduced to 1.8 
cases per 10,000 patient-days 
(P<0.001). The slope significantly 
changed with the introduction of the 

















To devise a local strategy for 
eradication of a hospital-wide 





1. Emergency department 
ﬂagging system 
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Adolescents 13–18 years, adults 
19–45 years, middle aged 46–64 
years, aged 65–79 years, elderly 
80+years 
Male: 410, female: 393 
 
Inclusion criteria: data from medical 
records of patients with CRKP 
infection 
 









2. Building of a cohort space or 
ward 
3. Intensive active surveillance 






Length of pre-intervention: 11 
months prior 
Length of post-intervention: 
36 months following 
During the intervention, the CRKP 
undetected ratio showed a significant 
increase from 55.7% for June–
December 2007 to 71.2% in 2008, 
78.9% in 2009 and 92.5% for 
February– May 2010 (P≤0.001).  
 
From May 2006 through April 2007 
(pre-intervention), the CRKP-IN 
incidence density per 10,000 patient-
days was 5.26. After the intervention 
programme was introduced, the 
incidence of clinical CRPK infection 
reduced to 2.91 cases per 10,000 
patient-days (P<0.001) in 12/2007, 
1.91 in 12/2008 and 1.28 in 12/2009. 
The slope changed significantly with 




Meropenem use showed a 
statistically significant decrease from 
2007 to 2010 (P≤0.001); colistin use 
increased significantly during the 



















To assess the possible effects of 
varying usage of levofloxacin, 
gatifloxacin and moxifloxacin on P. 





N: not reported 










1. Levofloxacin replaced with 
gatifloxacin in 2001 
2. Gatifloxacin replaced with 
moxifloxacin in 2006 
Ciprofloxacin available 
throughout study period  
Antibiotic resistance and 
susceptibility 
No association between the 
susceptibility of P. aeruginosa 
isolates to tobramycin and formulary 
changes was noted. With cefepime, 
a significant change in susceptibility 
was detected after the introduction of 









bias (low quality) 
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Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: data from clinical 
microbiology and pharmacy 
databases of the Medical University 
of South Carolina Medical Centre 
 





Length of pre-intervention: 15 
months prior 
Length of post-intervention 1: 
60 months 
Length of post-intervention 2: 
30 months following 
moxifloxacin (P=0.0571). In the case 
of piperacillin/tazobactam, a positive 
change in susceptibility over time 
was detected after introduction of 
moxifloxacin (P=0.0589). In each 
analysis, the effect of total 















To describe the implementation of 
an institution-wide, multiple-step 
intervention to curtail the epidemic 




Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: all patients 
affected by CRKP 
 














1. Single-room isolation and 
contact precautions  
2. Cohorting of patients and 
nursing staff, screening of 
patients in the same room as 
newly identiﬁed carriers of 
CRKP, and local protocol for 
continued cohorting of 
returning patients 
3. Weekly active surveillance in 
the ICU 
4. Active surveillance of 
patients on admission to the 
emergency department 
 
Length of pre-intervention: not 
reported 
Length of post-intervention 1: 
14 months 
Length of post-intervention 2: 
39 months  
Bacterial colonization and 
infection 
The incidence (total number of cases 
of in-hospital CRKP acquisition 
detected by clinical cultures) and 
weekly point prevalence were 
reported as the number of cases per 
1000 hospital beds 
 
Incidence was found to change 
significantly after intervention 2 
(06/2007) and 3 (10/2008). 
Prevalence was found to change 
signiﬁcantly only in September 2009 
(after intervention 4) 
 
In the emergency department, the 
mean rate of compliance with the 
active surveillance protocol (± SD) 
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Length of post-intervention 3: 
2 years 



















To examine the effect of the 
antibiotic stewardship programme 




SICU N=6044, TICU N=14,802  
Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
Male: 14,277, female: 6569 
 
Inclusion criteria: all patients 
admitted to the SICU or TICU during 
the study period who contracted an 
HAI with microbiological 
confirmation of at least one Gram-
negative pathogen, at least 18 years 
of age 
 



















1. Antibiotic stewardship: 
April 2002, guidelines for 
prophylactic antibiotics 
were devised for select 
procedures 
 
2. Antibiotic rotation: 
January 2005, 
institution-wide initiative 
for surgical prophylaxis 
based on the Surgical 
Care Improvement 
Project 
Length of pre-intervention: 15 
months 
Length of post-intervention 1: 
11 months 
Length of post-intervention 2: 
16 months 
 Antibiotic use 
Both in the SICU and TICU and 
there was a significant decrease in 
the utilization of total broad-spectrum 
antibiotics (BLIC, carbapenems, 
fluoroquinolones, third- and fourth-
generation cephalosporins) targeting 
Gram-negative pathogens over the 
observation period (P<0.001) 
 
Infection 
During the 8-year observation 
period, the proportion of healthcare-
associated infections caused by 
MDR Gram-negative pathogens 
decreased from 37.4% (2001) to 
8.5% (2008), whereas the proportion 
of healthcare-associated infections 
caused by pan-sensitive pathogens 




















To examine the effect of restricting 
ciproﬂoxacin use on the resistance 
of nosocomial Gram-negative bacilli, 
including P. aeruginosa, to group 2 
carbapenems in a hospital’s ICUs 




aerogenes, E. cloacae, 







Restriction of ciprofloxacin:  
ciproﬂoxacin use was restricted 
hospital wide in July 2007; after 
this restriction, pre-approval by 
the on-call infectious diseases 
fellow was required for its use 
 
Antibiotic use 
Following the restriction of 
ciprofloxacin, there was a significant 
decreasing trend (P=0.0027) in its 
use, from 87.09 DDD/1000 patient-
days in 2004 to 8.04 DDD/1000 
patient-days in 2010. Use of the 
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N: not reported 
Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: all clinical ICU and 
intermediate care unit specimens 
(blood, sterile ﬂuid, sputum, urine, 
wounds and anaerobic specimens) 
with test results that were positive 
for P. aeruginosa, E. aerogenes, E. 
cloacae, A. baumannii and S. 
maltophilia. Only nosocomial cases, 
defined as involving patients who 
had a hospital length of stay 
exceeding two days 
 
Exclusion criteria: results of 















Length of pre-intervention: 42 
months  
Length of post-intervention: 
42 months  
 
significantly (P=0.0134) from 11.96 
DDD/1000 patient-days in 2004 to 
28.19 DDD/1000 patient-days in 
2010. Overall, there was a hospital-
wide decrease of 18.4% (P<0.0001) 




There were no changes observed in 
the number of nosocomial S. 
maltophilia isolates per 10,000 




Over the seven-year time period, 
there was a decrease of 13.7% in 
the percentage of ciprofloxacin-
resistant P. aeruginosa isolates that 
were collected, which equates to a 
decrease of 3.9% per year 
(P=0.0017). No significant changes 
was observed in the susceptibilities 
to the group II carbapenems of 














To test whether reduction of third-
generation cephalosporin use has a 
sustainable positive impact on the 
high endemic prevalence of third 
generation cephalosporin-resistant 
K. pneumoniae and E. coli in an ICU 
 
Participants 









1. Education programmes for 
professionals and patients in 
July 2004 
2. Education sessions on 
antibiotic guidelines were 
Antibiotic use 
Following the implementation of 
guidelines in a surgical ICU, a 
significant and sustainable decrease 
in the use of third-generation 
cephalosporins of -110.2 DDD/1000 
patient-days (95% CI -140.0 to -80.4, 
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Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: not reported  
 





held in the departments of 
surgery and anaesthesiology 
3. Empiric standard therapy for 
peritonitis and other intra-
abominal infections was 
switched from third-
generation cephalosporins to 
piperacillin in combination 
with a beta-lactamase 
inhibitor. The duration of 
antibiotic therapy for open 




Length of pre-intervention: 30 
months  
Length of post-intervention: 
30 months  
  
a significant reduction in the use of 
ampicillins (-167.4 DDD/1000, 95% 
CI -223.8 to -110.9, R2=0.378) and in 
the use of imidazoles (-94.5 
DDD/1000, 95% CI -121.2 to -67.7, 
R2=0.463) 
 
The use of aminoglycosides 
decreased steadily before and after 
the intervention (slope -1.4 
DDD/1000 patient-days per month, 
95% CI -1.8 to -1.0, R2=0.430); 
piperacillin and 
piperacillin/tazobactam showed a 
significant increase in level of 64.4 
DDD/1000 patient-days (95% CI 
38.5–90.3) and continued to 
increase by 2.3 DDD/1000 patient-
days (95% CI 1.0–3.6) per month 

















To evaluate the impact of a reduced 
duration of antibiotic prophylaxis for 
cerebrospinal shunts on total 





Age: not reported 
Male: not reported, female: not 
reported 
 














Change in antibiotic prophylaxis:  
Revised recommendation of 
single-shot prophylaxis with 
cefuroxime for shunt catheters, 
beginning in January 2004 
 
Length of pre-intervention: 24 
months prior 
Length of post-intervention: 
36 months following 
 
 Antibiotic use 
Following the implementation of a 
comprehensive teaching session on 
antibiotic prophylaxis in 
cerebrospinal shunts in a surgical 
ICU, pre-operative prophylaxis for 
shunt catheters was changed into 
single-shot prophylaxis, and total 
antibiotic use decreased (–147.3 
DDD/1000 patient-days, P=0.052). 
This corresponded to a decrease of 
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Inclusion criteria: monthly data on 
antimicrobial use obtained from the 
computerized pharmacy database. 
Monthly resistance data collected 
from the microbiology laboratory. 
Only samples taken in the ICU were 
considered 
 
Exclusion criteria: copy strains – 
deﬁned as an isolate of the same 
species showing the same 
susceptibility pattern throughout a 1-
month period in the same patient, no 
matter what the site of isolation 
 
 
 The reduction in total antibiotic 
consumption was sustainable and 

















To perform an evaluation of changes 
in antibiotic susceptibility patterns in 
common Gram-negative organisms 
isolated from an ICU to demonstrate 
whether an observed reduction in 
broad-spectrum antibiotic use alters 





Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: not reported 
 
Exclusion criteria: not reported 
 
Bacteria: E. coli, 
Klebsiella spp., 

















National guidelines on 
antimicrobial prescribing; 
antibiotic stewardship via 
computerized decision support 
systems. In 2001, one system 
guiding antibiotic use outside the 
ICU – a web-based antimicrobial 
approval system for third-
generation cephalosporins 
(cefotaxime and ceftriaxone). In 
2002, targeting the ICU 
specifically – computerized 
decision support system for 
antibiotic prescribing 
Length of pre-intervention: 30 
months  
Length of post-intervention: 
54 months  
Antibiotic use 
Following the implementation of 
national guidelines on antimicrobial 
prescribing and antibiotic 
stewardship, there was a significant 
reduction in the number of 
imipenem-resistant E. coli and 
Klebsiella spp. isolates observed in 
the ICU. A small but significant 
improvement in the number of 
imipenem-resistant Acinetobacter 
spp. isolates was also observed. 
 
For Enterobacteriaceae with 
potentially inducible beta-
lactamases, no significant changes 
was observed in imipenem 
susceptibility, although gentamicin 
susceptibility increased at a rate of 
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ciprofloxacin susceptibility increased 
at a rate of 0.9%/year (95% CI 0.1–
1.7) 
 
ICU antibiotic consumption 
The use of antibiotics to cover Gram-
negative bacteria in the ICU, 




fluoroquinolones remained stable 
















To determine the relation of 
carbapenem restriction with the 





Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
 
Male: 15, female: 11 
 
Inclusion criteria: Patients receiving 
mechanical ventilation for more than 
five days and diagnosed with VAP 
 
Exclusion criteria: not reported 
 









Carbapenem restriction policy 
limiting the use of third-
generation carbapenems. Only 
used when severe sepsis and 
after consultation with a 
physician from the Department 
of Infectious Diseases. N=12 
 
Control group 
Conventional treatment: no 
restrictions of carbapenem 
(doctors were able to prescribe if 
necessary). N=15 
 
Length of follow-up: duration of 
treatment  
Mortality 
Mortality rates did not differ 
significantly between the treatment 




More patients in the conventional 
group developed a carbapenem-
resistant strain of A. baumannii, 
although the difference was not 









 K. pneumoniae, Klebsiella pneumonia; P.aeruginosa, Pseudomonas aeruginosa; A. baumanniii, Acinetobacter baumanniii; E. coli, Escherichia coli; E. 
aerogenes; Enterobacter aerogenes; E. cloacae, Enterobacter cloacae; S. maltophilia, Stenotrophomonas maltophilia; CRKP, carbapenem-resistant K. 
pneumoniae; SICU, surgical intensive care unit; TICU, trauma intensive care unit; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; ESBL, 
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extended-spectrum beta-lactamase; BLIC, beta-lactam/beta-lactamase inhibitor combinations; ITS, interrupted time series;  RCT, randomized controlled trial; 
ICU, intensive care unit; FQ, fluoroquinolones; 3/4CEPH, third- and fourth-generation cephalosporins; HAI, healthcare-associated infection; CI, confidence 
interval; RR, risk ratio; DDD, defined daily dose; SD, standard deviation.  
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To analyse whether single patient 
rooms in the ICU decreased 





Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: not reported 
 









resistance: ESBL  
 
Intervention 
ICU A converted to single patient 
rooms. Old ICU A N=64, new 
ICU A N=62 
 
Control group 
ICU B remained open plan. Old 
ICU B N=44, new ICU B N=39 
 
Length of follow-up: not 
reported 
Infection control 
The single-room ICU A had a 
significantly lower ICU acquisition of 
resistant organisms when compared 
with ICU B during the same period 
[3/62 (5%) vs 7/39 (18%), 
respectively, P=0.043], which was 
confirmed using survival analysis 
(P=0.011). ICU B showed no 






ICU, intensive care unit; ESBL, extended-spectrum beta-lactamase; CBA, controlled before–after study. 
 





















To determine the efficacy of SDD in 
patients with multi-drug-resistant A. 











SDD: a combination of 
polymyxin E (colistin) (150 mg) 
and tobramycine (80 mg) 
administered in 20-mL liquid 
form x 4/day (orally or through 
Bacterial colonization 
Rates of faecal, pharyngeal and 
axillary colonization did not 
significantly reduce during ICU stay 
in the control group (P value not 






























Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
Male: 16, female: 5 
 
Inclusion criteria:  
Intervention group 
1. All patients with A. baumannii 
fecal colonization  




1. All patients admitted 1 October–
30 Novembe 1998 with A. 
baumannii faecal colonization 
2. At least one series of axillary-
pharyngeal-rectal swab performed 
 






nasogastric tube), and 0.5 g of 
gel containing 2% of colistin and 
tobramycine applied round the 
gum margins and oropharynx x 
4/day. Duration of treatment 
from detection of A. baumannii 
to discharge from ICU. N=21 
 
Control group 
No intervention. N=33 
 
Length of follow-up: duration of 
treatment  
 
of faecal and pharyngeal carriage 
was reduced significantly (P<0.001 
and P=0.003, respectively), but not 
the rate of cutaneous carriage  
 
Antibiotic resistance 
MDR A. baumannii had not been 
detected at the time of faecal 
carriage in 21 of 33 (63.6%) of the 
control group and 11 of 21 (52.3%) 
of the SDD group. In the SDD group, 
all A. baumannii strains were 
tobramycin resistant and susceptible 
to colistin at the beginning of the 
study. No resistance to colistin 





















To study the efficacy of intestinal 
decontamination by oral non-
absorbable antibiotic agents to 
control a nosocomial outbreak of 
intestinal colonization and infection 
with MDR Enterobacteriaceae, and 
to examine its effects on endemic 




Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
















SDD: a combination of 
polymyxin E (colistin), 50 mg; 
neomycin, 1 g; and nalidixic acid 
(quinolone), 1 g administered in 
liquid form x 4/day either orally 
or through a nasogastric tube, 
starting within 24 h of admission 
and continuing until discharge 
from the unit. N=36 
 
Control group 
No prophylaxis. N=50 
 
Length of follow-up: not 
reported 
Mortality 
All-cause mortality and mortality from 
nosocomial infections did not differ 
significantly between patients 
receiving SDD or no prophylaxis 
 
Clinical success/improvement 
There was no significant difference 
between patients receiving SDD or 
no prophylaxis in:  
 the incidence of any nosocomial 
infection 























 Inclusion criteria:  
1. Consecutive patients with unit 
stay exceeding two days 
2. Severity score at admission ˃2 
 
Exclusion criteria:  
1. Severe neutropenia routinely 
receiving oral antibiotic prophylaxis 
 
 the number of nosocomial 
infections that needed antibiotic 
treatment 
There was no significant difference 
in the number of patients staying on 
ICU longer than seven or 15 days 
 
Bacterial colonization 
One SDD patient and 12 no 
prophylaxis patients were positive for 
MDR strains (RR 0.12; 95% CI 0.02–
0.85). No new cases of MDR strains 
of Enterobacteriacae were detected 




Three no prophylaxis patients 
needed therapy for a septic episode 
caused by Enterobacteriacae; 
however, this was not significantly 














To assess the effectiveness of SDD 
for eradicating CRKP oropharyngeal 




Middle aged 46–64 years, aged 65–
79 years, elderly 80+ years 
Male: 26, female: 14 
 












SDD: topical application in the 
oropharynx of colistin 
sulfomethate sodium 100,000 U 
per g and gentamicin sulfate 1.6 
mg per g incorporated into the 
gel. Dose of 0.5 g x 4/day for 
seven days. Plus an oral solution 
of 80 mg of gentamicin and 1x10 
U of polymyxin E (colistin), given 
orally or through a nasogastric 
Mortality 
The rate of mortality did not differ 
significantly between the SDD group 
and the placebo group. The causes 
of mortality were not reported. No 
adverse events were reported 
 
Antibiotic susceptibility 
CRKP isolates from patients in the 
SDD arm remained susceptible to 



























1. Hospitalized patients with CRKP 
colonization with or without infection 
2. ˃18 years of age 
3. Available for a follow-up period 
(while hospitalized or as outpatients) 
of at least seven weeks 
 
Exclusion criteria: ˂18 years of age, 
pregnancy, lactation, a known 
allergy to one of the study drugs, 
renal failure with creatinine 
clearance less than 50 mL/min, 
treatment with intravenous 
gentamicin or intravenous, 
polymyxin E at the time of 
randomization 
 




Placebo: topical application in 
the oropharynx of the placebo 
gel, which was compounded 
from carboxymethyl cellulose. 
Dose of 0.5 g x 4/day for seven 
days. Plus two oral solutions, 
one containing sodium chloride 
0.45% and the other containing 
pulverized sacarin, given orally 
or through a nasogastric tube X 
4/day for seven days. N=20 
 
Length of follow-up: six weeks 
throughout the study (MIC ≤2 mg/mL 
and ≤0.094 mg/mL, respectively) 
 
Bacterial colonization 
At the end of treatment, the number 
of participants in the SDD group that 
had a throat culture that was CRKP 
positive reduced from 30% to 0%, 
whereas in the placebo group, this 




 A. baumannii, Acinetobacter baumannii; K. pneumoniae, Klebsiella pneumoniae; MDR, multi-drug resistant; SDD, selective digestive decontamination; RR, 
risk ratio, CI, confidence interval; CRKP, carbapenem-resistant K. pneumonia; MIC, minimum inhibitory concentration; RCT, randomized controlled trial; ICU, 
intensive care unit. 
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To assess the clinical and 
microbiological effectiveness of 
fosfomycin in the treatment of MDR, 
XDR or PDR non-fermenting Gram-




Studies: 23 microbiological, one 
animal and three cohort studies and 
three case reports  
 
Inclusion criteria: microbiological, 
animal experimental or clinical data 
on the effect of fosfomycin against 
MDR non-fermenting Gram-negative 
pathogens such as Pseudomonas 
spp., Acinetobacter spp., 
Stenotrophomonas spp. and 
Burkholderia spp. MDR, XDR or 
PDR non-fermenting Gram-negative 
bacilli or to Gram-negative bacilli 
with resistance to two or more 




Exclusion criteria: studies written in 
languages other than English, 





and Burkholderia spp. 
 
See Table II in the 






Combination of fosfomycin with 
other antimicrobial agents 
 
 
Microbiological: a total of 1859 
MDR non-fermenting Gram-negative 
isolates. Susceptibility rate to 
fosfomycin of MDR P. aeruginosa 
isolates was ≥90% and 50–90% in 
7/19 and 4/19 relevant studies, 
respectively. 30.2% isolates of MDR 
P. aeruginosa, 3.5% MDR A. 
baumannii isolates were found to be 
susceptible to fosfomycin 
 
Clinical: 91% of the patients 
clinically improved (treatment of 






This review was 
included 




reached are not 
supported by the 
study design  


























9 July 2008, 






To evaluate the available clinical 
evidence regarding the effectiveness 
and safety of systemic colistin in 
children without cystic fibrosis 
Participants 
N=370 
Studies: 10 case series and 15 case 
reports  
 
Inclusion criteria: studies with data 
regarding the use of intravenous, 
intrathecal, intramuscular or 
intraventricular colistin in paediatric 
patients for the treatment of 
infections caused by colistin-
susceptible 
pathogens or for prophylaxis. All or 
the majority of patients involved in 
each individual study should not 
have cystic fibrosis 
 
Exclusion criteria: studies that 
focused on colistin use in paediatric 
patients with cystic fibrosis, or 
reporting the use of oral colistin or 
the use of colistin for 
topical treatment in paediatric 
patients. 
Abstracts in scientific conferences or 
studies published in languages other 
than English, Spanish, French, 






influenza, P. pyocyanin, 
P. aeruginosa, K. 
pneumoniae and A. 
aerogenes 
 
See Table I in the paper 
for details of studies 
Intervention 
Colistin for the treatment of 




Colistin for surgical prophylaxis 
or prophylaxis of infections in 
burns patients (N=44) 
 
Case series treatment:  





Adverse effects (included in safety 
assessment N=311) 
1. Nephrotoxicity: 33/311 had 
cylindruria or haematuria, 8/311 had 
a blood urea nitrogen elevation of 
>10% (in one child owing to an 
overdosage of colistin), 5/311 had 
renal tubular cells in the urine, 3/311 
had proteinuria and 2/311 had a 
signiﬁcant increase in serum 
creatinine levels during intravenous 
colistin treatment. Data regarding 
adverse events not provided for two 
children 
2. Neurotoxicity: 0/311 
3. Other: 8/311 
 
 
Case series prophylaxis: 
Incidence of infection: 0/44 
Death: 9/44 attributed to the 
underlying pathologies. No signs of 
colistin-related toxicity were found 
Adverse effects: 
1. Tubular epithelial cells in urine, 






This review was 
included 




reached are not 
supported by the 
study design 














 to one week after withdrawal of 
colistin: 16/44 
2. Proteinuria, disappearing right 
after colistin withdrawal: 14/44  
3. Oliguria during the initial stages of 
colistin treatment: 1/44 















To the evidence on fosfomycin as a 
treatment option for infections 
caused by members of the family 
Enterobacteriaceae with advanced 
resistance to antimicrobial drugs, 




Studies: 17 in-vitro microbiological 
studies, two prospective studies, 
one retrospective study and two 
case reports 
 
Inclusion criteria: studies on 
Enterobacteriaceae isolates with an 
advanced drug resistance (MDR, 
carbapenem resistance, or 
production of ESBLs, AmpC β-
lactamases, serine 
carbapenemases or metallo-β-
lactamases) profile and their 
susceptibility to fosfomycin, and the 
clinical effectiveness of treatment 





studies K. pneumoniae 
isolates, E. coli 
 
Clinical studies E. coli, 
S. typhimurium, S. typhi 
 
See Table III in the 







Fosfomycin–trometamol in two 
of the E. coli studies 
Microbiological success 
11 of the 17 studies reported that at 
least 90% of the isolates were 
susceptible to fosfomycin  
Clinical efficacy 
Measured in four studies. 
Two studies oral treatment for lower 
UTI with ESBL-producing E. coli 
(one prospective and one 
retrospective) resulted in the 
treatment group with clinical cure in 75 
of the 80 (93.8%) patients included in 
these studies.  
 
Two case reports of infection due to 
MDR Salmonella spp. Reported 







This review was 
included 




reached are not 
supported by the 
study design 














Exclusion criteria: abstracts in 
scientific conferences or studies 
published in languages other than 
English, Spanish, French, German, 














To identify and evaluate the 
available data regarding the 
susceptibility of recent Gram-
negative bacteria to 
isepamicin, including that of MDR 




Studies=11 microbiological, one 
RCT, one prospective study, one 
restrospective study 
 
Inclusion criteria: either a 
microbiological (in-vitro) study that 
evaluated the susceptibility of Gram-
negative bacterial isolates (including 
MDR ones) to isepamicin or a 
clinical study that evaluated the use 
of isepamicin, given for the 
treatment of infections by the 
aforementioned pathogens or for 
prophylaxis for this type of infection. 
In addition, studies 
deemed relevant should have been 
published between 2000 and 2010 
 
Exclusion criteria: studies that 








See Table II in the 






Two clinical studies – amikacin 
one clinical study – isepamicin + 
levofloxacin for prophylaxis 
Microbiological: isepamicin was 
more effective in four studies than 
amikacin, six studies reported as 
effective, one study both groups 
ineffective. In studies including MDR 
bacteria, 2/4 reported more effective 
than amikacin; 1/4 as effective as 




1. Paediatric infection treatment 
studies: 100% clinical and 
bacteriological response for both the 
isepamicin and the amikacin arms. 
Definition of clinical response not 
stated (e.g. cure, improvement) 






This review was 
included 




reached are not 
supported by the 
study design 














isolates or patients, studies referring 
to synergistic or pharmacodynamic/ 
pharmacokinetic parameters of 
isepamicin, studies that provided 
data regarding the susceptibility of 
isepamicin to micro-organisms other 
than Gram-negative bacteria or the 
susceptibility of other 
aminoglycosides only to Gram-
negative bacteria.  
Abstracts in scientific conferences or 
studies published in languages other 
than English, Spanish, French, 














To evaluate the current state of 
evidence for antimicrobial 
stewardship interventions in the 
critical care unit 
 
Participants 
N=not available/not reported for all 
included studies 
Studies: three RCTs, three ITSs, 
and 18 uncontrolled before–after 
studies 
 
Inclusion criteria: application of any 
intervention; to improve antimicrobial 
utilization; and within an intensive 
care setting 
 
Exclusion criteria: if no intervention 
was applied, non-human or non-
patient based, non-hospital based, 
or they did not involve intensive care 
Bacteria: 
P. aeruginosa,  
A. baumannii,  
E. coli, 
Klebsiella spp., ESBL 
 
See Table I in the paper 
for details of studies.  
Intervention 
Antimicrobial stewardship:  
1. Antibiotic restriction/ pre-
approval 
2. Computer-assisted decision 
support 
3. Infectious diseases consultant 
4. Re-assessment on pre-
speciﬁed date 
5. Antibiotic de-escalation 
protocols 
6. Antibiotic prophylaxis 
guideline 
7. Antibiotic treatment guideline 
 
Control group 
Not reported, presumably no 
stewardship 
Overall stewardship intervention: 
1. Reductions in antimicrobial 
utilization (11–38% deﬁned daily 
dose/1000 patient-days) 
2. Lower total antimicrobial costs 
(US$ 5–10/ 
patient-day) 
3. Shorter average duration of 
antibiotic therapy 
4. Less inappropriate use 
5. Fewer antibiotic adverse events.  
stewardship intervention beyond six 
months:  
1. Reductions in antimicrobial 
resistance rates 
 
Antibiotic stewardship was not 
associated with increases in 
nosocomial infection rates, length of 




















patients. Additionally, antibiotic 















To clarify whether carbapenems are 
more effective or safer than other 
broad-spectrum antibiotics for the 





Studies: 12 RCTs  
 
Inclusion criteria: randomized 
controlled clinical trial; 
studied the role of carbapenems in 
comparison with other broad-
spectrum antibiotics or a 
combination of antibiotics for the 
empirical treatment of patients with 
HAP; assessed the 
effectiveness, toxicity and mortality 
of both therapeutic regimens. 
Included both patients with HAP and 
patients with community-acquired 
pneumonia; however, only data 
regarding patients with HAP were 
extracted. Trials with both blind and 
unblind design were included, and 
only RCTs written in English, French 
and German 
 
Exclusion criteria: RCTs conducted 
primarily in neutropenic patients with 




See Table I in the paper 
for details of studies 
Intervention 
Carbapenems: 
1. Imipenem/ cilastatin (eight 
studies) 
2. Meropenem (four studies) 
 
Control group 
Imipenem/ cilastatin compared 
with:  
1. Fluoroquinolones: 
levofloxacin, ciprofloxacin (three 
studies) 






Meropenem compared with: 
combination of a cephalosporin 
(ceftazidime, cefuroxime) with an 
aminoglycoside (amikacin, 
gentamicin, tobramycin) 
1. All-cause mortality: lower mortality 
in the carbapenems group (OR 0.72, 
95% CI 0.55–0.95) 
2. Treatment success (clinical): no 
difference between groups (OR 1.08, 
95% CI 0.91–1.29)  
3. Treatment success 
(microbiological): no difference 
between groups (OR 1.04, 95% CI 
0.72–1.50)  
4. Adverse effects: no difference 
(0.81, 0.46–1.43) 
 
P. aeruginosa pneumonia subgroup: 
lower treatment success (OR 0.42, 
95% CI 0.22–0.82) and lower 
eradication of Pseudomonas spp. 
strains (OR 0.50, 95% CI 0.24–0.89) 
in the carbamenems group. 
 
Late onset of HAP subgroup: no 
difference between groups  




















haematological malignancies and 
trials that included fewer than 10 
patients with pneumonia who 
received a carbapenem. 
Experimental trials and trials 
focusing on pharmacokinetic and 
pharmacodynamics parameters. 
Finally, RCTs comparing the 
effectiveness and safety of two 
different carbapenems 
 
P. aeruginosa, Pseudomonas aeruginosa; A. baumannii, Acinetobacter baumannii; K. aerogenes, Klebsiella aerogenes; H. influenza, Haemophilus influenza; 
P. pyocyanin, Pseudomonas pyocyanin; K. pneumoniae, Klebsiella pneumoniae; A. aerogenes, Aerobacter aerogenes; E. coli; Escherichia coli; S. 
typhimurium, Salmonella typhimurium;S.typhi, Salmonella typhi; S. pneumoniae, Streptococcus pneumoniae; S. epidermidis, Staphylococcus epidermidis; 
MDR, multi-drug resistant; XDR, extensively drug resistant; PDR, pan-drug resistant; RCT, randomized controlled trial; ESBL, extended-spectrum beta-
lactamase; HAP, hospital-acquired pneumonia; OR, odds ratio; CI, confidence interval. 
 
1. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-
fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 
2009;34:111–120. 
2. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int 
J Antimicrob Agents 2009;33:503.e1–e13. 
3. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-
spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43–50. 
4. Falagas ME, Karageorgopoulos DE, Georgantzi GG, Sun C, Wang R, Rafailidis PI. Susceptibility of Gram-negative bacteria to isepamicin: a 
systematic review. Expert Rev Anti-Infect Ther 2012;10:207–218. 
5. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J 
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To evaluate the clinical efficacy and 
safety of high-dose regimen 
ampicillin sulbactam for the 





Age: not reported 
Male: 15, female: N=12 
 
Inclusion criteria: all patients 
mechanically ventilated for more 
than 72 h with positive tracheal 
aspirates for A. baumannii 
 
Exclusion criteria: episodes of VAP 
in which A. baumannii was isolated 
in conjunction with another micro-
organism 
 














Ampicillin/sulbactam at a rate 2: 
1 every 8 h. 24 g/12 g daily for 
seven to 10 days. N=13 
 
Control group 
Ampicillin/sulbactam at a rate 2: 
1 every 8 h. 18 g/9 g daily for 
seven to 10 days. N=14 
 
Length of follow-up: one month  
Mortality 
14-day VAP mortality and 30-day all-
cause mortality were not significantly 
different between treatment groups  
 
Clinical success/improvement 
The number of patients with clinical 
success and clinical failure was not 




The two treatment groups showed 
no difference in the eradication of A. 
baumannii isolates (bacteriological 




There was no difference in the 
















To compare the clinical efficacy and 
safety of high-dose 
ampicillin/sulbactam vs colistin as 
monotherapy for the treatment of 
Acinetobacter spp. VAP 






Colistin, intravenous 3 MIU 




14-day VAP mortality and 28-day all-
cause mortality were not significantly 

































Middle aged 46–64 years, aged 65–
79 years 
Male: 14, female: 14 
 
Inclusion criteria: ventilated patients 
for >72 h who developed MDR A. 
baumannii VAP 
 
Exclusion criteria: cases of VAP with 
mixed isolated micro-organisms, 
combination antibiotic therapy, 
allergy to beta-lactamase or 












Ampicillin/sulbactam, 9 g (at a 
rate 2:1) every 8 h for eight to 10 
days, administered as follows: 
three vials (20 mL each) 
containing 3.0 g of 
ampicillin/sulbactam diluted in 
200 mL of 5% dextrose provided 
within 1-h duration infusion. 
N=13 
 
Length of follow-up: two-week- 
and one-month mortalities  
Clinical success/improvement 
The number of patients with clinical 
success and clinical failure was not 




The two treatment groups showed 
no difference in the eradication of A. 
baumannii isolates (bacteriological 
success) or bacteriological failure 




There was no difference in the 




















To compare the efficacy of eight 
days vs 15 days of antibiotic 
treatment of patients with 




Middle aged 46–64 years, aged 65–
79 years 
Male: 141, female: 46 
 
Inclusion criteria:  
1. ˃18 years of age 
2. Clinical suspicion of VAP 
3. Positive quantitative cultures of 
distal pulmonary secretion samples 
Bacteria: E. coli, 
Klebsiella spp., 
Enterobacter spp., P. 
aeruginosa, 
Acinetobacter spp.,  
Proteus spp., Serratia 
spp., C. freundii, M. 
morgagnii 
 







Antibiotics for eight days: 
specific antibiotics, doses and 
schedules are not reported. 
Antibiotics were selected by the 
treating physicians. As per 
protocol, the initial regimen 
should have preferably 
combined at least an 
aminoglycoside, or a 
fluoroquinolone and a broad-
spectrum beta-lactam 





28-day and 60-day all-cause 
mortality and in-hospital mortality did 
not significantly differ between the 
eight- and 15-day regimes 
 
Clinical success/improvement 
Risk differences (90% CIs) to 
develop an unfavourable outcome 
(defined as death, pulmonary 
infection recurrence, or prescription 
of a new antibiotic for any reason 
provided for ≥48 h) were not 
significantly different between the 
eight- and 15-day regimes for all 
patients (RR 2.6, 90% CI -5.6 to 






















4. Instigation within the 24 h 
following of appropriate empirical 
antibiotic therapy directed against 
the micro-organism/s responsible for 
the infection 
 
Exclusion criteria:  
1. Pregnant 
2. Enrolled in another trial 
3. Little chance of survival 
4. Neutropenia 
5. Concomitant acquired 
immunodiffeciency syndrome 
6. Immunosuppressants or long-
term corticosteroid therapy 
7. Concomitant extrapulmonary 
infection that required prolonged 
antimicrobial treatment 
8. Attending physical declined full-
life support. 
9. Early-onset pneumonia (within the 
first five days of mechanical 
ventilation) and no antimicrobial 
therapy during the 15 days 
preceding infection. 
 
Antibiotics for 15 days: specific 
antibiotics, doses and schedules 
are not reported. Antibiotics 
were selected by the treating 
physicians. As per protocol, the 
initial regimen should have 
preferably combined at least an 
aminoglycoside or a 
fluoroquinolone and a broad-
spectrum beta-lactam 
antimicribial agent. N=204 
 
Length of follow-up: three 
months  
non-fermenting Gram-negative 
bacteria (RR 8.6, 90% CI -5.9 to 
23.1) 
 
The rate of and time to (Kaplan-
Meier method, log-rank test) 
pulmonary infection considered to be 
recurrence, relapses or 
superinfection was not significantly 
different between treatment regimes.  
 
Antibiotic use 
The number of antibiotic-free days 
was significantly less for all patients 
on the eight-day regime, but not for 
those patients with non-fermenting 
Gram-negative bacteria. 
 
No difference was found in the 
number of patients continuing to 
receive antibiotics after the end of 
the trial treatment regimen, or in the 
number of patients who received an 
additional course of antibiotics 
 
Antibiotic resistance 
For patients who developed 
recurrent pulmonary infections, those 
who had received the eight-day 
treatment of antibiotics had 
significantly less emergence of MDR 
pathogens compared with those who 
had received the 15-day treatment 
(42.1% vs 62.3% of recurrent 
infections, respectively; P=0.04) 
 





























To compare the efficacy of 
norfloxacin vs standard parenteral 





Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria:  
1. Hospitalized patients 
2. ˃18 years of age 
3. Documented UTI caused by an 
organism known or presumed 
susceptible to norfloxacin 
 
Exclusion criteria:  
1. ˂18 years of age 
2. Pregnant or not practising an 
effective means of birth control 
3. A history of allergic diathesis or 
an allergy to nalidixic acid, oxolinic 
acid or norfloxacin 
4. Functional renal abnormalities or 
unstable deteriorating renal function 
5. Comatose or high probability of 
imminent death 
6. Serious concurrent infection 
7. Treated or recently completed 
treatment  
with antibiotics 
8. History or visual disturbances, a 
psychiatric disorder or central 
nervous system disease 
Bacteria: E. coli, 
Klebsiella spp., 
Enterobacter spp., P. 
aeruginosa, Serratia 
spp., C. freundii, M. 
morgagnii 
 








Norfloxacin 400 mg x2/day, 
minimum treatment seven days. 








and vancomycin, cephalosporin, 
cefotaxime alone, administered 
in accordance with the 
manufacturers’ guidelines. N=52 
(48 evaluable patients) 
 
Length of follow-up: seven (SD 
two) days, optional four to six 
weeks 
Clinical success/improvement 
No significant differences were found 
between norfloxacin and standard 
parenteral antibiotic treatment in the 
rate of participants that were 
clinically cured, showed clinical 
improvement or had treatment failure 
 
Superinfection 
Rates of superinfection and early re-
infection also did not differ 
significantly between the norfloxacin 




No differences in the number of 
patients experiencing adverse 
events were found between those 
receiving norfloxacin and those 





































To evaluate the efficacy of 
monotherapy with pefloxacin in 
secondary ICU pulmonary infections 




Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years, 
elderly 80+ years 
Male: 42, female: 29 
 
Inclusion criteria: adult patients 
presenting serious bacterial 
infections of the respiratory tract 
 
Exclusion criteria: not reported 
 




























Pefloxacin intravenously 400 




Imipenem intravenously 1 g 
every 8 h for 12.9 (SD 6.2) days. 
N=36 
 
Length of follow-up: duration of 
treatment 
Mortality 
There were three deaths related to 
sepsis in the imipenem group and 
one in the pefloxacin group (although 
the sepsis was not related to the 
bronchopneumonia, but to an 
underlying abdominal infection). All-
cause mortality was not reported 
 
Clinical success/improvement 
No differences were found in the 
number of patients cured, the 
number with superinfection that was 
cured, the number showing 
improvement and the number 
experiencing treatment failure. 
Bacterial eradication rates were 
significantly lower in the imipemem 




Resistance development among 
persisting strains was also 




No systemic reactions or abnormal 
laboratory parameters were reported 










To investigate if intestinal carriage of 






Colistin sulfate 50 mg 
(equivalent to 42 mg colistin 
Clinical success/improvement 
The rate of eradication of ESBL-E 
was significantly different between 
RCT 





























Adolescents 13–18 years, adults 
19–45 years, middle aged 46–64 
years, aged 65–79 years, elderly 
80+ years 
Male: 34, female: 24 
 
Inclusion criteria: aged ≥18 years; 
ESLB-E-positive rectal swab 
 
Exclusion criteria: patients with 
active ESLB infection, patients 
treated with antibiotics active against 
ESLB-E, pregnancy/breastfeeding, 
contraindication to the use of study 
drugs, previous study enrolment and 
resistance of the colonizing ESLB-E 
















base or 1.26 million units 4x/day) 
and neomycin sulfate (250 mg 
equivalent to 178 mg neomycin 
base 4xday) for 10 days.  
In the presence of ESBL-E 
bacteriuria, the patients were 
also treated with nitrofurantoin 






Length of follow-up: 28 (SD 
seven) days 
treatment regimes during treatment 
(day 6; RR 0.40; 95% CI 0.23–0.70) 
or in the first day after treatment (RR 
0.42; 95% CI 0.23–0.76), but did not 
differ in the end of follow-up 
 
Treatment adherence 
There was no significant difference 
between groups in the number of 
patients that adhered to treatment, 
measured by counting the number of 




No statistically significant difference 
was found between the treatment 
groups in the number of patients with 




















To assess whether biofilm-growing 
bacteria susceptibility testing of P. 
aeruginosa correlates better with 
clinical outcomes in chronic cystic 
fibrosis airway infections, when 
compared with conventional 




Adolescents 13–18 years, adults 
19–45 years 
Male: 25, female: 14 
 











Biofilm testing: bioflim regimens 
of two antibiotics were selected 
centrally using a published 
algorithm, which calculated for 
each bacterial morphotype the 
biofilm minimum inhibitory 
quotient of each drug, defined as 
achievable serum concentration 




conventional regimens of two 
Antibiotic susceptibility 
Participants were assigned to 12 
different regimens. The most 
common regimens included 
meropenem (52%) and ciprofloxacin 
(49%). Azithromycin-containing 
regimens were used for only two 
participants (5%), both in the biofilm 
group. No participant received 
ceftazidime and tobramycin, a 
combination commonly used in 




























Inclusion criteria: diagnosis of cystic 
fibrosis, history of persistent P. 
aeruginosa airway infection, clinical 
stability at the time of screening, ≥14 
years with at least one prior course 
of intravenous antibiotics 
 
Exclusion criteria: sputum culture 
negative for P. aeruginosa, sputum 
culture positive for B. cepacia 
complex species, hospitalization or 
treatment for an acute pulmonary 
exacerbation, treatment with oral or 
inhaled antipseudomonal antibiotics, 
or azithromycin or other macrolides, 
within 14 days prior to screening 
 
antibiotics were selected 
centrally using a published 
algorithm, which calculated for 
each bacterial morphotype the 
conventional minimum inhibitory 
quotient of each drug defined as 
achievable serum concentration 
divided by conventional MIC. 
N=19 
 
Length of follow-up: 14 days 
Of the agents tested, meropenem 
was most active against biofilm-
grown bacteria, but antibiotic 
regimens based on biofilm testing 
did not differ significantly from 
regimens based on conventional 
testing in terms of microbiological 

















To determine whether nebulized 
CMS as adjunctive therapy of Gram-





Middle aged 46–64 years, aged 65–
79 years, elderly 80+ years 
Male: 64, female: 36 
 
Inclusion criteria: hospitalized 
patients, ≥18 years of age, diagnosis 
of Gram-negative VAP 
 
Exclusion criteria: not reported 
 
Bacteria: E. coli (ESBL 
+ve) and E. coli (ESBL -
ve), K. pneumoniae 
(ESBL +ve) and K. 
pneumoniae (ESBL -













Systemic antibiotic and 
nebulized CMS (parenteral) 
equivalent to 75 mg of colistin 
base reconstituted in 4 mL of 
NSS every 12 h via a nebulizer 
for 10 min. Continued until 
systemic antibiotic therapy of 




Systemic antibiotic(s) plus NSS 
equivalent to 75 mg of colistin 
base reconstituted in 4 mL of 
NSS every 12 h via a nebulizer 
for 10 min. Continued until 
systemic antibiotic therapy of 
VAP was ended. N=49 
Mortality 
Rates of mortality due to VAP and 
all-cause mortality did not differ 
between the groups receiving 
intervention or control 
 
Clinical success/improvement 
Favourable microbiological outcome 
was significantly higher in the 
intervention group compared with the 
control group (RR 1.57, 95% CI 
1.03–2.37),but no significant 
difference was observed on clinical 
outcomes 
 
The overall incidence of 
complications, bronchospasm and 
renal impairment did not differ 




































To study the use of mecillinam as a 




Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years, 
elderly 80+ years 
Male: not reported, female: not 
reported 
 
Inclusion criteria: Danish tourists 
travelling to Egypt and the Far East 
 
Exclusion criteria: not reported 
 
Bacteria: 
















Mecillincam, 200 g, 1x per day 





Length of follow-up: duration of 
treatment  
Antibiotic resistance 
Only 8% of E. coli strains were 
resistant to three or more antibiotics 
in the pre-travel samples. Post-
travel, after participants had received 
either mecillinam or placebo, 
approximately 50% or more of the E. 
























To test the efficacy of probiotic strain 
E. coli Nissle 1917 in reducing the 




Age: not reported 
Male: not reported, female: not 
reported 
 
Inclusion criteria: not reported 
 
Exclusion criteria: not reported 
 









Probiotic: strain E. coli Nissle 
1917, 5x109-5x1010 CFU one 




Placebo starch powder capsule. 
N=33 
 
Length of follow-up: five weeks  
Clinical success/improvement 
There was no significant difference 
between the probiotic and placebo 
groups in the number of people with 
faecal and urine samples becoming 
negative or remaining positive. 
 
Antibiotic resistance 
103 norfloxacin-resistant E. coli 
isolates from 20 probiotic patients 
were tested for susceptibility. All 
isolates were resistant to norfloxacin 
(MIC >256 µg/mL) and ciprofloxacin. 
The majority of norfloxacin-resistant 
E. coli isolates were MDR. The 




















among strains. None of the isolates 
















To report the effectiveness of 
extended-infusion meropenem 
compared with conventional bolus 
dosing in the management of HAP 




Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
Male: 19, female: 11 
 
Inclusion criteria: HAP due to MDR 
A. baumannii 
 
Exclusion criteria: not reported 
 












meropenem infusion: 500 mg 





intravenous meropenem 1 g. 
every 8 h over a 1-h infusion. 
N=15 
 
Length of follow-up: duration of 
treatment  
Clinical success/improvement 
No significant differences were found 
between extended-infusion 
meropenem and conventional bolus 
dosing in the number of patients with 
treatment success at days 3, 5 and 
7. The rates of relapse also did not 




No patient developed a meropenem-
resistant strain of A. baumannii, and 
the MIC90 for meropenem against A. 























To determine the relation of 
carbapenem restriction with the 





Adults 19–45 years, middle aged 
46–64 years, aged 65–79 years 
 
Male: 15, female: 11 
 
Inclusion criteria: patients receiving 
mechanical ventilation for more than 
five days and diagnosed with VAP 
 









Carbapenem restriction policy 
limiting the use of third-
generation carbapenems. Only 
used when severe sepsis and 
after consultation with a 
physician from the Department 
of Infectious Diseases. N=12 
 
Control group 
Conventional treatment: no 
restrictions of carbapenem 




The rates of mortality did not differ 
significantly between the treatment 




More patients in the conventional 
group developed a carbapenem-
resistant strain of A. baumannii, 
although the difference was not 























Exclusion criteria: not reported 
 
Length of follow-up: duration of 
treatment  
  
P. aeruginosa, Pseudomonas aeruginosa; E. coli, Escherichia coli; C. freundii, Citrobacter freundii; M. morgagnii, Morganella morgagnii; A. baumannii, 
Acinetobacter baumannii; A. anitratus, Acinetobacter anitratus; P. mira, Proteus mira; S.marcescens, Serratia marcescens; B. cepacia, Burkholderia cepacia; 
MDR, multi-drug resistant; VAP, ventilator-associated pneumonia; ESBL, extended-spectrum beta-lactamase; CMS, colistimethate sodium; RCT, randomized 
controlled trial; ICU, intensive care unit; UTI, urinary tract infection; HAP, hospital-acquired pneumonia; NSS, nebulized sterile normal saline; CFU, colony-
forming unit; SD, standard deviation; RR, risk ratio; CI, confidence interval.
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Appendix 5: CPD material 






Answer a, c, d, e 
2. Which of the following are true: 
a) Polymyxins do not require monitoring renal function in the elderly. 
b) Fluoroquinolones can be used to treat urinary infection due to multidrug resistant Gram-
negative bacteria  
c) Oral pivmecillinam should be used alone in the treatment of upper urinary infection 
d) Polymyxins should be given in combination with other agents if they are used in treating 
carbapenem-resistant Enterobacteriaceae.  
e)  Co-trimoxazole should be used in treatment of infections due to Stenotrophomonas maltophilia    
Answer b, d, e 
3. Which of the following are true: 
a) In uncomplicated urinary infection due to a proven ESBL-producing organism, treatment is 
recommended for 3 days  
b) If infection with MDR GNB is suspected, treat asymptomatic bacteriuria  
c) Give antibiotic prophylaxis for urinary catheter insertion if previous history of symptomatic 
urinary infections associated with a catheter change or there is trauma during the catheter 
insertion  
d) Daily antibiotic prophylaxis is preferable to standby antibiotics in recurrent urinary infection 
e) Always send a urine specimen for culture if an antibiotic-resistant organism is suspected AND 
the patient is asymptomatic  
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Answer c, 
4. Which of the following are true; 
a) Ceftolozane-tazobactam is active against AmpC producing Enterobacteriaceae 
b) Ceftazidime-avibactam is active against AmpC producing# 
 Enterobacteriaceae 
c)KPC-producing Klebsiella sp. often produce aminoglycoside 
 methyltransferases conferring pan-aminoglycoside resistance 
d) NDM-producing E. coli are usually mecillinam susceptible 
e) Proteus sp. are usually resistant to fosfomycin 
Answer b  
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   Generally a very useful document. My one 
concern is that there is no mention of 
children, infants, neonates. Paeds are 
increasingly faced particularly with 
multiresistant G-ve UTI’s and the data here is 
all from all adult studies/perspectives. 
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appear as a fairly disjointed and inconsistent 
collection of statements. For example, the 
first recommendation starts with the role of 
temocillin vs Enterobacteria and Burkholderia 
and the second recommendation is for 
ampicillin-sulbactam vs Acinetobacter. This is 
not a logical or helpful sequence for 
presentation. Some of the recommendations 
appear as a surprise as they do not relate 
back to the preceding evidence or discussion. 
Care should be taken to ensure that this link 
is made and a justification provided for all 
recommendations 
 
Perhaps the functionality of the guideline 
could be improved with a more structured 
approach to the management of MDR Gram 
negatives? For example the role of each of 
the different classes of agents (recommended 
Y/N + comments) could be systematically 
presented as a table for each of the common 









n checked for 
relationship to 
text and evidence 
3. Too many 
mechanisms to 
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resistance mechanisms, if necessary 
separated into different tables for the 
different organism groups (e.g. 
Enterobacteria, non-fermentors).  
Full 28 783 The conclusion that temocillin may be used as 
a carbapenem-sparing agent against 
Enterobacteria is (a reasonable) opinion of 
the authors but does not follow from the 
evidence presented. (The same opinion might 
also have be given for other classes of agent 
such as polymixins). Consideration should be 
given to simplifying and rephrasing the 
recommendation to ‘temocillin can be used 
to treat infections due to Enterobacteria, 
including ESBL and AmpC producers’ 
 Considered on a case by 
case basis 
Full 30 830 The recommendation that ‘Amoxicillin-
clavulanate should not be used to treat 
infection with known ESBL-producing 
organism unless sensitivity known ‘ is 
generally not very helpful for a typical 
diagnostic laboratory where apparent co-
amoxiclav susceptibility will be known either 
before or at the same time as ESBL 
production is confirmed.  
 
Alternatively, if the authors are suggesting 
that a patient with a history of ESBL positive 
UTI/infection should not be given co-
amoxiclav until sensitivity for the current 
episode is confirmed, the recommendation 
should be clearly reworded 
 Detailed consideration 
given of this 
recommendation but 
given 6+% recurrence rate 
with ESBL infection 
previous susceptibility is 
an important factor in 
making this choice. 
Substantual cavaeats 
against use of coamoxiclav 
and 
piperacillin/tazobactam 
use in UK added both 
because of in vitro 
resistance and prevalence 









The following recommendation is not 
supported by any evidence linking clinical 
outcomes to sepsis severity criteria: 
‘Piperacillin-tazobactam can be considered 
for use in mild-moderate infections (i.e. not 
severe sepsis) due to ESBL-producing 
Enterobacteriaceae if supported by 
susceptibility results.’ The evidence should be 
provided, the opinion justified, or the 
recommendation removed.   
 Recommendation changed 
to omit reference to 
severity of infection 
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Full 32 888 The following recommendation is not 
supported by any evidence. …‘However 
combination with an aminoglycoside is 
advisable for severe infections.’ The evidence 
should be provided, the opinion justified, or 
the recommendation removed. 
 Agree. Removed 
Full 36 986 It is unclear why there needs to be a separate 
recommendation for ertapenem: ‘Ertapenem 
is effective in treatment of infections with 
multi-resistant Enterobacteriaceae apart from 
carbapenemase producers’ when this has 
apready been covered by the previous 
recommendation: ‘ Carbapenems should be 
used to treat serious ESBL-producing Gram-
negative infections subject to antibiotic 
stewardship to minimize the risk of 
developing resistance’.  
 
Is there a reason why the general 
carbapenem recommendation is not 
extended to include AmpC resistance? For 
internal consistency within the document, we 
suggest merging these two recommendations 
as follow: ‘carbapenems can be used to treat 
infections due to ESBL or AmpC producing 
Enterobacteria’. 
 Ertapenem has different 
properties and is now 
recommended for OPAT. 
AmpC issue now 
considered 
Full 37 1010 The format of the following recommendation 
is internally inconsistent within the 
document: ‘Although it retains good efficacy 
against infections with Pseudomonas 
aeruginosa, ceftazidime is not recommended 
for the treatment of other serious infections 
due to ESBL / AmpC producing 
Enterobacteriaceae, even if in vitro tests 
suggest the isolate is susceptible.’  
 
We suggest 1) separating the 
recommendations for treating Pseudomonas 
and Enterobacterial infections, 2) rephrasing 
the recommendation for Enterobacteria as 
follows: ‘ceftazidime should NOT be used to 
 rephrased 
Accepted manuscript 384 
treat infections due to ESBL or AmpC 
producing Enterobacteria’   
Full 39 1074 Information relating to aztreonam-avibactam, 
while interesting, does not belong under a 
heading of ceftazidime-avibactam and is not 
directly relevant to the guideline – suggest 
remove 
 Separate aztreonam 
section added whoich 
houses the experimental 
combination aztreoname-
avibactam 
Full 40 1086 The format of the following recommendation 
is internally inconsistent within the 
document: ‘With the exception of infections 
with metallo-β-lactamase strains, 
ceftazidime-avibactam, when available, 
should be used as alternative treatment to 
carbapenems’.  
 
We suggest rephrase this recommendation as 
follows: ‘ceftazidime-avibactam can be used 
to treat infections due to Enterobacteria, 
including ESBL and AmpC producers’   
 Rewritten 
Full 42 1140 The format of the following recommendation 
is internally inconsistent within the document 
(and implies that it should be used in 
preference to carbapenems): ‘Ceftolozane-
tazobactam should be used as alternative 
treatment to carbapenems in treating ESBL-
producing Gram negative pathogens (but not 
carbapenemase producers). 
 
We suggest rephrase this recommendation as 
follows: ‘ceftolozane-tazobactam can be used 
to treat infections due to Enterobacteria, 
including ESBL and AmpC producers’   
 Rewritten 
Full 45 1231 There is potential overlap/duplication 
regarding combination therapy with this 
recommendation and the recommendation 
on page 56, line1518. Consider either 
removing  ‘and preferably used in 
combination with other agents’ and adding a 
cross reference to the later section    
 Cross-references inserted 
where useful 
Accepted manuscript 385 
Full 45 1234 The recommendation with regard to renal 
function is internally inconsistent within the 
document as side effects are not 
systematically considered for other agents. 
Many important unwanted effects occur for 
many different antimicrobials and relevant 
monitoring should be considered as a matter 
of course by the prescribing clinician (and this 
might include monitoring colistin levels also, 
which is not mentioned as a 
recommendation).  
 To contaienm a;lready 
voluminous length 
Unwanted effects  are 
highlighted where may be 
specifically over-looked. 
Full 46 1266 The format of the following recommendation 
is internally inconsistent within the 
document: ‘Fluoroquinolones can be used to 
treat urinary infection due to multidrug 
resistant Gram-negative bacteria based on 
susceptibility results.’ 
 
We suggest rephrase this recommendation as 
follows: ‘quinolones can be used to treat 
complicated urinary tract infections due to 
Gram negative bacteria’      
 Standardised 
Full 51 1390 The format of the following recommendation 
is internally inconsistent within the 
document: ‘Fosfomycin should be used in 
treatment of urinary infection due to 
multiresistant Gram-negative bacteria (oral 
administration only suitable for lower urinary 
infection)’ 
 
We suggest rephrase as follows:  ‘Fosfomycin 
can be used to treat urinary tract infections 
due to Gram-negative bacteria (oral 
administration only suitable for lower urinary 
infection)’ 
 Standardised 
Full 52 1410 To improve internal consistency within the 
document, we suggest adding the following 
additional recommendation (which follows 
from the preceding evidence): ‘aztreonam 
should NOT be used to treat infections due to 
ESBL or AmpC producing Enterobacteria’   
 Agreed 
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Full 65 1758 There is a recommendation to use 7 days 
therapy for ESBL simple UTIs to improve 
bacteriological clearance.  There is no 
mention of clinical outcomes evidence.  
Bacteriological clearance does not necessarily 
correlate well with clinical outcomes (e.g. 
high prevalence of asymptomatic bacteriuria 
in certain patient populations).  This 
recommendation could lead to a large 
increase in ab use if implemented widely and 
it would need strong clinical evidence before 
doing so. 
 Debated at length within 
WP. Considered that best 
possible bacteriological 
clearance should be 
obtained with proven 
MDR GNB infection but 
caveat inserted about 
clinical relevance of 
bacteriological cure. 
Full 66 1795 This recommendation: ‘admission for 
intravenous aminoglycoside therapy’ 
 is potentially confusing as it appears to 
exclude an inpatient carbapenem option 
(presumably temocillin or other agents 
recommended above for Enterobacteria 
could also be considered). 
 
We suggest rephrase as ‘admission for 
intravenous therapy with an aminoglycoside 
or carbapenem (? Or temocillin etc) 
 
 Whole section fo 
recommendations recast. 
Point accepted. 
Full General General Although the evidence base is weak in many 
areas, and the authors are to be commended 
for covering many topic areas, we feel the 
document does not read like it is focused on 
an infection specialist dealing with ‘real 
world’ problems e.g. a patient with KPC 
bacteraemia with MICs of x,y,z and renal 
failure and obesity etc – we note that the US 
has produced flowcharts previously (e.g. 
Medscape  
http://www.medscape.com/viewarticle/7800
65_9 ) see screenshot on following page, and 
more recent publications - clearly these may 
be based on minimal evidence but they do 
provide a start. We wonder whether 
consideration could be given by the WP to 
producing similar tools. 
 “ simple flow-charts 
inserted but subject is too 
diverse to deal with all 
possible clinical situations 
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row. 
 
Please do not paste other tables into this 
table, as your comments could get lost – 




Mark as “Exclude” OR 
“Include” (and reason for 
change or no change)  
 
EXAMPLE: Full 16 45 Our comments are as follows …… Exclude: Reason  WP Response 
Full 15 423 Typo – “uin” instead of “in” Exclude: correct the 
spelling 
All typos dealt with 
Full 38 1054 Typo – “Gram-egative” instead of “Gram-
negative” 
Exclude: correct the 
spelling 
All typos dealt with 
Full 52 1415 Typo – “mecillianam” instead of “mecillinam” Exclude: correct the 
spelling 
All typos dealt with 
Full 74-75 2004-2009 All bacteraemias or just MRGN bacteraemias? 
This would require a standardised format to 
enable direct comparison but is also a very 
complex, multifactorial issue and would also 
need to capture sufficient clinical detail e.g. 
not all mortality is a result of inappropriate 
antibiotic prescribing; blood cultures often 
signal positive after the patient has died plus 
were there risk factors for MRGN identified 
during primary assessment? 
This also sounds a very labour intensive 
requirement. Please be aware that many 
microbiology consultants are already having 
to collate a lot of information as a mandatory 
requirement for bodies such as PHE without 
any additional resources being identified and 
would struggle to add more to the pile. Not 
Exclude: needs modifying. 
Please specify whether all 
bacteraemias or not and 
give appropriate 
consideration to format 
and additional resources 
required, particularly if 
this were to become a 
mandatory requirement, 
to support business cases 
within local Trusts. 
Accept point on consultant 
time and specifically 
added but priority of 
required action and 
information on Gram-
negative bacteraemias is 
high. Extensive 
bacteraemia information 
added and advice taken 
from BIA. 
Accepted manuscript 391 
all departments have junior doctors to assist 
with this sort of responsibility. 
Full 82 2194 Would recommend that 1) the term “standby 
antibiotics” is explained and 2) that advice is 
given on how a clinician, bearing in mind this 
is often a GP, would decide which antibiotic 




Full 90 2246 There is a superscript β in the flowchart, but 
it does not appear to refer to anything 
Exclude: Needs reviewing Dealt with 
Full 90 2252 There is a comment marked ¥, but this 
symbol does not appear in the flowchart. 
Exclude: needs reviewing Dealt with 
Full General  MRGNs are an increasing problem for us but 
we are not yet seeing many MRGN 
bacteraemias and CPEs remain very rare 
locally. The management of sepsis necessarily 
requires empirical broad-spectrum antibiotic 
treatment before we have positive 
microbiology but we are not yet at the stage 
where our local guidance advises empirical 
cover for MRGNs unless there are risk factors 
for this. We are concerned that the recent 
CQUIN – re: reduction in antibiotic 
consumption which is particularly targeting 
piperacillin-tazobactam and carbapenems 
seems to be at odds with the empirical 
management of sepsis and if our Trust has 
any hope of achieving this target (which 
incidentally uses historic baseline data from a 
time when MRGNs were far less prevalent) 
then we would need to be moving empirical 
therapy back to cephalosorins and quinolones 
for example. We are reluctant to do this from 
a C. difficile perspective and from driving 
resistance mechanisms yet further. We 
appreciate that this document is not directly 
related to the CQUIN and that we are venting 
our frustration but it would be helpful if BSAC 
could issue a position statement or guidance 
on this CQUIN and outline the best approach 
for microbiologists to a) do the right thing in 
terms of empirical therapy for the septic 
 We are also concerned 
about the potneital 
conflict between 
antibiotic-use reduction 
targets and potential 
mortality in bacteraemia 
which has  similar 30 day 
mortality to C.difficile. 
Document extensively 
revised and your general 
points incorporated. 
Thank you 
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patient, particularly if there is a MRGN risk 
plus b) reduce the risk of promoting antibiotic 
resistance plus c) meet contractual 
obligations. I know we are not the only Trust 
that is exasperated by the specifics within this 
DH requirement which seems to totally 
disregard all the improvements made in 
recent years with regard to C. difficile and 
antibiotic stewardship.  
Full  General  The document discusses using antibiotics 
such as temocillin, tigecycline, colisitin and 
fosfomycin. EUCAST does not provide 
guidance on interpretation of temocillin 
susceptibility either by disk or MIC. 
Tigecycline needs to be tested via MIC for 
anything other than E coli. Fosfomycin & 
colistin need to be tested by MIC. These 
requirements reduce the turnaround times 
for results. In addition, the turnaround times 
for CPE resistance mechanisms/additional 
sensitivities do not help support optimum 
patient management. Could PHE Colindale 
publish its testing methods/MIC 
interpretations to enable local testing rather 
than sending isolates to them? Is there a way 
to expedite EUCAST guidance on temocillin 
interpretations? Can BSAC offer 
recommendations to support local business 
cases for introducing technology that enables 
faster identification of e.g.  CPEs in house as 
opposed to relying on reference laboratories? 
 In practice we now 
consider that molecular 
methodology is needed for 
colistin susceptibility 
testing and MICs for 
meropenem with MDR 
GNB  and this has been 
added. To track the fast 
changing situation we 
have now recommended 
that i) mandatory 
reporting of carbapenem 
resistant isolates is 
introduced ii) isolates are 
dealt with expeditiously 
for patient benefit and iii) 
isolates referred where 
testing is beyond the 
scope of local laboratories.  
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Full 56 1515 Klebsiella pneumoniae carbapenemase-
producing 
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full 47 1292 compared  Dealt with 
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Mark as “Exclude” OR 
“Include” (and reason for 
change or no change)  
WP Response 
Full Many Many Group the urinary tract infection summaries 
and cephalosporin/antibiotic  summaries 
Include Sections extensively re-
ordered 
Full Many Many The referencing seems to be sporadic, with 
some areas very well referenced and others 
less so or not at all.  A consistent approach 
throughout would be beneficial e.g. more 
references for UK statements in Pages 624-
634 
Include Re-referenced and 
numerous references 
added 
Full Many Many Quite a lot of sections do not have an added 
line break following a new paragraph  
Include Line breaks removed for 
JAC  
Full Many Many After evidence and recommendations 
sometimes there are  bullet points and other 
times not – consistency would be good 
Include Consistent approach 
adopted 
Full 5 163 Infection also happens through bacteria 
gaining access to organs or bloodstream from 
internal sources e.g. gut translocation  
Include Evidence for translocation 
in absence of local 
infection is poor 
Full 11 322 Extra space between ‘tazobactam’ and 
‘should’ 
Exclude Typos dealt with 
Full 13 370 Full stop required after ‘resistance’ Include Typos dealt with 
Full 13 381 Extra space between ‘of’ and ‘new’ Exclude Typos dealt with 
Full 13 388 Extra comma between ‘the’ and ‘community’ Exclude Typos dealt with 
Full 14 404 Full stop required after ‘incontinence’ Include Typos dealt with 
Full 15 423 Extra u in ‘uin’ Exclude Typos dealt with 
Full 17 471 Extra space between ‘treatment’ and ‘,’ Exclude Typos dealt with 
Full 17 483 Full stop required after ‘(Table 2)’ Include Typos dealt with 
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Full 2 131 No Appendix 5 listed Include Appendices renumbered 
and referred to in text 
Full 18 505 Extra comma required between ‘required’ 
and ‘notably’ 
Include Typos dealt with 
Full 18 505 Extra comma between ‘.’ and ‘There’ Exclude Typos dealt with 
Full 23 643 Extra space required between ‘2009,’ and 
‘and’ 
Include Typos dealt with 
Full 25 685 Et al should be italicised Include Typos dealt with 
Full 25 694 Extra space between ‘5%’ and ‘)’ Exclude Typos dealt with 
Full 26 702 Extra space between ‘imported’ and ‘to’ Exclude Typos dealt with 
Full 26 733 Extra space required between ‘compare,’ and 
‘(’ 
Include Typos dealt with 
Full 30 817 Extra space between ‘the’ and ‘study’ Exclude Typos dealt with 
Full 30 819 Extra space between ‘MICs’ and ‘to’ Exclude Typos dealt with 
Full 32 879 Extra space between ‘bactam’ and ‘is’ Exclude Typos dealt with 
Full 33 917 Extra full stop after ‘ceftazidime’ and‘.’  Exclude Typos dealt with 
Full 35 960 Extra space between ‘isolates’ and ‘of’ Exclude Typos dealt with 
Full 35 967 Extra comma between ‘result’ and ‘(Hyle)’ Exclude Typos dealt with 
Full 35 973 Extra space between ‘did’ and ‘not’ Exclude Typos dealt with 
Full 37 1024 Extra space between ‘responded’ and ‘.’ Exclude Typos dealt with 
Full 38 1044 Extra space required between ‘Eve’ and ‘in’ Include Typos dealt with 
Full 39 1066 Extra space between ‘lactamases’ and ‘(NDM’ Exclude Typos dealt with 
Full 39 1078 Extra space between ‘trials’ and ‘,’ Exclude Typos dealt with 
Full 40 1097 Extra space between ‘aeruginosa’ and ‘with’ Exclude Typos dealt with 
Full 42 1140 Extra space between ‘bactam’ and ‘should’ Exclude Typos dealt with 
Full 43 1184 Extra space between ‘period’ and ‘(Huttner’ Exclude Typos dealt with 
Full 44 1211 Extra space required between ‘toxicity’ and 
‘(Kelesidis’ 
Include Typos dealt with 
Full 46 1246 Extra space between ‘quinolones’ and ‘,’ Exclude Typos dealt with 
Full 46 1255 Extra space between ‘used’ and ‘to’ Exclude Typos dealt with 
Full 47 1276 Extra space between ‘most’ and 
‘Enterobacteriaceae’ 
Exclude Typos dealt with 
Full 48 1309 Extra space between ‘Tumbarello’ and ‘et al’ Exclude Typos dealt with 
Full 49 1345 Extra space between ‘activity’ and ‘:’ Exclude Typos dealt with 
Full 50 1370 Extra space between ‘gentamicin’ and ‘(’ Exclude Typos dealt with 
Full 56 1518 Should ‘except rifampicin’ be included in the 
recommendation for combination therapy 
with colistin 
Include Considered but dealt with 
in text 
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Full 56-57 1539-1543 Is this truly accurate of UK practice. Internal 
work at St Thomas’ Hospital several years ago 
highlighted much higher resistance rates than 
this.  
Include Agree. Modified with 
additional references 
Full 60 1624 Extra space between ‘GI’ and ‘effects’ Exclude Typos dealt with 
Full 60 1630 Extra space between ‘factors’ and ‘that’ Exclude Typos dealt with 
Full 56-63 N/A Should there be a section on the use of 
sterilising agents or the use of NSAIDs in 
uncomplicated UTIs 
Include Probably not as emphasis 
is primarily on serious 
infection 
Full 64 1738 Extra space between ‘cure’ and ‘Brayfield’ Exclude Typos dealt with 
Full 67 1824 Extra space between ‘or’ and ‘carbapenem’ Exclude Typos dealt with 
Full 67 1826 Extra space between ‘situations’ and ‘,’ Exclude Typos dealt with 
Full 68 1852 Extra space between ‘appropriate’ and ‘,’ Exclude Typos dealt with 
Full 68 1857 Extra space between ‘institutions’ and ‘,’ Exclude Typos dealt with 
Full 69 1862 Extra space between ‘and’ and ‘accounts’ Exclude Typos dealt with 
Full 70 1890 Extra space between ‘One’ and ‘controlled’ Exclude Typos dealt with 
Full 70 1892 Extra space between ‘most’ and ‘studies’ Exclude Typos dealt with 
Full 70 1898 Extra space between ‘trials’ and ‘,’ Exclude Typos dealt with 
Full 71 1917 Extra space between ‘few’ and ‘studies’ Exclude Typos dealt with 
Full 75 2011 Extra space between ‘of’ and ‘new’ Exclude Typos dealt with 
Full 76 2053 Extra space between ‘%’ and ‘absolute’ Exclude Typos dealt with 
Full 78 2088 Extra space required between ‘)’ and ‘in’ Include Typos dealt with 
Full 78 2107 Extra space required between ‘bacteriuria’ , 
which also needs an I removed, and ‘in’ 
Include/Exclude/Respell Typos dealt with 
Full 78 2110 Extra space between ‘of’ and ‘colonisation’ Exclude Typos dealt with 
Full 80 2135 Extra space between ‘resistance’ and ‘.’ Exclude Typos dealt with 
Full 80 2147 Extra space between ‘resistance’ and ‘.’ Exclude Typos dealt with 
Full 80 2148 Extra space between ‘on’ and ‘consensus’ Exclude Typos dealt with 
Full 80 2147 Full stop needed after ‘i’ Include Typos dealt with 
Full 81 2167 Extra space between ‘infection’ and ‘but’ Exclude Typos dealt with 
Full 81-83 N/A Should there again be a section on the use of 
sterilising agents or the use of NSAIDs in 
uncomplicated UTIs 
Include See previous response 
Full 84 2217 Extra space required between ‘studies’ and 
‘(SIGN’ 
Include Typos dealt with 
Full 85 2224 Extra space required between ‘grading’ and 
‘(SIGN’, which is also superscripted 
unnecessarily  
Include Typos dealt with 
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Full 85 2225 Table sometimes has full stop and at other 
times does not  





                                                        
